MORE THAN 200 DISEASES

- 1 DISEASE per page
- ▶ 1 PEARL per page
- ▶ 1 REFERENCE per page

CURRENT ESSENTIALS of CRITICAL CARE

Darryl Y. Sue Janine Vintch

CURRENT ESSENTIALS of CRITICAL CARE

Edited by

Darryl Y. Sue, MD

Professor of Clinical Medicine
David Geffen School of Medicine at UCLA
Division of Respiratory and Critical Care Physiology and Medicine,
Department of Medicine,
Harbor-UCLA Medical Center
Torrance, California

Janine R.E. Vintch, MD

Assistant Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Division of General Internal Medicine and Division of Respiratory and
Critical Care Physiology and Medicine, Department of Medicine,
Harbor-UCLA Medical Center
Torrance, California

Lange Medical Books/McGraw-Hill Medical Publishing Division

New York Chicago San Francisco Lisbon London Madrid Mexico City Milan New Delhi San Juan Seoul Singapore Sydney Toronto

Current Essentials of Critical Care

Copyright © 2005 by The McGraw-Hill Companies, Inc. All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher.

123456789 DOC/DOC 010987654

ISBN 0-07-143656-1

ISSN 1550-0705

NOTICE

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

This book was set in Times Roman by Matrix.

The editors were Jack Farrell, Shelley Reinhardt, Harriet Lebowitz, and Penny Linskey.

The production supervisor was Catherine H. Saggese.

The cover designer was Elizabeth Pisacreta.

The index was prepared by Patricia Perrier.

RR Donnelley was the printer and binder.

This book is printed on acid-free paper.

INTERNATIONAL EDITION ISBN: 0-07-111475-0

Copyright © 2005. Exclusive rights by the McGraw-Hill Companies, Inc., for manufacture and export. This book cannot be re-exported from the country to which it is consigned by McGraw-Hill. The International Edition is not available in North America.

Contents

Prei	ace	. XI
1.	Monitoring & Support Anxiety and Sedation	3
	Arterial Pressure Monitoring	
	Central Venous Pressure Monitoring	
	Deep Venous Thrombosis, Prevention in Medical Patients	6
	Deep Venous Thrombosis, Prevention in Surgical Patients Delirium	8
	Depression	
	End-Tidal Pco ₂ Monitoring	
	Geriatric Patient Considerations	
	Hyperglycemia Management in the ICU	12
	Intracranial Pressure Monitoring	13
	Nutrition, Enteral	
	Nutrition, Parenteral	
	Nutritional Support	16
	Obesity, Severe	
	Pain	
	Pulmonary Artery Catheter	
	Pulse Oximetry	20
	Upper GI Bleeding, Prevention	21
2.	ICU Supportive Care for Specific Medical Problems	23
	Burn Patients	25
	Chronic Renal Failure Patients	
	Pregnant Patients	27
	Solid Organ Transplant Recipients	28
3.	Ethical Issues	29
•	Brain Death	
	Do-Not-Resuscitate Orders (DNR)	
	Medical Ethics	
	Medicolegal Principles	
	Withholding & Withdrawing Care	35
4	Bleeding & Transfusions	37
••	Bleeding in the Critically III Patient	39
	Coagulopathy, Acquired	
	Coagulopathy, Inherited	41
	Heparin-Induced Thrombocytopenia (HIT)	42

	Qualitative Platelet Dysfunction	44
	Thrombocytopenia	45
	Transfusion of Red Blood Cells	46
	Transfusion Reactions	47
	Warfarin Overdose	
	Warfarin Skin Necrosis	49
_		
5.	Fluids, Electrolytes, & Acid-Base	
	Hypercalcemia	53
	Hypocalcemia	54
	Hyperkalemia	
	Hypokalemia	56
	Hypermagnesemia	57
	Hypomagnesemia	58
	Hypernatremia	59
	Hyponatremia	
	Hyperphosphatemia	
	Hypophosphatemia	62
	Hypervolemia	63
	Hypovolemia	64
	Metabolic Acidosis	
	Metabolic Alkalosis	66
	Mixed Acid-Base Disorders	67
	Respiratory Acidosis	68
	Respiratory Alkalosis	69
6	Chack	71
6.	Shock Apaphylactic Shock	
6.	Anaphylactic Shock	73
6.	Anaphylactic ShockCardiac Compressive shock	73 74
6.	Anaphylactic Shock	73 74 75
6.	Anaphylactic Shock	73 74 75 76
6.	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock	73 74 75 76 77
6.	Anaphylactic Shock	73 74 75 76 77
	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock	73 74 75 76 77 78
	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease	73 74 75 76 77 78
	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia.	73 74 75 76 77 78 79 81
	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia. Acute Inhalation Injury	73 74 75 76 77 78 79 81 82
	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia. Acute Inhalation Injury Anaphylaxis	73 74 75 76 77 78 79 81 82 83
	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia. Acute Inhalation Injury Anaphylaxis Angioedema	73 74 75 76 77 78 81 82 83 84
	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia. Acute Inhalation Injury Anaphylaxis Angioedema Chest Tube Thoracostomy	73 74 75 76 77 78 81 82 83 84 85
	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia. Acute Inhalation Injury. Anaphylaxis Angioedema Chest Tube Thoracostomy Obesity-Hypoventilation Syndrome.	73 74 75 76 77 78 81 82 83 84 85 86
	Anaphylactic Shock	73 74 75 76 77 78 81 82 83 84 85 86 87
	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia. Acute Inhalation Injury. Anaphylaxis. Angioedema Chest Tube Thoracostomy Obesity-Hypoventilation Syndrome. Obstructive Sleep Apnea Syndrome. Pleural Effusions in the ICU	73 74 75 76 77 78 81 82 83 84 85 86 87 88
	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia. Acute Inhalation Injury. Anaphylaxis. Angioedema Chest Tube Thoracostomy Obesity-Hypoventilation Syndrome. Obstructive Sleep Apnea Syndrome. Pleural Effusions in the ICU Pneumothorax.	73 74 75 76 77 78 81 82 83 84 85 86 87 88 88
7.	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia Acute Inhalation Injury Anaphylaxis Angioedema Chest Tube Thoracostomy Obesity-Hypoventilation Syndrome Obstructive Sleep Apnea Syndrome Pleural Effusions in the ICU Pneumothorax Pulmonary Thromboembolism	73 74 75 76 77 78 81 82 83 84 85 86 87 88 90
7.	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia Acute Inhalation Injury Anaphylaxis Angioedema Chest Tube Thoracostomy Obesity-Hypoventilation Syndrome Obstructive Sleep Apnea Syndrome Pleural Effusions in the ICU Pneumothorax Pulmonary Thromboembolism. Respiratory Failure	73 74 75 76 77 78 81 82 83 84 85 86 87 88 90 91
7.	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia. Acute Inhalation Injury Anaphylaxis Angioedema Chest Tube Thoracostomy Obesity-Hypoventilation Syndrome Obstructive Sleep Apnea Syndrome Pleural Effusions in the ICU Pneumothorax Pulmonary Thromboembolism. Respiratory Failure Acute Respiratory Distress Syndrome (ARDS)	73 74 75 76 77 78 81 82 83 84 85 86 87 88 90 91
7.	Anaphylactic Shock Cardiac Compressive shock Cardiogenic Shock Hypovolemic Shock Neurogenic Shock Septic Shock Pulmonary Disease Acute Chest Syndrome in Sickle Cell Anemia Acute Inhalation Injury Anaphylaxis Angioedema Chest Tube Thoracostomy Obesity-Hypoventilation Syndrome Obstructive Sleep Apnea Syndrome Pleural Effusions in the ICU Pneumothorax Pulmonary Thromboembolism. Respiratory Failure	73 74 75 76 77 78 81 82 83 84 85 86 87 88 90 91 93

	Life-Threatening Hemoptysis	
	Mechanical Ventilation	97
	Mechanical Ventilation in ARDS	98
	Mechanical Ventilation in Neuromuscular Disorders	
	Mechanical Ventilation in Status Asthmaticus	. 100
	Mechanical Ventilation, Complications of	. 101
	Mechanical Ventilation, Failure to Wean from	. 102
	Noninvasive Positive Pressure Ventilation (NIPPV)	
	Positive End-Expiratory Pressure (PEEP)	. 104
	Respiratory Failure from Chronic Obstructive Lung Disease	. 105
	Respiratory Failure from Neuromuscular Disorders	. 106
	Respiratory Failure from Thoracic Cage Disorders	. 107
	Respiratory Failure: Arterial Hypercapnia	. 108
	Respiratory Failure: Hypoxemia	
	Status Asthmaticus	. 110
	Ventilator-Associated Pneumonia	. 111
0	Cardiology	112
J. 1	Angina Pectoris	
	Aortic Dissection, Acute	
	Aortic Valvular Heart Disease	
	Arterial Insufficiency, Acute	110
	Atrial Fibrillation	110
	Cardiac Tamponade	120
	Congestive Heart Failure	121
	Heart Block	121
	Hypertensive Crisis & Malignant Hypertension	
	Mesenteric Ischemia and Infarction, Acute	120
	Mitral Valvular Heart Disease	125
	Myocardial Infarction (AMI), Acute	126
	Supraventricular Tachycardia	120
	Syncope	
	Unstable Angina (USA) & Non-ST-Segment Elevation	. 120
	Myocardial Infarction (NSTEMI)	120
	Ventricular Tachyarrhythmias	. 123 120
	Ventricular racinyarinyuninas	. 130
10.	Infectious Disease	. 131
	Bacterial Meningitis	
	Botulism	. 134
	Central Nervous System (CNS) Infections in	
	HIV-Infected Patients	. 135
	Clostridium difficile-Associated Diarrhea	. 136
	Community-Acquired Pneumonia	
	Encephalitis, Brain Abscess, Spinal Epidural Abscess	. 138
	Fever in the ICU	
	Hematogenously Disseminated Candidiasis	140
	Infections in Immunocompromised Hosts	. 141
	Infective Endocarditis	142
	Intra-ahdominal Infection	

	Intravenous Catheter-Associated Infection	144
	Mycobacterium tuberculosis	145
	Necrotizing Soft Tissue Infection	146
	Neutropenic Fever	
	Nonbacterial Meningitis	148
	Nosocomial Pneumonia	
	Peritonitis	
	Pneumocystis jiroveci Pneumonia (PCP)	151
	Prevention of Nosocomial Infection	152
	Pulmonary Infections in HIV-Infected Patients	153
	Sepsis	154
	Surgical Site Infection (SSI)	155
	Tetanus	156
	Toxic Shock Syndrome	157
	Urosepsis	158
11.	Gastrointestinal Disease	
	Acalculous Cholecystitis	161
	Adynamic (Paralytic) Ileus	
	Ascites	163
	Boerhaave Syndrome	164
	Cholangitis, Acute	
	Diarrhea	166
	Gastric or Esophageal Variceal Bleeding	167
	Gastritis	
	Hepatic Failure, Acute	
	Large-Bowel Obstruction	170
	Lower Gastrointestinal Bleeding, Acute	171
	Pancreatic Insufficiency	172
	Pancreatitis	173
	Peptic Ulcer Disease (PUD)	
	Small-Bowel Obstruction	175
	Upper Gastrointestinal Bleeding	176
12.	Endocrine Problems	
	Adrenal Insufficiency	1/9
	Cushing Syndrome	
	Diabetic Ketoacidosis	
	Hyperosmolar Non-ketotic Diabetic Coma	182
	Hypoglycemia	183
	Myxedema Coma	184
	Sick Euthyroid Syndrome	185
	Thyroid Storm	186
40	Neurology	407
13.	Neurology	18/
	Altered Mental Status in the ICU	
	Critical Illness Myopathy	190
	Critical Illness Polyneuropathy	
	Guillaill-daile Sylluiuille	132

	Head Injuries Increased Intracranial Pressure Muscular Dystrophy Myasthenia Gravis Neuroleptic Malignant Syndrome Seizures Spinal Cord Compression Spinal Cord Injury Stroke Stupor & Coma Subarachnoid Hemorrhage (SAH)	194 195 196 197 198 199 200 201 202
14.	Renal Disorders Acute Tubular Necrosis (ATN) Glomerulonephritis, Acute Hepatorenal Syndrome. Interstitial Nephritis, Acute. Pigment Nephropathy: Rhabdomyolysis & Hemolysis. Pulmonary-Renal Syndromes Renal Failure, Acute. Renal Failure, Drug Clearance in. Renal Failure, Prevention Renal Replacement Therapy (Hemodialysis)	207 208 209 210 211 212 213 214 215
15.	Rheumatology Catastrophic Antiphospholipid Syndrome Scleroderma/Progressive Systemic Sclerosis Systemic Lupus Erythematosus (SLE) Vasculitis	219 220 221
16.	Toxicology. Acetaminophen Overdose Alcohol Withdrawal Benzodiazepine Withdrawal Beta-Adrenergic Blocker Overdose Calcium Channel Blocker Overdose Cocaine Digitalis Toxicity Iron Overdose Ketamine & Phencyclidine (PCP) Lithium Methanol, Ethylene Glycol, & Isopropanol Opioid Overdose. Opioid Withdrawal Organophosphate Poisoning Salicylate Poisoning Sedative-Hypnotic Overdose Sympathomimetic Overdose Theophylline Overdose	225 226 227 228 229 230 231 232 233 234 235 236 237 240 241

	Tricyclic Antidepressant (TCA) Overdose	
17.	Environmental Injuries Carbon Monoxide (CO) Poisoning Electrical Shock & Lightning Injury Frostbite Heat Stroke Hypothermia Mushroom Poisoning Near Drowning Radiation Injury Snakebite Spider & Scorpion Bites	247 248 249 250 251 252 253 254 255
18.	Dermatology Candidiasis (Moniliasis) Contact Dermatitis Disseminated Intravascular Coagulation (DIC) & Purpura Fulminans Erythema Multiforme & Stevens-Johnson Syndrome Exfoliative Erythroderma Generalized Pustular Psoriasis Graft-Versus-Host Disease (GVHD) Meningococcemia Miliaria (Heat Rash) Morbilliform, Urticarial, & Bullous Drug Reactions Pemphigus Vulgaris Phenytoin Hypersensitivity Syndrome Rocky Mountain Spotted Fever Rubeola (Measles) Toxic Epidermal Necrolysis (TEN) Toxic Shock Syndrome Varicella-Zoster Virus (VZV)	259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274
19.	Oncology/Oncologic Emergencies Leukemia, Acute Spinal Cord Compression Superior Vena Cava (SVC) Syndrome Tumor Lysis Syndrome	279 280 281
20 .	Pregnancy Acute Fatty Liver of Pregnancy Amniotic Fluid Embolism Asthma in Pregnancy Preeclampsia and Eclampsia Pulmonary Edema in Pregnancy Pyelonephritis in Pregnancy Septic Abortion	285 286 287 288 289 290

Contributors

Chan-Chou Chuang, MD

Attending Physician, Division of Respiratory and Critical Care Physiology and Medicine, Department of Medicine, Harbor-UCLA Medical Center

Torrance, California

Brian Korotzer, MD

Assistant Clinical Professor of Medicine, David Geffen School of Medicine at UCLA, Pulmonary and Critical Care Medicine, Kaiser Permanente Medical Center

Bellflower, California

Mark T. Munekata, MD, MPH

Associate Clinical Professor of Medicine, David Geffen School of Medicine at UCLA, Division of General Internal Medicine, Department of Medicine, Harbor-UCLA Medical Center Torrance, California

Gunter K. Rieg, MD

Assistant Professor of Medicine, David Geffen School of Medicine at UCLA, Division of HIV Medicine, Department of Medicine, Harbor-UCLA Medical Center

Torrance, California

Darryl Y. Sue, MD

Professor of Clinical Medicine, David Geffen School of Medicine at UCLA, Division of Respiratory and Critical Care Physiology and Medicine, Department of Medicine, Harbor-UCLA Medical Center

Torrance, California

Janine R.E. Vintch, MD

Assistant Clinical Professor of Medicine, David Geffen School of Medicine at UCLA, Division of General Internal Medicine and Division of Respiratory and Critical Care Physiology and Medicine, Department of Medicine, Harbor-UCLA Medical Center

Torrance, California

Mallory D. Witt, MD

Associate Professor of Clinical Medicine, David Geffen School of Medicine at UCLA, Division of HIV Medicine, Department of Medicine, Harbor-UCLA Medical Center Torrance, California

Preface

Our goal in this book is to provide the reader with only the most crucial and important points for the variety of disorders likely to be encountered in the adult intensive care unit, including the key first steps in diagnosis, confirmation of diagnosis, and initial management strategies. In preparing the manuscript, we were struck by several insights. First was the importance of general supportive care of the patient regardless of the primary diagnosis leading to admission to the ICU. Paying attention to prevention of aspiration pneumonia, reduction of risk for deep venous thrombosis, improving glycemic control, providing nutritional support, and reducing upper gastrointestinal bleeding should be encouraged in all eligible patients. Second, we found that understanding the critically ill patient requires the knowledge and experience of sound training. There can be no substitute for a strong background in basic science (physiology, pharmacology, microbiology, and pathology) combined with training in clinical medicine and skills in the critical analysis of the literature. Finally, we were challenged tremendously in making the decisions about what to include and what to exclude in a book such as this. Thus, while this book gives the reader only the key points, these points focus on what to look for and what to do first in these critically ill patients.

Much of what is done in the ICU has evolved from what seems to be good common sense practice, and only recently has there been evidence-based data supporting how we diagnose and manage critically ill patients. Of course, there remains much to be studied and analyzed, and this reflects how difficult it is to perform valid clinical studies in these unstable and very sick patients. Nevertheless, there is now evidence on adjusting tidal volume in ARDS, controlling glucose in postoperative patients, positioning patients to reduce the risk of nosocomial pneumonia, and preventing complications in status asthmaticus. Those who take care of critically ill patients should look forward to more and better investigations that will help us improve care and outcomes.

Following in the footsteps of *Essentials of Diagnosis and Treatment*, we have tried to include a Clinical Pearl for each topic and to provide one up-to-date reference to guide further reading. Providing these was quite a challenge and we look forward to augmenting and updating both of these features.

We want to thank our colleagues at McGraw-Hill, Jack Farrell, for considering us for this project, and Shelley Reinhardt, for help and encouragement. We are grateful to our contributors for enthusiastically taking on the challenge of this book. Finally, we also would like to thank our families for their support and patience.


Darryl Y. Sue, MD Janine R.E. Vintch, MD

Torrance, California

1

Monitoring & Support

Anxiety & Sedation	. 3
Arterial Pressure Monitoring	. 4
Central Venous Pressure Monitoring	. 5
Deep Venous Thrombosis, Prevention in Medical Patients	. 6
Deep Venous Thrombosis, Prevention in Surgical Patients	. 7
Delirium	. 8
Depression	. 9
End-Tidal Pco ₂ Monitoring	10
Geriatric Patient Considerations	11
Hyperglycemia, Management in the ICU	12
ntracranial Pressure Monitoring	13
Nutrition, Enteral	14
Nutrition, Parenteral	15
Nutritional Support	16
Dbesity, Severe	17
Pain	18
Pulmonary Artery Catheter	19
Pulse Oximetry	20
Inner GI Bleeding Prevention	21



Anxiety and Sedation

Essentials of Diagnosis

- · Distress, often expressed as fear, agitation
- · Tachycardia, hypertension, diaphoresis
- May manifest as pain, restlessness, discoordination with mechanical ventilation
- Frequent complaint of patients, sometimes misinterpreted
- Contributing factors include stressful ICU environment, excessive noise, sleep deprivation, painful procedures, mechanical ventilation, medications, anticipation of surgery, fear
- Mechanical ventilation may contribute, especially low tidal volume, permissive hypercapnia

■ Differential Diagnosis

- · Hypoxemia
- · Alcohol or drug withdrawal
- · Hyperthyroidism
- · Beta-agonist excess
- · Infection, sepsis
- Psychiatric illness, including severe situational reaction to ICU environment

Treatment

- Exclude medical conditions, including pain, especially if patient shows delirium
- Explain anticipated events, procedures, current condition to patient; provide orientation to date, time; include family members in discussions, encourage visitation
- Anticipate and control pain; avoid sleep interruptions
- If sedation needed, objective scales for measuring effects of sedation useful; target sedation: follows verbal commands
- For most patients, lorazepam recommended for long-term use; midazolam, propofol useful for short-term sedation

Pearl

Daily interruption of sedation reduces duration of mechanical ventilation, length of ICU stay, and number of diagnostic studies for unexplained altered mental status.

Reference

Kress JP et al: Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000;34:1471. [PMID: 10816184]

Arterial Pressure Monitoring

Essential Concepts

- Allows continuous, accurate, repeated measurement of blood pressure when needed (hypotension, hypertension, highly vasoactive drugs)
- · Helpful for repeated sampling of arterial blood for blood gases
- Complications: bleeding, infection, thrombosis, "downstream" arterial emboli with ischemia
- Contraindications: increased risk of bleeding (coagulopathy, thrombocytopenia), local infection, hypercoagulable states, anticipated use of thrombolytic agents

Essentials of Management

- Use 16- to 20-g catheter inserted into radial or dorsalis pedis artery
- Avoid brachial artery (high risk for serious complications) and femoral artery (high risk for bleeding)
- Attach to continuous pressure infuser with low-dose continuous heparin infusion
- Measure pressure with transducer attached using nondistensible tubing
- Remove air bubbles to avoid damped arterial waveform (falsely low systolic and high diastolic pressure)
- Check insertion site at least daily for bleeding, infection, adequate distal pulses
- Remove catheter if local complications or within 3–4 days
- Relative contraindications: coagulopathy or thrombocytopenia, bacteremia, anticipated use of thrombolytic agents
- Complications during placement: bleeding, arterial damage
- Complications during use: infection, *in situ* thrombosis, distal arterial emboli with limb ischemia

Pearl

Arterial catheter blood pressure may be lower or higher than measured by cuff, depending on vascular disease, age, and stroke volume.

Reference

Martin C et al: Long-term arterial cannulation in ICU patients using the radial artery or dorsalis pedis artery. Chest 2001;119:901. [PMID: 11243975]

Central Venous Pressure Monitoring

Essential Concepts

- Pressure in central vein measured by catheter placed near entrance to right atrium
- · Reflects filling pressure or preload to right ventricle
- Normal central venous pressure (CVP) -4 to 10 mm Hg
- Lower in patients with low intravascular volume
- Higher CVP may mean volume overload, right ventricular failure (chronic: cor pulmonale; acute: right ventricular infarction), especially if CVP > pulmonary artery wedge pressure, or pericardial effusion/cardiac tamponade
- Use CVP to estimate volume status; but inaccurate in pulmonary hypertension, respiratory failure, right heart failure

■ Essentials of Management

- Insert central venous catheter via internal jugular or subclavian vein using sterile technique
- Measure CVP using water manometer (1.36 cm H₂O = 1 mm Hg) or strain gauge pressure transducer (electronic measurement) at end-expiration
- Volume depletion suggested by CVP < 5 mm Hg or especially by initial increase followed by rapid fall in CVP after intravenous volume challenge (250–500 mL)
- For adequate volume challenge, use target CVP 8-12 mm Hg
- Complications: bleeding, pneumothorax, catheter infection, thrombosis, pulmonary thromboembolism, air embolism (rarely)

Pearl

Measure O_2 saturation from blood drawn from central venous catheter. Low values may indicate inadequate systemic perfusion, similar to "mixed venous blood" drawn from pulmonary artery catheter.

Reference

McGee DC et al: Preventing complications of central venous catheterization. N Engl J Med 2003;348:1123. [PMID: 12646670]

Deep Venous Thrombosis, Prevention in Medical Patients

■ Essential Concepts

- High deep venous thrombosis (DVT) and pulmonary embolism (PE) risk in surgical or medical patients (15–50%); with myocardial infarction (24%), strokes
- Risk increased by stasis, immobilization, release of thromboplastins, hypercoagulable state (transient or chronic), infection, local venous trauma
- Preventive therapy indicated for all patients in ICU, unless contraindicated
- Intensity of treatment depends on underlying disease or procedure, risk of DVT, and likelihood of early ambulation

Essentials of Management

- LDUH = subcutaneous low-dose heparin, 5000–7000 units, 2–3 times daily; LMWH = subcutaneous low molecular weight heparin; ES = elastic stockings; SCD = sequential compression device
- Acute myocardial infarction: LDUH or IV heparin (aPTT 46-70 s)
- Ischemic stroke with impaired mobility: LDUH or LMWH; if anticoagulation contraindicated, ES or SCD
- Medical illness without contraindication: LDUH or LMWH plus ES or SCD; if contraindication, ES plus SCD

Pearl

Even patients with hemorrhagic strokes should be considered for DVT prophylaxis, but they should be closely observed to determine if the stroke is extending.

Reference

Geerts WH et al: Prevention of venous thromboembolism. Chest 2001;119(1 Suppl):132S. [PMID: 11157647]

Deep Venous Thromobosis, Prevention in Surgical Patients

Essential Concepts

• Highest deep venous thrombosis (DVT) and pulmonary embolism (PE) risk after hip fracture, total hip or knee replacement (40–70%); postoperative surgery patients (25%)

Essentials of Management

- LDUH = subcutaneous low-dose heparin, 5000-7000 units, 2-3 times daily; LMWH = subcutaneous low molecular weight heparin; ES = elastic stockings; SCD = sequential compression device; ADW = adjusted-dose warfarin
- General surgery, low risk (age < 40; minor procedure): early ambulation; moderate risk (minor procedure with risk factors; minor surgery age 40–60, no risks; major surgery age < 40, no risks): LDUH, LMWH, ES, or SCD
- General surgery: high risk with bleeding likely: ES or SCD; very high risk for DVT: LDUH or LMWH plus ES or SCD
- Gynecologic surgery, major, benign: LDUH twice/daily; or LMWH or SCD before and after surgery; extensive, malignant: LDUH three times/day plus ES or SCD; or higher dose LMWH
- Urologic surgery, brief, minor: early ambulation; major open: LMWH, LDUH, ES, or SCD; highest-risk: LDUH or LMWH plus ES with or without SCD
- Total hip replacement: LMWH (12 hours before or 12 to 24 hours after; or half usual high-risk dose 4 to 6 hours after, usual high-risk dose following day); or ADW therapy (INR 2.5), started pre- or immediately postoperatively
- Total knee replacement: LMWH or ADW (INR 2.5); alternative, optimal use of SCD
- Hip-fracture surgery: LMWH or ADW (INR 2.5)
- Intracranial neurosurgery: SCD with or without ES; LDUH or postoperative LMWH
- Head trauma, thrombosis risk: LMWH as soon as safe; if delayed or contraindicated, ES and SCD; if suboptimal prophylaxis, look for DVT; IVC filter if found
- Acute spinal cord injury: LMWH plus ES and SCD; if contraindicated, ES and SCD

Pearl

Epidural or spinal anesthesia in anticoagulated patients may cause paraspinous hematomas, which can lead to long-term neurological deficits.

Reference

Geerts WH et al: Prevention of venous thromboembolism. Chest 2001;119(1 Suppl):132S. [PMID: 11157647]

Delirium

Essentials of Diagnosis

- Agitation, altered sensorium, disorientation, waxing and waning of level of consciousness, incoherent speech
- Common problem, especially with advanced age, neuropsychiatric disorders, alcoholism, drug overdose, use of multiple medications, anemia; less common: chemical exposure, hepatic encephalopathy, hypoxemia, cerebral hypoperfusion, hyponatremia, hypercalcemia, renal failure
- Medications (neuroleptics, corticosteroids, lidocaine, cimetidine, antihistamines, benzodiazepines); withdrawal from alcohol or sedative-hypnotic drugs
- ICU environment contributes to sleep deprivation, disorientation, stress, but is almost never the only cause
- Delirium prolongs ICU stay, contributes to morbidity and mortality

Differential Diagnosis

 Anxiety, depression, psychosis; treatment with neuroleptic agents, neuroleptic malignant syndrome

■ Treatment

- Assess for hypoxemia, hypotension, fluid and electrolyte problems, sepsis, meningitis, stroke, intracranial hemorrhage, withdrawal from alcohol or sedative-hypnotic drugs
- Review medications, blood count, serum electrolytes, arterial blood gases
- Protect from falls, disconnection of life support (endotracheal tube, intravenous catheters); orient to location and time
- Consider benzodiazepines (lorazepam), haloperidol, or combination, if needed
- Complications of treatment: oversedation, respiratory depression, hypotension; for haloperidol-prolonged QT interval, dystonic reactions, rarely neuroleptic malignant syndrome

Pearl

Delirium from withdrawal from alcohol or benzodiazepines may begin as late as 5–7 days after stopping consumption.

Reference

McNicoll L et al: Delirium in the intensive care unit: occurrence and clinical course in older patients. J Am Geriatr Soc 2003;5:591. [PMID: 12752832]

Depression

Essentials of Diagnosis

- Complaints of unhappiness, worthlessness, hopelessness, lack of planning for future, guilt; but anticipate depressed mood in all ICU patients regardless of symptoms
- Decreased interest in condition, treatment plans, physical and mental activities; may exhibit lack of cooperation, refusal to agree to treatment or discuss with family
- · Suicidal ideation, lack of self-esteem
- 10–40% of seriously ill, hospitalized patients have depression; but only 25–33% are diagnosed
- · May be related to underlying major psychiatric illness

■ Differential Diagnosis

- · Medications: beta-blockers, sedatives, antihypertensives
- · Endocrinopathies: hypothyroidism, hyperadrenalism
- · Hyponatremia, hypoxia
- · Major depression
- · Sleep deprivation
- · Alcohol or substance abuse or withdrawal

Treatment

- Maximize interactions with family, visitors, nursing and physician staff; include patients in decision-making, daily activities; provide realistic support and prognostic information
- · Improve sleep quantity and quality
- Anxiolytic agents may be helpful
- Consider psychiatric consultation, if severe, or pharmacologic antidepressant therapy planned
- Antidepressant drugs limited by side effects in critically ill patients; selective serotonin reuptake inhibitors (SSRIs) less hazardous than tricyclic antidepressants; start SSRIs at low dose, gradual titration upwards, such as paroxetine 5–10 mg, sertraline 12.5–25 mg, fluoxetine 5 mg; effect may take days

Pearl

A depressed mood in seriously ill hospitalized adults is independently associated with increased mortality, after adjustment for disease severity and functional status.

Reference

Roach MJ et al: Depressed mood and survival in seriously ill hospitalized adults. The SUPPORT Investigators. Arch Intern Med 1998;158:397. [PMID: 9487237]

End-Tidal Pco₂ Monitoring

Essential Concepts

- In spontaneously breathing normal patients, end-tidal PCO₂ (PETCO₂) approximates arterial PCO₂ (PaCO₂)
- Difference between Petco₂ and Paco₂ widens in patients with lung disease (pneumonia, asthma, COPD, ARDS, pulmonary embolism)
- Increased PaCO2—PETCO2 difference associated with high deadspace/tidal volume ratio (VD/VT)
- Unpredictable Paco₂ Petco₂ differences with irregular breathing, tachypnea, prolonged exhalation
- Petco₂ cannot be substituted for Paco₂ when making ventilator changes or determining hyper- or hypoventilation
- Capnography looks at expiratory CO₂ concentration continuously; may be useful for estimating endotracheal tube cuff leak

Essentials of Management

- Measure arterial Pco₂ to determine Paco₂ Petco₂ difference
- Normal $Paco_2 Petco_2 = -2$ to 0 mm Hg
- Use Petco₂ to confirm endotracheal tube placement
- High PaCO₂ PETCO₂ difference predicts high VD/VT, potential difficulty with weaning
- If PacO₂ PetcO₂ difference remains constant (only rarely), changes in PetcO₂ may be used for adjusting minute ventilation.
- Increased Paco₂ Petco₂ difference may be sign of pulmonary embolism
- Attach CO₂ monitoring probe to end of endotracheal or tracheostomy tube according to directions

Pearl

PETCO₂ reflects perfusion of the lungs, which is related to cardiac output, much more than the arterial PCO₂, which reflects ventilation.

Reference

Anderson CT et al: Carbon dioxide kinetics and capnography during critical care. Crit Care 2000; 4:207 [PMID: 11094503]

Geriatric Patient Considerations

Essential Concepts

- Decline in maximum functional capacity of all organ systems with aging; normally functioning elderly have less reserve
- Normal arterial PaO₂, creatinine clearance, VC, FEV₁ decline with age
- · Drug metabolism and clearance reduced in older adults
- Delirium common in older patients in ICU, especially with cognitive impairment, fractures, neuroleptic drugs, infection, opioids
- Manifestations of disease more subtle, unusual; may be lack of fever with infection
- Have lower proportion of total body water (45–50%); lower lean body mass/muscle mass
- More prone to DVT, decubitus ulcers, malnutrition, insufficient fluid intake, falls, fractures, renal insufficiency, inadvertent drug interactions or overdosage, delirium, muscle atrophy
- Outcome of severe illness worse in elderly; higher mortality from sepsis, ARDS, acute renal failure, respiratory failure

Essentials of Management

- Adjust medications for expected decreases in renal, liver function; extra caution with digoxin, beta-blockers, ACE inhibitors, nephrotoxic antibiotics, radiographic contrast
- Expect more subtle and milder findings, even in severe illness
- Limit use of sedatives, opiates, antihistamines, neuroleptic drugs unless necessary
- Avoid sleep disruption, orient patient frequently, provide reassurance, minimal use of restraints
- · Encourage visitors, family participation in care

Pearl

Elderly patients often are prescribed many different drugs ("polypharmacy"); the risk of an adverse drug reaction increases exponentially when four or more drugs are being given.

Reference

Bo M et al: Predictive factors of in-hospital mortality in older patients admitted to a medical intensive care unit. J Am Geriatr Soc 2003;51:529. [PMID: 12657074]

Hyperglycemia, Management in the ICU

Essential Concepts

- · Elevated blood glucose
- Hyperglycemia affects fluid balance, possibly alters white blood cell function, impairs complement activity
- Increases mortality following stroke and myocardial infarction
- Demonstrated benefits of tight glycemic control: decreased wound infection following coronary artery bypass surgery; decreased mortality in diabetics following myocardial infarction; decreased mortality, bacteremia, critical illness polyneuropathy in patients admitted to surgical ICU
- Differential diagnosis: diabetes mellitus, laboratory error, stress, steroid induced diabetes

■ Essentials of Management

- Initiate intravenous infusion of insulin: titrate to goal blood glucose of 80 to 120 mg/dL; use of insulin infusion protocol helpful
- Consider switching to subcutaneous injections of long-acting insulin once at stable regimen
- · Monitor for and attempt to avoid hypoglycemia

Pearl

Intensive insulin therapy to treat hyperglycemia in critically ill patients, which may be due to illness related insulin resistance and not to previously known diabetes, appears to improve morbidity and mortality.

Reference

Montori VM et al: Hyperglycemia in acutely ill patients. JAMA 2002;288:2167. [PMID: 12413377]

Intracranial Pressure Monitoring

Essential Concepts

- Intracranial compartment in adults has fixed volume due to rigid skull; contains brain, cerebrospinal fluid (CSF), cerebral blood volume; increase in size of any one of these can lead to elevation of intracranial pressure (ICP)
- ICP measurements can estimate cerebral perfusion pressure (CPP): CPP = MAP - ICP where MAP is mean arterial pressure; CPP at or above 70 mm Hg by increasing MAP or decreasing ICP may improve survival
- ICP monitoring techniques used in management of severe head injury, subarachnoid hemorrhage, Reye syndrome, hepatic encephalopathy, other disorders causing intracranial hypertension
- Controlling ICP in < 20 mm Hg range associated with improved outcome
- Increased morbidity and mortality associated with ICP > 20 mm
 Hg that persists for more than 10 to 15 minutes, particularly in patients with severe closed head injuries

■ Essentials of Management

- Several monitoring systems available: catheters, hollow screw or bolt, fiberoptic transducer tipped catheters
- Devices can be placed into several locations: lateral ventricle, intraparenchymal, subdural or subarachnoid space, epidural space
- Intraventricular catheters remain gold standard in most cases with added benefit of CSF drainage to help control elevated pressures
- Complications include hemorrhage, hematoma formation, infection, cortical damage

Pearl

Misinterpretation of the data obtained from an ICP monitoring system may result in improper choice of therapeutic intervention.

Reference

Doyle DJ et al: Analysis of intracranial pressure. J Clin Monit 1992;8:81. [PMID: 1538258]

Nutrition, Enteral

Essential Concepts

- Enteral feeding preferred over parenteral; better outcome, fewer infections, maintenance of GI function
- Enteral formulas supply calories and protein, vitamins, trace elements
- Most contain protein hydrolysates, simple and complex carbohydrates, medium chain triglycerides; others elemental (amino acids, sugars)
- Enteral nutrition formulary includes standard formula (1 cal/mL); formulas for fluid restriction, higher or lower protein, hepatic encephalopathy (high branch chain amino acids)
- Use nasogastric tubes designed for enteral feeding or gastrostomy or jejunostomy tubes

■ Essentials of Management

- Start enteral feeding support in all patients who have no contraindication; no indication for parenteral feeding
- · Determine nutritional status and requirements
- Select enteral feeding formula based on underlying diseases, patient's volume status, protein and calorie requirements
- Choose starting and goal target rate (generally 60–90 mL/h for continuous feeding); use enteral feeding pump
- Place and check position of nasogastric or gastrostomy tube; elevate head of bed 30–45 degrees during feeding to avoid aspiration pneumonia
- In cases of malnutrition, hypoalbuminemia, diarrhea or prolonged disuse of GI tract, begin feeding at low rate and advance over 24 hours to goal.
- Consider metoclopramide or erythromycin (promotility agents) if high gastric residual volume
- Complications: high gastric residual volume (check every 2–4 hours), diarrhea, abdominal distension, aspiration pneumonia

Pearl

If diarrhea persists after slowing feeding rate and diluting formula with sterile water, consider antibiotic-induced diarrhea or C difficile infection.

Reference

ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002;26(1 Suppl):1SA. [PMID: 11841046]

Nutrition, Parenteral

Essential Concepts

- Enteral feeding superior to parenteral nutrition; parenteral indicated only if patient unable to be fed enterally
- Supplies intravenous calories and protein, vitamins, trace elements from amino acids, high concentrations of dextrose, and lipid emulsions (as mixture or separately)
- Hospitals have standard formula (20–25% dextrose plus 3–5% amino acids); formulas for fluid restriction, high or restricted protein, hepatic encephalopathy (high branch chain/low aromatic amino acids)
- Total parenteral nutrition (TPN) meets caloric and protein needs of critically ill; administered through a central vein
- Peripheral parenteral nutrition (PPN): limited calories and protein through peripheral veins; will generally not meet needs of critically ill
- Specific indications: short bowel syndrome, high output GI fistula, hyperemesis gravidarum, nonfunctional gut with severe hypoalbuminemia

Essentials of Management

- · Determine nutritional status and requirements
- Select parenteral nutrition formula based on underlying disease, fluid volume status, protein and calorie requirement
- Add insulin (1–5 units/h) to maintain blood glucose < 110 mg/100 mL; adjust electrolytes (Na, K, Cl, acetate); check electrolytes daily; glucose every 4 hours initially, then daily; if giving lipid emulsions, check serum triglycerides daily at start
- Complications: fluid overload, hyperglycemia, hypokalemia, hypophosphatemia, sepsis, hyperlipidemia, insertion site infection, candidemia, abnormal liver function tests, metabolic acidosis

Pearl

Hepatic steatosis, intrahepatic cholestasis and biliary sludge associated with total parenteral nutrition can be prevented, if possible, by concomitant enteral feeding.

Reference

ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002;26(1 Suppl):1SA. [PMID: 11841046]

Nutritional Support

Essential Concepts

- Critically ill patients often malnourished beforehand; severe illness associated with increased breakdown of lean body mass (catabolism) due to inflammatory response and high caloric requirements
- Increase catabolic rate highest in burns, head injury, sepsis, postsurgery, trauma
- Nutritional support may minimize loss of body stores of energy and protein; inadequate support increases infection, organ failure, mechanical ventilator dependence, mortality, length of hospitalization

■ Essentials of Management

- Nutritional support for all patients in ICU, but especially after 3–5 days without nutrition
- · Consult dietitian to estimate calorie and protein needs
- Low serum albumin indicates poor nutritional status, correlates with outcome
- For adults, estimate 30–35 kcal/kg ideal body weight plus 1.2–1.5 g protein per kg ideal body weight to start
- Ideal weight (kg): adult men = 50 + 2.7 kg/inch for heights over 60 inches; adult women = 45.5 + 2.3 kg/inch for heights over 60 inches
- Higher calorie needs for febrile or septic patients; higher protein needs for burns, head injury; reduce protein intake with acute renal failure (nondialyzed), hepatic encephalopathy
- Begin support as soon as possible, except with contraindications (lack of access, intolerant of fluids, unable to position properly)
- · Enteral feeding preferred over parenteral nutrition
- Follow serum electrolytes, albumin, prealbumin, urine urea nitrogen

Pearl

The most accurate measurements of nutritional requirements are made using indirect calorimetry (from oxygen uptake) and nitrogen balance (protein), but these are not shown to improve patient outcome.

Reference

ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002;26(1 Suppl):1SA. [PMID: 11841046]

Obesity, Severe

Essential Concepts

- Severe obesity (body mass index [BMI]) > 28) may be associated with increased ICU mortality and complications
- Linked directly to obesity-hypoventilation syndrome (OHS), obstructive sleep apnea (OSA), restrictive lung disease
- Risk factor for malignancy, heart failure, coronary artery disease, hypertension, diabetes mellitus, glucose intolerance, respiratory failure, deep venous thrombosis, pulmonary embolism, nonalcoholic steatohepatitis, decubitus ulcers, hip fractures
- Jeopardizes weaning from mechanical ventilation because of increased breathing work
- Complicates mechanical ventilator settings, drug dosing, nutritional support calculations, fluid and electrolyte replacement
- Total body water as proportion of weight falls in obesity (35–40%) compared to 50–60% in nonobese
- Extremely obese unable to have CT imaging, cardiac catheterization, angiography

■ Essentials of Management

- Calculate most drug dosages for "ideal weight" estimated from height, not actual weight in obese
- Dosage of low molecular weight heparin unreliable in obesity
- Use ideal weight estimated from height for setting tidal volume during mechanical ventilation; eg, 6 mL/kg ideal body weight High peak and plateau airway pressures due to non-compliant chest wall (diaphragm) do not increase risk of barotrauma
- Most obese patients have normal to low lean body mass; nutritional support important to maintain function; estimate calorie, protein, fluid needs from ideal weight

Pearl

To estimate "ideal" weight in kg: adult men = 50 + 2.7 kg/inch over 60 inches tall; adult women = 45.5 + 2.3 kg /inch over 60 inches tall.

Reference

El-Solh A et al: Morbid obesity in the medical ICU. Chest 2000; 120:1989. [PMID: 11742933]

Pain

Essentials of Diagnosis

- Frequent complaint of ICU patients; relief of pain results in better outcomes
- May not be expressed by patient, especially if sedated, delirious, altered level of consciousness; may show restlessness, confusion, agitation
- Tachycardia, hypertension, diaphoresis; may increase oxygen consumption, myocardial oxygen demand
- · Anxiety increases pain response
- Adequate analgesia sometimes avoided for fear of respiratory depression, hypotension, alteration of sensorium, ileus

Differential Diagnosis

- Hypoxemia
- · Drug reactions
- · Anxiety
- Delirium

Treatment

- Anticipate and treat pain from procedures, mechanical ventilation, postsurgery
- Use objective pain scales to evaluate and adjust analgesia; titrate analgesics to desired effect
- · Explain potentially painful procedures in advance
- · Morphine sulfate preferred analgesia for pain in critically ill
- Fentanyl preferred if hemodynamically unstable, histamine release with morphine, morphine allergy
- · Consider patient-controlled analgesia in selected patients
- Anxiolytics, sedation (benzodiazepines) useful adjuncts, not substitutes for adequate analgesia

Pearl

Avoid meperidine in critically ill patients; metabolites cause neuroexcitability and have adverse drug interactions.

Reference

Jacobi J et al: Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002;30:119. [PMID: 11902253]

Pulmonary Artery Catheter

■ Essential Concepts

- Measures pressure in pulmonary artery (PA), central venous pressure (CVP), and pulmonary artery wedge pressure (PAWP) (estimate of left atrial pressure)
- Most measure cardiac output using thermodilution; some with oximeter probe for mixed venous O₂ saturation
- Blood can be sampled from distal tip (mixed venous blood) or from proximal port (central venous blood)
- Calculate cardiac index (CI), systemic vascular resistance (SVR), and pulmonary vascular resistance (PVR)

■ Essentials of Management

- Indications: cardiogenic shock, cardiogenic pulmonary edema, acute myocardial infarction with hemodynamic compromise, cardiac tamponade
- May be helpful in patients with acute hypoxemic respiratory failure, sepsis and septic shock, but value unknown
- Use caution in estimating PAWP with tachycardia, pulmonary hypertension, large intrathoracic pressure swings during respiratory cycle
- · Measure pressures at "end-expiration"
- Inflate balloon only enough to achieve "wedge" position (do not exceed 1.5 mL)
- Optimal PAWP = 18 mm Hg in patient with cardiogenic shock
- Increased pulmonary edema (normal lungs) when PAWP > 25 mm Hg; in noncardiogenic pulmonary edema, PAWP should be < 10 mm Hg, if patient is hemodynamically stable
- Mixed venous Po₂ < 30 mm Hg associated with poor organ oxygenation and lactic acidosis; but > 30 mm Hg is not a reliable sign of adequate oxygenation
- Relative contraindications: coagulopathy, thrombocytopenia, bacteremia, anticipated use of thrombolytic agents
- Complications: bleeding, pneumothorax, arrhythmias, heart block and bradycardia, pulmonary artery, infection

Pearl

In cardiac tamponade, look for equalization of RA and LA pressures by displaying pressure waveforms on same screen at same scale.

Reference

Cruz K, Franklin C: The pulmonary artery catheter: uses and controversies. Crit Care Clin 2001;17:271-91. [PMID: 11450316]

Pulse Oximetry

Essential Concepts

- Finger, ear, or other cutaneous probe measures transmission or reflectance of red and infrared light through tissue
- Pulsatile absorbance ("beat-to-beat") determines percentage of oxyhemoglobin in blood
- Oxyhemoglobin, carboxyhemoglobin, and methemoglobin read as "oxyhemoglobin"
- Pulsatile waveform essential for calculation; low perfusion, hypotension, arterial disease, motion artifacts interfere with measurement
- Correlates well with arterial blood O2 saturation

Essentials of Management

- Use for routine monitoring of patients in ICU and during endoscopy, bronchoscopy, minor surgery, suctioning, sleep apnea episodes, bronchodilator therapy
- Use to adjust supplemental oxygen therapy, including mechanical ventilation
- Provides estimate of arterial oxygenation; still need arterial blood gases for Paco₂ and pH.
- Do not use to exclude significant carboxyhemoglobinemia (eg, after smoke inhalation)
- May not be accurate during cardiopulmonary resuscitation
- Attach to ear lobe or finger according to manufacturer's instructions
- Check for pulsatile waveform on monitor (if provided)
- If waveform is poor or pulse oximeter does not provide an adequate reading, try other locations

Pearl

Very high methemoglobin levels have the peculiar effect of causing the pulse oximeter to read 75% regardless of concentration or oxygenation.

Reference

Lee WW et al: The accuracy of pulse oximetry in the emergency department. Am J Emerg Med 2000;18:427. [PMID: 10919532]

Upper GI Bleeding, Prevention

Essential Concepts

- 10–25% incidence of shallow, stress-induced ulceration of gastric mucosa with subclinical or clinically important upper GI bleeding in critically ill patients; associated with poor outcome, increased mortality
- May have clinical bleeding or persistent unexplained fall in hemoglobin
- Risk factors: mechanical ventilation, coagulopathy, thrombocytopenia, renal failure, burns, postsurgical, possibly lack of enteral feeding, aspirin; may be due to cytokine-mediated decrease in upper GI mucosal resistance to gastric acid, *H pylori*, multiorgan system failure, impaired hemostasis, medications, decreased mucosal blood flow

■ Essentials of Management


- Give prophylactic therapy for all patients receiving mechanical ventilation, with thrombocytopenia, qualitative platelet dysfunction, coagulopathy, significant burns, renal or liver failure
- Consider in all patients in ICU, especially if hypotension, low cardiac output, inability to feed enterally
- Sucralfate, a nonantacid, possibly associated with less nosocomial pneumonia; may be less effective
- For antacid therapies, best results with pH > 4.0 (measurement of pH not clinically indicated)
- Ranitidine, 150 mg IV per day, continuous infusion or every 8 hours, or famotidine 20 mg IV every 12 hours; adjust for renal insufficiency.
- Alternative: pantoprazole 40 mg IV daily for 5–7 days, then switch to oral pantoprazole or omeprazole

Pearl

Patients with highest risk for stress-related upper GI bleeding are those receiving mechanical ventilation and those with disorders tending to lead to bleeding.


Reference

Steinberg KP: Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit. Crit Care Med 2002;30(6 Suppl):S362. [PMID: 1207266]



ICU Supportive Care for Specific Medical Problems

Burn Patients	25
Chronic Renal Failure Patients	26
Pregnant Patients	27
Solid Organ Transplant Recipients	28



Burn Patients

Essential Concepts

- Assess burn depth: first-degree burns red, dry, painful; seconddegree burns red, wet, very painful; third-degree burns leathery, dry, insensate
- Assess extent of total body surface area (TBSA) involved: in adults each body segment assigned 9%: head and neck; anterior chest; posterior chest; anterior abdomen; posterior abdomen including buttocks; each upper extremity; each thigh; each leg and foot; genitals assigned 1%
- Attention to surrounding circumstances important to identify potential toxic exposures; evaluate for associated injuries: neurologic and musculoskeletal examinations
- Patients sustaining serious burns should be transferred to burn center based on American Burn Association criteria: any burn > 10% TBSA in patients < 10 or > 50 years of age; burns involving > 20% TBSA; second- and third-degree burns involving face, hands, feet, genitalia, perineum, major joints; third-degree burns > 5% TBSA; significant electrical, chemical, inhalational burns

Essentials of Management

- Maintenance of cardiopulmonary function including intubation and mechanical ventilation if airway compromised or breathing appears insufficient
- Immediate fluid resuscitation with half estimated needs administered within first 8 hours; use formulas based on body size, depth, extent of burn to estimate fluid needs; most recommend avoiding colloid during first 24 hours and using crystalloid solutions
- Escharotomy may be necessary to prevent secondary ischemic tissue necrosis and to relieve elevated tissue pressures
- Topical antimicrobial therapy with mafenide, silver sulfadiazine, silver nitrate may decrease incidence of invasive infection
- Increased metabolic rates in postburn period increase caloric and protein needs; require early nutritional support

Pearl

Burns involving more than 25% of the total body surface area require intravenous fluid resuscitation because ileus precludes oral resuscitation.

Reference

Sheridan RL: Burns. Crit Care Med 2002 Nov;30:S500. [PMID: 12528792]

Chronic Renal Failure Patients

Essential Concepts

- · Elevated BUN and creatinine present over weeks to years
- Malaise, nausea, hiccups, pruritis, confusion, metallic taste, impotence
- Hypertension, fluid overload, uremic fetor, pericardial friction rub, asterixis, sallow complexion
- · Anemia, platelet dysfunction, metabolic acidosis, hyperkalemia
- Hyperphosphatemia and hypocalcemia lead to renal osteodystrophy
- · Renal imaging reveals bilateral small echogenic kidneys

Essentials of Management

- · Renal biopsy not helpful in identifying underlying cause
- Sodium and fluid restriction; blood pressure control
- Nutritional support: protein restriction (unless receiving hemodialysis), reduced dietary potassium and phosphorus
- Avoid hypotension, excessive diuresis
- Avoid nephrotoxic agents: aminoglycosides, NSAIDs, contrast agents
- Monitor medications interfering with creatinine clearance: ACE inhibitors, histamine blockers, trimethoprim
- · Adjust dosages of medications eliminated by kidneys
- Avoid excessive magnesium-containing compounds: antacids, laxatives
- Administer oral phosphate binders
- Correct metabolic acidosis, especially if limited ventilatory capacity
- Recombinant erythropoietin with or without iron for anemia
- Monitor for cardiac tamponade when pericarditis present
- Urgent hemodialysis if severe acidosis, hyperkalemia with ECG changes, fluid overload, symptomatic uremia
- Kidney transplantation

Pearl

While severe hypocalcemia is a common laboratory finding in chronic renal failure, clinical manifestations of tetany are rarely seen because ionized calcium is favorably increased in the setting of acidemia that accompanies chronic renal impairment.

Reference

Yu HT: Progression of chronic renal failure. Arch Intern Med 2003;163:1417. [PMID: 12824091]

Pregnant Patients

Essential Concepts

- Altered maternal physiology, presence of fetus, diseases specific to pregnancy make management challenging
- Organ systems adapt to optimize fetal and maternal outcome
- Cardiovascular system: electrical axis changes with lateral deviation of apex; cardiac output, heart rate, stroke volume increase; reduced peripheral vascular resistance leads to decreased systemic blood pressure
- Respiratory system: minute ventilation increases in excess of need for oxygen delivery; "hyperventilation of pregnancy" hormonally mediated and results in decreased Paco₂ (28 to 32 mm Hg); compensatory bicarbonate loss maintains normal pH
- Hematologic system: disproportionate plasma volume increase compared to red cell mass leads to "dilutional anemia"; increased thromboembolic risk due to alterations in clotting factors, venous stasis, vessel wall injury
- Laboratory changes: creatinine decreases while creatinine clearance increases; elevated alkaline phosphatase related to placental production

Essentials of Management

- Position: avoid supine position after 20 weeks gestation; right lateral decubitus or Fowler position (head of bed elevated) preferred for immobilized patient
- Monitoring: fetal heart tones should be part of vital signs; continuous fetal monitoring after 23 weeks' gestation if maternal condition affects cardiopulmonary function
- Thromboembolism prophylaxis: unfractionated or low molecular weight heparin if not contraindicated; venous compression stockings of lesser benefit
- Nutrition: address early as pregnant women more susceptible to starvation ketosis
- Imaging studies: ionizing radiation known to be teratogenic; limit radiographs appropriately but do not withhold if results may lead to therapeutic intervention

Pearl

Although care of the mother is the primary concern in most circumstances, attention must also be paid to fetal health and well-being.

Reference

Naylor DF et al: Critical care obstetrics and gynecology. Crit Care Clin 2003;19:127. [PMID: 12688581]

Solid Organ Transplant Recipients

Essential Concepts

- High risk for complications related to transplanted organ, anatomical disturbances, immunosuppressive therapies
- Graft failure and chronic rejection major concern but infections leading cause of death; organism depends on time elapsed since transplantation: first month bacterial processes (wound, urine, lung); 1 to 6 months viral (CMV, EBV) and opportunistic (PCP, Aspergillus); beyond 6 months resemble general community
- Classic signs of infection such as fever often masked by immunosuppression
- Pancreatitis and hepatotoxicity due to viral infection or medications
- Posttransplant malignancies: lymphoproliferative disorder (PTLD), Kaposi sarcoma
- · Steroid-induced diabetes, avascular necrosis, osteoporosis
- · Hyperlipidemia and accelerated atherosclerosis
- · Adrenal axis suppression
- Medication interactions and potential toxicity: metabolism of immunosuppressive agents often affected by antibiotics, antifungal agents, antituberculosis drugs, anticonvulsants, antacids, histamine blockers, calcium channel blockers

Essentials of Management

- · Continue prophylactic antibiotics and antiviral medications
- · Aggressively treat suspected or identified infections
- If life-threatening infection present, discontinue immunosuppressive regimen despite risk of graft rejection
- "Stress" dose steroids required in acutely ill patient recently on corticosteroids as part of immunosuppression regimen
- Evaluate for drug-drug interactions and monitor for toxicity when adding new medications
- Biopsy of transplanted organ required for diagnosis of rejection; may require additional immunosuppressive agents
- If PTLD suspected, reduction of immunosuppression indicated combined with acyclovir or ganciclovir

Pearl


Graft-versus-host disease, although most commonly associated with bone marrow transplantation, can also be seen in intestinal and multivisceral transplantations.

Reference

Dunn DL: Hazardous crossing: immunosuppression and nosocomial infections in solid organ transplant recipients. Surg Infect 2001;2:103. [PMID: 12594865]

Ethical Issues

Brain Death	31
Do-Not-Resuscitate Orders (DNR)	32
Medical Ethics	33
Medicolegal Principles	34
Withholding & Withdrawing Care	35



Brain Death

Essentials of Diagnosis

- · Irreversible cessation of brain function, cortical and brain stem
- Brain stem: no oculocephalic reflex, pupils fixed, lack of motor reflexes, absence of spontaneous respiration
- No spontaneous breathing for 10 minutes after discontinuing mechanical ventilation (patient given 100% O₂ to breathe) and/or Paco₂ > 55 mm Hg
- Local or institutional policy may require determination by neurologist or neurosurgeon, need more than one examiner, require two examinations conducted at a defined interval, or mandate electroencephalogram (EEG)

Differential Diagnosis

- · Hypothermia
- Presence of sedative-hypnotic drugs (benzodiazepines, barbiturates, etc.).
- Severe vegetative state (some brain stem function)

■ Treatment

- Determine if brain death is present by institutional or local criteria
- According to institutional procedure, determine and act accordingly if patient is potential organ donor
- If brain death declaration is made, time of death is time determination made
- Remove life support therapy after declaration of death, except for organ donation

■ Pearl

When testing for apnea, give 100% oxygen through the endotracheal tube to avoid hypoxic injury, then observe for at least 10 minutes or until the Paco₂ rises above 60 mm Hg.

Reference

Wijdicks EF: The diagnosis of brain death. N Engl J Med 2001;344:1215. [PMID: 11309637]

Do-Not-Resuscitate Orders (DNR)

■ Essential Concepts

- The Do-Not-Resuscitate (Do-Not-Attempt Resuscitation; DNR) order stops automatic cardiopulmonary resuscitation
- Only applies to patient at time of cardiopulmonary arrest; withholding or withdrawing other care separate decisions
- DNR extends patient's autonomy to make informed choice, while knowing consequences of decision
- In multiple organ failure or critical illness, cardiopulmonary resuscitation < 10% likelihood of success and very poor outcome (<5% normal function)
- Resuscitation of acute, reversible, witnessed arrest often more successful

Essentials of Management

- Consider DNR discussion with patient or other decision maker for all critically ill patients in ICU
- · Determine if DNR already addressed in advance directives
- Assure patient and family that DNR does not discontinue comfort measures and pain control
- Follow institution's DNR policy for documentation; include time of discussion, persons who participated, level of understanding of patient, other decisions about patient care
- If disagreement about DNR, make efforts to clarify misunderstandings, misconceptions, concerns
- DNR may be temporarily suspended for general anesthesia or cardiac catheterization, during which there is increased risk of cardiopulmonary arrest

Pearl

Only about 30% of patients with likely very poor outcome have DNR orders.

Reference

Burns JP et al: Do-not-resuscitate order after 25 years. Crit Care Med 2003;31:1543. [PMID: 12771631]

Medical Ethics

Essential Concepts

- Ethical decisions based on four basic principles
- Autonomy: Patient has right to make informed decisions and refusals, if has capacity to understand consequences of decisions; capacity means understanding consequences of decision
- Beneficence: Care must achieve good not harm; goals of medicine are saving life, prolonging life, relieving suffering, curing disease
- Nonmaleficence: Avoid harm while meeting other goals and principles; at times, may conflict with beneficence
- Justice: Treat fairly in relationship to others; allocate resources where likely to do most good

Essentials of Management

- Let patients or other decision makers make autonomous decisions but only after giving sufficient information and confirming understanding
- · Care must focus on achieving goals of medicine
- All options and decisions must weigh benefits against risks for each diagnostic or therapeutic intervention
- Physicians responsible to individual patient; may conflict at times with responsibility to community (eg, costs of care, limited resources)
- Common conflicts: Patient has autonomy to make informed choices, but physicians must not allow them to harm themselves.
 When striving to relieve suffering (pain), analgesia may shorten life. Patients have right to make decisions, even if they conflict with family members

■ Pearl

Designated surrogate decision makers often do not make same decision as the patient would; prior discussion and communication greatly improve agreement.

Reference

Henig NR et al: Biomedical ethics and the withdrawal of advanced life support. Annu Rev Med 2001;52:79. [PMID: 11160769]

Medicolegal Principles

Essential Concepts

- A patient with capacity to understand consequences may choose or refuse medical care offered
- Capacity to make medical decisions may be present even without capacity to make other decisions (e.g., financial)
- Informed consent: Patient consents after understanding benefits, risks, and their likelihood for a test or treatment
- Informed denial (refusal): Patient declines a test or procedure, but only after demonstrating understanding the consequences of refusal
- When patient lacks capacity, use surrogate decision maker, often, but not always, a family member; ideally chosen in advance by patient
- Surrogate must decide based on patient's likely choice, either explicit or implicit
- In absence of surrogate, may need to make a "best interests" decision—what would a reasonable person choose?

■ Essentials of Management

- Evaluate capacity as patient's ability to understand consequences of individual medical choices presented
- For informed consent, explain likely events, consequences, results; very rare events need not be mentioned
- Always make a judgment about the patient's level of understanding, whether consenting to or declining offered treatment
- If a surrogate does not know patient's wishes, make a "best interest" decision weighing benefits and burdens of treatment to patient
- In absence of any surrogate who knows patient's wishes, physicians may make decisions according to local policy, including forgoing of treatment.

Pearl

Forgoing treatment in the absence of clear-cut direct knowledge that this is the patient's wish can still be undertaken.

Reference

Meisel A et al: Seven legal barriers to end-of-life care: myths, realities, and grains of truth. JAMA 2000;284:2495. [PMID: 11074780]

Withholding & Withdrawing Care

Essential Concepts

- Any medical care may be withdrawn or withheld, not just extraordinary measures
- Under no obligation to provide care that does not meet a goal of medicine—prolonging life, relieving suffering, or curing disease
- Patient with capacity to make decisions can ask that care be withdrawn or withheld
- Advance directive may designate withholding of treatment
- Not helpful to distinguish ordinary (feeding, hydration, pain medication) from extraordinary care (mechanical ventilation, major surgery, blood transfusions)
- Extensive discussions with patient, family, and staff essential for decisions regarding forgoing care
- · Always maintain patient comfort, dignity, hygiene

■ Essentials of Management


- Patient or surrogate decision maker asks that care be withheld or withdrawn
- Physician believes current or proposed care not indicated because of very low likelihood of benefit
- Risks of current or proposed care outweigh potential benefit;
 such care conflicts with prolonging life or relieving suffering
- If forgoing of treatment decided, follow institutional policy for documenting in medical record; include date and time of discussion, persons who participated (patient, family members, surrogate decision makers), level of understanding of patient
- Involve ICU staff in decision-making process; inform of decisions
- Continue comfort measures, including adequate analgesia and sedation
- · Reassess patient's wishes periodically

Pearl

A patient or surrogate may be unaware of the option to withhold or withdraw care


Reference

Nyman DJ Sprung CL: End-of-life decision making in the intensive care unit. Intensive Care Med 2000;26:1414. [PMID: 11126250]



Bleeding & Transfusions

Bleeding in the Critically III Patient	39
Coagulopathy, Acquired	40
Coagulopathy, Inherited	41
Heparin-Induced Thrombocytopenia (HIT)	42
Plasma Transfusions	43
Qualitative Platelet Dysfunction	44
Thrombocytopenia	45
Transfusion of Red Blood Cells	46
Transfusion Reactions	47
Warfarin Overdose	48
Warfarin Skin Necrosis	49



Bleeding in the Critically III Patient

Essentials of Diagnosis

- Spontaneous bleeding or bleeding from invasive procedures due to one or more defects in hemostasis
- Normal hemostasis needs intact vascular endothelium, coagulation factors, adequate platelet number and function
- Thrombocytopenia or platelet dysfunction: ecchymoses and mucosal bleeding, posttraumatic or surgical bleeding
- Acquired or inherited coagulopathies: spontaneous hemarthroses or soft tissue hematomas
- Severe coagulopathy, thrombocytopenia, or disseminated intravascular coagulation (DIC): generalized bleeding, especially new acute onset
- · Excessive warfarin: soft tissue hematoma

■ Differential Diagnosis

- Abnormal prothrombin time (PT) only: vitamin K deficiency, liver disease, warfarin, specific inhibitor
- Abnormal activated partial thromboplastin time (aPTT) only: inherited coagulopathy, heparin, lupus anticoagulant, specific inhibitor
- Both aPTT and PT abnormal: vitamin K deficiency, DIC, liver disease, heparin or warfarin
- Abnormal aPTT, PTT, platelet count: DIC (microangiopathic hemolytic anemia, low fibrinogen, elevated fibrin degradation products, elevated D-dimer)
- Screening tests normal: platelet dysfunction, endothelial damage, factor XIII deficiency

■ Treatment

- Assess severity and acuity of bleeding; estimate rapidity of blood loss; treat if active or anticipated bleeding, invasive procedures necessary
- Management depends on etiology; vitamin K, fresh frozen plasma, cryoprecipitate, platelet transfusions, stopping anticoagulants

Pearl

Consider acute acquired dysfunction of platelets if unexplained bleeding with no previous history; may be due to renal failure, drugs such as aspirin, NSAIDs, or platelet inhibitors.

Reference

DeSancho MT et al: Bleeding and thrombotic complications in critically ill patients with cancer. Crit Care Clin 2001;17:599. [PMID: 11525050]

Coagulopathy, Acquired

Essentials of Diagnosis

- Excessive or prolonged bleeding from punctures, incisions, GI tract, mucosal membranes, joints, retroperitoneal space, other sites
- Abnormal coagulation time (prothrombin time [PT] or activated partial thromboplastin time [aPTT]) in absence of inherited coagulopathy
- Causes: warfarin, heparin administration; liver disease; vitamin
 K deficiency (malnutrition, antibiotics, poor intake); disseminated intravascular coagulation (sepsis, hypotension, release of bone marrow thromboplastins, liver injury, abruptio placenta, amniotic fluid embolism), trauma (fat embolism, brain injury); acquired circulating anticoagulant (antibody to coagulation factor)

Differential Diagnosis

- · Inherited coagulopathy
- Thrombocytopenia or qualitative platelet disorder, vitamin C deficiency
- Abnormal aPTT without increased risk of bleeding (lupus anticoagulant)

Treatment

- Establish etiology
- Treat if active bleeding, high risk for bleeding, anticipated procedure (lumbar puncture, central venous catheter, surgery)
- Vitamin K, 1–10 mg orally or subcutaneously, if vitamin K deficiency suspected
- Replace factors if moderate to severe bleeding; fresh frozen plasma (FFP) contains factors absent in liver disease, vitamin K deficiency, warfarin treatment, DIC; give FFP equal to 50% of plasma volume (20 mL/kg ideal body weight); one unit FFP approximately 250–300 mL, so give 4–6 units FFP over 6–12 hours

Pearl

Many antibiotics destroy enteric bacteria, which produce vitamin K; give weekly vitamin K to ICU patients who are receiving antibiotics.

Reference

Teitel JM: Clinical approach to the patient with unexpected bleeding. Clin Lab Haematol 2000;22 (1 Suppl):9. [PMID: 11251652]

Coagulopathy, Inherited

Essentials of Diagnosis

- Excessive or prolonged bleeding from punctures, incisions, GI tract, mucosal membranes, joints, retroperitoneal space, other sites
- History of lifelong abnormal bleeding or family history of bleeding disorders
- Abnormally prolonged coagulation time (prothrombin time [PT] or activated partial thromboplastin time [aPTT])
- Common: von Willebrand disease (autosomal dominant deficiency of von Willebrand factor with qualitative platelet dysfunction and prolonged aPTT due to factor VIII deficiency); hemophilia A (sex-linked, variably dysfunctional factor VIII); hemophilia B (sex-linked deficiency of active factor IX).
- Rare: deficiency of factors II, V, VII, X, XI, XIII, fibringen
- Inheritance of gene coding abnormal coagulation factor or insufficient production of a factor; X-linked or autosomal

■ Differential Diagnosis

- Acquired coagulopathy
- Thrombocytopenia or qualitative platelet disorder, vitamin C deficiency
- Abnormal aPTT without risk of bleeding (lupus anticoagulant)

■ Treatment

- · Establish etiology
- Treat if active bleeding, high risk for bleeding, anticipated invasive procedure (lumbar puncture, central venous catheter, surgery)
- von Willebrand disease: desmopressin (intravenous or intranasal), cryoprecipitate
- VIII deficiency: desmopressin for mild bleeding, purified or recombinant factor VIII
- · IX deficiency: Purified or recombinant factor IX
- Fresh frozen plasma contains factors VIII, IX, most other factors, but should not be used unless others not available

Pearl

A woman with a hereditary coagulopathy almost always has von Willebrand disease.

Reference

Bolton-Maggs PH et al: Haemophilias A and B. Lancet 2003;361:1801. [PMID: 12781551]

Heparin-Induced Thrombocytopenia (HIT)

Essentials of Diagnosis

- Unexplained arterial or venous thrombosis, pulmonary embolism, stroke, coronary occlusion, upper extremity DVT, with fall in platelet count 4–14 days after starting heparin
- Occurs with both therapeutic and prophylactic heparin, including heparin flushing of catheters; may occur after heparin stopped
- Type I: slight fall in platelet count in 10–20% with unfractionated heparin; nonimmune mediated, no clinical consequence, earlier onset
- Type II: 1% given unfractionated heparin, 0.3% low molecular weight heparin, severe immune-mediated, associated with thrombosis (often arterial), later onset (unless due to re-exposure to heparin)
- In type II, heparin-platelet factor 4 complex triggers antibody; antibody-antigen complex binds to platelet surface causing aggregation and platelet-rich clots; no risk of bleeding from thrombocytopenia (platelet count usually > 20,000)
- Suspect in all patients with thrombocytopenia receiving heparin; especially if rapid return of platelets after heparin stopped

■ Differential Diagnosis

- · Other causes of thrombocytopenia
- Warfarin skin necrosis
- Other thrombotic states, including malignancies, protein C or S deficiency

Treatment

- Stop all heparin: therapeutic, prophylactic, flushes
- Use direct thrombin inhibitor (lepirudin or argatroban) for patients who continue to need anticoagulation, then warfarin; avoid starting warfarin until platelet count > 100,000/μL (may contribute to hypercoagulable state)
- Avoid future exposure to heparin

Pearl

Even small amounts of heparin can cause HIT, even heparin being given to keep intravenous catheters from clotting.

Reference

Walenga JM et al: Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy. Hematol Oncol Clin North Am 2003;17:259. [PMID: 12627671]

Plasma Transfusions

Essential Concepts

- Fresh frozen plasma (FFP) replaces coagulation factors in acquired or inherited coagulopathy (liver disease, vitamin K deficiency, DIC, warfarin therapy, hemophilia A or B, other inherited coagulopathies; antithrombin deficiency); also for plasma exchange therapy
- Cryoprecipitate replaces fibrinogen, factor VIII; cryoprecipitatepoor plasma useful for TTP/HUS
- Plasma transfusion not indicated for volume expansion or treatment of hypovolemic shock, hypoalbuminemia

Essentials of Management

- Treat underlying disorder
- Assess need for FFP: active bleeding, anticipated bleeding from invasive procedure, severe coagulopathy, effect of alternative therapy (vitamin K), response to discontinuing warfarin
- FFP requirement for coagulopathy based on increasing coagulation factors > 50% of normal; assume patient has 0% factors to start
- Give volume of FFP equal to 50% of plasma volume (20 mL/kg ideal body weight); each FFP unit approximately 250–300 mL; therefore, provide 4–6 units FFP over 6–12 hours, depending on patient tolerance to volume replacement and urgency of bleeding
- Coagulation factors effective in circulation 4–24 hours, depending on factor
- For TTP/HUS, use cryoprecipitate-free FFP for TTP/HUS during plasmapheresis; to replace fibrinogen in DIC and hypofibrinogenemia, use cryoprecipitate
- · Complications of plasma therapy: volume overload, infection

Pearl

In patients with severe liver disease, FFP transfusions will almost never completely "correct" the coagulopathy; avoid fluid overload by limiting total transfused.

Reference

Hellstern P et al: Practical guidelines for the clinical use of plasma. Thromb Res 2002;107 (1 Suppl):S53. [PMID: 12379294]

Qualitative Platelet Dysfunction

■ Essentials of Diagnosis

- · Mucosal bleeding, ecchymoses, or surgical bleeding
- Platelet count $> 50,000 \text{ per mm}^3$
- · May have abnormal bleeding time
- Inherited or acquired condition or medication associated with qualitative platelet dysfunction
- Acquired common; medications (aspirin, NSAIDs, dextran, glycoprotein IIb/IIIa inhibitors, ticlopidine, clopidogrel), uremia, recent cardiopulmonary bypass
- Inherited rare; lifelong history of bleeding, normal platelet count; defects may be in adhesion (Bernard-Soulier syndrome), aggregation (Glanzmann disease or glycoprotein IIB/IIIa deficiency), release of platelet components, or decreased platelet factor 3

Differential Diagnosis

- Thrombocytopenia
- Coagulopathies (normal bleeding time)
- · Disseminated intravascular coagulation with thrombocytopenia
- · Severe vitamin C deficiency

Treatment

- · Determine risk of or severity of bleeding
- Discontinue potentially responsible medications
- · Avoid invasive procedures
- If bleeding, intravenous desmopressin acetate may improve platelet function
- · Renal failure patients may benefit from hemodialysis
- Platelet transfusions may be tried in cases of persistent severe bleeding due to drugs, inherited platelet dysfunction

Pearl

Measuring bleeding time may not be helpful because of poor correlation between bleeding time and risk of bleeding from platelet disorders.

Reference

George JN: Platelets. Lancet 2000;355:1531. [PMID: 10801186]

Thrombocytopenia

Essentials of Diagnosis

- Platelet count < 50,000; petechiae or ecchymoses, or mild to severe mucosal membrane or intracranial bleeding
- Decreased production (bone marrow infiltration by infection or malignancy, toxins, alcohol, drugs, aplastic anemia); increased destruction (idiopathic, DIC, drugs, hypersplenism, heparin-associated thrombocytopenia, HELLP syndrome)
- Spontaneous bleeding when platelet count < 20,000, but highly variable; for same platelet count, platelet destruction less bleeding than low production; qualitative platelet dysfunction worsens bleeding

Differential Diagnosis

- Pseudothrombocytopenia (platelet clumping *in vitro* due to EDTA anticoagulant)
- Nonthrombocytopenic disorders of hemostasis (coagulopathy, vascular injury)
- Vasculitis with palpable nonthrombocytopenic purpura
- Thrombotic thrombocytopenic purpura (TTP) not associated with increased bleeding

■ Treatment

- Transfuse if < 50,000/μL and major surgical procedure planned; < 30,000/μL, minor surgery or spontaneous bleeding; < 5000–10,000, prophylactically
- Transfuse at higher count if bleeding, fever, infection, renal failure, platelet dysfunction, low production (bone marrow failure); at lower counts if platelet destruction (transfusions minimally useful); transfusion contraindicated in TTP/HUS, heparin-induced thrombocytopenia
- Type-specific random-donor platelets, 6–8 units; expect 5000–10,000/μL increase per unit
- Complications: volume overload, infections, sensitization to platelets with decreased transfusion effectiveness
- Other therapy: idiopathic thrombocytopenic purpura (corticosteroids, IgG); renal failure, von Willebrand disease (desmopressin), anemia (red cell transfusions)

Pearl

If platelet count does not rise by 5000–10,000 for each unit of platelets, suspect platelet destruction, such as ITP.

Reference

Drews RE, Weinberger SE: Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med 2000; 162:347. PMID: 10934051

Transfusion of Red Blood Cells

Essential Concepts

- Anemia adversely affects oxygen delivery to organs, increases risk of bleeding; may be acute (blood loss, hemolysis, decreased production) or chronic (underlying disease)
- Transfusion of red blood cells (RBC) indicated for anemia plus limited oxygen delivery, organ ischemia (myocardial infarction, unstable angina), likelihood of future blood loss, symptomatic anemia
- For patients with acute recurrent bleeding, anticipate need for RBC transfusions and maintain Hgb approximately 10 g/100 mL
- RBC transfusion not indicated for stable mild anemia (Hgb > 8-10 g/100 mL), if no evidence of impaired O₂ delivery, no myocardial ischemia, recent myocardial infarction, shock, hypotension

Essentials of Management

- Provide specific treatment for anemia (iron, folate, vitamin B₁₂, epoetin alfa)
- Transfuse homologous packed RBC; expect Hgb rise 0.5–1 g/100 mL per unit (if no ongoing loss)
- Leukocyte-poor RBCs limit nonhemolytic transfusion reaction and HLA sensitization for potential transplant recipients; washed RBCs for patients sensitive to plasma components
- Number of transfused RBC units depends on hemodynamic stability, ongoing losses, changes in intravascular volume, bone marrow response
- Multiple transfusions associated with thrombocytopenia, coagulation factor deficiency; rarely citrate intoxication, hyperkalemia, hypothermia
- Complications: transfusion reactions (fever, anaphylaxis, hemolysis, alloimmunization); volume overload (especially with heart failure, renal failure); infections (hepatitis B and C, HIV, CMV)

Pearl

Unnecessary RBC transfusions associated with worse ICU outcome; may be due to increased immunosuppression.

Reference

Hebert PC, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409. [PMID: 9971864]

Transfusion Reactions

Essentials of Diagnosis

- > 90% acute reactions nonhemolytic: fever, lung injury (infiltrates, hypoxemia over 1–4 days), allergic (urticaria, fever, rash, pruritis, bronchospasm, anaphylaxis); 1–3% of transfusions
- Acute hemolysis < 10%; back, joint pain, chills, fever, hypotension, tachycardia; acute renal failure, cardiovascular collapse, DIC; from transfusion of incompatible blood with recipient antibodies to donor cells or donor antibodies to recipient cells
- Chronic reactions > 1 week; antibodies to non-ABO antigens; may be subclinical (unable to find subsequent compatible donor blood by crossmatching) or mild antibody-mediated hemolysis
- Nonspecific complications of transfusions: hyperkalemia, circulatory overload, hypothermia, hypocalcemia, thrombocytopenia, immunosuppression, infections

■ Differential Diagnosis

- · Infection and sepsis
- · Allergic reaction to medications
- · Pulmonary edema
- · Other causes of hemolysis

Treatment

- Stop transfusion immediately to minimize incompatible blood administered; assess severity, type of reaction
- Send remainder of blood and patient sample for repeat crossmatching; check for hemolysis (blood smear, bilirubin, haptoglobin, free hemoglobin), DIC
- Hemolytic reaction: intravascular volume expansion to maintain renal perfusion; diuretics to maintain urine output
- Minor nonhemolytic reactions in patient requiring multiple repeated transfusions: decide whether repeat evaluation needed; antipyretics prior to transfusions

Pearl

Transfusion-related acute lung injury (TRALI) is caused by donor antibodies; "high-risk" donors can sometimes be identified.

Reference

Goodnough LT, et al: Transfusion medicine. First of two parts—blood transfusion. N Engl J Med 1999;340:438. [PMID: 9971869]

Warfarin Overdose

Essentials of Diagnosis

- · History of coumadin therapy or known overdose
- Prolonged prothrombin time, expressed as international normalized ratio, INR > 5
- · May or may not have clinical bleeding

Differential Diagnosis

- · Congenital coagulopathy
- · Acquired coagulopathy
- Heparin

Treatment

- Treat if serious bleed into critical area (intracranial), active bleeding, severe anemia, high risk for future bleeding, anticipated invasive procedure (lumbar puncture, central venous catheter, surgery)
- INR > therapeutic and < 5.0; no significant bleeding: Lower or omit dose; resume therapy at lower dose when INR therapeutic
- INR > 5.0, < 9.0; no significant bleeding: Omit next 1-2 doses, resume at lower dose when INR therapeutic; vitamin K₁ (1-2.5 mg orally); if patient at increased risk for bleeding; give vitamin K₁ (2-4 mg orally)
- INR > 9.0; no significant bleeding; omit warfarin; vitamin K₁ (3–5 mg orally)
- INR > 20; serious bleeding. Omit warfarin; vitamin K₁ (10 mg, slow IV infusion) plus fresh plasma; repeat vitamin K₁ every 12 h.
- Life-threatening bleeding: Omit warfarin; prothrombin complex concentrate and vitamin K₁ (10 mg, slow IV infusion); repeat if necessary, depending on INR
- Patients who need anticoagulation (prosthetic valve, atrial fibrillation, deep venous thrombosis, etc.) should have anticoagulation restarted when safe

Pearl

Without severe bleeding and INR < 9, low-dose oral vitamin K usually returns INR to therapeutic range quickly and safely.

Reference

Crowther MA et al: Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002;137:251. [PMID: 12186515]

Warfarin Skin Necrosis

Essentials of Diagnosis

- Painful petechiae beginning 2–6 days after starting warfarin; may progress to demarcated ecchymosis, bullae, and skin necrosis
- Seen most often over subcutaneous fat of buttocks, breasts, abdomen; more common in women
- Rare (0.01–0.1%), very serious complication of warfarin
- Suspect in patients with rapid increase in INR with early doses
 of warfarin, hypercoagulable states (deficiency of proteins C or
 S, heparin-induced thrombocytopenia, resistance to activated
 protein C), previous complications suspected to be warfarin skin
 necrosis
- Starting warfarin may lead to transient decrease in anticoagulant proteins C and S (short half-lives) while procoagulant factors (factor Xa) not reduced; imbalance favors coagulation and thrombosis; imbalance more likely with deficiency of naturally occurring anticoagulants

■ Differential Diagnosis

- Disseminated intravascular coagulation with purpura fulminans
- · Necrotizing fasciitis
- · Arterial or venous insufficiency
- · Vasculitis

Treatment


- Stop warfarin
- Administer vitamin K, fresh frozen plasma
- Use alternative method of anticoagulation, such as heparin, if necessary
- · May need skin debridement
- Prevention: use low starting dosages of warfarin, usually 5 mg orally daily; overlap with heparin therapy

■ Pearl

If INR rapidly rises after the first dose of warfarin, watch patient closely for signs of skin necrosis.


Reference

Ansell J et al: Managing oral anticoagulant therapy. Chest 2001;119(1 Suppl):22S. [PMID: 11157641]



Fluids, Electrolytes, & Acid-Base

Hypercalcemia	53
Hypocalcemia	54
Hyperkalemia	55
Hypokalemia	56
Hypermagnesemia	57
Hypomagnesemia	58
Hypernatremia	59
Hyponatremia	60
Hyperphosphatemia	61
Hypophosphatemia	62
Hypervolemia	63
Hypovolemia	64
Metabolic Acidosis	65
Metabolic Alkalosis	66
Mixed Acid-Base Disorders	67
Respiratory Acidosis	68
Resniratory Alkalosis	60



Hypercalcemia

Essentials of Diagnosis

- Serum calcium [Ca²⁺] > 10.5 mg/dL (corrected for albumin) or elevated ionized calcium
- Anorexia, nausea, vomiting, adynamic ileus, constipation, abdominal pain, pancreatitis
- · Altered mental status with apathy, obtundation, coma, psychosis
- Polyuria, polydipsia, nephrocalcinosis, impaired urinary concentrating ability
- Band keratopathy of eyes
- · Increased risk of bone fractures
- ECG with shortened QT interval; cardiac arrhythmias especially in patients on digitalis

Differential Diagnosis

- Hyperparathyroidism
- Vitamin A or D intoxication
- Milk-alkali syndrome
- Adrenal insufficiency
- Paget disease of bone
- Familial hypocalciuric hypercalcemia
- Granulomatous diseases: sarcoidosis, tuberculosis, fungal infections

■ Treatment

- · Aggressive fluid resuscitation with normal saline
- Once euvolemic, loop diuretics to induce calciuresis; avoid thiazides
- Calcitonin useful with life-threatening hypercalcemia in initial phase of therapy due to rapid onset of action but transient effect
- Bisphosphonates lower calcium over several days
- Glucocorticoids effective in steroid-sensitive malignancy, granulomatous disease, vitamin D induced hypercalcemia
- · Hemodialysis
- Evaluate for underlying etiology especially malignancy

Pearl

The serum calcium level should be corrected according to the patient's albumin level based on the following calculation:

$$calcium_{measured} + 0.8 \times (4 - albumin).$$

Reference

Fukugawa M et al: Calcium homeostasis and imbalance. Nephron 2002;92:41. [PMID: 12425329]

Malignancy

· Thiazide diuretics

· Thyrotoxicosis

Immobilization

Hypocalcemia

Essentials of Diagnosis

- Serum calcium [Ca²⁺] < 8.5 mg/dL (corrected for albumin) or reduced ionized calcium
- Correction for albumin: calcium_{measured} + $0.8 \times (4 \text{albumin})$
- · Symptoms correlate with rapidity and magnitude of fall
- Tetany, paresthesias, hyperreflexia most common manifestations; acute hyperventilation may evoke tetany
- Altered mental status, seizures, muscle weakness, papilledema
- · Chvostek sign: tapping facial nerve leads to grimace
- Trousseau sign: inflating blood pressure cuff causes carpopedal spasm of outstretched hand
- Reduced myocardial contractility can precipitate congestive heart failure
- · ECG with prolonged QT interval; ventricular arrhythmias

Differential Diagnosis

- Chronic renal failure
 Following parathyroidectomy
- Hypomagnesemia
 Acute hyperphosphatemia
- Acute pancreatitis
- · Septic shock
- · Hypoparathyroidism, pseudohypoparathyroidism
- · Vitamin D deficiency or malabsorption
- · Rhabdomyolysis, tumor lysis syndrome
- · Medications: loop diuretics, aminoglycosides
- Massive blood transfusion due to citrate

Treatment

- Intravenous calcium for acute symptoms; avoid if serum phosphate elevated due to risk of calcium-phosphate precipitation
- Oral calcium between meals with vitamin D supplementation
- · Thiazide diuretics may be considered to prevent hypercalciuria
- Correct hypomagnesemia
- · Address underlying etiology
- Anticonvulsants may be used to treat seizures but may exacerbate hypocalcemia by increasing vitamin D metabolism

Pearl

When hypocalcemia develops immediately after a subtotal parathyroidectomy, it may be due to a stunned parathyroid gland with transient hypoparathyroidism or hungry-bone syndrome. In hungry-bone syndrome, serum phosphate is decreased while it is elevated in hypoparathyroidism.

Reference

Carlstedt F et al: Hypocalcemic syndromes. Crit Care Clin 2001;17:139. [PMID: 11219226]

Hyperkalemia

Essentials of Diagnosis

- Serum potassium [K⁺] level > 5 mEq/L
- · Weakness beginning in legs, paresthesias, hyporeflexia
- ECG changes occur at plasma [K⁺] > 5.7 mEq/L with peaked T-waves; subsequent ECG progression: reduced P-wave amplitude, PR prolongation, QRS widening, broad sine waves, ventricular fibrillation
- Transtubular potassium gradient (TTKG) can differentiate renal from nonrenal causes: Urine/Plasma (K⁺) × Plasma/Urine (Osm); product < 6 renal or hypoaldosterone effect; > 10 nonrenal

■ Differential Diagnosis

- · Excess intake: potassium supplements or salts
- Reduced excretion: renal failure, adrenal insufficiency, hypoaldosteronism, type IV renal tubular acidosis
- Intracellular shift: acidosis, rhabdomyolysis, tumor lysis, severe hemolysis, burns
- Factitious: hemolysis of blood sample, extreme leukocytosis or thrombocytosis
- Medications: K⁺-sparing diuretics, ACE-inhibitors, beta-blockers, succinylcholine, penicillin VK, trimethoprim-sulfamethoxazole

Treatment

- Calcium gluconate or chloride solution: immediate cardioprotective effect; drug of choice with acute ECG changes
- Bicarbonate shifts potassium intracellularly, especially if acidemic
- Nebulized beta-agonist albuterol can decrease [K⁺] by 0.6 mEq/L within 1 hour
- Insulin shifts potassium intracellularly and should be given along with dextrose infusion
- Binding resin kayexalate removes potassium enterally; use cautiously in constipation as may develop concretions
- · Loop diuretics lower body potassium over hours
- Hemodialysis most reliable and efficient method in reducing total body potassium
- Limit potassium in diet, intravenous fluids, medications

Pearl

Attempts made to correct hyperkalemia in the setting of acidosis may result in significant total body potassium depletion and serum hypokalemia once acidosis is resolved.

Reference

Kim HJ et al: Therapeutic approach to hyperkalemia. Nephron 2002;92:33. [PMID: 12401936]

Hypokalemia

Essentials of Diagnosis

- Serum potassium [K⁺] < 3.5 mEq/L
- · Usually asymptomatic
- Muscle weakness, respiratory failure, paralysis, paresthesias, ileus, postural hypotension
- Exacerbates hepatic encephalopathy
- Transtubular potassium gradient (TTKG) can differentiate renal from nonrenal causes: Urine/Plasma [K⁺] × Plasma/Urine (Osm); product > 4 renal loss or hyperaldosterone effect; < 2 gastrointestinal loss
- ECG with flattened T-waves, ST depression, U-waves; arrhythmias include premature ventricular beats, ventricular tachycardia, ventricular fibrillation

■ Differential Diagnosis

- Renal losses: hyperaldosteronism, glucocorticoid excess, licorice ingestion, osmotic diuresis, renal tubular acidosis (I, II), hypomagnesemia; Fanconi, Bartter, Gitelman, Liddle syndromes
- Extrarenal losses: severe diarrhea, nasogastric suctioning, sweating
- Intracellular shift: alkalosis, insulin, hypokalemic periodic paralysis
- Medications: loop diuretics, thiazides, carbenicillin, amphotericin B, cisplatin, aminoglycosides
- Inadequate intake

Treatment

- Oral and intravenous replacement; oral supplementation preferred because parenteral replacement rate limited by local irritation; central venous catheter infusions may lead to high intracardiac levels precipitating arrhythmias
- · Cautiously replace in patients with renal impairment
- Magnesium replacement essential as hypokalemia may be refractory until magnesium level in normal range
- Goal potassium level > 4 mEq/L in acute myocardial infarction when prone to hypokalemia-related arrhythmias
- Correct underlying etiologies whenever possible

Pearl

As a rule of thumb, replacing 10 mEq/L of potassium (oral or intravenous) will increase serum potassium levels by 0.1 mEq/L.

Reference

Kim GH et al: Therapeutic approach to hypokalemia. Nephron 2002;92:28. [PMID: 12401935]

Hypermagnesemia

Essentials of Diagnosis

- Serum magnesium [Mg⁺⁺] > 2.7 mg/dL
- · Reduced deep-tendon reflexes
- May progress to respiratory muscle failure
- · Hypotension with reduced vascular resistance
- · Somnolence and coma with extremely elevated levels
- · Decreased serum calcium may be seen
- Progression of ECG changes: interventricular conduction delay, prolonged QT interval, heart block, asystole
- Generally occurs with renal insufficiency and excessive intake
- Other risk factors: nephrotoxic agents, hypotension or hypovolemia with oliguria, preeclampsia-eclampsia receiving large therapeutic doses

Differential Diagnosis

- · Renal failure: acute and chronic
- · Excess ingestion: antacids, laxatives
- Intravenous administration: parenteral nutrition, intravenous fluids

■ Treatment

- Eliminate infusion of all magnesium-containing compounds
- Intravenous calcium gluconate or chloride reverses acute cardiovascular toxicity and respiratory failure
- · Hemodialysis with magnesium-free dialysate
- Monitor deep tendon reflexes when treating with "therapeutic hypermagnesemia" as in obstetric patients
- · Correct renal insufficiency

Pearl

Magnesium can be thought of as "nature's calcium channel blocker."

Reference

Topf JM: Hypomagnesemia and hypermagnesemia. Rev Endocr Metab Disord 2003;4:195. [PMID: 12766548]

Hypomagnesemia

Essentials of Diagnosis

- Serum magnesium [Mg⁺⁺] < 1.7 mg/dL
- · Weakness, muscle cramps, tremor, tetany, altered mental status
- · Positive Babinski response
- May occur with acute myocardial infarction; increases risk of arrhythmias including atrial and ventricular tachycardias; torsade de pointes
- Associated with hypokalemia, hypocalcemia, metabolic alkalosis

Differential Diagnosis

- Excessive diuresis: postobstructive, osmotic, resolving ATN
- Malabsorption, severe diarrhea
- · Hyperparathyroidism
- · Thyrotoxicosis
- Alcoholism
- Drugs: diuretics, amphotericin B, aminoglycosides, cisplatin, cyclosporine, loop diuretics
- Acute pancreatitis
- · Inadequate nutritional intake
- · Gitelman syndrome

Treatment

- Serum magnesium level may not reflect total body depletion because most magnesium is intracellular
- Intravenous magnesium replacement: limit to 50 mmol in 24 hours except in severe life-threatening hypomagnesemia
- Reduce replacement dose in renal impairment
- Follow serum levels and deep-tendon reflexes during replacement
- Address underlying etiology

Pearl

In hypomagnesemia associated hypokalemia and hypocalcemia, magnesium replacement is essential to the correction of the other two electrolytes abnormalities.

Reference

Topf JM: Hypomagnesemia and hypermagnesemia. Rev Endocr Metab Disord 2003;4:195. [PMID: 12766548]

Hypernatremia

Essentials of Diagnosis

- Serum sodium [Na⁺] > 145 mEq/L associated with hypertonicity
- · Altered mentation, impaired cognition, loss of consciousness
- · Thirst present if mentation preserved
- Polyuria suggests diabetes insipidus
- Elderly living in chronic care facilities with dementia and decreased access to water constitute highly susceptible group
- Free water deficit: depletion of total body water (TBW) relative to total body solute
- Evaluate urine osmolality, serum osmolality, responsiveness to antidiuretic hormone administration

■ Differential Diagnosis

- Inadequate water intake: decreased access to water, impaired thirst response
- Excessive nonrenal hypotonic water loss: vomiting, diarrhea, sweating
- Water diuresis: diabetes insipidus (central or nephrogenic)
- Exogenous solute administration: hypertonic saline, sodium bicarbonate, glucose, mannitol, feeding solutions

Treatment

- Estimate free water deficit: $TBW_{patient} \times [([Na^+]_{patient} [Na^+]_{normal})/[Na^+]_{normal}]$
- Rate of correction depends on acuity of onset of hypernatremia; in general, recommended to be 10 mEq/L per day
- Excessively rapid replacement of free water may lead to cerebral edema
- · Volume resuscitation with normal saline
- Once euvolemic, correction of hypernatremia changed to hypotonic fluid replacement
- Addressing underlying etiology necessary as some causes require specific intervention; central diabetes insipidus treated with desmopressin acetate

Pearl

The presence of polyuria with dilute urine in the face of hypernatremia suggests that excessive water loss is due to the inability to concentrate urine appropriately and is consistent with central or nephrogenic diabetes insipidus.

Reference

Kang SK et al: Pathogenesis and treatment of hypernatremia. Nephron 2002;92:14. [PMID: 12401933]

Hyponatremia

■ Essentials of Diagnosis

- Serum sodium [Na⁺] < 135 mEq/L
- Generally asymptomatic until serum sodium < 125 mEq/L
- Symptoms related to acuity of change: irritability, nausea, vomiting, headache, lethargy, seizures, coma
- Can be associated with hypertonic, isotonic, and hypotonic states; hypotonic hyponatremia can be seen in clinical situations in which extracellular volume is low, normal, or high
- Comparing serum and urine osmolality and assessing volume status important in identifying etiology

Differential Diagnosis

- Hypotonic hypovolemic: vomiting, diarrhea, third-spacing, diuretics (especially thiazides)
- Hypotonic normovolemic: SIADH (associated with pulmonary or CNS disorders), hypothyroidism, adrenal insufficiency, psychogenic polydipsia
- Hypotonic hypervolemic: congestive heart failure, cirrhosis, nephrotic syndrome, protein-losing enteropathy, pregnancy
- Isotonic states: pseudohyponatremia (hyperproteinemia, hyperlipidemia)
- Hypertonic states: hyperglycemia ([Na⁺] falls 1.6 mEq/L for each 100 mg/dL increase in glucose), mannitol administration

■ Treatment

- Aggressiveness of correction depends on severity of hyponatremia, acuity of onset, presence of neurological symptoms
- In general, correction should not exceed 8 mEq/L per day
- When hypovolemia present, restoring effective extracellular volume takes priority
- Fluid restriction key in all other forms of hypotonic hyponatremia
- · Consider demeclocycline in SIADH
- Combination therapy with hypertonic saline and furosemide reserved for significant neurologic symptoms
- Underlying cause should be addressed and treated

■ Pearl

Excessively rapid correction of sodium (> 20 mEq/L in the first 24 hours) or overcorrection (> 140 mEq/L) may lead to central pontine myelinolysis. Those at highest risk include alcoholics and premenopausal women with acute hyponatremia.

Reference

Halperin ML et al: Clinical approach to disorders of salt and water balance. Crit Care Clin 2002;18:249. [PMID: 12053833]

Hyperphosphatemia

Essentials of Diagnosis

- Serum phosphate > 5 mg/dL
- Usually without significant symptoms
- Associated hypocalcemia may lead to tetany, seizures, cardiac arrhythmias, hypotension
- Complications primarily result from calcium phosphate salt precipitation within solid organs including heart, lung, kidney; heart block from conduction system involvement
- Highest risk with acute tissue injury in setting of renal failure

■ Differential Diagnosis

- · Chronic renal failure
- · Acute renal failure
- · Hypoparathyroidism
- Cellular destruction: rhabdomyolysis, tumor lysis, hemolysis
- · Excess nutritional intake
- · Phosphate enemas or bowel preparations

Treatment

- Treatment dependent on symptoms and clinical findings; not on absolute level
- Urgent intervention should be considered in presence of heart block or symptomatic hypocalcemia
- · Discontinue all exogenous sources of phosphate
- · Normal saline infusion enhances phosphate excretion
- Hemodialysis readily removes extracellular phosphate; effect transient due to large intracellular stores
- · Phosphate-binders given with food are effective chronically
- · Address underlying etiology

Pearl

A calcium-phosphate product greater than 70 is predictive of metastatic calcification in various organs and calcium containing phosphate binders should be avoided.

Reference

Malluche HH et al: Hyperphosphatemia: pharmacologic intervention yesterday, today and tomorrow. Clin Nephrol 2000;54:309. [PMID: 11076107]

Hypophosphatemia

Essentials of Diagnosis

- Serum phosphate < 2.5mg/dL; severe < 1.5 mg/dL
- Generally asymptomatic with mild to moderate hypophosphatemia
- · Altered mental status, seizures, neuropathy, coma
- Muscle weakness, rhabdomyolysis, hemolysis, impaired platelet and leukocyte function, respiratory failure, death in severe hypophosphatemia
- · Concurrent hypokalemia and hypomagnesemia
- · High risk groups: chronic alcoholics, diabetic ketoacidosis

Differential Diagnosis

- · Chronic alcoholism
- · Refeeding after prolonged starvation
- · Diabetic ketoacidosis: insulin infusion, osmotic diuresis
- · Respiratory alkalosis
- · Hyperparathyroidism
- · Hypercalcemia
- · Vitamin D deficiency or malabsorption
- · Chronic ingestions of antacids, phosphate binders, or both
- · Postrenal transplantation

Treatment

- Oral phosphorus replacement preferred given fewer side effects
- · Intravenous phosphate may lead to metastatic calcification
- Severe case with symptoms: intravenous phosphorous infusion given over 6 to 8 hours
- Response to phosphorus replacement unpredictable; monitor levels during treatment
- Replacement form with sodium or potassium salt; monitor these electrolytes as well
- Prevention important in high risk groups
- · Address underlying etiology

Pearl

In elderly patients with renal insufficiency, phosphate salts given for bowel preparation are associated with severe hyperphosphatemia, marked anion gap metabolic acidosis, and hypocalcemia.

Reference

DiMeglio LA et al: Disorders of phosphate metabolism. Endocrinol Metab Clin North Am 2000;29:591. [PMID: 11033762]

Hypervolemia

Essentials of Diagnosis

- Increase in extracellular volume: generalized or localized to certain compartments
- · Peripheral dependent pitting edema
- · Ascites with abdominal distention
- Pulmonary edema or pleural effusions with dyspnea, rales, wheezes; resulting hypoxemia causing peripheral cyanosis, respiratory failure, altered mentation
- Can be associated with decreased, normal or increased "effective" intravascular volume

■ Differential Diagnosis

- · Congestive heart failure
- · Liver cirrhosis with ascites
- · Pre- and posthepatic portal hypertension with ascites
- · Nephrotic syndrome
- · Protein-losing enteropathy
- Excess sodium intake: hypertonic solutions, dietary sources
- · Renal failure with oliguria
- · Hyperaldosteronism and hypercortisolism

Treatment

- · Treatment depends on mechanism of disease
- · Diuretics mainstay of therapy
- In reduced effective intravascular volume: delay diuresis until intravascular fluid deficit corrected; some worsening of hypervolemia acceptable during fluid resuscitation
- · Dietary sodium and fluid restriction
- · Large volume paracentesis or thoracentesis for symptom relief
- Oxygen supplementation
- Cardiogenic pulmonary edema: morphine, vasodilators (nitroprusside, hydralazine, ACE inhibitors), venodilators (nitrates), inotropes
- Ventilatory support: mechanical or noninvasive ventilation
- · Hemodialysis or ultrafiltration in refractory cases

Pearl

The common practice of renal-dose dopamine to induce diuresis has failed to be supported by the literature.

Reference

Kreimeier U: Pathophysiology of fluid imbalance. Crit Care 2000;4:S3. [PMID: 11255592]

Hypovolemia

Essentials of Diagnosis

- · Reduced effective intravascular volume
- Thirst, oliguria; may have altered mental status: confusion, lethargy, coma
- Postural lightheadedness; orthostatic decrease in systolic blood pressure and increased heart rate
- Hypotension, hypoperfusion, shock leading to hepatic, renal, cardiac dysfunction
- Cold skin and extremities; dry axilla, sunken eyes some diagnostic value; poor skin turgor, dry mucous membranes poor diagnostic value
- Reduced central venous pressure (CVP) and pulmonary capillary wedge pressure (PCWP)
- Impaired renal function: BUN/creatinine > 30; reduced fractional excretion of sodium (FENA) < 1%

Differential Diagnosis

- Gastrointestinal loss: vomiting, diarrhea, nasogastric suction, enteric fistulas
- Renal loss: osmotic diuresis, diuretic use, post-ATN or obstructive diuresis
- · Skin loss: excessive sweating, burns
- · Hemorrhage: external or internal
- · Decreased intake of sodium and water
- · Adrenal insufficiency
- Associated with increased extracellular volume: congestive heart failure, cirrhosis with ascites, hypoalbuminemia

Treatment

- · Fluid resuscitation with colloid, crystalloid, or blood products
- Amount of fluid depletion difficult to estimate; with known or suspected heart disease consider "fluid challenge"; follow urine output, CVP, PCWP, or blood pressure to guide therapy
- · Identify and correct source of volume loss
- · Careful review of daily intakes and outputs
- · Monitor for overcorrection and fluid overload states

Pearl

Among all the physical findings for hypovolemia, an orthostatic increase in heart rate greater than 30 beats per minute has the highest specificity.

Reference

Boldt J: Volume therapy in the intensive care patient—we are still confused, but. . . Intensive Care Med 2000;26:1181. [PMID: 11089741]

Metabolic Acidosis

Essentials of Diagnosis

- Arterial pH < 7.35; decreased serum HCO₃⁻ and compensatory reduction in Paco₂; due to increased acid accumulation or decreased extracellular HCO₃⁻
- Fatigue, weakness, lethargy, somnolence, coma, nonspecific abdominal pain
- Kussmaul (rapid and deep) respirations develop as acidosis progresses; rarely subjective dyspnea
- Hypotension, shock poorly responsive to vasopressors; decreased cardiac contractility when pH < 7.10
- · Often associated with hyperkalemia
- Calculate anion gap (AG) to help with diagnosis: $Na^+ (HCO_3^- + Cl^-)$; normal value $12 \pm 4 \text{ mEq/L}$
- Calculate urinary anion gap with hyperchloremic nongap metabolic acidosis: urine (Na⁺ + K⁺) – urine Cl⁻; normal is < 0 due to presence of unmeasured ammonium cations; if > 0 then likely renal cause of metabolic acidosis

■ Differential Diagnosis

Anion gap acidosis (AG > 12)

- Lactic acidosis
 Renal failure/uremia
- Ketoacidosis: diabetic, ethanol induced, starvation
- Toxin ingestion: salicylates, methanol, ethylene glycol, paraldehyde; not isopropyl alcohol
- · Massive rhabdomyolysis

Non-anion-gap metabolic acidosis

Renal tubular acidosis (positive urinary anion gap); hypoaldosteronism, diarrhea

Treatment

- · Identify and correct underlying disorder
- · Correct fluid and electrolyte disturbances
- Bicarbonate therapy controversial in most cases of metabolic acidosis
- Nonbicarbonate buffers (THAM, dichloroacetate, carbicarb) remain under investigation
- · Hemodialysis in severe, life-threatening circumstances
- · Mechanical ventilation to support respiratory failure

Pearl

An anion gap acidosis can exist even in the presence of a normal anion gap in the setting of hypoalbuminemia or pathological paraproteinemia. For every 1 g/dL reduction in serum albumin, a decrease of approximately 3 mmol in anion gap can be expected.

Reference

Gauthier PM et al: Metabolic acidosis in the intensive care unit. Crit Care Clin 2002;18:289. [PMID: 12053835]

Metabolic Alkalosis

Essentials of Diagnosis

- Arterial pH > 7.45; increased serum HCO₃⁻ and compensatory elevation in Paco₂
- Circumoral paresthesias, tetany, lethargy, confusion, seizure due to reduced ionized calcium
- Hypoventilation usually not clinically evident
- · Often volume contracted with tachycardia and hypotension
- If hypertension present consider glucocorticoid use, hyperaldosterone state; associated with hypokalemia
- Lowers arrhythmia threshold; supraventricular and ventricular arrhythmias
- Measure urinary chloride to differentiate between chloride-sensitive (volume-contracted) from chloride-resistant etiologies

Differential Diagnosis

- Diuretics: loop, thiazides
- Posthypercapnic states
- Hypomagnesemia
- Cushing syndrome or disease
- · Hypokalemia
- · Hyper-renin states
- · Hyperaldosterone states
- · Carbohydrate refeeding after starvation
- · Gastrointestinal loss: emesis, gastric suction, villous adenoma
- Exogenous bicarbonate load: milk-alkali syndrome, citrate, lactate, acetate
- · Nonreabsorbed anions: penicillin, carbenicillin, ketones
- · Bartter or Gitelman syndrome

Treatment

- Restore circulating volume with normal saline in chloride/ saline-responsive states
- In chloride/saline-resistant states, identify and address source of mineralocorticoid excess; spironolactone may play temporizing role in hyperaldosterone states
- · Correct electrolytes: magnesium, potassium
- Acetazolamide used with extreme caution; administer only when volume status restored

Pearl

In a patient with borderline respiratory function, administration of acetazolamide in an attempt to "normalize" a metabolic alkalosis may precipitate fulminant respiratory failure due to increased production of carbon dioxide.

Reference

Khanna A et al: Metabolic alkalosis. Respir Care 2001;46:354. [PMID: 11262555]

Mixed Acid-Base Disorders

Essentials of Diagnosis

- Concurrent existence of more than one primary acid-base disturbance
- Clues for mixed disorders: normal pH with abnormal Paco₂ and HCO₃⁻; Paco₂ and HCO₃⁻ deviating in opposite directions; pH change in opposite direction for known primary disorder
- Anion gap > 20 mmol/L always indicates primary metabolic acidosis
- Obtain Δ gap and "corrected" bicarbonate ([HCO₃]_c) to determine if additional metabolic process present: metabolic alkalosis if [HCO₃]_c > 25; nongap metabolic acidosis if [HCO₃]_c < 25
- Check pH to determine if metabolic process primary (pH > 7.4 for metabolic alkalosis, pH < 7.4 for metabolic acidosis) or compensatory for respiratory process
- Check PaCo₂ for appropriate respiratory compensation for primary metabolic acidosis using PaCo₂ = 1.5 × [HCO₃⁻] + 8 ± 2; metabolic alkalosis using ΔPaCo₂ = 2/3 × ΔHCO₃⁻

Differential Diagnosis

- Respiratory acidosis & metabolic acidosis: cardiopulmonary arrest, respiratory failure with renal failure
- Respiratory alkalosis & metabolic alkalosis: cirrhosis with diuretic use or vomiting, pregnancy with hyperemesis, overventilation in COPD
- Respiratory acidosis & metabolic alkalosis: COPD with diuretic use or vomiting
- Respiratory alkalosis & metabolic acidosis: sepsis, salicylate intoxication, advanced liver disease with lactic acidosis
- Metabolic acidosis & metabolic alkalosis: uremia or ketoacidosis with vomiting
- Triple disturbance usually occurring in the setting of ketoacidosis with vomiting, liver disease, or sepsis

Treatment

· Identify and treat underlying etiology

Pearl

Before embarking on excessive calculations to decipher any "complex acid-base disorder," always check for internal consistency between the pH, Paco₂, and serum HCO_3^- using the Henderson-Hasselbalch equation: $[H^-] = 24 \times (Paco_2/[HCO_3^-])$.

Reference

Kraut JA et al: Approach to patients with acid-base disorders. Respir Care 2001;46:392. [PMID: 11262558]

Respiratory Acidosis

Essentials of Diagnosis

- Arterial pH < 7.35; elevated PaCO₂ and, if chronic, compensatory retention of serum HCO₃; due to ineffective alveolar ventilation or increased CO₂ production
- Symptoms depend on absolute increase and rate of rise in Paco₂
- Tremor, asterixis, incoordination, confusion, somnolence, coma
- · Headache, papilledema, retinal hemorrhages
- · Dyspnea, respiratory fatigue and failure
- Hypoxemia common unless receiving supplemental oxygen

Differential Diagnosis

- Central nervous system depressants
- · Obesity hypoventilation syndrome
- · Chronic obstructive lung disease
- Acute airway obstruction: acute aspiration, laryngospasm, bronchospasm
- Restrictive defects: large pleural effusion, hemothorax, pneumothorax, fibrothorax, pulmonary fibrosis, flail chest
- Pulmonary edema: cardiogenic or pulmonary permeability (ARDS)
- Neurologic and neuromuscular disorders: Guillain-Barré syndrome, botulism, tetanus, phrenic nerve injury, cervical spine lesion, multiple sclerosis, poliomyelitis, myasthenia gravis
- · Organophosphate toxicity
- · Muscular weakness: electrolytes, muscular dystrophy

Treatment

- Correct underlying etiology
- · Avoid central suppressing agents
- Mechanical ventilation or noninvasive positive-pressure ventilation
- Aim to normalize pH and not Paco₂; overcorrection of chronic hypercapnia leads to alkalemia
- Mild degree of respiratory acidosis well tolerated; may be beneficial in management of ARDS ("permissive hypercapnia")

Pearl

The acute worsening of respiratory acidosis seen in chronic CO₂-retaining patients with COPD receiving high-flow oxygen supplementation is more likely due to worsening of V/Q mismatch and not necessarily due to suppression of hypoxic drive.

Reference

Epstein SK et al: Respiratory acidosis. Respir Care 2001;46:366. [PMID: 11262556]

Respiratory Alkalosis

Essentials of Diagnosis

- Arterial pH > 7.45; decreased Paco₂ and compensatory reduction in serum HCO₃⁻; due to increased and excessive alveolar ventilation
- Decreased cerebral perfusion with confusion, lightheadedness, anxiety, irritability
- Circumoral paresthesias, tetany, seizures; indistinguishable from hypocalcemia
- Cardiac arrhythmias when pH > 7.6
- Flattened ST segment or T-waves
- · Other clinical features associated with underlying etiology

■ Differential Diagnosis

- · Meningoencephalitis
- · Pulmonary fibrosis
- Pulmonary edema
- Fever
- Liver disease, hepatic failure
- Hypoxemia
- · Pulmonary embolism
- Anxiety, pain
- Sepsis
- Salicylate toxicity

- · High altitude
- · Pregnancy and elevated progesterone states
- · Mechanical ventilation with overventilation
- Central nervous system lesions: herniation, cerebrovascular accident

Treatment


- Address and treat underlying disorders
- Remove and avoid any central suppressing agents
- · Avoid excessive minute ventilation on mechanical ventilator
- Increasing workload on ventilator (SIMV, CPAP, lengthening ventilator circuit tubing) to counteract primary respiratory alkalosis ineffective, dangerous, and not recommended
- Paralysis with subsequent mechanical ventilation can be considered in severe cases

Pearl

Primary hyperventilation must be distinguished from compensation for metabolic acidosis. The difference is that in respiratory alkalosis, low PaCO₂ is primary and pH is above normal, whereas in metabolic acidosis pH is in the acidic range and low HCO₃⁻ represents the primary disturbance.

Reference


Foster GT: Respiratory alkalosis. Respir Care 2001;46:384.[PMID: 11262557]





Shock

Anaphylactic Shock	73
Cardiac Compressive Shock	74
Cardiogenic Shock	75
Hypovolemic Shock	76
Neurogenic Shock	77
Septic Shock	78



Anaphylactic Shock

Essentials of Diagnosis

- Urticaria and angioedema; other manifestations include laryngeal edema, bronchospasm, pulmonary edema, tachycardia, hypotension, arrhythmias, abdominal cramps, diarrhea, syncope, seizures
- Signs and symptoms typically develop within 5–30 minutes after exposure to offending agent; reaction can be delayed for several hours
- Acute life-threatening immunologic reaction resulting from release of chemical mediators from mast cells and basophils
- Classical IgE mediated agents include foods (peanuts, shellfish), medications, venoms, latex, vaccines, aspirin and NSAIDs, radiographic contrast media

■ Differential Diagnosis

- · Vasovagal reactions
- · Pulmonary embolism
- · Myocardial ischemia
- · Septic or hypovolemic shock
- · Acute poisoning
- · Seizure disorder

Treatment

- Maintenance of airway, breathing, circulation with intubation, ventilatory support, volume expansion as needed
- Epinephrine as soon as possible, 0.3–0.5 mg of 1:1000 dilution subcutaneously every 5–10 minutes as needed; use with caution in elderly and patients with coronary artery disease
- Histamine antagonists such as diphenhydramine (H₁ antagonist) and ranitidine (H₂ antagonist)
- Intravenous pressor agents such as dopamine may be required for persistent hypotension
- Corticosteroids such as hydrocortisone may prevent late-phase manifestations which can occur up to 8 hours after initial presentation

Pearl

Patients taking beta-blocking medications may be resistant to the effects of epinephrine. Atropine and glucagon may be helpful in these cases of anaphylactic shock.

Reference

Kemp SF et al: Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002;110:341. [PMID: 12209078]

Cardiac Compressive Shock

Essentials of Diagnosis

- Low cardiac output state caused by compression of heart or great vessels
- Hypotension, tachycardia, cool extremities, elevated neck veins, pulsus paradoxus, distant heart sounds, oliguria, altered mental status
- ECG with reduced amplitudes; may have electrical alternans
- "Water bottle" shaped cardiac silhouette on chest radiograph
- Echocardiogram demonstrates fluid within pericardium causing right cardiac chamber collapse
- Pulmonary artery catheter reveals equalization of central venous, pulmonary capillary, and pulmonary artery diastolic pressures with low cardiac index
- Cardiac tamponade most common cause; accumulation of fluid in pericardial sac sufficient to prevent filling of cardiac chambers
- Causes of cardiac tamponade: malignancy, trauma, uremia, connective tissue disorders, uremia, infection, idiopathic pericarditis

Differential Diagnosis

- Restrictive cardiomyopathy
- Right ventricular infarction
- Left ventricular failure
- · Constrictive pericarditis
- · Tension pneumothorax

Treatment

- · Intravascular volume expansion with intravenous fluids
- Immediate drainage of pericardial effusion via pericardiocentesis
- Pericardial catheter can be left in place for period of days for ongoing drainage
- Surgical or percutaneous balloon pericardial window can be performed for definitive treatment depending on cause of effusion and rapidity of reaccumulation

■ Pearl

The cardinal finding of elevated neck veins in cardiac tamponade may be absent in the volume depleted patient.

Reference

Bogolioubov A et al: Circulatory shock. Crit Care Clin 2001;17:697. [PMID: 11525054]

Cardiogenic Shock

Essentials of Diagnosis

- Severely low cardiac output state caused by myocardial or valvular dysfunction leading to inadequate tissue perfusion
- Hypotension, cool extremities, distended neck veins, third heart sound, oliguria, respiratory distress due to pulmonary edema
- Pulmonary artery catheter typically demonstrates elevated central venous pressure, increased pulmonary capillary wedge pressure, high systemic vascular resistance, low cardiac index (< 2 L/min/m²)
- · Acute myocardial infarction most common cause
- Other etiologies: acute valvular abnormalities, septal defects or rupture, free wall rupture, traumatic myocardial contusion

Differential Diagnosis

- Hypovolemic shock
- Aortic dissection
- · Septic shock
- · Severe aortic stenosis

■ Treatment

- When cardiogenic shock results from acute myocardial infarction, efforts to improve myocardial perfusion and reduce ischemia are priority; consider prompt thrombolytic therapy or cardiac catheterization with primary coronary intervention
- Intravascular volume should be optimized; pulmonary artery catheter may help; goal pulmonary capillary wedge pressure 17–18 mm Hg
- Dobutamine useful in congestive heart failure and cardiogenic shock given its positive inotropic effects, minimal chronotropic and peripheral vasoconstricting properties
- Dopamine or norepinephrine for persistent hypotension
- Vasodilators such as nitroglycerin and nitroprusside can lower left ventricular afterload; use often limited by hypotension
- · Diuretics helpful in treatment of pulmonary edema
- Intra-aortic balloon pump can be utilized for refractory hypotension with poor organ perfusion

Pearl

In patients with acute myocardial infarction, the onset of cardiogenic shock is often delayed, with median onset of shock occurring 5.5–7 hours after the initial ischemic insult.

Reference

Hollenberg SM: Cardiogenic shock. Crit Care Clin 2001;17:391. [PMID: 11450323]

Hypovolemic Shock

Essentials of Diagnosis

- Hypotension, cool extremities, collapsed neck veins, poor capillary refill
- · Orthostatic hypotension and oliguria
- Elevated BUN to creatinine ratio, concentrated hematocrit; anemia if blood loss is cause
- Rapid correction of signs occurs with adequate fluid resuscitation
- Trauma most common cause
- Other etiologies: gastrointestinal bleeding, fistulas, diarrhea, excessive diuresis, diabetes insipidus, burns, disruption of suture lines

Differential Diagnosis

- · Cardiogenic shock
- · Septic Shock
- · Neurogenic shock
- · Anaphylactic shock

Treatment

- · Establish intravenous access with two large bore catheters
- Rapid fluid resuscitation; infuse at rate adequate to correct calculated or estimated fluid deficit
- Fluid for resuscitation can be crystalloid (normal saline, lactated Ringer's), colloid (albumin, hetastarch, dextran), blood products (packed red blood cells, plasma)
- Transfusion of platelets and coagulation factors may be necessary if large volume of packed red blood cells given
- Continue rapid fluid resuscitation until reversal of abnormal signs such as improved blood pressure, decreased heart rate, increased urine output; avoid excessive volume leading to pulmonary edema
- Evaluate patient for source of blood loss to tailor additional therapeutic interventions

Pearl

If oliguria is not present in the face of clinical hypovolemic shock, evaluate the urine for the presence of osmotically active substances such as glucose, radiographic dyes, or toxins

Reference

Orlinsky M et al: Current controversies in shock and resuscitation. Surg Clin North Am 2001;81:1217. [PMID: 11766174]

Neurogenic Shock

Essentials of Diagnosis

- Loss of peripheral vasomotor tone as a result of spinal cord injury, regional anesthesia, autonomic blocking agents
- · Signs and symptoms depend on location within nervous system
- Injury above midthorax/T6 level: hypotension and bradycardia from loss of thoracic sympathetic tone, vasodilatation, increased vagal tone
- Spinal cord interruption below the midthorax/T6 level: activation of adrenergic system above level of injury leading to tachycardia and increased cardiac contractility
- Extremities are warm above and cool below level of injury
- · Hypotension may be profound
- Decreased venous return and cardiac output due to peripheral venous blood pooling
- Cervical, thoracic, and/or lumbosacral spine imaging to evaluate for fractures; MRI and CT scan for further evaluation of spinal cord

■ Differential Diagnosis

- · Anaphylactic shock
- · Hypovolemic shock

Treatment

- Endotracheal intubation, ventilatory support, volume resuscitation, vasopressors as needed
- Blood pressure may improve with adequate fluid resuscitation
- Fiberoptic or nasal intubation may be required if cervical spine instability suspected
- Norepinephrine or phenylephrine for hypotension refractory to fluids

■ Pearl

Isolated head trauma does not cause neurogenic shock but can cause the Cushing reflex of increased blood pressure accompanied by bradycardia.

Reference

Manley G et al: Hypotension, hypoxia, and head injury: frequency, duration, and consequences. Arch Surg 2001;136:1118. [PMID: 11585502]

Septic Shock

■ Essentials of Diagnosis

- Hypotension and inadequate organ perfusion despite adequate fluid resuscitation in presence of systemic inflammatory response syndrome (SIRS) due to infection
- Wide spectrum of clinical findings ranging from subtle fever, tachycardia, tachypnea to severe shock with multisystem organ failure
- · Warm skin with vasodilated peripheral vascular bed
- Associated organ system dysfunction: lactic acidosis, acute respiratory distress syndrome (ARDS), acute renal failure, disseminated intravascular coagulopathy (DIC), central nervous system dysfunction, hepatobiliary abnormalities
- Elevated cardiac output, low systemic vascular resistance, low blood pressure, elevated pulse pressure

Differential Diagnosis

- Hypovolemic shock
- Cardiogenic shock
- Neurogenic shock
- · Anaphylactic shock

Treatment

- Antibiotics directed against likely sources of infection instituted as quickly as possible; initial regimen often empiric as causative microorganism rarely known initially
- Aggressive fluid resuscitation with blood products, crystalloid, or colloid; central venous pressure monitoring may be helpful
- Vasopressors (dopamine or norepinephrine) if hypotension persists after initial fluid resuscitation
- Ventilatory support to maintain adequate oxygenation and ventilation
- Low-dose hydrocortisone (50 mg every 6 hours) when evidence of adrenal insufficiency complicates sepsis
- Adjunctive recombinant human activated protein C demonstrated statistically significant decrease in mortality in appropriate patients with severe sepsis and multiorgan system dysfunction

Pearl

Elderly and debilitated patients may not exhibit significant symptoms at the onset of sepsis.

Reference

Hotchkiss RS: The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138. [PMID: 12519925]

Pulmonary Disease

Acute Chest Syndrome in Sickle Cell Anemia	81
Acute Inhalation Injury	82
Anaphylaxis	83
Angioedema	84
Chest Tube Thoracostomy	85
Obesity-Hypoventilation Syndrome	86
Obstructive Sleep Apnea Syndrome	87
Pleural Effusions in the ICU	88
Pneumothorax	89
Pulmonary Thromboembolism	90



Acute Chest Syndrome in Sickle Cell Anemia

Essentials of Diagnosis

- New pulmonary infiltrates, fever, chest pain, cough, sputum production, dyspnea in patient with sickle cell disease (SCD)
- May appear toxic with high fever, tachypnea, tachycardia
- Rales, wheezes, decreased breath sounds, dullness to percussion
- Chest radiographs most commonly reveal lower lobe infiltrates, atelectasis
- Anemia, thrombocytopenia, leukocytosis, indirect hyperbilirubinemia, elevated LDH
- · Often develops after vaso-occlusive crisis
- · Etiology multifactorial but clinically resembles pneumonia
- Respiratory distress related to infection, pulmonary fat embolism from bone infarct, pulmonary vascular occlusion by sickled erythrocytes, iatrogenic fluid overload, hypoxemia, splinting due to painful rib or sternal infarcts
- Risk factors: children, hemoglobin SS genotype, low hemoglobin F, elevated WBC, previous acute chest syndrome
- Most common cause of death and second most common cause of hospitalization in adults with sickle cell anemia

Differential Diagnosis

- Pulmonary embolism
- Congestive heart failure
- Community acquired pneumonia
- · Myocardial infarction
- Sickle cell pain crisis
- ARDS

Treatment

- Supportive care with oxygen, bronchodilators, incentive spirometry, pain control
- Empiric antibiotics to cover community-acquired pneumonia; include chlamydia and mycoplasma coverage
- · Fluid management individualized to avoid pulmonary edema
- Role of blood transfusion unclear but exchange transfusion with goal to reduce hemoglobin S to 20–30% indicated for persistent hypoxemia and tachypnea, deteriorating vital signs

■ Pearl

More than 50% of patients present with an acute pain crisis 2.5 days prior to the onset of findings consistent with acute chest syndrome.

Reference

Platt O: The acute chest syndrome of sickle cell disease. N Engl J Med 2000;342:1904. [PMID: 10861328]

Acute Inhalation Injury

Essentials of Diagnosis

- Suspect in patients with facial burns, singed facial hair, intraoral burns, carbonaceous deposits in oropharynx
- Findings depend on exposure: transient airway irritation; bronchospasm; pulmonary edema; toxic pneumonitis with fever, chills, chest pain; flu-like syndrome with cough, myalgias, fatigue; respiratory failure
- Edema, erythema, mucosal ulcerations, carbonaceous material on laryngoscopy
- Injury sustained is function of toxins and their physical properties, intensity and duration of exposure, host factors
- Water solubility determines where inhaled gas gets deposited; highly soluble gases (ammonia, sulfur dioxide, hydrogen chloride) cause acute irritant injury to eyes, nose, upper airway; spare lower airways; less soluble gases (phosgene, ozone, nitrogen oxides) penetrate and damage lower airways
- Most particles <100 microns enter airways; <10 microns enter lower airways; <5 microns deposit in terminal bronchioles and alveoli
- Direct thermal injury occurs from steam exposure overwhelming protective cooling defenses
- Obtain carboxyhemoglobin level in all smoke inhalations
- Elevated lactate may indicate cyanide toxicity
- Poor prognostic signs: rales, burns to face, hypoxemia, altered mental status, respiratory compromise

■ Differential Diagnosis

- Asthma or COPD exacerbation
- ARDS
- Cardiogenic pulmonary edema
- Pneumonia

■ Treatment

- Supplemental oxygen; important in treating CO poisoning
- Early intubation if signs of upper airway compromise
- Pulmonary toilet with bronchodilators and inspiratory maneuvers; antibiotics if clinical signs of pneumonia develop
- Steroid therapy remains controversial
- Treat for cyanide toxicity if suspected

Pearl

A detailed exposure history may alert the clinician to the possibility of delayed effects and later clinical deterioration.

Reference

Rabinowitz PM et al: Acute inhalation injury. Clin Chest Med 2002;23:707. [PMID: 12512160]

Anaphylaxis

Essentials of Diagnosis

- Urticaria, pruritis, flushing, shortness of breath, localized edema; onset 5–60 minutes after exposure to inciting antigen
- Wheezing, laryngeal edema, respiratory failure, pulmonary edema
- Hypotension (anaphylactic shock)
- Causes in ICU: antibiotics (penicillins), radiocontrast media, food, blood products; rarely to latex or other allergens
- Antigen exposure through air, contact, blood or other injection with immediate, life-threatening allergic reaction; usually IgE mediated immediate hypersensitivity; may be non-antibody-mediated
- Release of histamine, complement components, prostaglandins, and leukotrienes from mast cells and basophils through bound IgE
- May or may not have history of previous anaphylaxis

■ Differential Diagnosis

- Angioedema
- Asthma
- Urticaria
- · Vasculitis

■ Treatment

- Maintain airway and cardiopulmonary function; endotracheal intubation
- Remove antigen; discontinue drug or blood products
- Epinephrine, 0.5–1.0 mL of 1:10,000 IV for severe airway compromise or shock; otherwise 0.3–0.5 mL of 1:1000 subcutaneously
- Hydrocortisone, 100 mg every 6-8 hours
- Diphenhydramine, 25–50 mg IV every 4–6 hours plus cimetidine, 300 mg IV every 8–12 hours
- May require large volumes of IV crystalloids (0.9% NaCl); epinephrine, dopamine for persistent hypotension
- Observe for late or persistent reactions

Pearl

Radiocontrast agents are the most common cause of anaphylaxis in the ICU.

Reference

Kemp SF et al: Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002; 110:341 [PMID: 12209078]

Angioedema

Essentials of Diagnosis

- Acute or chronic recurrent episodes of facial, cutaneous, mucosal membrane swelling; may have narrowing of upper airways
- · May be associated with urticaria
- Acute related to medications (angiotensin converting enzyme (ACE) inhibitors), NSAIDs, aspirin
- Chronic congenital (autosomal dominant C1 esterase inhibitor deficiency), rarely acquired chronic angioedema
- Mechanisms similar to anaphylaxis but different mediators and precipitating events
- Associated conditions include malignancy, collagen vascular disease, infections, allergic phenomena

Differential Diagnosis

- Anaphylaxis
- · Acute asthma exacerbation
- Upper airway obstruction including acute epiglottis, foreign body, retropharyngeal abscess
- · Allergic transfusion reactions

Treatment

- Maintain patent airway
- · Assess severity; anticipate further complications
- Discontinue suspected drugs especially ACE inhibitors
- Administer epinephrine, antihistamines, corticosteroids as for anaphylaxis
- Long-term therapy for hereditary angioedema may include recombinant C1 inhibitor concentrate, fresh frozen plasma, danazol

Pearl

Angioedema from angiotensin-converting enzyme inhibitors can occur anytime after the drug is started, even after years without side effects; now also reported with angiotensin-receptor blockers as well.

Reference

Cohen EG et al: Changing trends in angioedema. Ann Otol Rhinol Laryngol 2001;110:701. [PMID: 11510724]

Chest Tube Thoracostomy

Essential Concepts

- Bedside procedure performed to remove fluid or air from pleural space or to instill agents to ablate pleural space
- May require ultrasound or CT imaging to guide tube placement if loculated fluid or air collection
- No absolute contraindication exists but care should be taken in patients with coagulopathies, bullae, large effusions due to main airway occlusion, previous thoracotomy, pleurodesis

Essentials of Management

- Chest tube size depends on type of material to be aspirated: smaller caliber tubes (12 to 28 Fr) for air and larger tubes for fluid (32 to 36 Fr for effusion, 36 to 42 Fr for pus or blood)
- Drainage system prepared at bedside before beginning procedure: three "bottle" system consisting of collection compartment, water seal chamber, manometer for suction control
- Most chest tubes inserted in fourth or fifth intercostal space along anterior axillary line
- Positioning of tube depends on indication for insertion: apically placed tubes for pneumothoraces; dependently placed tubes for pleural effusions or fluid drainage
- Once tube inserted into pleural space, apply suction (10–20 cm H₂O) until all air or fluid removed
- System should be evaluated to assure proper function: fluctuation of fluid column with respiration suggests tube is within pleural space and subjected to intrapleural pressures
- Once lung fully expanded, air leak resolved, or drainage < 150 mL per day, system can be switched to water seal and monitored; if lung remains expanded and no significant reaccumulation of fluid or air, tube can be removed
- If persistent air leak, evaluate entire system to locate source as it may come from within apparatus and not patient
- · If drainage ceases, "milking" tubing may help reestablish flow
- Complications: improper positioning, subcutaneous emphysema, bleeding, intercostal nerve damage, diaphragm or abdominal organ injury, pain, re-expansion pulmonary edema

■ Pearl

A tension pneumothorax may develop if a chest tube is clamped during transportation or movement of the patient.

Reference

Gilbert TB et al: Chest tubes: indications, placement, management, and complications. J Intensive Care Med 1993;8:73. [PMID: 10148363]

Obesity-Hypoventilation Syndrome

Essentials of Diagnosis

- Lethargy and coma from acute respiratory acidosis or signs of right heart failure (weight gain, lower extremity edema)
- Dyspnea or wheezing suggests presence of concomitant obstructive lung disease or pulmonary edema
- Hypercapnic respiratory failure due to combination of depressed ventilatory responsiveness to carbon dioxide (CO₂) and hypoxemia, increased work of breathing, possible abnormal heart and lung function
- · Uncommon condition affecting morbidly obese individuals
- Often develop pulmonary hypertension leading to cor pulmonale
- · Variable relationship to obstructive sleep apnea

Differential Diagnosis

- · Central nervous system disease
- Cardiomyopathy
- · Hypothyroidism and myxedema coma
- · Central respiratory drive suppressants: benzodiazepines, opioids

Treatment

- Ventilatory support with mechanical ventilation may be necessary to provide adequate oxygen and to improve ventilatory drive by resetting hypercapnic central drive sensitivity
- Consider noninvasive positive pressure ventilation; especially if concomitant obstructive sleep apnea present
- · Diuresis with oxygen and diuretics may help volume overload
- Assess for presence of abnormal left ventricular function that may require additional treatment with afterload reduction and beta-blockers
- Medroxyprogesterone acetate may be beneficial for long-term management but role in acute decompensation unclear
- Use of sedative-hypnotic and centrally suppressing agents contraindicated

Pearl

Patients with obesity-hypoventilation syndrome who present with respiratory failure will often regain significant ventilatory responsiveness to CO₂ after several days of mechanical ventilatory support.

Reference

Krachman S et al: Hypoventilation syndromes. Clin Chest Med 1998;19:139. [PMID: 9554224]

Obstructive Sleep Apnea Syndrome

Essentials of Diagnosis

- Excessive daytime somnolence with evidence of upper airway obstruction occurring at any site above glottis during sleep
- Obstructive events last 10–90 seconds and terminate with arousal from sleep leading to sleep fragmentation
- Accessory muscle use, intercostal retractions, paradoxical inspiratory chest wall movements observed during apneas
- Acute hypercapnia, hypoxemia, disrupted sleep, hemodynamic alterations occur with obstruction and can lead to systemic hypertension and cor pulmonale
- Bradycardia with pauses up to 13 seconds and ventricular ectopy seen in severe cases during desaturations
- Daytime hypoventilation not common
- Common characteristics: male sex, age over 40 years, habitual snoring, observed apneas, systemic hypertension
- Risk factors: obesity, tonsillar hypertrophy, craniofacial abnormalities with narrowing of posterior oropharynx, edema of airway structures, diminished neural reflexes or ventilatory control

Differential Diagnosis

- Simple snoring
 Cheyne-Stokes respirations
- · Central sleep apnea syndrome

Treatment

- Nasal continuous positive airway pressure (CPAP) is treatment of choice; acts as pneumatic splint preventing airway closure
- Oxygen therapy alone can prolong apneic events and should be used with careful monitoring
- Endotracheal intubation or tracheostomy highly effective for select patients failing noninvasive ventilation
- · Lateral decubitus position or elevated head of bed preferred
- Use of sedative-hypnotic and centrally suppressing agents contraindicated
- No role for respiratory stimulants or carbonic anhydrase inhibitors

Pearl

Obstructive sleep apnea syndrome should be suspected in obese hypersomnolent snorers who are hypertensive.

Reference

Strollo PJ Jr: Indications for treatment of obstructive sleep apnea in adults. Clin Chest Med 2003;24:307. [PMID: 12800786]

Pleural Effusions in the ICU

Essentials of Diagnosis

- · Accumulation of fluid within pleural space
- Symptoms range from none to dyspnea, pleuritic chest pain, respiratory failure
- Radiographic findings may be subtle in ICU patients as radiographs frequently taken with patient in semirecumbent or reclining position; < 500 mL of fluid may appear as haziness over lower lung fields in these positions
- Primary pleural disease rarely reason for admission to ICU; pleura can be secondarily affected as part of spectrum of critical illness
- Clinical relevance of small effusions (< 100 mL) found only by ultrasound or CT scan in this patient population remains unclear
- Performing thoracentesis generally safe in critically ill patients
- Risk factors for development of pleural effusion in ICU include immobility, sedation, paralytic agents
- Common etiologies: congestive heart failure (bilateral transudates or "pseudoexudate"), atelectasis (unilateral transudate), uncomplicated parapneumonic effusion (unilateral exudate)

■ Differential Diagnosis

- · Parenchymal consolidation or atelectasis
- · Pleural thickening
- · Lung or pleural-based mass
- · Elevated hemidiaphragm

Treatment

- Diagnostic thoracentesis if pleural effusion and fever, lack of clinical response to antibiotic therapy, atypical presentation for underlying disease
- Majority resolve with therapy aimed at underlying disease
- Antibiotic therapy alone for uncomplicated parapneumonic effusions; chest tube thoracostomy for empyemas
- Chest tube drainage for complicated parapneumonic effusions, large hemothoraces, symptomatic malignant effusions

Pearl

Consider thoracentesis in critically ill patients with pleural effusions as the finding of an unsuspected infectious etiology will have a dramatic impact on therapy and outcome.

Reference

Fartoukh M et al: Clinically documented pleural effusions in medical ICU patients. Chest 2002;121:178. [PMID:11796448]

Pneumothorax

Essentials of Diagnosis

- Shortness of breath, chest pain, hypoxemia, hypercapnia; chest resonant to percussion, asymmetric decreased breath sounds
- If tension pneumothorax (check-valve mechanism causing positive intrapleural pressure), hypotension, cardiopulmonary arrest
- Air collects in pleural space (or extrapleural space between parietal pleura and chest wall) from lung rupture or disruption of chest wall; subsequent lung collapse
- Etiologies include: spontaneous; traumatic; complication of lung abscess, *Pneumocystis carinii*, tuberculosis, emphysema; complication of mechanical ventilation, thoracentesis, central venous catheter, pleural or lung biopsy
- Chest radiograph: separation of lung from chest wall, deep sulcus sign (hyperlucent costophrenic angle); pneumomediastinum; subcutaneous air in neck or chest wall

■ Differential Diagnosis

- Atelectasis
- Pleural effusion
- · Pulmonary embolism
- · Upper or central airway obstruction

Treatment

- · High Fio₂ speeds resolution
- Observation only if small pneumothorax in stable patient due to inadvertent introduction of air (thoracentesis), no further accumulation, not on mechanical ventilation
- Otherwise evacuate air with percutaneous catheter if moderate size, no mechanical ventilation, stable; surgical tube thoracostomy for all others
- Emergent evacuation by catheter or chest tube if hypotension, respiratory failure
- Attach pleural drain to collection device with "water seal" and suction; when no air leak, discontinue suction; if lung remains inflated, consider removing tube

Pearl

If a pneumothorax is suspected and a chest radiograph with the patient in a supine position does not demonstrate a pneumothorax, a CT scan (which is very sensitive) should be obtained.

Reference

Chen KY et al: Pneumothorax in the ICU: patient outcomes and prognostic factors. Chest 2002;122:678. [PMID: 12171850]

Pulmonary Thromboembolism

Essentials of Diagnosis

- Dyspnea, tachypnea, tachycardia, pleuritic chest pain; calf pain and swelling consistent with deep vein thrombosis (DVT)
- Hypotension, syncope, cyanosis, shock if "massive" (>50% pulmonary vascular bed occlusion); or submassive in patient with poor cardiopulmonary reserve
- Mild to moderate hypoxemia, increased P(A-a)O₂, mildly reduced Paco₂
- Sinus tachycardia most frequent ECG abnormality; "S1Q3T3" pattern of right heart strain considered highly predictive but seen in <12% of patients with pulmonary embolism (PE)
- D-dimer, fibrin degradation product in patients with DVT and PE usually >500 µg/dL
- Normal chest radiograph in hypoxemic individual should lead to suspicion of PE; other common radiographic findings include platelike atelectasis, small pleural effusions
- Diagnostic imaging techniques include Doppler ultrasound of symptomatic extremity, radionuclide ventilation-perfusion scan, helical (spiral) CT angiogram, pulmonary angiogram
- Risk factors: immobilization, trauma to extremity, previous DVT/PE, recent surgery, obesity, nephrotic syndrome, congestive heart failure, stroke, malignancy, estrogen use

■ Differential Diagnosis

- · Acute coronary syndrome
- Acute chest syndrome
- Fat embolism
- Asthma

• Spontaneous pneumothorax

Treatment

- Prevention in ICU patients with risk factors is paramount
- If no contraindications, once DVT or PE suspected, anticoagulation with unfractionated or low-molecular-weight heparin should be instituted while awaiting confirmatory diagnostic testing
- Thrombolytic therapy may be option in patients with "massive PE"; may consider in patients with hypotension to hasten hemodynamic stabilization

Pearl

Ventilation-perfusion scans in patients with COPD are generally considered to be of limited value because airway obstruction can cause a falsely positive perfusion defect due to hypoxemic mediated vaso-constriction.


Reference

Rocha AT, et al: Venous thromboembolism in intensive care patients. Clin Chest Med 2003;24:103. [PMID: 12685059]

8 ----

Respiratory Failure

Acute Respiratory Distress Syndrome (ARDS)	93
Air Embolism Syndrome	94
Aspiration Pneumonitis & Pneumonia	95
Life-Threatening Hemoptysis	96
Mechanical Ventilation	97
Mechanical Ventilation in ARDS	98
Mechanical Ventilation in Neuromuscular Disorders	99
Mechanical Ventilation in Status Asthmaticus 1	00
Mechanical Ventilation, Complications of 1	01
Mechanical Ventilation, Failure to Wean from 1	02
Noninvasive Positive Pressure Ventilation (NIPPV) 1	03
Positive End-Expiratory Pressure (PEEP) 1	04
Respiratory Failure from Chronic Obstructive Lung Disease 1	05
Respiratory Failure from Neuromuscular Disorders 1	06
Respiratory Failure from Thoracic Cage Disorders 1	07
Respiratory Failure: Arterial Hypercapnia1	80
Respiratory Failure: Hypoxemia1	09
Status Asthmaticus 1	10
Ventilator-Associated Pneumonia 1	11



Acute Respiratory Distress Syndrome (ARDS)

■ Essentials of Diagnosis

- Severe hypoxemia refractory to supplemental oxygen (Pao₂/Fio₂ < 200–300); acute diffuse chest radiograph infiltrates consistent with noncardiogenic pulmonary edema (increased lung permeability); no evidence of heart failure; if measured, normal or low pulmonary artery wedge pressure
- 75–80% due to sepsis, pneumonia, aspiration of gastric contents, severe trauma; other causes: fat embolism, pancreatitis, transfusion related lung injury, amniotic fluid embolism
- Mortality 30–60%; highest in sepsis, elderly, multiorgan system failure; due to nonrespiratory organ failure, infection; rarely respiratory failure

Differential Diagnosis

- · Cardiogenic pulmonary edema
- · Severe extrapulmonary right-to-left shunt (intracardiac shunt)
- Severe localized pneumonia or atelectasis without diffuse lung involvement

■ Treatment

- Treat underlying disease (sepsis, trauma, pneumonia, pancreatitis)
- High oxygen concentrations ($Fio_2 > 0.4$)
- Endotracheal intubation, mechanical ventilation needed for increased work of breathing
- · Positive end-expiratory pressure
- Low tidal volume (<6 mL/kg) improves survival; may lead to hypercapnia (keep f <35/min)
- Minimal fluid intake and diuretics may help reduce pulmonary edema; may not be compatible with treating underlying diseases
- Complications of high Fio₂: lung injury; high positive end-expiratory pressure (PEEP): low cardiac output, hypotension, pneumothorax, lung injury

Pearl

Attack rate of ARDS for patients with similar underlying disorders may be higher in chronic alcoholics, smokers, and the elderly.

Reference

Ware LB et al: The acute respiratory distress syndrome. N Engl J Med 2000;342:1334. [PMID: 10793167]

Air Embolism Syndrome

Essentials of Diagnosis

- Sudden cardiovascular collapse with hypotension, hypoxemia, respiratory distress, occasionally stroke symptoms and signs caused by air entering systemic venous, pulmonary arterial, pulmonary venous circulation
- In ICU, most frequently related to central venous catheter insertion, removal, disconnection, or accidental injection of air
- Seen in trauma, diving accidents, hemodialysis, open heart surgery, thoracotomy, neurosurgical procedures
- May have paradoxical arterial emboli with stroke or systemic arterial occlusion via patent foramen ovale or pulmonary rightto-left shunts
- Air bubbles occasionally seen on chest imaging, echocardiogram, head CT scan

Differential Diagnosis

- · Shock: cardiogenic, hypovolemic, anaphylactic
- · Pulmonary thromboembolism
- · Cardiac tamponade
- · Tension pneumothorax

Treatment

- · Place patient on left side, head down
- If air entry from CVP catheter, stop air entry; aspirate air from right ventricle
- Supportive care, oxygen, cardiopulmonary resuscitation
- Hyperbaric oxygen recommended but usually impractical and delayed
- Prevention: place CVP catheter with patient head down, prevent air injection, remove catheter with patient head down, take precautions to avoid accidental disconnection

Pearl

Position patient to keep central venous catheter entry site below "heart" level whenever inserting, adjusting, using, or removing the catheter.

Reference

Heckmann JG et al: Neurologic manifestations of cerebral air embolism as a complication of central venous catheterization. Crit Care Med 2000;28:1621. [PMID: 10834723]

Aspiration Pneumonitis & Pneumonia

Essentials of Diagnosis

- Aspiration pneumonitis: chemical irritation (food, gastric acid)
 plus inflammation; may be witnessed; symptoms and chest radiograph changes 2–5 hours after event; aspiration of gastric
 contents from impaired consciousness, loss of gag reflex, enteral feeding, impaired gastric motility, endotracheal intubation,
 supine positioning
- Aspiration pneumonia: aspiration of bacteria from oropharynx or stomach; usually unwitnessed; increased with periodontal infection, alcoholism, impaired consciousness; increased in critically ill (altered bacterial flora, impaired swallowing, endotracheal intubation, advanced age)

Differential Diagnosis

- Community-acquired pneumonia, tuberculosis, fungal pneumonia
- Ventilator-associated pneumonia
- · Pulmonary edema

■ Treatment

- · Treat respiratory failure due to acute lung injury
- Keep airway clear by suctioning; may need endotracheal intubation if severe
- Antibiotics not needed in pneumonitis unless high risk of bacterial colonization of stomach (small bowel obstruction, inhibition of gastric acid production) or fever, abnormal chest radiograph, respiratory failure > 48 hours after suspected aspiration; corticosteroids contraindicated
- Aspiration pneumonia: Antibiotics indicated; if hospitalized < 72 hours, treat as community-acquired pneumonia (ceftriaxone or levofloxacin); hospitalized > 72 hours or resident in longterm care facility, treat Gram-negative bacilli including Pseudomonas; high likelihood of anaerobic or mixed infection (alcoholism, periodontal disease), levofloxacin or ceftriaxone plus clindamycin or metronidazole

Pearl

Routine elevation of head of bed to 30–45 degrees decreases risk of aspiration and ventilator-associated pneumonia by as much as 60% over first 7 days.

Reference

Marik PE: Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001;344:665. [PMID: 11228282]

Life-Threatening Hemoptysis

Essentials of Diagnosis

- Hemoptysis with large volume in patient with normal pulmonary function, or smaller volumes if impaired cardiopulmonary function, cough, consciousness
- Tuberculosis, tuberculous cavity with aspergilloma (mycetoma), trauma, mitral stenosis; less common with lung cancer
- > 600 mL hemoptysis in 16 hours has 75% mortality without surgery; < 600 mL about 5% mortality
- Respiratory failure occurs before hemodynamic compromise with hemoptysis
- Risk factors: coagulopathy, infection, thrombocytopenia, renal failure
- Bronchial arteries source 90%, pulmonary arteries 10%

■ Differential Diagnosis

- · Severe epistaxis
- · Upper gastrointestinal bleeding

Treatment

- · Establish and maintain patent airway
- Consider endotracheal intubation if cough inadequate; doublelumen split bronchial intubation useful, but requires experienced personnel to position
- · Measure quantity of blood expectorated over time
- Establish severity of underlying lung disease (chest radiograph, CT scan, arterial blood gases)
- Localize bleeding site with fiberoptic bronchoscopy (if mild to moderate bleeding) or bronchial arteriography
- Control bleeding; bronchial artery embolization preferred over emergent surgical resection
- Definitive therapy requires surgery but outcome better if delayed
- Treat underlying infection (bacterial, tuberculous), correct thrombocytopenia or coagulopathy

Pearl

Don't worry about the patient's loss of blood; if there is that much hemoptysis, the patient will asphyxiate first.

Reference

Jean-Baptiste E: Clinical assessment and management of massive hemoptysis. Crit Care Med 2000;28:1642. [PMID: 10834728]

Mechanical Ventilation

Essential Concepts

- Usually delivered through endotracheal tube; sometimes "noninvasively" using mask (noninvasive positive-pressure ventilation or NIPPV)
- Defined by changeover from expiration to inspiration ("trigger"); and changeover from inspiration to expiration ("mode")
- Volume-Cycle Ventilation (VCV): most common; preset tidal volume (VT) each breath; preset breaths per minute or patient may "trigger" at own rate; preset inspiratory flow rate or time
- Pressure-Controlled Ventilation (PCV): inspired flow at preset pressure; V_T determined by pressure, compliance of respiratory system; preset breaths per minute or patient may "trigger"; set inspiratory time
- Pressure-Support Ventilation (PSV): provides preset inspiratory pressure but V_T determined by patient effort and pressure gradient between ventilator and patient; used mostly for weaning
- Intermittent Mandatory Ventilation (IMV): provides preset breaths per minute; patient can breathe spontaneously (with or without PSV) at other times; used mostly for weaning
- May cause impaired venous return leading to hypotension, low cardiac output; pneumothorax, pneumomediastinum, lung injury
- Indications: respiratory failure, especially worsening gas exchange or muscle fatigue; absent (apnea) or inadequate ventilatory drive; high work of breathing; hemodynamic instability or acute pulmonary edema

Essentials of Management

- Select ventilator mode (VCV, PCV, PSV, IMV)
- For VCV or IMV: preset VT, backup rate, peak inspiratory flow; PCV, preset inspiratory pressure, backup rate, I:E ratio or inspiratory time
- · For PSV: preset inspiratory pressure
- Adjust Fto₂ and PEEP; usual goal Pao₂ > 55 mm Hg, O₂ saturation >90%; adjust minute ventilation to achieve Paco₂ needed for pH between 7.32 and 7.45 (unless contraindications)

Pearl

Using a low tidal volume (6–8 mL/kg ideal weight) improves outcome in ARDS, asthma, and COPD patients, possibly because of decreased lung injury and barotrauma.

Reference

Tobin MJ: Advances in mechanical ventilation. N Engl J Med 2001;344:1986. [PMID: 11430329]

Mechanical Ventilation in ARDS

Essential Concepts

- Lung injury diffuse but nonhomogeneous, ranging from completely normal areas to severely atelectatic regions
- Oxygenation goal: Increase Fio₂ and PEEP as needed to achieve Pao₂ > 55 mm Hg, but minimize O₂ toxicity by keeping Fio₂ < 0.4 and using PEEP judiciously to avoid complications
- PEEP increases end-expiratory lung volume, keeping lung units from collapsing and may "recruit" collapsed lung units
- Mechanical ventilation counters high work of breathing with low compliance lungs
- Low tidal volume (VT = 6 mL/kg ideal weight) strategy minimizes lung damage; improves survival, lessens barotrauma and cardiovascular compromise, but may result in hypercapnia

Essentials of Management

- Volume-cycled ventilation preferred; alternative pressure-controlled ventilation
- Tidal volume (VT) at 6 mL/kg ideal weight; keep inspiratory plateau pressure < 30 cm H_2O , if necessary, lower V_T to 4–5 mL/kg
- Respiratory rate up to 35/min with goal pH 7.30–7.45; if pH < 7.30 and rate = 35, consider sodium bicarbonate; if pH < 7.15, consider increased VT
- Use least of these Fio₂/PEEP combinations to achieve Pao₂ 55–80 mm Hg: Fio₂ 0.4/PEEP 5 cm H₂O, 0.4/8, 0.5/8, 0.5/10, 0.6/10, 0.7/10, 0.7/12, 0.7/14, 0.8/14, 0.9/16, 0.9/18, 1.0/18–25
- Check daily chest radiographs for endotracheal tube position, evidence of barotrauma

Pearl

A low tidal volume strategy (VT 6 mL/kg or less) is the only therapy shown to improve outcome in ARDS.

Reference

The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301. [PMID: 10793162]

Mechanical Ventilation in Neuromuscular Disorders

Essential Concepts

- Hypercapnia often seen with vital capacity < 55% predicted or < 15 mL/kg
- Generally requires mechanical ventilation when hypercapnia develops, especially if disease progressive or worsening
- Patients with respiratory muscle weakness prone to impaired cough, poor mucociliary clearance of secretions, pneumonia
- Hypoxemia due to atelectasis, mucous plugging of airways, pneumonia; usually absence of increased airway resistance and abnormal lung mechanics

Essentials of Management

- Consider mechanical ventilation in patient with progressive neuromuscular weakness with VT < 15 mL/kg and falling; Paco₂ > 50 mm Hg and rising; unresponsive to other treatments; central nervous system disorder with central hypoventilation unresponsive to treatment
- · Volume-cycled ventilation
- Tidal volume (VT) 6–8 mL/kg ideal weight to start, keep inspiratory plateau pressure < 30 cm H₂O.
- Adjust respiratory rate to maintain pH 7.35-7.45
- PEEP to help prevent or reverse atelectasis from breathing at low lung volumes
- Frequent suctioning, postural drainage, chest percussion (if indicated)
- Patients with ventilatory control disorders (central hypoventilation) may not "trigger" ventilator adequately
- Daily chest radiographs for endotracheal tube position, evidence of barotrauma
- Consider noninvasive positive pressure ventilation (NIPPV), if acute reversible neurological disorder, mild respiratory failure, patient awake, alert

Pearl

Ventilator-associated pneumonia frequently complicates respiratory failure from neuromuscular diseases.

Reference

MacDuff A, Grant IS: Critical care management of neuromuscular disease, including long-term ventilation. Curr Opin Crit Care 2003;9:106. [PMID: 12657972]

Mechanical Ventilation in Status Asthmaticus

Essential Concepts

- Mechanical ventilation may be needed because of respiratory muscle fatigue, especially because reversal of airway obstruction may take hours to days
- Patients with severe hyperinflation have very high end-inspiratory and high end-expiratory volume; therefore at risk for barotrauma, hypotension, respiratory acidosis
- Goal to minimize hyperinflation by maximizing expiratory time (low respiratory rate), minimizing inspiratory time (low tidal volume, high inspiratory flow rates)
- Reduction of hyperinflation improves gas exchange and decreases work of breathing
- · May accept mild-to-moderate hypercapnia to meet goals

Essentials of Management

- Indications: Status asthmaticus with severe acidosis; very high work of breathing, heavy airway secretions, impending inspiratory muscle failure
- · Maximize pharmacotherapy: bronchodilators, corticosteroids
- Volume-cycled ventilation; set tidal volume (VT) 6–8 mL/kg ideal weight; use inspiratory flow rate 70–100 L/min to minimize inspiratory time
- Goals: inspiratory plateau pressure <25–30 cm H₂O, I:E ratio at least 1:3 (preferably 1:4–5), low intrinsic PEEP (<5 cm H₂O)
- Low VT and respiratory rate combination may lead to hypercapnia; hypercapnia acceptable if pH > 7.25
- Daily chest radiographs for endotracheal tube position, evidence of barotrauma

Pearl

As long as hyperinflation is avoided, be patient with status asthmaticus and mechanical ventilation; it may take 3–7 days or even more for airway inflammation to resolve.

Reference

Peigang Y et al: Ventilation of patients with asthma and chronic obstructive pulmonary disease. Curr Opin Crit Care 2002;8:70. [PMID: 12205409]

Mechanical Ventilation, Complications of

Essentials of Diagnosis

- Pulmonary: barotrauma, such as pneumothorax, pneumomediastinum, acute lung injury, hypo- or hyperventilation, ventilator-associated pneumonia, atelectasis, rarely O₂ toxicity
- Extrapulmonary: hemodynamic, such as hypotension, low cardiac output, impaired venous return; increased intracranial pressure (mild), psychological dependence on ventilator; multiorgan system failure; misinterpretation of intravascular pressures measured inside thorax (pulmonary artery or central venous catheter)

Differential Diagnosis

- · Nosocomial infection, including pneumonia
- Sepsis
- · Hypovolemia
- · Cardiac tamponade
- · Pulmonary thromboembolism
- Cardiogenic pulmonary edema, noncardiogenic pulmonary edema, transfusion-associated lung injury
- Pneumothorax or pneumomediastinum from catheter placement, ruptured esophagus

Treatment

- Anticipate complications with daily chest radiograph (pneumothorax), follow arterial blood gases
- Suspect positive-pressure ventilation if hypotension, low cardiac output (oliguria, prerenal azotemia, hypotension), pneumothorax, pneumomediastinum
- If hypotension or low cardiac output, consider volume challenge, 250–500 mL of 0.9% NaCl, monitor CVP and blood pressure
- Use low tidal volume (VT 6–8 mL/kg) combined with adequate respiratory rate to achieve goal PaCO₂ and PaO₂ to minimize barotrauma risk
- Suspect ventilator-associated pneumonia if fever, infiltrates on chest radiograph, >3 days of mechanical ventilation

Pearl

Oxygen toxicity is associated with prolonged use of 100% O_2 , but is considered unlikely with $F_{102} < 0.50$.

Reference

Tobin MJ: Advances in mechanical ventilation. N Engl J Med 2001;344:1986. [PMID: 11430329]

Mechanical Ventilation, Failure to Wean from

Essentials of Diagnosis

- Excessive dyspnea or hypercapnia, hypoxemia when ventilatory support withdrawn; often imbalance between ventilatory requirement and inadequate capacity
- Anticipate if minute ventilation (VE) on ventilator >12 L/min, spontaneous rate/VT (L) >100, spontaneous VE < 6 L/min, vital capacity <15 mL/kg

Differential Diagnosis

- High VE requirement (>12 L/min): fever, metabolic acidosis, renal failure, agitation, activity, infection, hyperthyroidism, administration of excessive calories (especially carbohydrate), lung or heart disease (high dead space/tidal volume ratio).
- Low VE capacity (spontaneous VE < 6 L/min): neuromuscular weakness (critical illness polyneuropathy or myopathy), malnutrition, hypophosphatemia, hypokalemia, primary muscle disease, diaphragmatic weakness, flail chest, rib fractures, ascites, abdominal distension, pain, high resistance of endotracheal tube (<7.0 mm)

■ Treatment

- Wean when Ve < 10–12 L/min; patient afebrile, stable hemodynamically; normal serum potassium and phosphorus, adequate nutritional support, minimal respiratory secretions, little or no bronchospasm, no pulmonary edema, serum bicarbonate >18 mmol/L
- Relieve severe ascites or abdominal distension, abdominal or chest wall pain (especially if with respiration)
- If stable, perform daily spontaneous breathing trial; respiratory rate/tidal volume (L) <60, predicts successful weaning; >110 predicts failure; 60–110, marginal predictive value
- Correct electrolytes; consider malnutrition, neuropathy or myopathy, diaphragmatic fatigue or paralysis; avoid excessive sedation
- Transient noninvasive positive pressure ventilation helpful after extubation

Pearl

Routine daily trials of spontaneous breathing in stable patients decreases length of stay in ICU and duration of mechanical ventilation.

Reference

MacIntyre NR et al: Evidence-based guidelines for weaning and discontinuing ventilatory support. Chest 2001;120(6 Suppl):375S. [PMID: 11742959]

Noninvasive Positive Pressure Ventilation (NIPPV)

Essential Concepts

- Delivery of positive-pressure ventilation without endotracheal tube via nasal or oronasal facemask; success depends on alert, cooperative patient with proper fitting interface
- Continuous positive airway pressure (CPAP): delivers constant pressure during both inspiration and expiration
- Bilevel devices: cycle between two different positive pressures; inspiratory pressure (IPAP) set higher than expiratory pressure (EPAP)
- Useful in select patients with acute or chronic respiratory failure
- Obstructive sleep apnea (OSA): maintains upper airway patency
- COPD: improves gas exchange, vital signs, dyspnea scores; reduces need for invasive mechanical ventilation
- Weaning from invasive mechanical ventilation: shorter duration of support, fewer ICU days, improved 60-day mortality
- Pulmonary edema: afterload reduction and improved cardiac output achieved by lowering left ventricular transmural pressure
- Contraindications: acute respiratory arrest, ischemia, hypotensive shock, uncontrolled arrhythmias, excessive secretions, inability to protect airway, facial abnormalities
- Complications: nasal bridge skin breakdown, sinus congestion, sinusitis, dry eyes, dry mouth, headache, gastric distention

Essentials of Management

- OSA: CPAP treatment of choice; if unable to tolerate high pressure levels required to maintain airway patency switch to bilevel device adjusting EPAP level until obstructive apneas abolished; adjust IPAP level to reduce hypopneas, desaturations, snoring
- COPD: Bilevel devices with high IPAP to reduce work of inspiratory muscles and EPAP lower than intrinsic PEEP
- Pulmonary edema: CPAP starting at 10–12.5 cm H₂O; caution with bilevel modes until further studies available

Pearl

Patients are not subject to the potential complications of intubation, loss of airway defense mechanisms, and self-extubation with the use of NIPPV compared to invasive mechanical ventilation.

Reference

Liesching T et al: Acute applications of noninvasive positive pressure ventilation. Chest 2003 Aug;124:699. [PMID: 1290756]

Positive End-Expiratory Pressure (PEEP)

Essential Concepts

- PEEP given with positive-pressure ventilation or as continuous positive airway pressure (CPAP)
- Normally, exhalation continues until alveolar equals atmospheric pressure (0 cm H₂O); end-expiratory lung volume determined by lung and chest wall compliance
- If PEEP applied, end-expiratory alveolar pressure then equals PEEP; thereby increasing end-expiratory volume, which decreases or reverses atelectasis, adding lung participating in gas exchange
- PEEP decreases RV and LV preload, increases RV but decreases LV afterload; may reduce cardiac output; contributes to hypotension, organ hypoperfusion
- Cardiovascular effects most if lungs normal or more compliant; smaller effects with stiff lungs

■ Essentials of Management

- Use PEEP for hypoxemia in ARDS, pulmonary edema, atelectasis; may be helpful for patients with low lung volume (obesity, postsurgery, neuromuscular weakness, ascites)
- Usually avoid with hypotension, volume depletion, increased intracranial pressure, obstructive lung disease
- Use least PEEP to improve hypoxemia, minimize inspired O₂ concentration, reduce or reverse atelectasis
- One protocol for Fio₂ and PEEP in ARDS—use least Fio₂/PEEP combination to achieve Pao₂ 55–80 mm Hg: Fio₂ 0.4/PEEP 5 cm H₂O, 0.4/8, 0.5/8, 0.5/10, 0.6/10, 0.7/10, 0.7/12, 0.7/14, 0.8/14, 0.9/16, 0.9/18, 1.0/18–25
- For other disorders, optimal PEEP not known, but can use same for ARDS
- Consider lower levels of PEEP for nonhomogeneous atelectasis, hypotension, low cardiac output
- Adverse effects of PEEP: hypotension, low cardiac output, decreased nonrespiratory organ failure, pneumothorax, pneumomediastinum

Pearl

Both high PEEP and low tidal volume or low PEEP and high tidal volume can damage the lungs.

Reference

Gattinoni L et al: Physiologic rationale for ventilator setting in acute lung injury/acute respiratory distress syndrome patients. Crit Care Med 2003;31(4 Suppl):S300. [PMID: 12682456]

Respiratory Failure from Chronic Obstructive Lung Disease

Essentials of Diagnosis

- · Chronic bronchitis or emphysema
- Increasing dyspnea, often with cough, decreased exercise capacity, increased sputum production, respiratory muscle fatigue
- Mild to moderate hypoxemia; may have Paco₂ >50 mm Hg with acute respiratory acidosis (pH < 7.35), even in those without chronic CO₂ retention
- Mechanisms include increased airway resistance (bronchospasm, increased secretions, airway edema), infection and host response to infection (change in bacterial type, purulent sputum), altered lung mechanics (hyperinflation)

Differential Diagnosis

- · Asthma, pneumonia, pulmonary edema
- Neuromuscular weakness or central hypoventilation syndrome

■ Treatment

- Identify most severe: very low peak expiratory flow, pH < 7.25 with Paco₂ >60, right heart failure, pneumothorax, pneumonia, poor response to bronchodilators, malnutrition, multiorgan failure
- Oxygen: 2–4 L/min nasal cannula or Fio₂ 0.28–0.40 by Venturi mask
- Aerosolized albuterol and ipratropium bromide; theophylline not recommended
- Intravenous or oral corticosteroids; taper 7–10 days
- Antibiotics against S pneumoniae, H influenzae, M catarrhalis (2nd generation cephalosporins, extended-spectrum macrolides, fluoroquinolones)
- In selected patients, noninvasive positive pressure ventilation up to 12–24 hours
- Mechanical ventilation if severe, nonresponse to therapy, altered mental status, muscle fatigue

Pearl

Patients with most severe hypoxemia and lowest pH (acute respiratory acidosis) are at highest risk for worsening hypercapnia with administration of oxygen.

Reference

Bach PB et al: Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001;134:600. [PMID: 11281745]

Respiratory Failure from Neuromuscular Disorders

Essentials of Diagnosis

- Weakness of respiratory muscles or dysfunction of ventilatory control from neuromuscular or neurological disease
- $Paco_2 > 50$ mm Hg, usually with additional hypoxemia
- If weakness, vital capacity (VC) <1500 mL associated with hypercapnia
- Disorders of ventilatory control due to sedative or opioid overdose, head trauma, brain stem stroke, hypothyroidism, poliomyelitis
- Respiratory muscle weakness due to spinal cord disease (trauma, cancer, paraspinous abscess, amyotrophic lateral sclerosis); neuropathic disease (myasthenia gravis, botulism, Guillain-Barré syndrome, tick paralysis, drugs, peripheral neuropathy); primary muscle disease (polymyositis, endocrinopathies, hypophosphatemia, hypokalemia); ICU patients (critical illness polyneuropathy or polymyopathy); extremity strength may not reflect strength of respiratory muscles

Differential Diagnosis

- Primary lung disease with acquired neuromuscular weakness (critical illness polyneuropathy)
- · Chest wall deformity or abnormality

Treatment

- · Treat underlying disease
- Oxygen for hypoxemia due to atelectasis or pneumonia
- Consider endotracheal intubation and mechanical ventilation when VC<15 mL/kg or 1200 mL in adults, especially if worsening
- Patients with weakness have disproportionate atelectasis, inability to clear secretions and pneumonia, pulmonary thromboembolic disease

■ Pearl

Suspect acquired neuromuscular weakness due to critical illness polyneuropathy or myopathy in a patient who fails to wean from mechanical ventilation.

Reference

Rabinstein AA et al: Warning signs of imminent respiratory failure in neurological patients. Semin Neurol 2003;23:97. [PMID: 12870111]

Respiratory Failure from Thoracic Cage Disorders

Essentials of Diagnosis

- · Structural or functional abnormality of chest wall or diaphragm
- $Paco_2 > 50 \text{ mm Hg}$, usually with hypoxemia
- Some disorders limit chest expansion (restriction), such as kyphoscoliosis or ankylosing spondylitis, pleural effusions, restrictive pleuritis
- Truncal obesity, pregnancy, ascites, severe abdominal organomegaly, recent abdominal surgery limit diaphragmatic excursion
- Severe chronic thoracic cage disorders may lead to pulmonary hypertension and cor pulmonale
- Severely obese patients have a high likelihood of obstructive sleep apnea (OSA) and obesity hypoventilation syndrome (OHS)

■ Differential Diagnosis

- Primary lung diseases (COPD, asthma, interstitial lung disease)
- · Neuromuscular disease with respiratory muscle weakness

■ Treatment

- · Treat underlying disease
- · Oxygen for hypoxemia due to atelectasis or pneumonia
- Endotracheal intubation and mechanical ventilation for hypercapnia; may try noninvasive positive pressure ventilation if mild, reversible cause

■ Pearl

Patients with weakness have disproportionate atelectasis, inability to clear secretions and pneumonia (frequent suctioning and mobilization of secretions), and pulmonary thromboembolic disease compared to other chest wall disorders.

Reference

Goldstein RS: Hypoventilation: neuromuscular and chest wall disorders. Clin Chest Med 1992;13:507. [PMID: 1521416]

Respiratory Failure: Arterial Hypercapnia

■ Essentials of Diagnosis

- Arterial Paco₂ (Paco₂) >45 mm Hg, with pH < 7.35
- · May have headache, bradycardia, confusion, lethargy, or coma
- Other features depend on presence of hypoxemia or features of underlying disease
- · May be seen with severe pulmonary diseases
- Nonpulmonary causes of respiratory failure often have hypercapnia, such as disorders of ventilatory control or chest wall, neuromuscular diseases

Differential Diagnosis

- Severe COPD, status asthmaticus, interstitial lung diseases, pulmonary edema
- Head injury, stroke, brain stem dysfunction, sedative overdose impairing ventilatory control
- Neuromuscular disorders affecting respiratory muscles, such as phrenic nerve injury, brain stem stroke, myasthenia gravis, Guillain-Barré syndrome, metabolic muscle diseases, electrolyte disorders, critical illness polyneuropathy or polymyopathy
- · Chest wall or diaphragmatic weakness, injury, or diseases

Treatment

- Establish patent airway (positioning, suctioning, artificial airway)
- Measure Pao2 to assess oxygenation status
- · Treat underlying disease
- Provide adequate ventilation to achieve goal PaCo₂ for pH >7.35 (unless contraindicated)
- Endotracheal intubation, mechanical ventilation if necessary; in selected patients, noninvasive positive pressure ventilation useful

Pearl

Use formula to determine minute ventilation ($\dot{V}E$) needed: $\dot{V}E = 863 \times VCO_2/[PacO_2 \times (1 - VD/VT)]$ where $\dot{V}E$ is minute ventilation (L/min); $\dot{V}CO_2$ is CO_2 output (L/min); VD/VT is dead-space/tidal volume ratio.

Reference

Epstein SK et al: Respiratory acidosis. Respir Care 2001;46:366. [PMID: 11262556]

Respiratory Failure: Hypoxemia

Essentials of Diagnosis

- Arterial Po₂ (Pao₂) <60 mm Hg, equivalent to arterial O₂ saturation <92%
- If Pao_2 is less than expected when breathing supplemental O_2 ($Fio_2 > 21\%$), should also consider as hypoxemia
- May have tachycardia, tachypnea, diaphoresis, anxiety, cyanosis, arrhythmias
- If severe, may have confusion, lethargy, or coma
- May coexist with respiratory acidosis (Paco₂ >45 mm Hg with pH < 7.35); may have respiratory depression, impaired level of consciousness
- Any pulmonary disease, pneumonia, COPD, asthma, pulmonary embolism, ARDS, atelectasis, interstitial lung diseases; also pleural effusions, pulmonary edema, extrapulmonary right-toleft shunt

■ Differential Diagnosis

- Decreased O₂ delivery—low cardiac output, shock, anemia—without arterial hypoxemia (i.e. normal Pao₂)
- · Carboxyhemoglobinemia

Treatment

- Establish airway (positioning, suctioning, artificial airway)
- Measure Paco₂ to assess ventilation status
- Supplemental O₂; amount based on likely disease and mechanism of hypoxemia; goal Pao₂ >60 mm Hg or O₂ saturation >92%
- Asthma, COPD, pulmonary embolism, mild pneumonia and atelectasis respond to Fio₂ 0.24–0.4 (usually caused by WQ mismatching)
- ARDS, severe pneumonia or atelectasis, and extracardiac rightto-left shunts require FiO₂ 0.4–1.0 (due to hypoxemia from rightto-left shunts)
- Endotracheal intubation, PEEP and mechanical ventilation needed if severe

Pearl

You cannot predict the new Pao₂ when you change the F₁₀₂ because Pao₂ depends on the mechanism of hypoxemia.

Reference

Henig NR et al: Mechanisms of hypoxemia. Respir Care Clin N Am 2000;6:501. [PMID: 11172576]

Status Asthmaticus

■ Essentials of Diagnosis

- Severe asthma (severely reduced peak flow, FEV₁, VC) poorly or nonresponsive to therapy
- Hypoxemia; may have hypercapnia with acute respiratory acidosis
- Poor air movement, severe wheezing but wheezing absent when very severe, hyperinflation, use of accessory muscles of respiration, pulsus paradoxus
- Associated with worsening asthma and increasing bronchodilator use over days, but may develop suddenly without warning

Differential Diagnosis

- Acute upper airway obstruction (larnygeal edema, angioedema, tumor, foreign body, trauma, epiglottis)
- · Vocal cord dysfunction syndrome
- · COPD exacerbation
- Cardiogenic pulmonary edema, pneumothorax, pulmonary embolism, pneumonia

Treatment

- Oxygen, 2–4 L/min nasal cannula or 40–60% by mask, to achieve Pao₂ >60–70 mm Hg
- Inhaled bronchodilators: albuterol every 20–30 minutes; then hourly; ipratropium bromide every 2–4 hours
- Systemic corticosteroids: prednisone, 40–60 mg, 1–4 times per day; or IV methylprednisolone, 20–40 mg every 6 hours
- If needed, noninvasive positive pressure ventilation; endotracheal intubation and mechanical ventilation
- Antibiotics not usually indicated; but consider if purulent sputum, fever, pneumonia
- Other therapy: IV magnesium sulfate (2–8 g IV every 4 hours) may benefit very severe asthma; no clear role for leukotriene modifiers, inhaled corticosteroids

Pearl

Because airway inflammation, not bronchospasm, is the cause of status asthmaticus, be patient; several days might be needed before obstruction reverses.

Reference

McFadden ER Jr: Acute severe asthma. Am J Respir Crit Care Med 2003;168:740 [PMID: 14522812]

Ventilator-Associated Pneumonia

Essentials of Diagnosis

- In patient on mechanical ventilation, three or more of fever, new infiltrates, leukocytosis, purulent secretions
- Occurs in 10–25% of mechanically ventilated patients, resulting in 5–30% increase in mortality; increased duration of ventilation
- Due to aspiration of bacterial-laden oropharyngeal secretions or gastric contents through or around endotracheal tube and cuff
- Community-acquired bacteria if pneumonia occurs <4 days after admission; otherwise Gram-negative bacilli, staphylococcus more common
- Culture of sputum helpful for antibiotic selection, not for diagnosis; contamination-protected brushes, bronchoscopic sampling, or bronchoalveolar lavage possibly helpful if quantitative cultures used

■ Differential Diagnosis

- · Community-acquired pneumonia
- · Pulmonary edema, ARDS
- · Aspiration pneumonitis
- · Atelectasis
- · Pulmonary thromboembolism

■ Treatment


- Suction secretions, chest physical therapy (only if increase in sputum production)
- Antibiotics directed against community-acquired organisms (S pneumoniae, H influenzae) if <4 days; if >4 days, antibiotics against aerobic Gram-negative bacilli, (E coli, K pneumoniae, Pseudomonas, Acinetobacter) and S aureus
- Plan to reduce spectrum of antibiotic coverage within 3–7 days using clinical response, cultures, epidemiology of bacteria in ICII
- Prevention: Suction secretions above endotracheal tube cuff; continuous enteral feedings

Pearl

Noninvasive positive pressure ventilation is associated with decreased risk of infection.

Reference


Hoffken G et al: Nosocomial pneumonia: the importance of a deescalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002;122:2183. [PMID: 12475862]





Cardiology

Angina Pectoris	115
Aortic Dissection, Acute	116
Aortic Valvular Heart Disease	117
Arterial Insufficiency, Acute	118
Atrial Fibrillation	119
Cardiac Tamponade	120
Congestive Heart Failure	121
Heart Block	122
Hypertensive Crisis & Malignant Hypertension	123
Mesenteric Ischemia and Infarction, Acute	124
Mitral Valvular Heart Disease	125
Myocardial Infarction (AMI), Acute	126
Supraventricular Tachycardia	127
Syncope	128
Unstable Angina (USA) & Non-ST-Segment Elevation Myocardial	
Infarction (NSTEMI)	129
Ventricular Tachvarrhythmias	130



Angina Pectoris

Essentials of Diagnosis

- Heavy, pressure-like substernal chest discomfort; precipitated by exertion or stress; lasting <15 minutes; relieved with rest or nitroglycerin
- · Radiation to left arm, neck, or jaw; dyspnea, nausea
- Examination usually benign; may detect gallop or mitral regurgitation murmur during anginal event
- ECG varies between normal and ST segment depression; increased specificity when dynamic ST segment changes occur with symptoms
- Different stress testing modalities available for diagnostic purpose
- Coronary angiography provides anatomical roadmap to guide therapy

Differential Diagnosis

- Cardiovascular: unstable angina, myocardial infarction, Prinzmetal angina, pericarditis, myocarditis, aortic dissection
- Pulmonary: pneumothorax, pulmonary embolism, pneumonia
- Gastrointestinal: esophageal reflux or spasm, gastritis, peptic ulcer disease, cholangitis, hepatitis, pancreatitis
- · Musculoskeletal pain and costochondritis

Treatment

- Increase oxygen supply and reduce myocardial oxygen demand
- · Rapid administration of aspirin
- Reduce heart rate and blood pressure with beta-blockers
- Nitrates for symptom relief
- Oxygen
- Calcium channel blockers are negative inotropes and coronary vasodilators; may be used for patients unable to tolerate betablockade
- Angioplasty with possible stenting indicated for persistent symptoms on optimal medical management
- Long-term recommendations for behavioral modification, blood pressure control, addition of HMG-CoA reductase inhibitors

Pearl

Except for left main or three-vessel disease with left ventricular dysfunction, angioplasty and coronary artery bypass graft surgery (CABG) have not yet demonstrated benefits in mortality reduction.

Reference

Gibbons RJ et al: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina. Circulation 2003;107:149. [PMID: 12515758]

Aortic Dissection, Acute

■ Essentials of Diagnosis

- Abrupt onset of severe, tearing chest pain radiating to back; reaches maximal intensity immediately
- Symptoms related to area of arterial compromise: paraplegia (anterior spinal), stroke (carotid), abdominal pain (mesenteric), tamponade (proximal aorta)
- · Dizziness, dyspnea, oliguria
- Tachycardia, unequal blood pressures in upper extremities, murmur of aortic insufficiency
- · Myocardial infarction from coronary ostia involvement rare
- · Chest radiograph with widened mediastinum
- CT and MRI highly sensitive and specific; transesophageal echocardiogram if imaging not feasible
- · Aortography carries significant risk and time delay
- Risk factors: hypertension, Marfan/Ehlers-Danlos syndromes, coarctation, bicuspid aortic valve, aortitis (syphilis), age 60–80, pregnancy, cardiac catheterization, intra-aortic balloon pump, trauma

■ Differential Diagnosis

- · Acute myocardial infarction
- Angina pectoris
- Pneumothorax

- · Acute pericarditis
- · Boerhaave syndrome
- · Pulmonary embolism

Treatment

- Close hemodynamic monitoring with goal to decrease systolic blood pressure and sheer forces across aortic wall
- · Labetalol drug of choice to reduce sheer forces
- Calcium-channel blockers alternative for beta-blockers
- Vasodilators (nitroprusside, nitroglycerin, hydralazine) for blood pressure control once adequate beta-blockade achieved
- · Pain control
- · Avoid anticoagulation and thrombolytics
- Surgical repair for Stanford Type A dissection (involves ascending aortic arch); Stanford Type B (distal to take-off of last great vessel) managed medically unless rupture, limb or organ ischemia, persistent pain, saccular aneurysm formation

Pearl

The mortality rate from untreated acute aortic dissection is estimated to be approximately 1% per hour.

Reference

Erbel R et al: Diagnosis and management of aortic dissection. Eur Heart J 2001;22:1642. [PMID: 11511117]

Aortic Valvular Heart Disease

Essentials of Diagnosis

- Dyspnea, orthopnea, paroxysmal nocturnal dyspnea, cough, syncope, chest pain; signs and symptoms differ between acute and chronic lesions
- Aortic stenosis (AS): angina, syncope, pulsus parvus et tardus, harsh crescendo-decrescendo systolic murmur; may be due to rheumatic heart disease, congenital abnormalities, calcification
- Aortic regurgitation (AR): wide pulse pressure, water-hammer pulse, Quincke pulse, Duroziez sign, early diastolic murmur; may be due to leaflet disorders (endocarditis, myxomatous degeneration, bicuspid valve) or dilated aortic root (syphilis, aortic dissection, connective tissue disorders)
- Echocardiogram essential in confirming and assessing diagnosis

Differential Diagnosis

- Aortic stenosis: mitral regurgitation, hypertrophic cardiomyopathy (HCM), ventricular septal defect (VSD)
- Aortic regurgitation: mitral stenosis, pulmonary hypertension with Graham-Steele murmur

Treatment

- Aortic stenosis: no medical management; when severe, requires surgery or valvuloplasty (transiently effective); vasodilator drugs may cause severe hypotension
- Aortic regurgitation: diuretics with sodium and fluid restriction; digoxin; preload and afterload reduction with ACE inhibitors, hydralazine plus nitrates, nitroprusside
- · Infective endocarditis prophylaxis
- Cardiac catheterization often necessary prior to surgery
- Surgical valve repair or replacement ideally indicated for all symptomatic patients

Pearl

Symptomatic aortic stenosis confers a poor prognosis with the average time to death often limited to only a few years: with angina—3 years, syncope—3 years, and pulmonary edema—2 years.

Reference

Bonow RO et al: ACC/AHA guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 1998;32:1486. [PMID: 9809971]

Arterial Insufficiency, Acute

Essentials of Diagnosis

- Sudden reduction or cessation of blood flow to peripheral artery followed by ischemic insult with severe localized pain
- · Affected limb pale, cool, mottled; distal pulse absent
- · Numbness common; paralysis late sign
- Compartment syndrome from excessive muscle necrosis and swelling
- Doppler exam and ankle-brachial index (ABI) helpful screening tools
- Arteriography remains standard for diagnosis and locates extent of occlusion
- Usually caused by arterial emboli (from heart) or thrombosis; often in setting of atrial fibrillation

■ Differential Diagnosis

- · Deep venous thrombosis with phlegmasia alba dolens
- Heparin-induced thrombocytopenia syndrome (HITS)
- Hypoperfusion and shock states
- · Atheroembolism: cholesterol emboli
- · Peripheral neuropathic pain
- · Aortic dissection or aneurysm
- Vasculitis

Treatment

- Goal to restore blood supply to compromised area
- Immediate anticoagulation with heparin; unless HITS suspected
- · Surgical thromboembolectomy treatment of choice
- Fasciotomy if compartment syndrome develops
- Intra-arterial thrombolytics for acute thrombosis especially in nonoperable lesions
- Correct electrolyte and acid-base disturbances especially postreperfusion
- · Monitor for rhabdomyolysis and renal failure
- Mannitol to reduce cellular edema and prevent myoglobin induced renal failure
- Pain control

Pearl

The "six-Ps" commonly associated with acute arterial insufficiency are pain, paralysis, paresthesias, pallor, pulselessness, and poikilothermia.

Reference

Henke PK et al: Approach to the patient with acute limb ischemia: diagnosis and therapeutic modalities. Cardiol Clin 2002;20:513. [PMID: 12472039]

Atrial Fibrillation

Essentials of Diagnosis

- Irregularly occurring irregular heart beat with loss of synchronized atrial rhythm and irregular ventricular response
- · Chest pain, dyspnea, palpitations, dizziness
- Acute onset may lead to hypotension, myocardial ischemia, acute congestive heart failure, hypoperfusion to end-organs
- Embolic symptoms may be seen in chronic atrial fibrillation: stroke, ischemic limb, mesenteric ischemia, renal impairment
- ECG with fibrillatory waves, loss of P waves, irregular QRS intervals, rapid ventricular rate
- Etiologies: alcohol, hyperthyroidism, mitral valve disease, ischemic heart disease, hypokalemia, hypomagnesemia, sepsis, pericarditis, post—cardiac surgery, idiopathic

■ Differential Diagnosis

- · Atrial flutter with variable block
- · Multifocal atrial tachycardia
- · Atrial tachycardia with variable block
- · Atrioventricular nodal reentrant tachycardia
- · Sinus arrhythmia
- Pre-excitation/accessory pathway
- Normal sinus rhythm with multiple premature atrial contractions

Treatment

- Identify underlying etiology and precipitating factors
- Immediate electrical countershock if hemodynamic compromise
- Rate control with digoxin, beta-blockers, Ca-channel blockers; avoid excessive AV nodal blockade
- · Anticoagulation if not contraindicated
- May cardiovert without anticoagulation if onset <48 hours; otherwise, anticoagulate and cardiovert in 4 weeks
- Can cardiovert sooner if transesophageal echocardiogram without thrombus; continue anticoagulation for 4 weeks
- Cardioversion may be electrical or pharmacologic (type Ia, Ic, III antiarrhythmics)
- Echocardiogram to evaluate valvular lesions, chamber sizes, thrombus formation

■ Pearl

The "atrial kick" contributes to about 20% of the cardiac output. The loss of the atrial kick, as in atrial fibrillation, can be significant in patients with already reduced systolic function.

Reference

Fuster V et al: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Circulation 2001:104:2118. [PMID: 11673357]

Cardiac Tamponade

Essentials of Diagnosis

- Beck triad: hypotension, elevated jugular venous pressure (JVP), muffled heart sounds
- · Pleuritic chest pain, dyspnea, orthopnea, palpitations, oliguria
- Tachycardia, pericardial rub, pulsus paradoxus, peripheral edema, distended neck veins
- · Kussmaul sign: increased JVP with inspiration; nonspecific
- Chest radiograph may not show enlarged cardiac silhouette (water-bottle shaped heart) if acute onset
- · ECG with reduced voltages, electrical alternans
- Echocardiogram with pericardial effusion, "swinging heart," right atrial systolic or ventricular diastolic collapse
- Pulmonary artery catheterization with equalization of pressures: right atrial, left atrial, left ventricular end-diastolic
- Pericardial effusion compromises ventricular filling with reduced cardiac output
- Etiologies: uremia, pericarditis, malignancy, infection (viral, bacterial, fungal, tuberculosis), myocardial infarction/rupture, trauma, idiopathic, hypothyroidism, anticoagulation (especially post–cardiac surgery)

■ Differential Diagnosis

- Constrictive pericarditis
- Tension pneumothorax
- · Restrictive cardiomyopathy
- End-stage cardiac failure
- Right ventricular infarction

■ Treatment

- Volume resuscitation for hypotension; dopamine if blood pressure does not improve with fluids
- · Pericardiocentesis with or without pigtail catheter drainage
- · Hemodynamic monitoring with pulmonary artery catheter
- Treat underlying cause of pericardial effusion
- Surgical pericardial window (pericardiectomy or balloon pericardiotomy) if recurrent accumulation
- Positive pressure ventilation may worsen symptoms

Pearl

The "rule of 20s" in cardiac tamponade: CVP >20 mm Hg, HR increase >20 beats per minute, pulsus paradoxus >20, systolic BP, decrease >20 mm Hg, and pulse pressure <20.

Reference

Spodick DH: Acute cardiac tamponade. N Engl J Med 2003;349:684. [PMID: 12917306]

Congestive Heart Failure

Essentials of Diagnosis

- Shortness of breath, dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, weight gain, leg swelling, pink frothy sputum
- Tachypnea, inspiratory crepitations, gallops, cyanosis, peripheral edema
- Chest radiograph with pulmonary edema, pleural effusions, cardiomegaly
- Elevated B-type natriuretic peptide, hypoxemia, metabolic acidosis
- Echocardiogram or right heart catheterization with reduced ejection fraction (systolic dysfunction) or inadequate diastolic filling (diastolic dysfunction)

Differential Diagnosis

- · Noncardiogenic pulmonary edema: ARDS
- Valvular heart disease
 Pericardial disease
- Hypoalbumin states Fluid overload
- · Hypothyroidism and myxedema
- · Pulmonary vascular disease

Treatment

- Acute left ventricular failure: oxygen; preload and afterload reduction: nitrates, nitroprusside, morphine; diuresis: loop diuretics (furosemide), spironolactone
- ACE inhibitors, angiotensin-receptor antagonists recommended; hydralazine and nitrates for those intolerant of these agents
- Beta-blockers may exacerbate short-term symptoms; beneficial long-term
- · Digoxin improves symptoms in systolic failure
- · Dietary sodium and fluid restriction
- Anticoagulation in normal sinus rhythm controversial
- Dobutamine, milrinone, intra-aortic balloon pumps used in refractory cardiac failure as a bridge to surgery
- Optimal management of diastolic heart failure: primarily betablockers and calcium-channel blockers

Pearl

Symptomatic heart failure confers a worse prognosis than most cancers in the United States with a one-year mortality rate approaching 45%

Reference

Liu P et al: The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol 2003;19:347. [PMID: 12704478]

Heart Block

Essentials of Diagnosis

- Impaired conduction through atrioventricular (AV) node or bundle of His
- First-degree block: PR interval >210 msec; all atrial impulses conducted; asymptomatic
- Mobitz type I second-degree block (Wenckebach): PR interval lengthens with RR shortening before blocked beat; "grouped beating"; seen with inferior myocardial infarction; enhanced vagal tone
- Mobitz type II second-degree block: intermittent blocked beats without PR lengthening
- Third-degree block: complete AV dissociation; cannon a waves
- Fatigue, chest pain, dyspnea, dizziness, syncope when bradycardia associated with high-degree blocks (Mobitz II, third degree)
- Associated with myocardial injury, medications, myocarditis, infiltrative disorders (amyloid, sarcoid), electrolyte disturbances

Differential Diagnosis

- Sinus arrhythmia
- · Atrial flutter
- Idioventricular rhythm
- Wandering pacemaker
- · Atrial fibrillation
- · Junctional rhythm
- AV dissociation
- · Multifocal atrial tachycardia

■ Treatment

- Atropine treatment of choice for acute symptoms or severe bradycardia
- Blood pressure can be supported with dopamine or epinephrine
- Temporary pacing may be necessary: transcutaneous, transvenous
- Permanent pacemaker indicated in high-degree blocks
- Identify and treat underlying etiology: stop beta-blockers or AV blocking calcium channel blockers; reverse hyperkalemia
- Evaluate and manage ischemic cardiac disease

Pearl

AV dissociation and complete heart block are not synonymous. AV dissociation can occur without complete heart block when the intrinsic ventricular rate exceeds the sinus rate.

Reference

Brady WJ et al: Diagnosis and management of bradycardia and atrioventricular blocks associated with acute coronary ischemia. Emerg Med Clin North Am 2001;19:371. [PMID: 11373984]

Hypertensive Crisis & Malignant Hypertension

Essentials of Diagnosis

- Hypertensive crisis: blood pressure >240/130 or hypertension with comorbid condition requiring urgent control: angina, heart failure, cerebral hemorrhage, edema
- Malignant hypertension: severe hypertension with end-organ damage such as papilledema, encephalopathy, renal failure
- Irritability, headache, visual changes, nausea, confusion, chest pain, seizures
- · Tachycardia, retinal hemorrhage or exudates, neurologic deficits
- · Azotemia, disseminated intravascular coagulation
- · Hematuria, red cell casts, proteinuria
- ECG: left ventricular hypertrophy, ischemic changes

■ Differential Diagnosis

- Accelerated essential hypertension
- · Renovascular disease: renal artery stenosis
- · Pheochromocytoma
- · Acute glomerulonephritis
- · Collagen vascular disease
- Food/drug interaction with monoamine oxidase inhibitor

Treatment

- Rapid reduction of blood pressure with short-acting titratable agents: nitroprusside, labetalol, esmolol, nitroglycerin
- Nitroprusside drug of choice; monitor thiocyanate levels after 24 hours of infusion especially in renal failure
- Labetalol or esmolol drip: utilize with underlying coronary artery disease
- · ACE inhibitors: use in heart failure, myocardial infarction
- Nitroglycerin: primarily venodilator; variable blood pressure reduction; indicated for myocardial ischemia and heart failure
- Hydralazine: used as bridge from intravenous to oral medications
- · Phentolamine preferred if pheochromocytoma suspected
- · Hemodialysis can help with blood pressure control
- Assess degree of end-organ damage based on symptoms: head CT, renal ultrasound, echocardiogram

Pearl

Overly aggressive blood pressure reduction, especially in the case of an acute stroke, may lead to further cerebral ischemia and infarction secondary to impaired cerebral autoregulation.

Reference

Phillips RA et al: Hypertensive emergencies: diagnosis and management. Prog Cardiovasc Dis 2002;45:33. [PMID: 12138413]

Mesenteric Ischemia and Infarction, Acute

Essentials of Diagnosis

- Severe acute abdominal pain out of proportion to physical exam findings
- · Anorexia, nausea, vomiting, diarrhea, distention
- Progression of ischemia and perforation leads to peritonitis, sepsis, shock, confusion
- Leukocytosis, increased CK and LDH, severe metabolic acidosis, hyperamylasemia
- Radiographs reveal air-fluid levels, dilated and thickened loops of bowel, pneumatosis intestinalis, perforation
- "Thumbprinting" signs on barium contrast studies
- Abdominal CT and angiography can be diagnostic
- Risk factors: advanced age, cardiovascular disease, atherosclerosis, hypercoagulable states, malignancy, portal hypertension, systemic disorders, inflammation, trauma

Differential Diagnosis

- · Pancreatitis
- · Appendicitis
- Inflammatory bowel diseases
- Cholecystitis and cholangitis
- · Diverticulitis
- · Vasculitis
- · Renal colic
- Abdominal trauma
- · Peptic ulcer disease with or without perforation
- Aortic dissection and ruptured aneurysms
- · Gynecologic pathologies

Treatment

- · Aggressive fluid resuscitation
- Maintain perfusion pressures; minimize vasopressor use
- Correct electrolyte and acid-base disturbances
- · Broad-spectrum antibiotics covering enteric flora
- · Anticoagulation with heparin if not contraindicated
- · Angiographic evaluation if hemodynamically stable
- Intra-arterial infusion of papaverine if emboli identified; utilized pre- and postoperatively
- Surgical intervention often indicated: diagnosis, restoration of blood flow, resection of necrotic bowel
- Thrombolytic therapies with anecdotal success; often used in poor surgical candidates

Pearl

Controlling cardiac arrhythmias with digoxin may worsen mesenteric ischemia as this drug may promote mesenteric vasoconstriction.

Reference

Trompeter M et al: Non-occlusive mesenteric ischemia: etiology, diagnosis, and interventional therapy. Eur Radiol 2002;12:1179. [PMID: 11976865]

Mitral Valvular Heart Disease

■ Essentials of Diagnosis

- · Dyspnea, orthopnea, paroxysmal nocturnal dyspnea, cough
- · Signs and symptoms differ between acute and chronic lesions
- Mitral stenosis (MS): low-pitched diastolic murmur, crisp S1, opening snap, sternal heave, may have hemoptysis; atrial fibrillation common; >90% due to rheumatic heart disease (only 50–70% report history of rheumatic fever)
- Mitral regurgitation (MR): pansystolic murmur radiating to axilla; due to leaflet problems (endocarditis, myxomatous degeneration, rheumatic fever) or other problems of chordae tendineae, papillary muscles, mitral annulus; acute MR (myocardial infarction with papillary muscle dysfunction or endocarditis)
- Echocardiogram essential in confirming and assessing diagnosis

■ Differential Diagnosis

- Mitral stenosis: left atrial myxoma, mitral valve prolapse, pulmonary hypertension, atrial septal defect
- Mitral regurgitation: aortic stenosis, hypertrophic cardiomyopathy, ventricular septal defect (VSD)

Treatment

- Mitral stenosis: slow heart rate maximizes left ventricular filling time, especially if atrial fibrillation (beta-blockers, digoxin, diltiazem); cardioversion; diuretics; no role of afterload reduction; balloon valvuloplasty; mitral valve replacement
- Mitral regurgitation: afterload reduction may help forward flow (ACE inhibitors, hydralazine plus nitrates, nitroprusside); diuretics; mitral valve replacement
- Infective endocarditis prophylaxis
- · Cardiac catheterization often necessary prior to surgery
- Surgical valve repair or replacement ideally indicated for all symptomatic patients

■ Pearl

Acute mitral regurgitation may have sudden onset of pulmonary edema, hypotension, and shock; chronic mitral regurgitation may cause unexplained fatigue and exercise intolerance.

Reference

Bonow RO et al: ACC/AHA guidelines for the management of patients with valvular heart disease. J Am Coll Cardiol 1998;32:1486. [PMID: 9809971]

Myocardial Infarction (AMI), Acute

■ Essentials of Diagnosis

- Prolonged substernal chest pressure; lasting >15 minutes
- Discomfort radiates to left arm, neck, or jaw; sweating, nausea, vomiting, syncope
- Right ventricular MI: suspect with inferior MI or hypotension with nitrate administration; confirm with right-sided ECG
- ECG with ST segment elevation (tombstones) >1 mm in two contiguous leads or new bundle branch block
- Elevation of CK-MB, troponins, AST, LDH
- Echocardiogram: identifies wall motion abnormalities, residual ventricular function, valvular abnormalities, MI associated tamponade
- Complications: tachy/bradyarrhythmias, heart block, valvular insufficiencies, pulmonary edema, hypoxemia, cardiogenic shock, pericarditis

Differential Diagnosis

- Cardiovascular: stable or unstable angina, Prinzmetal angina, pericarditis, myocarditis, aortic dissection
- Pulmonary: pneumothorax, pulmonary embolism, pneumonia
- Gastrointestinal: esophageal reflux or spasm, gastritis, peptic ulcer disease, cholangitis, hepatitis, pancreatitis
- · Musculoskeletal pain and costochondritis

Treatment

- · Bed rest, monitoring, oxygen, serial cardiac enzymes, ECGs
- Immediately chew and swallow aspirin; clopidogrel in those intolerant of aspirin
- Pain control with nitrates and/or morphine; anxiolytics
- Beta-blockers to reduce myocardial oxygen consumption
- ACE inhibitors confer survival benefit when EF < 40%,
- Thrombolytic reperfusion in ST segment elevation or new left bundle branch block if no contraindication
- Primary angioplasty alternative to thrombolytics if unstable hemodynamics or chest pain on optimal medical regimen
- Right heart catheterization may aid management of hypotension

Pearl

When an AMI is thought to be associated with cocaine use, the use of selective beta-blockers may lead to unopposed alpha-adrenergic stimulation and worsening hypertension and cardiac injury.

Reference

Cannon CP et al: Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J 2002;143:777. [PMID: 12040337]

Supraventricular Tachycardia

Essentials of Diagnosis

- Tachycardia (heart rate >100) with origin of electrical rhythm within atria or atrioventricular (AV) node resulting in narrow QRS complex (<120 msec)
- · Palpitations, dyspnea, chest pain
- · ECG and rhythm strip essential for diagnosis
- Constant rate as clue to arrhythmia: 150 consider atrial flutter with 2:1 block; 180 consider AV nodal reentry
- Regularity can guide differential diagnosis: regular (ST, AVNRT, AVRT, AT, JT), irregular (MFAT, A-fib), either (A-flut)
- · MFAT often associated with severe lung disease
- Suspect accessory tract if PR interval shortened and ventricular rate >200; examine rhythm strip for delta waves

Differential Diagnosis

- Sinus tachycardia (ST)
- AV nodal reentry tachycardia (AVNRT)
- Atrioventricular reentry via accessory pathway (AVRT)
- Ectopic atrial tachycardia (AT)
- Multifocal atrial tachycardia (MFAT)
- Junctional tachycardia (JT)
- Atrial flutter (A-flut)
- Atrial fibrillation (A-fib)

■ Treatment

- Adenosine to evaluate underlying rhythm; often terminates AVNRT; uncovers fibrillatory and flutter waves
- · AV nodal blockade and rate control
- Urgent electrical cardioversion when hemodynamically unstable
- Reverse potential precipitating factors: electrolytes, hypoxemia, alkalosis, ischemia
- Antiarrhythmics useful in A-fib, A-flut, AT
- Overdrive atrial pacing can be attempted
- Electrophysiological study in refractory cases with or without ablation

Pearl

In patients with supraventricular tachycardia and evidence of an accessory bypass tract (Wolff-Parkinson-White syndrome), the use of AV nodal blocking agents should be avoided as they can promote antegrade accessory pathway conduction and worsen tachycardia. Procainamide is the agent of choice.

Reference

Blomstrom-Lundquist C et al: ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias. J Am Coll Cardiol 2003 Oct 15;42:1493. [PMID: 14563598]

Syncope

Essentials of Diagnosis

- Transient loss of consciousness and postural tone with prompt recovery
- · Pallor and generalized perspiration prior to event
- · Cardiac syncope: chest discomfort, dyspnea, palpitations
- Vasovagal syncope: prodrome of light-headedness, diaphoresis, nausea. "aura"
- · Bradycardia and hypotension not always identified
- · Monitor ECG and rhythm strip
- · Echocardiogram to identify structural heart disease
- · Tilt-table testing to evaluate vasovagal symptoms

■ Differential Diagnosis

- · Cardiovascular: arrhythmias, outflow tract obstruction
- Pulmonary vascular disease: pulmonary embolism, pulmonary hypertension
- Vasovagal syndrome and situational syncope: cough, micturition, pain
- · Postural hypotension and autonomic dysfunction
- Neurologic: cerebrovascular accidents, vertebrobasilar insufficiency, seizures
- · Metabolic derangements: hypoglycemia
- Hypoxemia
- Hysterical fainting

Treatment

- · Identify and correct underlying etiology
- When patient is unconscious, position horizontally and secure airway
- In vasovagal syncope effective prophylaxis can be achieved with beta-blockers; theophylline, scopolamine, disopyramide, ephedrine, support stockings tried with varying success
- Pacemakers: adjunct in management of cardioinhibitory responses seen in vasovagal syndromes; indicated in bradyarrhythmias
- · Fludrocortisone helpful in autonomic dysfunction
- Electrophysiology studies and implantable defibrillators can be considered in tachyarrhythmias especially ventricular in origin
- Advise against driving

Pearl

In tilt-table testing for vasovagal syndromes, vasodepressor and cardioinhibitory responses may be seen but are diagnostic only when associated with symptoms.

Reference

Kapoor WN et al: Current evaluation and management of syncope. Circulation 2002;106:1606. [PMID: 12270849]

Unstable Angina (USA) & Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)

Essentials of Diagnosis

- Heavy, pressure-like substernal chest discomfort with radiation to neck, jaw, left arm; nausea, diaphoresis, dyspnea
- · Complications: arrhythmia, hypotension, pulmonary edema
- ECG may reveal ≥1 mm ST segment depression or T wave inversion
- Elevated cardiac enzymes (troponin, CK-MB) indicate myocardial necrosis

Differential Diagnosis

- Angina pectoris, Prinzmetal angina, pericarditis, myocarditis, aortic dissection
- · Pneumothorax, pulmonary embolism, pneumonia
- · Reflux esophagitis, esophageal spasm, gastritis, pancreatitis
- · Musculoskeletal pain and costochondritis

Treatment

- Bed rest, oxygen, monitoring, serial cardiac enzymes
- Initiate aspirin and continue indefinitely
- Beta-blockers for heart rate and blood pressure control; nondihydropyridine calcium antagonists if beta-blockers contraindicated
- · Nitrates for relief of symptoms
- Morphine for persistent pain or pulmonary edema
- ACE inhibitors when hypertension persists: especially if EF < 40% or if diabetic
- HMG-CoA reductase inhibitors with goal LDL < 100
- Clopidogrel for those intolerable of aspirin or as adjunct for percutaneous coronary intervention (PCI)
- · Unfractionated or low-molecular-weight heparin with benefits
- Platelet glycoprotein IIb/IIIa antagonists if PCI planned
- Early PCI for high-risk patients: recurrent symptoms on medications, congestive heart failure, ventricular arrhythmia, unstable hemodynamics, elevated troponin

Pearl

A minority of patients with normal coronary arteries may present with USA due to increased workload on the heart: anemia, thyrotoxicosis, hypoxemia, hypotension.

Reference

Braunwald E et al: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2002;40:1366. [PMID: 12383588]

Ventricular Tachyarrhythmias

Essentials of Diagnosis

- More than three consecutive ventricular beats or broad-complex tachycardia with rate >100 and QRS >120 msec; "sustained" if ventricular tachycardia (VT) lasts >30 seconds
- Chest pain, dyspnea, flushing, palpitations, dizziness, syncope, sudden death
- Torsade de pointes associated with prolonged QT; can degenerate into ventricular fibrillation (VF)
- · ECG and rhythm strip key to diagnosis
- Features highly suggestive of VT: AV dissociation, fusion beats, concordance of QRS, failure to slow down with adenosine, extreme right or left axis deviation
- Etiologies: ischemia, cardiomyopathy, valvular heart disease, antiarrhythmics, sympathomimetics, electrolyte disturbances, drugs that prolong QT interval, mechanical irritation (central lines)

Differential Diagnosis

- Preexisting conduction defect (bundle branch block, BBB) with supraventricular tachyarrhythmia (SVT)
- · SVT with aberrant conduction
- · Antegrade conduction through an accessory pathway

Treatment

- Immediate cardioversion when hemodynamically compromised
- Adenosine if unclear if VT or SVT
- Treat correctable underlying factors
- Evaluate potential ischemic cardiac disease
- Acute antiarrhythmics unnecessary if episode brief and self-terminating
- Consider antiarrhythmics when episode prolonged especially if hemodynamic changes or underlying myocardial disease: lidocaine, procainamide, amiodarone
- · May use beta-blockers in setting of high catecholamine state
- · In VF and pulseless VT: amiodarone and procainamide
- Magnesium drug of choice in torsade de pointes

Pearl

All antiarrhythmic agents can be proarrhythmic. Thus, the use of these agents in asymptomatic individuals with episodic premature ventricular contractions may carry a higher risk than benefit profile.

Reference

Hohnloser SH et al: Changing late prognosis of acute myocardial infarction: Impact on management of ventricular arrhythmias. Circulation 2003;107:941. [PMID: 12600904]

Infectious Disease

Bacterial Meningitis	133
Botulism	134
Central Nervous System (CNS) Infections in	
HIV-Infected Patients	135
Clostridium difficile-Associated Diarrhea	136
Community-Acquired Pneumonia	137
Encephalitis, Brain Abscess, Spinal Epidural Abscess	138
Fever in the ICU	139
Hematogenously Disseminated Candidiasis	140
Infections in Immunocompromised Hosts	141
Infective Endocarditis	142
Intra-abdominal Infection	143
Intravenous Catheter-Associated Infection	144
Mycobacterium tuberculosis	145
Necrotizing Soft Tissue Infection	146
Neutropenic Fever	147
Nonbacterial Meningitis	148
Nosocomial Pneumonia	149
Peritonitis	150
Pneumocystis jiroveci Pneumonia (PCP)	151
Prevention of Nosocomial Infection	152
Pulmonary Infections in HIV-Infected Patients	153

132 Current Essentials of Critical Care

Sepsis	154
Surgical Site Infection (SSI)	155
Tetanus	156
Toxic Shock Syndrome	157
Urosepsis	158

Bacterial Meningitis

Essentials of Diagnosis

- Acute-onset fever, headache, neck stiffness, altered sensorium; may have vomiting, seizures; mild to very severe systemic features of sepsis (hypotension, cardiovascular collapse, disseminated intravascular coagulation); N meningitidis may have petechial or ecchymotic skin or mucous membrane rash
- Purulent cerebrospinal fluid with increased leukocytes (usually neutrophil predominance), increased protein, low glucose (<50% of serum); occasionally with bacteria seen on Gram stain of fluid
- Culture of bacterial pathogen from cerebrospinal fluid confirms diagnosis
- In adults, S pneumoniae, N meningitidis, L monocytogenes; gram-negative bacilli in elderly; staphylococcus following neurosurgical procedures

Differential Diagnosis

- · Viral, fungal, or tuberculous meningitis
- · Carcinomatous meningitis
- · Drug-induced meningitis

Treatment

- Supportive care, including treatment of hypotension or shock, respiratory failure
- Third-generation cephalosporin (ceftriaxone, cefotaxime)
- Add ampicillin if L monocytogenes suspected; add vancomycin for suspected penicillin-resistant S pneumoniae

Pearl

Look for an infection source adjacent to meninges, such as otitis, mastoiditis, sinusitis, vertebral osteomyelitis or abscess requiring surgical drainage.

Reference

Beaman MH: Acute community-acquired meningitis and encephalitis. Med J Aust 2002;176:389. [PMID: 12041637]

Botulism

Essentials of Diagnosis

- Acute descending paralysis caused by neurotoxin produced by Clostridium botulinum; at least three of nausea, vomiting, dysphagia, diplopia, dilated fixed pupils, dry mouth in 90%
- Cranial nerves affected first, followed by descending symmetrical flaccid paralysis, respiratory muscle involvement slowly or rapidly progressive
- No sensory disturbances, changes in sensorium, fever; cranial nerves I, II spared
- Confirm by detection of toxin in serum, stool, vomitus, gastric aspirate, suspected food
- Three clinical forms: (1) food-borne from ingestion of preformed toxin (onset 2 hours to 8 days); (2) wound with toxin produced by infection with *C botulinum* (rare, incubation period 4–14 days, seen with cutaneous illicit drug use); (3) in infants, ingestion of botulism spores, which germinate in the gut and produce toxins
- Toxin irreversibly blocks acetylcholine release at peripheral neuromuscular junctions leading to flaccid paralysis

Differential Diagnosis

- · Myasthenia gravis and Eaton-Lambert syndrome
- · Tick paralysis
- Poliomyelitis
- Guillain-Barré syndrome (Miller-Fisher variant)
- Stroke
- · Rabies
- · Diphtheria

Treatment

- Supportive care with frequent monitoring of vital capacity to predict respiratory failure; intubation, mechanical ventilation
- Equine botulinum antitoxin (trivalent or polyvalent); patients must be tested for hypersensitivity
- Debridement of devitalized tissue for wound botulism; penicillin for wound infection
- Antibiotics to decrease GI colonization with C botulinum controversial

Pearl

If an injection drug user develops descending paralysis, suspect wound botulism caused by "black tar heroin."

Reference

Robinson RF: Management of botulism. Ann Pharmacother 2003;37:127. [PMID: 12503947]

Central Nervous System (CNS) Infections in HIV-Infected Patients

Essentials of Diagnosis

- Cryptococcal meningitis: headache and/or fever dominant findings, India ink test on CSF—sensitivity 70%; CSF cryptococcal antigen >95% sensitive; CSF culture >98% sensitive
- Toxoplasmosis: focal neurologic deficits common; CT scan: >2
 ring-enhancing lesions involving basal ganglia; serum toxoplasma antibody in >95%; primary CNS lymphoma usually single large lesion in deep periventricular space with variable enhancement
- PML: cognitive deficits common; multiple hypodense lesions in white matter on MRI, usually without edema or enhancement; JC virus CSF PCR 80% sensitive; distinguish from HIV dementia and encephalopathy

■ Differential Diagnosis

- Noninfectious HIV-associated neurologic disorders: HIV dementia and encephalopathy, primary CNS lymphoma
- Stroke
- · Primary or metastatic brain tumor

Treatment

- CNS toxoplasmosis: sulfadiazine plus pyrimethamine and leucovorin; empiric therapy for suspected cases pending results of serum toxoplasma antibody; reevaluate clinical and radiographic response (MRI or CT) in 7–10 days
- Cryptococcal meningitis: Amphotericin B + 5-flucytosine followed by fluconazole
- Secondary prophylaxis indicated for toxoplasmosis and cryptococcal meningitis
- PML and HIV dementia: no specific therapy available; antiretroviral therapy associated with improved outcome
- Consider optimal timing of antiretroviral therapy to avoid immune reconstitution syndrome (toxoplasmosis, tuberculous meningitis, PML)

Pearl

Meningismus is rare in cryptococcal meningitis, and CSF profile may be completely normal.

Reference

Ammassari A: Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 1997;48:687. [PMID: 9065549]

Clostridium difficile-Associated Diarrhea

■ Essentials of Diagnosis

- Ranges from simple diarrhea to pseudomembranous colitis; rarely megacolon, perforation and death
- Low-grade fever, leukocytosis common; abdominal pain rare in uncomplicated cases
- Occurs in patients colonized with C difficile, when selective antibiotic pressure induces toxin production; frequency of colonization increases with duration of hospitalization (20% colonized at 1 week, 50% at 1 month); may occur after single dose of antibiotic, up to 6 weeks after antibiotic
- C difficile produces two toxins (toxin A, enterotoxin; toxin B, cytotoxin); send stool for toxin assay; repeat increases diagnostic yield
- Ampicillin, clindamycin and cephalosporins most frequently associated; trimethoprim-sulfamethoxazole, quinolones, aztreonam, carbapenems, metronidazole rarely

Differential Diagnosis

- Noninfectious diarrhea (ischemic colitis, inflammatory bowel disease, gastrointestinal bleeding)
- Antibiotic-associated diarrhea (not *C difficile*-induced)
- Enteric pathogens (rare in ICU)

Treatment

- · Discontinue toxin-inducing antibiotics
- Oral metronidazole
- Oral vancomycin more expensive, associated with risk of vancomycin-resistant enterococci
- 20% relapse within 2 weeks; retreat with metronidazole; increased risk of relapse if prior C difficile diarrhea, continuation of inducing antibiotics, community-acquisition, significant leukocytosis
- Asymptomatic C difficile carriage should not be treated (prolongs carrier stage)

Pearl

C difficile can survive on environmental surfaces (medical devices, countertops); use precautions to prevent nosocomial transmission.

Reference

Mylonakis E: Clostridium difficile-associated diarrhea: a review. Arch Intern Med 2001;161:525. [PMID: 11252111]

Community-Acquired Pneumonia

■ Essentials of Diagnosis

- Acute onset of fever, productive cough, respiratory distress; sometimes chills, occasional pleuritic chest pain; fever, tachypnea, hypoxemia
- Chest radiograph with patchy, localized infiltrates or consolidation; may be bilateral, diffuse
- Mortality 5–36%; higher if male, diabetes mellitus, neurologic or neoplastic disease, hypothermia, hypotension, leukopenia, multilobar infiltrates, bacteremia, advanced age, resistant organism
- Streptococcus pneumoniae most common pathogen identified followed by Haemophilus influenzae; aerobic gram-negative bacilli uncommon except in alcoholics, nursing home residents; Chlamydia pneumoniae, Mycoplasma pneumoniae typically cause milder pneumonia
- Suspect legionella, if outbreak; tuberculosis, endemic mycosis (C immitis, H capsulatum), if relevant exposure; Pneumocystis carinii (jiroveci), if HIV risk

■ Differential Diagnosis

- · Pulmonary edema
- Lung cancer
- Pulmonary hemorrhage
- Chemical pneumonitis
- · Hypersensitivity pneumonitis

■ Treatment

- · Manage respiratory failure, hypotension
- Obtain sputum Gram stain, blood cultures
- · Early antibiotics improve outcome
- For most patients, third-generation cephalosporin plus macrolide or doxycycline, or fluoroquinolone with antipneumococcal activity (levofloxacin) alone
- Consider broader antibiotic coverage if patient diabetic, alcoholic

Pearl

Pneumonia caused by penicillin-resistant Streptococcus pneumoniae (except very highly resistant strains) is effectively treated with usual antibiotics; however, vancomycin should be added if meningitis suspected.

Reference

Bartlett JG: Practice guidelines for management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347. [PMID: 10987697]

Encephalitis, Brain Abscess, Spinal Epidural Abscess

Essentials of Diagnosis

- Encephalitis: altered sensorium, headache, fever, sometimes progressing to stupor, coma, occasionally seizures, focal neurologic signs; Herpes simplex most common sporadic viral encephalitis; arboviruses, West Nile virus
- Brain abscess: fever, seizures, focal neurologic signs, progressive obtundation; abnormal head CT (with radiographic contrast) or MRI; may have local infection (otitis media, sinusitis, dental infection)
- Spinal epidural abscess: fever, back pain, radiculopathy, progressive motor or sensory deficits depending on location, percussion tenderness; may have adjacent osteomyelitis

Differential Diagnosis

- CNS tumor (primary or metastatic to spine or brain)
- · Bacterial or viral meninigitis
- Fungal or tuberculous infection, especially in immunocompromised host
- · Vasculitis or collagen vascular diseases

■ Treatment

- · Evaluate for CNS or spinal cord mass effect or compression
- · High-dose acyclovir for herpes encephalitis
- · Surgical drainage for spinal epidural abscess
- Antibiotics for epidural abscess active against staphylococci, streptococci, gram-negative bacilli; for brain abscess active against streptococci plus anaerobes

Pearl

Brain abscesses arising from the oral cavity and frontal or ethmoid sinuses tend to locate in the frontal lobes of the brain; hematologically seeded abscesses are more often multiple and occur in the area supplied by the middle cerebral artery.

Reference

Beaman MH: Acute community-acquired meningitis and encephalitis. Med J Aust 2002;176:389. [PMID: 12041637]

Fever in the ICU

■ Essentials of Diagnosis

- Temperature >38.3°C orally or rectally; axillary temperature measurements not accurate
- In critically ill, both noninfectious and infectious etiologies must be considered, including drug reactions
- Evaluate based on underlying medical conditions, symptoms and signs, recent infections, current or recent antibiotics, review of medication record, laboratory findings

Differential Diagnosis

- Infectious causes: sepsis, pneumonia, urinary tract infection (especially if indwelling urinary catheter), intravenous catheter infection (with or without signs of inflammation at insertion site), Clostridium difficile colitis, infected decubitus ulcer, sinusitis (especially with nasotracheal or nasogastric tube), intra-abdominal infections, endocarditis
- Noninfectious causes of fever include drugs or allergic reactions, deep venous thrombosis, central nervous system fever, intraventricular hemorrhage, tissue necrosis, malignancy, hyperthyroidism, neuroleptic-malignant syndrome

Treatment

- · Specific treatment determined by etiology of fever
- Empiric antibiotic therapy if high suspicion for infection; obtain cultures prior to initiating antibiotics
- Administer antipyretics; consider physical cooling (ice packs, cooling blanket, cool fluids, intravenously or via peritoneum, cold hemodialysis) if severe hyperthermia

Pearl

Antibiotic treatment of colonized sites unnecessary, and likely to select for resistant organisms.

Reference

Cunha BA: Fever in the intensive care unit. Intensive Care Med 1999;25:648. [PMID:10470566]

Hematogenously Disseminated Candidiasis

Essentials of Diagnosis

- Persistent fever despite broad-spectrum antibiotics; may be complicated by candida endocarditis, osteomyelitis, arthritis, hepatosplenic candidiasis, endophthalmitis, CNS abscesses
- Risk factors: number of antimicrobial agents given, duration of antimicrobial therapy, total parenteral nutrition, neutropenia, hemodialysis, colonization with candida, extensive surgeries, burns
- Candida fourth leading organism isolated from blood cultures in hospitalized patients; however, sensitivity of blood cultures for detecting candidemia <50%
- C albicans most common species isolated (59%); but increasing isolation of nonalbicans species, especially C glabrata

Differential Diagnosis

- Noninfectious source of persistent fever (DVT, drug fever, embolic events)
- Other infectious causes of fever (bacteria, mycobacteria, viruses, other fungi)

■ Treatment

- Empiric antifungal therapy in patients with persistent fever and significant risk factors
- Antifungal agent selected depends on knowledge of Candida spp and patient's status
- Amphotericin B standard treatment; consider fluconazole in non-neutropenic patients with susceptible *Candida* spp
- Role of newer antifungal agents in candida bloodstream infection under investigation
- · Removal of indwelling catheters strongly advised

Pearl

Presence of endophthalmitis must be excluded in patients with candidemia; if found, prolonged systemic therapy, and, in advanced cases, vitrectomy required.

Reference

Spellberg B: The pathophysiology and treatment of candida sepsis. Curr Infect Dis Rep 2002;5:387. [PMID: 12228025]

Infections in Immunocompromised Hosts

Essentials of Diagnosis

- Suspected infection in patients with immunocompromising condition, such as neutropenia, organ transplantation with immunosuppressive therapy, diabetes, splenectomy, chronic corticosteroid therapy, HIV infection; type of immunocompromise determines risk, nature of opportunistic infection
- Neutropenia associated with gram-negative bacilli, gram-positive cocci, fungi
- Organ transplant recipients susceptible to *Pneumocystis jiroveci*, *Listeria monocytogenes*, *Nocardia asteroides*, *Cryptococcus neoformans*, *Aspergillus* spp, cytomegalovirus (2–6 months after transplant)
- Postsplenectomy: overwhelming infection with encapsulated organisms, such as S pneumoniae, N meningitides, H influenzae
- Diabetics prone to more severe manifestations of common infections (emphysematous cholecystitis and pyelonephritis, necrotizing soft tissue infection) plus specific infections (rhinocerebral mucormycosis, malignant otitis externa)

Treatment

- Antimicrobial therapy against likely organisms based on immunocompromising condition, specific clinical features
- Surgical debridement for emphysematous infections, infections with necrosis, rhinocerebral mucormycosis
- Vaccination against S pneumoniae, H influenzae and N meningitidis in asplenic and HIV-infected patients, others at increased risk

■ Pearl

A functional asplenic state can occur in congenital hyposplenism, sickle cell disease, graft-versus-host disease, rheumatoid arthritis, systemic lupus erythematosus, amyloidosis, ulcerative colitis, celiac disease, and chronic alcoholism.

Reference

Fishman JA: Infection in organ-transplant recipients. N Engl J Med 1998;338:1741. [PMID: 9624195]

Infective Endocarditis

Essentials of Diagnosis

- · Presentation depends on infecting organism
- Acute staphylococcal endocarditis: short prodrome, sepsis syndrome; viridans streptococci: classical subacute endocarditis with murmur, conjunctival hemorrhage, Janeway lesions, immunologic phenomena (Roth spots, Osler nodes, immune complex glomerulonephritis)
- Diagnosis by Duke criteria: major (positive blood cultures or typical findings on echocardiography) plus minor (vascular and immunologic phenomenon, echocardiography and blood culture results not meeting major), fever, predisposing factors
- Risk factors: underlying valvular abnormality, prosthetic valves, injection drug use
- Common organisms: S aureus (~50%; injection drug users and diabetics), viridans streptococci, enterococci; less common pathogens S pneumoniae, group A, B, C streptococci, L monocytogenes, P aeruginosa, S marcescens
- If blood cultures negative, consider "HACEK" group (Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella), and Brucella, Legionella, Bartonella, Coxiella, fungi
- · Transesophageal echocardiography preferred imaging study

■ Differential Diagnosis

- · Bacteremia from other sites
- Marantic endocarditis
- · Atrial myxoma

- · Thrombophlebitis
- Rheumatic diseases

Treatment

- Systemic antibiotic directed against causative organism for 4–6 weeks; consider 2 weeks of combination therapy for uncomplicated right sided endocarditis in selected patients
- Surgical valve replacement for failure of medical therapy, decompensated CHF from valvular insufficiency, continued septic emboli despite antibiotic therapy, fungal endocarditis

■ Pearl

Consider endocarditis in every patient presenting with fever and stroke.

Reference

DiNubile MJ: Infective endocarditis. N Engl J Med 2002;346:782. [PMID: 11882739]

Intra-abdominal Infection

Essentials of Diagnosis

- Wide array of clinical syndromes, including intraperitoneal, pancreatic and hepatic abscesses, spontaneous and secondary peritonitis, colitis, cholangitis
- Symptoms often nonspecific, such as vague abdominal pain, anorexia, fever
- · Bowel sounds may be diminished or absent
- · Laboratory findings nonspecific
- Abdominal imaging by CT scan (abscess or perforation) or ultrasound (biliary process) useful to localize site of infection
- Majority of infections are polymicrobial, involving native gastrointestinal flora (aerobic and microaerophilic streptococci, enterobacteriaceae, enterococci and anaerobes); hepatic abscess from Entamoeba histolytica
- GI colonization with Candida spp in about 50% of patients
- Antibiotic use increases likelihood of Candida spp, resistant gram-negative bacilli, enterococci

■ Differential Diagnosis

- Ischemic bowel
- Perforated viscus, pancreatitis, peptic ulcer disease, biliary colic
- Tumors

■ Treatment

- Broad-spectrum antimicrobial therapy targeting enteric flora (especially gram-negative bacilli and anaerobes)
- · Antifungal therapy in patients with significant risk factors
- Surgical drainage of abscesses and debridement of necrotic tissue

Pearl

Lack of physical findings in intra-abdominal infection is common in immunocompromised (steroids, chemotherapy, neutropenia), obese, and elderly patients.

Reference

McClean KL: Intraabdominal infection: a review. Clin Infect Dis 1994;19:100. [PMID: 7948510]

Intravenous Catheter-Associated Infection

■ Essentials of Diagnosis

- Local infection at catheter exit site with erythema, purulence, tenderness up to 2 cm from insertion site
- Tunnel infection has signs of infection >2 cm from skin insertion site
- Catheter-associated sepsis caused by migration of skin-colonizing organism to tip of catheter, contamination of catheter hub, or rarely hematogenous seeding of catheter or infusion of contaminated fluids
- Catheter-associated bloodstream infection when same organism grown from catheter tip and blood cultures
- Gram-positive organisms most common (coagulase negative staphylococci, Staphylococcus aureus), but increasing incidence of candida, gram-negative organisms (associated with monitoring devices and contaminated intravenous fluids)
- No agreement on quantitative and semiquantitative cultures for diagnosis; some define infection as >15 colony-forming units or >10³ organism cultured from distal catheter tip

Differential Diagnosis

- · Chemical phlebitis
- · Thrombophlebitis or thrombosis of central venous catheter
- · Bacteremia, sepsis from noncatheter source

Treatment

- Remove catheter whenever possible; removal strongly indicated in presence of sepsis, or if resistant or difficult to treat pathogen isolated (fungi, *Pseudomonas aeruginosa*)
- Antibiotic therapy against most likely pathogens (empiric vancomycin plus aminoglycoside or cephalosporin is appropriate)

Pearl

To minimize risk of infection, always use a new insertion site for replacement of an intravenous catheter.

Reference

Cunha BA: Intravenous line infections. Crit Care Clin 1998;14:339. [PMID: 9561821]

Mycobacterium tuberculosis

Essentials of Diagnosis

- Fever, night sweats, weight loss, fatigue, productive cough; sometimes hemoptysis
- Upper lobe infiltrate most common (posterior and apical segments), if reactivation; primary TB involves lower lobes; chest radiograph may be normal in presence of HIV infection
- Acid-fast smear; tuberculosis cultured from sputum; positive cultures from blood and urine in disseminated disease; if localized to lymph nodes, may require biopsy for diagnosis
- TB skin test (PPD) may be nonreactive in critically ill patients
- Pulmonary tuberculosis most common syndrome in adults; adenitis in children
- Increased tuberculosis incidence in HIV-infected persons, homeless, foreign-born, institutionalized patients; high mortality (>50%) if respiratory failure
- Susceptibility testing recommended in all cases to identify drugresistant strains

Differential Diagnosis

- Bacterial pneumonia
 Lung abscess
- Malignancy
- Fungal pneumonia (cocidioidomycosis, histoplasmosis)
- · Pulmonary emboli
- Pneumocystis pneumonia in HIV-positive patients

■ Treatment

- · Respiratory isolation for all suspected patients
- · Manage respiratory failure
- If no prior treatment, isoniazid (INH), rifampin, pyrazinamide, ethambutol for 2 months; followed by INH and rifampin for at least 4 months; directly observed treatment (DOT) strongly recommended
- If prior treatment for tuberculosis, expert consultation recommended; if resistant mycobacteria isolated, modify therapy according to susceptibility testing

Pearl

In the presence of a positive TB skin test, risk for developing active tuberculosis is 10% during lifetime in immunocompetent patients, but 10% per year in patients with HIV infection.

Reference

Lee PL: Patient mortality of active pulmonary tuberculosis requiring mechanical ventilation. Eur Respir J 2003;22:141. [PMID: 12882464]

Necrotizing Soft Tissue Infection

Essentials of Diagnosis

- Rapidly spreading infection with widespread tissue necrosis with potentially high mortality rate
- Clinical features disproportionate to physical findings; edema and tenderness beyond area of erythema, palpable crepitus, vesicles or bullae
- · Fever, tachycardia, hypotension common
- Leukocytosis, disseminated intravascular coagulation, elevated creatinine kinase, acidosis, renal failure
- Three types: Group A streptococcal infection; clostridial infection (gas gangrene, myonecrosis); polymicrobial infection (eg, Fournier disease)
- · Patients with impaired host defense at higher risk

■ Differential Diagnosis

- · Cellulitis
- · Myositis
- · Thrombophlebitis
- · Compartment syndrome
- · Soft tissue abscess

Treatment

- · Early diagnosis and aggressive treatment critical for survival
- Emergent surgical exploration indicated for any suspicion of necrotizing soft tissue infection
- Immediate surgical exploration and debridement; surgical reexploration every 1–2 days to ensure that wound edges are free of necrosis
- Broad-spectrum antibiotics to cover aerobic and anaerobic organisms

Pearl

Findings suggestive of invasive soft tissue involvement, such as crepitus or blistering, are present in <40% of patients.

Reference

Nichols RL: Clinical presentations of soft-tissue infections and surgical site infections. Clin Infect Dis 2001;33(Suppl 2):S84. [PMID: 11486304]

Neutropenic Fever

Essentials of Diagnosis

- Single temperature >38.3°C, or ≥38°C for 1 hour, in patient with neutropenia (absolute neutrophil count <500/μL, or <1000/μL with anticipated decline to <500/μL)
- Up to 90% of neutropenic patients develop fever
- Duration, depth, cause of neutropenia determine likelihood of infection; infection most common cause of death during neutropenic episodes
- Common pathogens include aerobic gram-negative bacilli, with increasing incidence of gram-positive cocci; but etiology identified in only 30–50%; only 10–20% have documented bacteremia or fungemia
- Fever often only sign of infection; however, complete history and careful examination essential (inspect skin, mucous membranes, perirectal area)

Differential Diagnosis

- · Drug fever or allergic reaction
- · Fever secondary to hematologic malignancy
- · Deep venous thrombosis

Treatment

- Prompt initiation of empiric antimicrobial therapy using antipseudomonal beta-lactam antibiotic with or without aminoglycoside
- Add antistaphylococcal/streptococcal agent (vancomycin) in patients at higher risk for gram-positive cocci (central IV catheter, mucositis, prior treatment with fluoroquinolones)
- Antifungal agents indicated in prolonged neutropenic fever (>5 days) despite broad-spectrum antibacterial drugs
- · Avoid rectal exams, which can lead to bacteremia

Pearl

Physical exam may be misleading because lack of neutrophils precludes usual pus formation, fluctuance, or development of abscesses.

Reference

Hughes WT: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730. [PMID: 11850858]

Nonbacterial Meningitis

Essentials of Diagnosis

- Acute onset of headache, mild neck stiffness, fever (viral meningitis); chronic symptoms with gradual increase in severity over days to weeks (tuberculous or fungal meningitis)
- May have features of underlying disease (viral syndrome or pulmonary or disseminated tuberculosis or fungal infection)
- Viral meningitis: acute onset, resolves within days; cerebrospinal fluid with predominance of lymphocytes, normal glucose; enteroviruses most commonly implicated
- Tuberculous meningitis: subacute or chronic onset of symptoms; cerebrospinal fluid with predominance of lymphocytes, low glucose, high protein
- Fungal meningitis: subacute or chronic onset of symptoms; cerebrospinal fluid has predominance of lymphocytes; variably low glucose and high protein (*Coccidioides immitis*); in *Cryptococcus neoformans* meningitis, symptoms, signs often unremarkable; may have high CSF opening pressure and positive CSF India ink stain, but normal glucose, protein, cell counts

Differential Diagnosis

- · Carcinomatous meningitis
- · Partially treated bacterial meningitis
- · Drug-induced meningitis

Treatment

- · No specific treatment for viral meningitis
- Tuberculous meningitis: begin empiric therapy with 3–4 antituberculous drugs
- Cryptococcal meningitis: amphotericin B plus 5-flucytosine followed by fluconazole
- Coccidioides meningitis: high dose fluconazole, or fluconazole + amphotericin B

Pearl

Mumps, Herpes simplex, and lymphochoriomeningitis (LCM) meningoencephalitis may cause low CSF glucose levels.

Reference

Beaman MH: Acute community-acquired meningitis and encephalitis. Med J Aust 2002;176:389. [PMID: 12041637]

Nosocomial Pneumonia

Essentials of Diagnosis

- Common nosocomial infection, with mortality rate up to 70%
- Aspiration of oropharyngeal material most common route of acquisition; oropharynx often colonized with gram-negative, hospital-acquired organisms; 20–40% polymicrobial
- Risk factors: neurologic impairment, mechanical ventilation, witnessed aspiration, lung and heart disease, supine position, older age, nasogastric tube
- Less commonly, inhalation and nosocomial acquisition of tuberculosis, legionellosis, influenza, aspergillosis
- Nosocomial bacteremia with Staphylococcus aureus and Candida spp can lead to hematogenous pneumonia

Differential Diagnosis

- · Acute respiratory distress syndrome
- · Pulmonary emboli
- · Cardiogenic pulmonary edema
- Malignancy (primary lung or metastatic disease)
- Atelectasis

Treatment

- Antibiotic therapy targeting local nosocomial flora
- Sputum Gram stain, culture may guide therapy; quantitative endotracheal aspirate (sensitivity 52–100%), bronchoalveolar lavage (80–100%), protected brush specimen (65–100%) more useful
- Supportive care with frequent suctioning of respiratory secretion, postural drainage and, in some patients, bronchoscopy for drainage
- Use preventive measures such as semirecumbent position (elevate head of bed), avoid long-term nasal intubation, use frequent supraglottic suctioning

■ Pearl

Consider nosocomial pulmonary aspergillosis in neutropenic patients.

Reference

Johanson WG: Nosocomial pneumonia. Intens Care Med 2003;29:23. [PMID: 12528018]

Peritonitis

Essentials of Diagnosis

- Spontaneous bacterial peritonitis (SBP); or secondary peritonitis from perforation of abdominal viscus
- SBP defined as ascitic fluid with >250 neutrophils/mm³ or positive Gram stain (rarely) or culture of ascitic fluid; 50% with fever, abdominal tenderness; 30% asymptomatic
- SBP seen in 8–27% of patients with cirrhosis and ascites; likely due to translocation of bacteria across gut lumen; *E coli* most common, then *K pneumoniae*, streptococci, enterococci, anaerobes; mortality up to 50%
- Secondary peritonitis patients have severe abdominal pain, nausea, vomiting, fever, abdominal tenderness, hypotension; secondary to perforation of viscus; ascitic fluid with leukocytosis, Gram stain and cultures polymicrobial; abdominal radiographs or CT scan may show free intraperitoneal air

Differential Diagnosis

- · Appendicitis, intra-abdominal abscess
- · Sickle cell crisis
- · Diabetic ketoacidosis
- Porphyria
- Familial Mediterranean fever
- Lead poisoning
- Uremia
- Systemic lupus erythematosus with serositis

Treatment

- SBP, use third-generation cephalosporin
- Secondary peritonitis requires evaluation and surgical management for perforated viscus; antibiotic coverage must include anaerobes and enteric gram-negative bacilli

Pearl

Suspect secondary peritonitis if more than one microorganism on Gram stain or culture of ascitic fluid.

Reference

Malangoni MA: Current concepts in peritonitis. Curr Gastroenterol Rep 2003;5:295. [PMID: 12864959]

Pneumocystis jiroveci Pneumonia (PCP)

Essentials of Diagnosis

- Nonproductive cough, fever, progressive dyspnea; chest radiograph with interstitial infiltrates, often bilateral
- Arterial hypoxemia, sometimes out of proportion to chest radiographic findings
- Diagnosis confirmed by Giemsa or methenamine silver stain or immunofluorescent antibody stain of sputum or bronchoalveolar lavage
- Commonly seen in patients with advanced HIV infection, low CD₄ cell count, and those not receiving Pneumocystis prophylaxis
- Prolonged administration of corticosteroids associated with increased risk in HIV-negative hosts

■ Differential Diagnosis

- · Bacterial, viral, or fungal pneumonia
- · Tuberculosis
- · Congestive heart failure
- · Acute respiratory distress syndrome
- · Pulmonary emboli

Treatment

- High-dose trimethoprim-sulfamethoxazole (15 mg/kg/day of trimethoprim component)
- Alternatives: atovaquone, clindamycin plus primaquine, dapsone plus trimethoprim, pentamidine
- Oxygen or mechanical ventilation, if indicated, for respiratory failure
- Adjunctive therapy with corticosteroids if $P(A-a)O_2 > 35$ mm Hg or $PO_2 \le 70$ mm Hg
- For HIV-infected patients, secondary prophylaxis against Pneumocystis until CD4 count consistently >200 cells/mm³ with antiretroviral therapy

Pearl

A patient with suspected PCP who has a normal serum LDH should be evaluated for an alternative diagnosis.

Reference

Morris A: Improved survival with highly active antiretroviral therapy in HIVinfected patients with severe Pneumocystis carinii pneumonia. AIDS 2003;17:73. [PMID: 12478071]

Prevention of Nosocomial Infection

Essential Concepts

- Infection acquired in hospital (not present or incubating at the time of admission); onset at least 2–4 days after hospitalization depending on site and pathogen identified
- · Manifestations specific for site and source
- Occurs in 5–35% of ICU patients; most common urinary tract infection, pneumonia, surgical site infection, bloodstream
- Sources: bacterial flora colonizing patients, with pathogens increasingly resistant to antibiotics, and patient's endogenous flora

Essentials of Management

- Prevent cross-contamination using universal precautions (hand washing; gloves, masks, gowns when necessary; special care with patient soiled linen and removed devices); appropriate isolation of patients with easily transmissible pathogens (*C difficile*, *M tuberculosis*) or highly resistant pathogens (methicillinresistant *S aureus*, vancomycin-resistant enterococcus)
- Appropriate use of antimicrobial agents to limit selection of resistant pathogens
- Ventilator-associated pneumonia: use semirecumbent rather than supine positioning, sucralfate rather than antacid therapy for prevention of stress gastritis (controversial), continuous subglottic aspiration, noninvasive ventilation when possible
- Nosocomial sinusitis: limit duration of nasogastric or nasolaryngeal tubes; oral hygiene
- Bloodstream infection: use careful sterile technique in insertion and handling of devices; use "tunneled" catheters for long-term intravenous use; minimize use of femoral venous catheters; consider use of antimicrobial impregnated catheters in selected patients
- Urinary tract infection: use indwelling urinary catheter only when necessary; reassess need daily, discontinue if possible
- Surgical site infections: stress optimal sterile surgical techniques; antimicrobial prophylaxis when and only if appropriate

Pearl

Hand washing is the single most effective method to avoid nosocomial transmission of pathogens.

Reference

Eggimann P: Infection control in the ICU. Chest 2001;120:2059. [PMID: 11742943]

Pulmonary Infections in HIV-Infected Patients

Essentials of Diagnosis

- Pneumococcal or other bacterial pneumonia: abrupt onset of productive cough, fever, pleuritic chest pain (pneumococcal or other bacterial pneumonia)
- Tuberculous or fungal pneumonia (including *Pneumocystis jiroveci*): more gradual onset of fever, less purulent sputum, cough, weight loss
- Pneumocystis pneumonia: gradual onset of dyspnea, fever, no or very minimal sputum
- Chest radiographic findings vary from focal infiltrates to diffuse interstitial markings
- Diagnosis by sputum smear and culture (pneumococcus, TB), bronchoscopic sampling (PCP), serologies (coccidioides, histoplasma, cryptococcal pneumonia)
- Immune-suppression (CD₄ cell count) determines likelihoods;
 CD₄ count >200/mm³ (S pneumoniae, M tuberculosis, S aureus, influenza); <200/mm³ (Pneumocystis jiroveci (PCP), C neoformans, M tuberculosis; <50/mm³ (Pneumocystis jiroveci, histoplasmosis, P aeruginosa, CMV (coinfection with PCP), M avium complex)
- M tuberculosis and S pneumoniae at increased incidence across all CD₄ strata

■ Differential Diagnosis

- Tumors (primary lung carcinoma, Kaposi sarcoma, lymphoma)
- · Interstitial lung disease
- Acute respiratory distress syndrome; congestive heart failure; pulmonary emboli

■ Treatment

- Evaluate and manage respiratory failure
- · Respiratory isolation of patient if tuberculosis suspected
- Empiric antimicrobial therapy against likely organism, guided by clinical presentation and CD₄ count
- Diagnostic thoracentesis if pleural effusion present

Pearl

In presence of either pleural effusion or purulent sputum production, consider diagnoses other than Pneumocystis pneumonia.

Reference

Wolff AJ: HIV-related pulmonary infections: a review of the recent literature. Curr Opin Pulm Med 2003;9:210. [PMID: 12682566]

Sepsis

Essentials of Diagnosis

- Defined as infection with accompanying systemic inflammatory response syndrome (SIRS), with two or more of following: temperature $>38^{\circ}\text{C}$ or $<36^{\circ}\text{C}$; heart rate >90/minute; respiratory rate >20/minute; white blood cell count $>12,000/\mu\text{L}$ or $<4000/\mu\text{L}$ or >10% bands
- Clinical features range from sepsis (SIRS plus culture-documented infection) to severe sepsis (sepsis with organ dysfunction or hypotension) to septic shock (sepsis with hypotension and hypoperfusion)
- Any microorganism can cause sepsis; bacteria most commonly implicated; blood cultures positive in only 40%
- Immune suppression or uncontrolled immune response may contribute to sepsis syndrome
- · Leading cause of death in ICU patients in the United States

Differential Diagnosis

- Multiple trauma
- Severe hemorrhagic or necrotizing pancreatitis
- · Severe burns
- · Acute myocardial infarction
- · Pulmonary emboli
- · Metabolic and hematologic derangements

Treatment

- Early recognition of sepsis crucial for successful treatment
- Supportive care with oxygen and ventilatory support, intravenous fluid administration, vasopressor agents to increase oxygen delivery
- Antibiotic therapy guided towards clinically and epidemiologically suspected pathogens
- · Surgical drainage of abscesses or necrotic tissue
- · Intensive insulin therapy for hyperglycemia
- Consider adjunctive therapy with recombinant human activated protein C in selected patients (severe sepsis without active risk of bleeding); other adjunctive therapies targeting the immune response under investigation.

Pearl

Mortality approaches 100% in septic patients with shock or failure of ≤ 3 organ systems.

Reference

Hotchkiss RS: The pathophysiology and treatment of sepsis. NEJM 2003;348:138. [PMID: 12519925]

Surgical Site Infection (SSI)

Essentials of Diagnosis

- Infection of surgical incision site(s), both superficial and deep
- Endogenous or hospital-acquired flora involved; usually occurs within 4–8 days of surgery, if caused by staphylococci and gramnegative organisms; earlier infection (<48 hours) caused by clostridia and beta-hemolytic streptococci
- Risk factors include host (extremes of age, poor nutritional status, diabetes, smoking, obesity, coexisting remote infection, bacterial colonization, altered immune response, prolonged preoperative hospital stay); operative factors (hygiene and antiseptic procedures, prophylactic antibiotics); postoperative factors (incision care)

Differential Diagnosis

- Other causes of postoperative fever (eg, atelectasis, thrombophlebitis, aspiration and drug reaction)
- · Inadequate postoperative pain control

■ Treatment

- Exploration of surgical wound or site of suspected infection; fluid draining from wound should have Gram stain and culture
- Debridement of necrotic tissue and/or removal of foreign body
- Antibiotic therapy targeting nosocomial gram positive as well as gram negative organisms

Pearl

Antimicrobial prophylaxis indicated in surgery involving opening hollow viscus, placement of foreign bodies, or when potential SSI poses catastrophic risk; should consist of 1–2 doses of antibiotics only, administered pre- and sometimes postoperatively, to decrease intraoperative organism burden.

Reference

Mangram AJ: Guideline for prevention of surgical site infection 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999;20:250. [PMID: 10219875]

Tetanus

Essentials of Diagnosis

- Neurologic disorder caused by neurotoxin produced by Clostridium tetani; toxin binds to presynaptic inhibitory neurons causing uncontrolled motor neuron activity
- Presentations: (1) neonatal tetanus; and (2) generalized; (3) local; or (4) cephalic tetanus in adults; local and cephalic tetanus can progress to generalized
- Trismus ("lockjaw") most common; advanced tetanus with generalized spasms, opisthotonos, abdominal rigidity, spastic facial expression ("risus sardonicus"); involvement of respiratory muscles leads to hypoventilation; autonomic nervous system disturbances common (sweating, tachycardia, arrhythmias, fluctuating blood pressure); fever notably absent, except in patients with seizures
- 1 to 54 days following wound contaminated with C tetani spores; crush, frostbite wounds with higher risk; wound cultures frequently negative for C tetani
- Lack of C tetani antibody (no immunization) supports diagnosis
- C tetani spores survive years in dust, soil, areas contaminated by human or animal excreta; common in developing countries; rare in the U.S. (50 cases per year); entirely preventable by tetanus vaccination

Differential Diagnosis

- · Strychnine poisoning, phenothiazine overdose
- · Mandibular or other lesions causing jaw lock
- Meningoencephalitis, opioid withdrawal, diphtheria, mumps, rabies

Treatment

- · Tetanus immune globulin
- Debridement of wound; penicillin G (kills active bacteria; spores not affected by antibiotics)
- Supportive care with tracheostomy, mechanical ventilation, benzodiazepines, nutritional support, therapy of seizures and cardiac arrhythmias
- · Active immunization during convalescent phase

Pearl

Binding of toxin is irreversible; rapid administration of antitoxin crucial to prevent progression and likelihood of death.

Reference

Farrar JJ et al: Tetanus. J Neurol Neurosurg Psychiatry 2000;69:292–301. [PMID: 10945801]

Toxic Shock Syndrome

Essentials of Diagnosis

- Multisystem illness characterized by rapid onset of fever, vomiting, watery diarrhea, pharyngitis, profound myalgias with accompanying hypotension
- Diffuse blanching truncal erythema early, accentuated in axillary and inguinal folds, spreading to extremities
- Desquamation of skin, palms and soles occurs in second or third week
- Multiorgan system involvement, with acute renal failure, ARDS, refractory shock, ventricular arrhythmias, and DIC may occur
- Highest incidence in menstruating women, persons with localized or postsurgical staphylococcal infection, and women using diaphragm or contraceptive sponge

■ Differential Diagnosis

- · Scarlet fever/Streptococcal toxic-shock-like disease
- Kawasaki's disease
- · Rocky Mountain spotted fever
- · Drug eruptions/Stevens-Johnson syndrome
- Measles
- Leptospirosis
- · Sepsis syndrome with multiorgan system failure

■ Treatment

- Immediate removal of tampon, contraceptive device, or surgical packing
- · Surgical drainage, irrigation of focal abscess
- Supportive care, with fluid resuscitation and management of organ system failure
- · Antistaphylococcal antibiotic, though effect on outcome unclear

Pearl

Intense hyperemia of conjunctival, oropharyngeal, and vaginal surfaces are frequent findings in toxic shock syndrome.

Reference

Provost TT, Flynn JA (editors): Cutaneous Medicine: Cutaneous Manifestations of Systemic Disease. BC Decker, 2001.

Urosepsis

Essentials of Diagnosis

- Urinary tract infection with secondary sepsis; ascending route of infection most common
- Vesiculoureteral reflux and renal transplant (short ureter with high risk of reflux) predispose to pyelonephritis; women higher risk for cystitis secondary to short urethra
- E coli most common pathogen but multidrug-resistant gramnegative rods, candida, coagulase negative staphylococci may cause nosocomial urosepsis
- Complications: intrarenal or perinephric abscess, obstruction, and infected renal stones; emphysematous pyelonephritis rare complication of elderly women with diabetes mellitus, chronic urinary tract infection, underlying renal vascular disease; organism typically E coli

Differential Diagnosis

- · Sepsis from other sources
- · Simple acute pyelonephritis or cystitis

Treatment

- Systemic antibiotics targeting most likely pathogen (urine Gram stain may guide empiric therapy)
- If negative urine Gram stain, empiric therapy with aminoglycoside, extended-spectrum penicillin, third-generation cephalosporin, or fluoroquinolone
- Obtain imaging studies (ultrasound examination, computed tomography, or CT urogram) to evaluate possible complications
- Emphysematous pyelonephritis requires immediate nephrectomy

Pearl

In uroseptic patient, urine culture growing S aureus should prompt work up for S aureus bacteremia (eg, infective endocarditis).


Reference

Paradisi F: Urosepsis in the critical care unit. Crit Care Clin 1998;14:165. [PMID: 9561812]

11 ——

Gastrointestinal Disease

Acalculous Cholecystitis	161
Adynamic (Paralytic) Ileus	162
Ascites	163
Boerhaave Syndrome	164
Cholangitis, Acute	165
Diarrhea	166
Gastric or Esophageal Variceal Bleeding	167
Gastritis	168
Hepatic Failure, Acute	169
Large-Bowel Obstruction	170
Lower Gastrointestinal Bleeding, Acute	171
Pancreatic Insufficiency	172
Pancreatitis	173
Peptic Ulcer Disease (PUD)	174
Small-Bowel Obstruction	175
Upper Gastrointestinal Bleeding	176



Acalculous Cholecystitis

Essentials of Diagnosis

- Acute inflammation and necrosis of gallbladder with unexplained fever, leukocytosis, vague abdominal or right upper quadrant pain; often insidious onset in susceptible patient
- Right upper quadrant abdominal tenderness highly variable; mass in 20%; jaundice, positive Murphy sign
- Leukocytosis, elevated bilirubin, alkaline phosphatase, aminotransferases
- Thickening of gallbladder wall, pericholecystic fluid, absence of gallstones on abdominal ultrasound; positive ultrasonographic Murphy sign; sometimes may fail to visualize gallbladder
- Severe cases with emphysematous cholecystitis, perforation with abscess formation
- Predisposing conditions: critical illness, especially with hypotension, sepsis, postoperative, immunosuppression, total parenteral nutrition, diabetes, biliary surgery; may have no predisposing factors
- Caused by combination of bile stasis, ischemia, local inflammation; part of multiorgan failure in ICU patients

■ Differential Diagnosis

- · Calculous cholecystitis
- · Acute pancreatitis
- · Pyogenic hepatic, subphrenic, or intra-abdominal abscess
- · Ascending cholangitis

Treatment

- Antibiotics directed against enteric pathogens and anaerobes (ampicillin, aminoglycoside, metronidazole)
- Cholecystectomy (open or laparoscopic); laparoscopic preferred in critically ill patients
- · Drain abscesses

Pearl

In patients too ill to undergo surgery, temporizing strategies with antibiotics and percutaneous drainage until more stable for cholecystectomy may be useful.

Reference

McChesney JA et al: Acute acalculous cholecystitis associated with systemic sepsis and visceral arterial hypoperfusion: a case series and review of pathophysiology. Dig Dis Sci 2003;48:1960. [PMID: 14627341]

Adynamic (Paralytic) Ileus

Essentials of Diagnosis

- Mild to moderate continuous abdominal pain, vomiting, obstipation
- Massive abdominal distention with localized tenderness common; decreased or absent bowel sounds
- Hemoconcentration; volume and electrolyte depletion with prolonged vomiting, sequestration into distended bowel loops
- · Leukocytosis and elevated amylase can be present
- Radiographs demonstrate gas-filled loops of bowel and multiple air-fluid levels; air may be evident in rectum
- Barium swallow with small bowel follow-through or contrast enema will differentiate ileus from mechanical obstruction
- Associated with neurogenic or muscular impairment of smallor large-bowel function
- Precipitating factors: recent abdominal surgery, ruptured viscus, peritonitis, pancreatitis, medications, anoxic injury, spinal cord trauma, uremia, diabetic coma, hypokalemia

■ Differential Diagnosis

- Idiopathic small-bowel pseudoobstruction
- Colonic pseudoobstruction (Ogilvie syndrome)
- · Small- or large-bowel mechanical obstruction

Treatment

- Identify and treat precipitating event or remove causative agent; decrease or avoid opioids
- · Restrict oral intake
- · Replete fluids and electrolytes with isotonic fluids
- Nasogastric suction useful for symptomatic relief but probably does not improve clinical outcome
- Postoperative ileus: NSAIDs help reduce opioid use and may decrease bowel inflammation
- · Prokinetic agents including erythromycin or metoclopramide
- After failure of conservative therapy, a trial of neostigmine may be beneficial for Ogilvie syndrome
- Colonoscopy if colonic dilation present
- · Surgery rarely needed

Pearl

Recent abdominal surgery is the most common cause of adynamic ileus in the ICU; function returns to the small bowel generally within 24 hours but may take several days to return to normal motility in the colon.

Reference

Luckey A et al: Mechanism and treatment of postoperative ileus. Arch Surg 2003;138:206. [PMID: 12578422]

Ascites

Essentials of Diagnosis

- Increasing abdominal girth and pressure, anorexia, early satiety, nausea, dyspnea
- · Shifting dullness, fluid wave, bulging flanks
- If due to liver disease: jaundice, spider angiomas, caput medusa, palmar erythema, testicular atrophy, gynecomastia
- Ascitic fluid assessment: cell count and differential, albumin, protein, Gram stain plus culture; amylase, cytology, glucose, LDH, triglycerides
- Calculate serum-ascites albumin gradient (SAAG): portal hypertension (>1.1 g/dL) or nonportal hypertensive causes (<1.1 g/dL)
- Spontaneous bacterial peritonitis (SBP) frequent complication; ascitic fluid with >250 neutrophils/µL diagnostic
- Ultrasound and CT scan: useful in localizing small volume ascites, identifying vascular thrombosis, determining etiology
- Grossly bloody ascites: repeat paracentesis in another location; if hemoperitoneum confirmed, emergent CT scan and surgical consult

Differential Diagnosis

- Portal Hypertension (High SAAG): cirrhosis, cardiac failure, portal or hepatic venoocclusive disease, fatty liver of pregnancy
- Nonportal Hypertensive Ascites (Low SAAG): malignancy, intraperitoneal infection, nephrotic syndrome, pancreatitis

■ Treatment

- · Sodium and fluid restriction for mild ascites
- · Spironolactone and loop diuretics for moderate ascites
- · Monitor weight, electrolytes, creatinine during diuresis
- Paracentesis for tense refractory ascites; consider salt-poor albumin infusions during large volume paracentesis
- Transjugular intrahepatic portosystemic shunt (TIPS) for intractable ascites; other options include surgical peritoneovenous shunting, liver transplantation
- Treat SBP with antibiotics, albumin infusion; consider prophylactic antibiotics for prior SBP, upper GI hemorrhage, low protein ascites

Pearl

Over 50% of patients with cirrhosis will develop ascites. Once ascites develops, the median survival is only 1 year.

Reference

Moore KP et al: The management of ascites in cirrhosis. Hepatology 2003;38:258. [PMID: 12830009]

Boerhaave Syndrome

Essentials of Diagnosis

- · Esophageal perforation leading to suppurative mediastinitis
- · History of excessive or rapid alcohol or food ingestion
- Vomiting or retching followed by severe, typically left sided chest pain; exacerbated by respiration and swallowing
- · Dyspnea can be prominent feature
- · Fever, hypotension, tachycardia, tachypnea
- · Subcutaneous emphysema, Hamman crunch
- · Leukocytosis and elevated serum amylase
- Radiographic findings: pneumomediastinum, pneumopericardium, pneumothorax, pleural effusion, subcutaneous emphysema
- Esophagogram with water-soluble contrast material has 75% sensitivity; consider repeating if negative
- · CT scan of chest helpful if esophagogram negative
- Pleural fluid demonstrates low pH and high amylase; may detect food particles

Differential Diagnosis

- Aortic dissection
- Myocardial infarction
- Perforated peptic ulcer
- Pulmonary embolism
- Spontaneous pneumothorax
- Pancreatitis
- · Iatrogenic esophageal rupture

Treatment

- · Immediate broad-spectrum antibiotics
- Supportive measures including aggressive hydration with isotonic crystalloid
- · Restrict all oral intake
- · Total parenteral nutrition to support nutritional status
- · Nasogastric intubation with suctioning
- · Aggressive and early surgical treatment
- Rare patients may recover with conservative therapy and pleural drainage only

Pearl

Factors predicting a poor outcome in Boerhaave syndrome include spontaneous perforation and a greater than 24 hour delay in diagnosis and initiation of treatment.

Reference

Janjua KJ: Boerhaave's syndrome. Postgrad Med J 1997;73:265. [PMID: 9196697]

Cholangitis, Acute

Essentials of Diagnosis

- Fever, jaundice, abdominal pain in 50–75%; fewer symptoms in elderly, patients receiving corticosteroids
- Right upper quadrant tenderness, jaundice, hypotension, manifestations of sepsis
- Leukocytosis; elevated bilirubin, alkaline phosphatase, amylase
- Common bile duct dilatation, stone, stricture seen on abdominal ultrasonography; MR cholangiopancreatography also useful
- Caused by ascending bacteria into biliary tract; almost always associated with obstruction from gallstones, strictures, malignancy, after biliary procedures (ERCP)

■ Differential Diagnosis

- · Liver abscess
- Acute pancreatitis
- · Acute cholecystitis
- · Biliary leaks

Treatment

- · Support patient with fluids and vasopressors if hypotensive
- Antibiotics for gram-negative enteric bacteria (E coli, K pneumoniae), enterococcus; often ampicillin, aminoglycoside; avoid fluoroquinolones, third-generation cephalosporins alone; treatment for anaerobic bacteria usually unnecessary
- Consider biliary drainage if unresponsive to antibiotics and persistent pain, hypotension, fever, altered sensorium using ERCP, percutaneous drainage, or open surgical procedure
- · ERCP useful for sphincterotomy, drainage, stent placement
- All patients should have correction of obstruction 72 hours after resolution of fever; overall outcome depends on mechanism of obstruction (benign or malignant)

Pearl

Abnormal sensorium in patients with acute cholangitis has been associated with poorer outcome.

Reference

Sugiyama M et al: Treatment of acute cholangitis due to choledocholithiasis in elderly and younger patients. Arch Surg 1997;132:1129. [PMID: 9336514]

Diarrhea

Essentials of Diagnosis

- Increase in fluidity, frequency, or quantity (>200 g/day) of stool, any loose stool, or >500 mL watery stool per day for two days
- Stool studies: fecal leukocytes, *C difficile* toxin, stool electrolytes to determine stool osmolar gap, ova and parasites
- Consider flexible sigmoidoscopy if ischemic colitis or inflammatory bowel disease suspected
- Etiologies: medications (antacids, antibiotics, metoclopramide), enteral feedings, infections, cholestatic syndromes (hepatitis, bile duct obstruction, steatorrhea), malabsorption (short-bowel syndrome, afferent loop syndrome), diabetic neuropathy, hyperthyroidism, immunodeficiency, inflammatory colitis
- Complications: volume depletion, electrolyte losses, skin breakdown with secondary infection.

Differential Diagnosis

- · Celiac disease
- Pancreatic insufficiency
- · C difficile colitis
- · Ischemic colitis
- · Lactase deficiency
- Hyperthyroidism
- · Drug-related diarrhea

Treatment

- · Replete fluid and electrolyte losses
- Discontinue possible causative agents and medications
- Use antidiarrheal agents with great caution
- Metronidazole or vancomycin for suspected or confirmed C difficile colitis; enteric precautions to prevent spread to other patients
- Enteral feeding associated diarrhea: discontinuation only proven effective therapy; other options include changing to peptidebased formula, adding fiber, or changing rate, fat content, osmolality, or temperature of feeding solution
- · Consider parenteral nutrition if unable to tolerate enteral feedings
- · Disimpaction if related to constipation and fecal impaction
- · Specific treatment directed once etiology determined

■ Pearl

C difficile colitis in the ICU can be acquired from environmental exposures, person-to-person contacts, and hand carriage from health care providers.

Reference

Ringel AF et al: Diarrhea in the intensive care patient. Crit Care Clin 1995;11:465. [PMID: 7788541]

Gastric or Esophageal Variceal Bleeding

Essentials of Diagnosis

- History of chronic liver disease or previous variceal bleed; varices are dilated collateral veins caused by elevated portal venous pressure; most commonly seen in cirrhosis
- Acute onset of painless large volume hematemesis
- Melena or hematochezia may be present
- Orthostatic hypotension, tachycardia
- Stigmata of chronic liver disease: jaundice, ascites, palmar ervthema, splenomegaly, telangiectasias, gonadal atrophy
- Confusion related to hypotension or encephalopathy
- Anemia may not be present with acute bleeding
- Chronic hepatic dysfunction common: hyperbilirubinemia, hypoalbuminemia, elevated serum aminotransferases and alkaline phosphatase, prolonged coagulation times, thrombocytopenia
- Nasogastric aspiration may demonstrate blood or "coffee grounds"
- Esophagogastroduodenoscopy (EGD) demonstrates esophagogastric varices

■ Differential Diagnosis

Gastritis

- · Peptic ulcer disease
- Mallory-Weiss tear Malignancy

Treatment

- Stabilize hemodynamics: adequate intravenous access; infuse isotonic crystalloid; transfuse blood products as necessary
- Support and protect airway
- Serial assessment of vital signs, hemoglobin, platelets, coagulation panel
- Early administration of octreotide or terlipressin
- Intravenous or oral proton pump inhibitors
- · EGD for confirmation and therapeutic intervention: sclerotherapy, band ligation
- Consider use of balloon tamponade device or proceed to transjugular intrahepatic portosystemic shunt (TIPS) in uncontrolled variceal bleeding
- Surgery reserved when above measures fail
- · Consider empiric antibiotics for spontaneous bacterial peritonitis

If isolated gastric varices are identified on endoscopy, suspect splenic vein thrombosis.

Reference

Sharara AI et al: Gastroesophageal variceal hemorrhage. N Engl J Med 2001;345:669. [PMID: 11547722]

Gastritis

Essentials of Diagnosis

- · Mild epigastric tenderness, fecal occult blood, melena
- · May be asymptomatic
- Decreasing hemoglobin may be only finding with acute gastritis
- · Iron deficiency anemia seen with chronic gastritis
- Esophagogastroduodenoscopy (EGD) reveals erythema and erosions; biopsy diagnostic
- Etiologies: critical illness, sepsis, or burns which may cause hypoperfusion to gastric mucosa; pharmacologic agents (NSAIDs); *H pylori* infection; alcohol use; atrophic gastropathy; previous surgery; prolonged mechanical ventilation

Differential Diagnosis

- · Peptic ulcer disease
- · Esophagitis
- Malignancy

Treatment

- Supportive measures: ensure adequate intravenous access; infuse isotonic crystalloid; transfuse blood if anemic, plasma to correct coagulopathy, platelets if thrombocytopenic
- Intravenous or oral acid suppressive agents: histamine type-2 antagonists, proton pump inhibitors
- · Treat underlying cause of hypoperfusion and shock
- · Avoid and remove offending agents
- EGD can identify lesions and treat with different measures to obtain hemostasis
- Eradicate H pylori if suspected or confirmed during EGD
- Vasopressin infusion, selective angiography, or surgery rarely indicated

Pearl

Stress gastritis, although common in ICU setting, is rarely a lifethreatening event.

Reference

Wu JC et al: Ulcers and gastritis. Endoscopy 2002;34:104. [PMID: 11822005]

Hepatic Failure, Acute

Essentials of Diagnosis

- · Rapid onset of severe impairment of liver function
- Hepatic encephalopathy predominant: asterixis, slowing of mentation, sleep disruption, confusion, coma
- · Malaise, fatigue, anorexia
- · Hypotension, tachycardia, occasionally fever
- · Jaundice, hepatomegaly, right upper quadrant tenderness
- Dramatic elevations of serum aminotransferases and bilirubin; hypoalbuminemia, hypoglycemia
- · Leukocytosis, thrombocytopenia, coagulopathy
- Progression to multiorgan system failure, including hepatorenal syndrome
- Poor prognostic signs: age <10 or >40, jaundice >7 days before onset of encephalopathy, serum bilirubin >17.5, coma, respiratory failure, coagulopathy, hepatitis C, halothane exposure, idiosyncratic drug reaction

Differential Diagnosis

- Acute viral hepatitis
- Drugs/toxins
- Acute fatty liver of pregnancy
- Ischemia/hypoperfusion
- Acute choledocholithiasis
- · Acute Wilson disease

Treatment

- Stabilize and protect airway; intubate to facilitate correction of acidosis, prevent aspiration
- Hemodynamic support: adequate intravenous access; infuse isotonic crystalloid; transfuse red blood cells if significantly anemic; correct coagulopathy if actively bleeding or planning invasive procedure; vasopressors
- Add dextrose to intravenous fluids to avoid hypoglycemia
- Manage encephalopathy and cerebral edema: may need direct intracranial pressure monitoring; elevate head of bed to 20–30°; hyperventilate; minimize patient stimulation; consider mannitol
- Administer N-acetylcysteine until acetaminophen toxicity excluded
- Consider liver transplantation early in treatment course

Pearl

Acute hepatic failure may alter the pharmacokinetics of commonly used ICU medications metabolized by the liver.

Reference

Marrero J et al: Advances in critical care hepatology. Am J Respir Crit Care Med 2003;168:1421. [PMID: 14668256]

Large-Bowel Obstruction

Essentials of Diagnosis

- Symptoms vary with location and degree of obstruction
- Constipation or obstipation
- Cramping pain referred to hypogastrium
- Continuous pain suggestive of intestinal ischemia
- Vomiting late finding; may not occur if ileocecal valve does not allow reflux
- High-pitched metallic tinkling, rushes, gurgles may be auscultated; abdominal distention; peristaltic waves may be seen
- Radiographs demonstrate large dilated loops of large bowel; absence of rectal gas
- Barium enema confirms diagnosis and may be therapeutic
- Colonoscopy or sigmoidoscopy can confirm diagnosis and may be therapeutic; can be complicated by perforation
- Etiologies: malignancy, volvulus, diverticular disease, inflammatory bowel disease, fecal impaction, strictures, adhesions, benign tumors
- Complications: progressive increase in intraluminal pressure leading to impaired circulation and subsequent gangrene and perforation

Differential Diagnosis

- Small-bowel obstruction
- Colonic pseudoobstruction
- · Ischemic enteritis
- Adynamic ileus

Volvulus

Treatment

- Replete fluids and electrolytes with isotonic fluids
- Barium enema, colonoscopy, or sigmoidoscopy may decompress and correct obstruction
- Mechanical obstruction generally requires surgery; other indications for surgery: perforation, ischemia, unchanged or worsening distention after 12-24 hours of conservative management
- Some descending colonic lesions may respond to endoscopic techniques including stent placement
- Broad spectrum antibiotics should be administered promptly if strangulation or perforation suspected

Pearl

In the presence of large-bowel obstruction, suspect carcinoma if rectal examination reveals occult blood, while fresh blood is more characteristic of diverticular disease.

Reference

Lopez-Kostner F et al: Management and causes of acute large-bowel obstruction. Surg Clin North Am 1997;77:1265. [PMID: 9431339]

Lower Gastrointestinal Bleeding, Acute

Essentials of Diagnosis

- Hematochezia and bright red blood per rectum with source below ligament of Treitz
- Symptoms depend on amount and acuity of blood loss, underlying comorbid diseases: asymptomatic, lightheadedness, syncope, dyspnea, angina; abdominal pain and anorectal complaints may be present
- Decreased caliber stools seen in colon cancer
- Physical findings variable: normal; orthostatic hypotension; anorectal mass; multiple telangiectasias
- Acute bleeding initially with normal blood cell count; chronic bleeding leads to iron deficient microcytic anemia
- Colonoscopy diagnostic in up to 80% of patients; distal sources seen with sigmoidoscopy
- Consider nuclear medicine scan or angiography if adequate preparation not possible
- Bleeding stops spontaneously in 85% of cases

Differential Diagnosis

- · Massive upper gastrointestinal hemorrhage
- · Arteriovenous malformations, angiodysplasia
- Diverticulosis
- Hemorrhoids
- Malignancy
- Inflammatory bowel disease

■ Treatment

- Stabilize hemodynamics: adequate intravenous access; infuse isotonic crystalloid; transfuse blood products
- Serial assessment of vital signs, hemoglobin, platelets, coagulation panel
- Nasogastric lavage to evaluate for upper gastrointestinal source when large amounts maroon colored stool present
- Colonoscopy: identify culprit lesion, provide therapeutic intervention with electrocoagulation, sclerotherapy, resection
- Angiodysplasia can be managed if identified during angiography with embolization or injection techniques
- Surgery warranted for uncontrolled bleeding with unidentifiable cause; also indicated in recurrent diverticular disease, persistent bleeding from angiodysplasia

Pearl

Gastrointestinal bleeding and calcific aortic stenosis (Heyde syndrome) has a high likelihood of angiodysplasia and has been reported to resolve with replacement of the diseased aortic valve.

Reference

Billingham RP: The conundrum of lower gastrointestinal bleeding. Surg Clin North Am 1997;77:241. [PMID: 9092113]

Pancreatic Insufficiency

Essentials of Diagnosis

- · Steatorrhea with frequent bulky light-colored stools
- Significant abdominal pain if associated with chronic pancreatitis
- Increased symptoms with high fat content meals as fat absorption affected more than protein or carbohydrate
- · Increased fecal fat excretion; decreased serum cholesterol
- Fecal elastase and chymotrypsin are decreased
- Secretin or cholecystokinin test demonstrates pancreatic fluid bicarbonate of <80 mEq/L
- · Vitamin deficiency rare
- Etiologies: pancreatic surgery, pancreatectomy, pancreatitis
- Chronic pancreatitis may be identified by ERCP, MRCP, endoscopic ultrasound, or CT scan
- Loss of >90% of pancreas exocrine function required before signs and symptoms of pancreatic insufficiency appear

■ Differential Diagnosis

- Lactase deficiency
- Celiac disease/sprue
- · Chronic infectious diarrhea

Treatment

- Daily dietary intake of 3,000-6,000 kcal
- · Caloric supplementation with medium chain triglycerides
- Pancreatic enzyme replacement; titrate dose based on dietary fat content
- Dietary fat restriction to control diarrhea
- · Pain control

Pearl

Because gastric acid can destroy oral lipase, administration of acidsuppressing agents may improve efficacy.

Reference

Petersen JM et al: Chronic pancreatitis and maldigestion. Semin Gastrointest Dis 2002;13:191. [PMID: 12462705]

Pancreatitis

Essentials of Diagnosis

- Severe epigastric or upper-abdominal pain radiating to back; associated with nausea, vomiting, anorexia
- · Fever, volume depletion, shortness of breath may be present
- · Hemodynamic and respiratory compromise in severe cases
- Epigastric and upper-quadrant tenderness, distention
- Ecchymosis of umbilicus (Cullen sign), flanks (Grey Turner sign) rare; suggest hemorrhagic pancreatitis when present
- Elevated amylase and lipase; leukocytosis
- · Radiographs may demonstrate "sentinel loop"
- CT scan and ultrasound: confirms organ enlargement; helps identify possible causes and complications
- Etiologies: alcohol consumption, biliary disease (gallstones, ductal abnormalities, tumor), hypercalcemia, infections, hypertriglyceridemia, trauma, scorpion venom, medications
- Complications: hemorrhage, necrosis, extrapancreatic fluid collections, pseudocyst, abscess, ARDS

Differential Diagnosis

- · Acute cholecystitis or cholangitis
- Mesenteric ischemia or infarction
- · Penetrating or perforating ulcer
- · Intestinal obstruction
- · Inferior wall myocardial infarction

Treatment

- Volume resuscitation with isotonic crystalloid; consider albumin infusion if serum level <3.0 g/dL; central venous or pulmonary artery catheter may help guide fluid replacement
- · Nasogastric suctioning for ileus or nausea
- · Pain control and antiemetics
- Early nutritional support may expedite recovery
- Intubation and mechanical ventilation for hypoxemia and ARDS
- Broad-spectrum antibiotics for complicated pancreatitis
- Fluid collections may be drained via endoscopic procedures, percutaneous drainage, surgical decompression
- Surgery indicated for sterile necrotizing pancreatitis not responsive to medical therapy, infected necrotizing pancreatitis

Pearl

Acute pancreatitis patients with more than 6 of Ranson criteria have a mortality rate greater than 40% and a complication rate greater than 80%.

Reference

Mitchell RMS et al: Pancreatitis. Lancet 2003;361:1447. [PMID: 12727412]

Peptic Ulcer Disease (PUD)

Essentials of Diagnosis

- Epigastric pain that may (duodenal) or may not (gastric) be relieved by food or antacids; worsens 1 to 3 hours after meals
- · Vomiting with gastric ulcers; back pain with duodenal ulcers
- · Hematemesis, melena, hematochezia with acute PUD bleeding
- · Epigastric tenderness and positive fecal occult blood
- Nasogastric tube aspiration demonstrates coffee ground material or blood
- Esophagogastroduodenoscopy (EGD) diagnostic
- ICU "stress ulcer" risk factors: ventilatory support, lack of enteral feeding, elderly, burns, head injury
- Associated diseases: COPD, cystic fibrosis, alpha-1 antitrypsin deficiency, chronic renal failure, cirrhosis
- · Complications: perforation, penetration, obstruction

Differential Diagnosis

- Gastric erosions/gastritis
- Esophagitis

- · Varices
- · Mallory-Weiss tear

■ Treatment

- Stabilize hemodynamics: adequate intravenous access; infuse isotonic crystalloid; transfuse blood products if necessary
- Serial assessment of vital signs, hemoglobin, platelets, coagulation panel
- · Intravenous or oral proton pump inhibitors
- Eradicate H pylori if present or suspected in cases of duodenal or prepyloric ulcers
- Avoid all ulcerogenic medications and agents
- Endoscopy to identify cause and achieve hemostasis: local injection of sclerosing or vasoconstricting agents, thermal probes, bipolar coagulation, application of hemostatic agents
- Angiography with embolization and surgery reserved for uncontrolled bleeding

Pearl

Risk of rebleeding based on endoscopic findings is least for clean based ulcer, increases if adherent clot or visible vessel, and most with active bleeding.

Reference

Shiotani A et al: Pathogenesis and therapy of gastric and duodenal ulcer disease. Med Clin N Am 2002;86:1447. [PMID 12510460]

Small-Bowel Obstruction

Essentials of Diagnosis

- Intermittent or colicky abdominal pain with crescendo-decrescendo pattern; insidious onset with progressive abdominal bloating, constipation, or obstipation
- · Vomiting progressively feculent as illness progresses
- Poorly localized crampy pain at site of involvement; progresses distally over course of illness
- Distended, tender abdomen; may have peritoneal signs and abdominal wall hernias
- Peristaltic "rushes" are auscultatory hallmark; may occur along with gurgles and high-pitched tinkles
- · Volume and electrolyte depletion common
- Radiographs demonstrate ladderlike pattern of dilated small bowel loops and air-fluid levels; "thumbprinting" and gas in bowel wall suggest bowel necrosis
- · CT should be considered if plain films nondiagnostic
- Etiologies: adhesions from previous surgeries, malignancies, hernias through the abdominal wall, volvulus, foreign bodies, inflammatory bowel disease, radiation therapy
- Complications: aspiration pneumonia, strangulation, perforation, peritonitis, bacteremia, sepsis

Differential Diagnosis

- · Adynamic ileus
- Large bowel obstruction
- Mesenteric vascular occlusion
- · Ischemic enteritis
- · Inflammatory bowel disease
- Pancreatitis
- · Cystic fibrosis
- Appendicitis
- · Large bowel obstruction

■ Treatment

- · Replete fluids and electrolytes with isotonic fluids
- · Nasogastric suctioning to decompress bowel
- · Serial abdominal examinations and radiographic studies
- Broad-spectrum antibiotics if strangulation or perforation suspected
- Consider surgical intervention early; indications include strangulation, failure of conservative therapy

Pearl

A strangulated obstruction should be suspected in the presence of early appearance of shock, gross hematemesis, and marked leukocytosis.

Reference

Wilson MS et al: A review of the management of small bowel obstruction.

Ann R Coll Surg Engl 1999;81:320. [PMID: 10645174]

Upper Gastrointestinal Bleeding

Essentials of Diagnosis

- Hematemesis, coffee ground emesis, melena with source above the ligament of Treitz; occasionally hematochezia
- Symptoms depend on amount and acuity of blood loss: asymptomatic, lightheadedness, syncope, dyspnea, angina; early satiety seen in gastric cancer
- Physical findings variable: none; orthostatic hypotension; stigmata of liver disease; mucosal pigmentation (Peutz-Jeghers syndrome); multiple telangiectasias (Osler-Weber-Rendu)
- Acute bleeding initially with normal blood cell count; chronic leads to iron deficient microcytic anemia
- · Nasogastric lavage demonstrates coffee ground material, blood
- Esophagogastroduodenoscopy (EGD) to determine bleeding source; nuclear medicine scan or angiography helpful if EGD nondiagnostic
- Mortality risks: advanced age; signs of systemic shock; significant comorbidities; diagnosis of malignancy; endoscopic findings of large varices, active bleeding, or visible vessel

■ Differential Diagnosis

- Gastric erosions/gastritis
- Varices
- Mallory-Weiss tear
- · Peptic ulcer disease
- Esophagitis
- Malignancy

■ Treatment

- Support and protect airway
- Stabilize hemodynamics: adequate intravenous access; infuse isotonic crystalloid; transfuse blood products as necessary
- Serial assessment of vital signs, hemoglobin, platelets, coagulation panel
- EGD can identify lesions and treat with sclerotherapy, band ligation, application of hemostatic agents
- Intravenous or oral proton pump inhibitors
- Consider early use of octreotide or terlipressin in suspected cases of variceal bleeding
- · Surgery reserved when above measures fail

Pearl


Early endoscopy is indicated in patients over 60 years of age, history of chronic liver disease, bright red blood per rectum associated with hypotension, and bleeding requiring more than 4 units of blood in a 6-hour period.

Reference

Conrad SA: Acute upper gastrointestinal bleeding in critically ill patients: causes and treatment modalities. Crit Care Med 2002;30:S365. [PMID: 12072663]

Endocrine Problems

Adrenal Insufficiency	179
Cushing Syndrome	180
Diabetic Ketoacidosis	181
Hyperosmolar Non-ketotic Diabetic Coma	182
Hypoglycemia	183
Myxedema Coma	184
Sick Euthyroid Syndrome	185
Thyroid Storm	186



Adrenal Insufficiency

Essentials of Diagnosis

- Weakness, nausea, vomiting, abdominal pain, fever
- Hypotension from hypovolemia, impaired vascular response to catecholamines, loss of inotropic effects of cortisol
- Altered mental status and confusion may be present
- Hyperpigmentation of skin and mucous membranes in primary adrenal insufficiency
- Hyponatremia, hyperkalemia, hypoglycemia, azotemia, hypercalcemia, eosinophilia, lymphocytosis
- Serum cortisol $> 20 \mu g/dL$ makes diagnosis unlikely
- ACTH stimulation test: increment of $>7 \mu g/dL$ or peak cortisol level $> 17 \mu g/dL$ excludes adrenal insufficiency
- Low to absent serum cortisol, elevated ACTH, abnormal ACTH simulation test in primary adrenal insufficiency
- Suspect in anyone taking >30 mg of hydrocortisone per day (or equivalent) for more than 3 weeks in past 1 year
- Etiologies of acute adrenal insufficiency: trauma; surgical stress; hemorrhage; infection; hypoperfusion; drugs; autoimmune; uncontrolled or poorly controlled chronic adrenal insufficiency with precipitating event

Differential Diagnosis

- Sepsis
- Hypovolemia
- Metastatic cancer
- Salt wasting nephropathy
- Medications
- Acute abdomen
- · Secondary adrenal insufficiency: pituitary or hypothalamic disorders

Treatment

- Immediately treat with intravenous hydrocortisone when suspected; may use dexamethasone if ACTH stimulation test delayed
- Add mineralocorticoid replacement with fludrocortisone if dexamethasone is used; not needed when >50 mg/d hydrocortisone administered
- Correct hypovolemia and electrolyte abnormalities
- · Monitor and infuse glucose if hypoglycemic
- May require vasopressors for blood pressure support
- Consider empiric antibiotic therapy if infection suspected
- Identify and treat precipitating event

■ Pearl

Despite aggressive volume resuscitation and vasopressor use, patients with acute adrenal insufficiency may remain hypotensive until corticosteroid replacement has been administered.

Reference

Cooper MS et al: Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727. [PMID: 12594318]

Cushing Syndrome

Essentials of Diagnosis

- Weakness, proximal myopathy, weight gain, irregular menses, hirsutism, acne, neuropsychiatric problems
- Plethoric moon facies, supraclavicular fullness, "buffalo hump," hypertension, cutaneous wasting, purple striae, poor wound healing, easy bruising
- Insulin resistance, central obesity, hypertension, dyslipidemia, impaired glucose tolerance (similar to "metabolic syndrome")
- Atherosclerosis, cardiovascular disease, nephrolithiasis, osteoporosis, polycystic ovary syndrome, hypogonadism
- Hyperglycemia, glycosuria, leukocytosis, lymphocytopenia; possibly hypokalemia and metabolic alkalosis
- Elevated levels of late-night serum and salivary cortisol levels or 24-hour urinary free cortisol levels
- Overnight low-dose dexamethasone suppression test does not suppress plasma cortisol level
- · Consider dexamethasone-CRH test if above studies equivocal
- Obtain ACTH levels once diagnosis of Cushing syndrome established
- Additional tests may include pituitary or adrenal MRI or bilateral petrosal sinus ACTH sampling

Differential Diagnosis

- · Metabolic syndrome
- Obesity
- Chronic alcoholism
- · Diabetes mellitus
- Depression
- Anorexia nervosa

Treatment

- Surgical removal of pituitary adenoma, adrenal tumor, or ectopic ACTH-producing tumor if present and resectable
- Bilateral adrenalectomy for adrenal hyperplasia in refractory cases of ACTH-dependent Cushing syndrome
- Ketoconazole or metyrapone to suppress cortisol production in unresectable cases

■ Pearl

Cushing disease refers to manifestations of hypercortisolism due to pituitary hypersecretion of ACTH, while Cushing syndrome is produced by excessive exogenous corticosteroid use or excessive production from the adrenal cortex.

Reference

Raff HR et al: A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med 2003;138:980. [PMID: 12809455]

Diabetic Ketoacidosis

Essentials of Diagnosis

- Polyuria, polydipsia, fatigue, weakness, weight loss, anorexia, nausea, vomiting, abdominal pain, lethargy
- Marked volume depletion: decreased skin turgor, dry mucous membranes, sunken eyes, tachycardia, orthostatic hypotension
- Deep rapid Kussmaul respirations; "fruity" odor on breath
- · Hypothermia unless precipitating event is infectious
- Hyperglycemia >250 mg/dL, ketonemia, anion gap acidosis
- Glycosuria, ketonuria, leukocytosis, hyperamylasemia, hypertriglyceridemia; hyperkalemia despite depleted body stores
- Serum osmolality variable; may be very high resulting in lethargy or coma
- Typically occurs in younger lean patients with type 1 diabetes mellitus; increasingly seen in type 2; may be initial presentation
- Precipitating event: infection, myocardial infarction, trauma, pancreatitis, medications, inadequate insulin

Differential Diagnosis

- Alcoholic ketoacidosis
- Sepsis
- · Toxic ingestion
- · Starvation ketoacidosis
- · Lactic acidosis

■ Treatment

- Aggressive fluid replacement with normal saline; once glucose reaches 250–300 mg/dL add dextrose to infusion
- Initial insulin bolus followed by intravenous insulin therapy (0.1 units/kg/h)
- Replete potassium, phosphate, magnesium; begin potassium replacement immediately if initially normokalemic or hypokalemic
- Frequent monitoring key to successful management: assessment
 of volume status especially in elderly or with cardiopulmonary
 disease; blood glucose every hour; electrolytes, renal function,
 ketones every 2–4 hours.
- · Identify and treat any precipitating event

Pearl

A hyperchloremic non-gap metabolic acidosis is a common manifestation of the later treatment phase of diabetic ketoacidosis and takes longer to resolve than the gap ketoacidosis as its correction depends on the kidney's ability to regenerate bicarbonate.

Reference

Kitabchi AE et al: Hyperglycemic crises in patients with diabetes mellitus. Diabetes Care 2003;26:S109. [PMID: 12502633]

Hyperosmolar Non-ketotic Diabetic Coma

Essentials of Diagnosis

- Gradual onset of polyuria, polydipsia, polyphagia, fatigue, weakness, weight loss, anorexia, nausea, vomiting, altered mental status progressing to coma
- Severe volume depletion: decreased skin turgor, dry mucous membranes, sunken eyes, tachycardia, orthostatic hypotension
- Plasma glucose >600 mg/dL and serum osmolality >320 mOsm/kg; pH >7.3; absent or small amount of ketones; variable anion gap
- · Hypothermia common
- · Glycosuria, azotemia, leukocytosis
- Risk factors: lack of prior knowledge of diabetes; older, obese patients with type 2 diabetes mellitus, underlying renal insufficiency, decreased access to water, female sex, underlying infection

Differential Diagnosis

- · Diabetes insipidus: central or nephrogenic
- · Poorly controlled diabetes mellitus
- · Diabetic ketoacidosis
- · Toxic ingestion

■ Treatment

- Aggressive fluid replacement with normal saline (0.9% NaCl) to correct volume depletion; change to hypotonic fluid (0.45% NaCl or D₅ water) to reduce serum [Na⁺] by 0.5–1.0 mEq/Lh
- Once glucose reaches 300 mg/dL add dextrose to infusion
- Goal glucose concentration should decrease by 100 mg/dL/h; may initiate intravenous insulin bolus and continuous insulin infusion but glucose may improve with hydration alone
- Replete potassium, phosphate, magnesium; potassium loss is typically more severe than in diabetic ketoacidosis
- Frequent monitoring key to successful management: assessment of volume status especially in elderly or with cardiopulmonary disease; blood glucose every hour; electrolytes, renal function, osmolality every 2–4 hours
- Identify and treat any precipitating event

■ Pearl

The lack of ketosis in hyperglycemic hyperosmolar non-ketotic coma may delay presentation resulting in ongoing osmotic diuresis that results in more severe volume depletion.

Reference

Kitabchi AE et al: Hyperglycemic crises in patients with diabetes mellitus. Diabetes Care 2003;26:S109. [PMID: 12502633]

Hypoglycemia

Essentials of Diagnosis

- Plasma glucose <45 mg/dL
- Sweating, trembling, feeling of warmth, palpitations, anxiety, nausea, hunger, blurred or double vision, weakness
- Neuroglycopenic symptoms with prolonged hypoglycemia: dizziness, confusion, tiredness, difficulty speaking, headache, inability to concentrate, nightmares, bizarre behavior
- Clinical diagnostic criteria for insulinoma (Whipple triad): hypoglycemic symptoms in fasting or exercising state, low plasma glucose level, relief of symptoms through correction of hypoglycemia
- · Insulin and C-peptide levels may help determine cause
- In nondiabetic hospitalized patients common etiologies include renal insufficiency, malnutrition, liver disease, infection, sepsis
- Other causes: alcoholism, adrenal insufficiency, medications (insulin, sulfonylurea, pentamidine, trimethoprim-sulfamethoxazole, salicylates, beta-blocking agents), insulin-secreting tumors

■ Differential Diagnosis

- Delirium
- Pheochromocytoma
- · Factitious hypoglycemia
- Liver failure

- Psychoneurosis
- · Sepsis syndrome
- · Myxedema coma

Treatment

- Administer glucose intravenously or orally (if awake and alert)
- Monitor blood glucose closely as patient may need continuous dextrose infusion until precipitating cause removed
- Glucagon and hydrocortisone can be given for refractory hypoglycemia
- · Identify and treat underlying disease or remove causative agent

Pearl

Because the liver and kidneys are the primary organs involved in the metabolism of insulin and the sulfonylurea drugs, development of renal or hepatic failure may delay drug clearance and result in hypoglycemia.

Reference

Service FL: Hypoglycemic disorders. N Engl J Med 1995;332:1144. [PMID: 7700289]

Myxedema Coma

Essentials of Diagnosis

- Cold intolerance, weight gain, constipation, depression, menstrual irregularities
- Puffy expressionless face; dry, rough, cold skin; non-pitting doughy edema; loss of eyebrows and scalp hair; delayed relaxation phase of tendon reflexes; enlarged tongue; bladder distention; decreased gastrointestinal motility
- · Hypothermia, bradycardia, elevated diastolic blood pressure
- · Hypercapnic respiratory failure with hypoxemia
- · Altered mental status: confusion, somnolence, coma
- Low T₄ and T₃, low T₃ resin uptake, elevated TSH
- Hypoglycemia, hyponatremia, anemia, elevated creatine phosphokinase, elevated creatinine, hyperlipidemia
- Radiographs may reveal enlarged cardiac silhouette, pleural and pericardial effusions
- ECG findings: bradycardia, low voltage, diffuse T wave depression, nonspecific ST changes, prolonged QT and PR intervals, conduction blocks
- Risk factors: known hypothyroidism with absent or inadequate thyroid replacement and precipitating stress or illness

Differential Diagnosis

- · Primary amyloidosis
- Exposure hypothermia
- Toxic ingestion
- · Parkinson disease
- Obstructive sleep apnea, obesity hypoventilation syndrome

Treatment

- Intravenous T₄ until able to tolerate oral therapy; decrease dose in frail patients or with significant cardiac disease
- Intravenous glucocorticoids until adrenal insufficiency excluded by cortisol level or ACTH stimulation test
- · Correct hypothermia, hypovolemia, electrolyte abnormalities
- · May require mechanical ventilation for hypoventilation
- Medication dose adjustment given impaired drug clearance with severe hypothyroidism
- · Identify and treat precipitating event

Pearl

In patients with hypothyroidism, the manifestations of adrenal insufficiency may be masked. If in doubt, administer glucocorticoids concomitantly with levothyroxine therapy to avoid precipitating adrenal crisis.

Reference

Ringel MD: Management of hypothyroidism and hyperthyroidism in the intensive care unit. Crit Care Clin 2001;17:59. [PMID 11219235]

Sick Euthyroid Syndrome

Essentials of Diagnosis

- Low T₃ in clinically euthyroid patients with acute or chronic nonthyroidal illness; reverse T₃ may be increased; free T4 almost always normal; can be reduced in prolonged severe illness
- · Normal TSH indicate "euthyroid state"
- TSH > 20 μ U/mL in sick individuals suggestive of primary hypothyroidism
- TSH < 0.1 μU/mL may be hyperthyroidism or sick euthyroid syndrome; differentiate by thyrotropin-releasing hormone stimulation test: sick euthyroid patients show detectable responses of TSH, hyperthyroid have absent response
- Very common; may affect up to 70% of hospitalized patients; complex, multifaceted response of endocrine system to illness
- Medications may affect thyroid function: dopamine, high-dose corticosteroids, and octreotide suppress TSH secretion; amiodarone results in low T₃ and normal or elevated T₄; propranolol, metoprolol, atenolol in large doses decrease T₃; rifampin increases T₄ clearance

■ Differential Diagnosis

- · Primary hypothyroidism
- · Secondary hypothyroidism
- · Diabetes mellitus
- Renal disease
- Acute myocardial infarction
- Malnutrition/caloric deprivation
- AIDS
- Chronic liver disease
- Cancer
 - Infection
- Surgery
- Medications

Treatment

- Supportive measures: adequate nutrition; specific and successful treatment of underlying illness should result in normalization of thyroid function abnormalities
- Replacing T₃ and T₄ have not demonstrated mortality benefits; animal studies suggest increased mortality with T₃ and T₄ replacement

■ Pearl

In prolonged critical illness, the fall in T_3 is accompanied by a fall in T_4 and portends a poor outcome. In patients with a T_4 concentration <3 µg/dL mortality rates reach as high as 80%.

Reference

Vasa FR et al: Endocrine problems in the chronically critically ill patient. Clin Chest Med 2001;1:193. [PMID 11315456]

Thyroid Storm

Essentials of Diagnosis

- Heat intolerance, nervousness, increased number of bowel movements, increased appetite, weight loss, thinning of hair and skin, sweating, weakness
- · Confusion, agitation, overt psychosis, coma
- · Fever due to breakdown of thermoregulatory system
- Cardiovascular manifestations: tachycardia, atrial fibrillation, hypertension, widened pulse pressure, congestive heart failure; hypotension late manifestation
- Ophthalmopathy, dermopathy, thyroid bruit with Graves disease
- Warm, moist, flushed, soft "velvety" skin; tremor; brisk tendon reflexes; proximal myopathy; generalized cachexia
- · Goiter almost always present
- Elevated T₄ and T₃ typically seen; nearly undetectable TSH
- Elevated aminotransferases, hyperbilirubinemia, alkaline phosphatase (bone fraction), calcium
- Uncontrolled or poorly controlled hyperthyroidism with precipitating event: surgical procedure, infection, cardiovascular disease, diabetic ketoacidosis, stroke, trauma, anesthesia, administration of iodinated contrast material

Differential Diagnosis

- Sepsis
- Acute psychiatric illness
- · Toxic ingestion
- Pheochromocytoma
- · Levothyroxine overdose
- · Alcohol withdrawal

Treatment

- · Identify and treat precipitating event
- Reduce thyroid hormone synthesis or peripheral conversion of T₄ to T₃ using thiourea (propylthiouracil or methimazole) followed by ipodate sodium (iodine-containing contrast agent)
- Inhibit release of thyroid hormone with iodide (sodium iodide or Lugol solution); lithium if intolerant of iodine
- Sympathetic blockade with propranolol; also weakly inhibits peripheral conversion of T₄ to T₃
- Glucocorticoids inhibit TSH secretion, lower T₄ levels; also use in those with suspected adrenal insufficiency
- · Correct hyperthermia, hypovolemia, electrolyte abnormalities

Pearl

Avoid salicylates in the management of hyperthermia in thyroid storm as they can displace thyroid hormone from its binding sites and worsen this hyperthyroid state.


Reference

Tietgens ST et al: Thyroid storm. Med Clin North Am 1995;79:169. [PMID: 7808090]

13 —

Neurology

Altered Mental Status in the ICU	189
Critical Illness Myopathy	190
Critical Illness Polyneuropathy	191
Guillain-Barré Syndrome	192
Head Injuries	193
Increased Intracranial Pressure	194
Muscular Dystrophy	195
Myasthenia Gravis	196
Neuroleptic Malignant Syndrome	197
Seizures	198
Spinal Cord Compression	199
Spinal Cord Injury	200
Stroke	201
Stupor & Coma	202
Subarachnoid Hemorrhage (SAH)	203



Altered Mental Status in the ICU

Essentials of Diagnosis

- Agitation, delirium, decreased sensorium, or waxing and waning of consciousness
- Disorganized thinking with rambling, incoherent speech, shouting, moaning
- · Hallucinations or illusions; appear fearful, restless
- · Disorientation to time, place, situation
- Serial examinations imperative as symptoms may fluctuate
- Agitated patients can demonstrate hypertension, tachycardia, tachypnea, increased oxygen needs, ventilatory difficulties
- Difficult to assess pharmacologically sedated patients
- Mini Mental Status Examination (MMSE), Cognitive Test for Delirium (CTD), Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) may be helpful
- Dementia and delirium may be differentiated by EEG findings
- Delirium in ICU associated with increased mortality, length of stay, need for subsequent nursing home placement

■ Differential Diagnosis

- · Hypoxemia, hypoperfusion
- · Hypoglycemia, electrolyte abnormalities
- Thyrotoxicosis
- · Postoperative states
- · Sleep deprivation, head trauma
- · Postictal states
- · Medications, withdrawal or intoxication
- · Infection: systemic, CNS, HIV

Treatment

- Identify causes, withdraw potential offending drugs, treat underlying etiology
- Symptomatic treatment if patient is danger to self or others
- Enlist assistance from family to aid in orientation to self, location, time (day/night), situation
- If unexplained, consider trial of benzodiazepines to exclude alcohol or benzodiazepine withdrawal; haloperidol with or without a benzodiazepine; or atypical antipsychotic

■ Pearl

Instructing patients to report strange phenomenon, empathetically informing them you understand their sense of confusion, and reassuring family members are important aspects of the social and psychologic management of ICU patients.

Reference

Cohen IL et al: Management of the agitated intensive care unit patient. Crit Care Med 2003;30:S97. [PMID: 11852874]

Critical Illness Myopathy

Essentials of Diagnosis

- Weakness of extremities or respiratory muscles without sensory deficit; no evidence of neuropathy, spinal cord, central nervous system disorders
- Rarely elevated creatine kinase or aldolase unless necrotizing component
- · May occur with or without critical illness polyneuropathy
- Electromyogram insensitive; muscle biopsy may be useful
- Probably caused by cytokine-induced effects on muscle protein; potential mediators include IL-1, TNF
- Myopathy with prolonged weakness frequent complication of corticosteroids plus non-depolarizing neuromuscular blockers

■ Differential Diagnosis

- · Primary muscle disorders: polymyositis, dermatomyositis
- · Steroid myopathy
- · Prolonged effects of non-depolarizing muscle relaxants
- · Alcoholic myopathy
- Malnutrition
- Drugs: statins, nucleoside reverse transcriptase inhibitor, colchicine, vincristine
- Electrolyte abnormalities: hypokalemia, hypophosphatemia
- · Hypo- and hyperthyroidism

Treatment

- No specific treatment; correct underlying sepsis or organ failure
- Discontinue potentially myopathic medications; correct electrolyte abnormalities
- Most have slow spontaneous improvement; recovery may be limited or absent if severe
- · Weakness may persist long after critical illness resolves

Pearl

Corticosteroids plus non-depolarizing neuromuscular blockers cause a synergistic myopathy with severe prolonged weakness; avoid if possible

Reference

Deem S et al: Acquired neuromuscular disorders in the intensive care unit. Am J Respir Crit Care Med 2003;168:735. [PMID: 14522811]

Critical Illness Polyneuropathy

Essentials of Diagnosis

- Flaccid weakness, loss of reflexes, sensory deficits indicating peripheral neuropathy
- Consider with weakness, failure to wean, decreased sensation in extremities
- Up to 70% of sepsis or multiorgan failure, especially with prolonged ICU stay
- Distal axonopathy, degeneration of axons without inflammation due to neuropathic consequence of decreased perfusion; no evidence of nutritional deficiency, neuritis, drug effects
- Nerve conduction studies: reduced muscle and sensory action potentials, fibrillations, loss of motor unit potentials with maximal effort; no slowing of nerve conduction, conduction blocks, demyelination

Differential Diagnosis

- · Guillain-Barré syndrome
- Botulism
- · Myasthenia gravis
- Prolonged effects of non-depolarizing muscle relaxants
- Malnutrition
- Paraneoplastic syndromes
- Myopathies, including critical illness myopathy, corticosteroids, hypokalemia

Treatment

- No specific treatment; correct underlying sepsis or organ failure; discontinue potentially neuropathic and myopathic medications (isoniazid, aminoglycosides, vincristine, corticosteroids); correct electrolyte abnormalities
- Treat for vitamin deficiency (pyridoxine, thiamine)
- Most have slow spontaneous improvement; recovery may be limited or absent if severe

Pearl

Critical illness polyneuropathy should be considered in any patient who is difficult to wean from mechanical ventilation.

Reference

Hund E: Critical illness polyneuropathy. Curr Opin Neurol 2001;14:649. [PMID: 11562578]

Guillain-Barré Syndrome

Essentials of Diagnosis

- Acute or subacute ascending progressive symmetric flaccid paralysis with antecedent flulike syndrome or vaccination
- Paresthesias and pain; sensory symptoms mild or absent; occasional cranial nerve deficits; autonomic dysfunction variable
- · Areflexia occurs early; pupils and eyelids spared
- Lumbar puncture demonstrates "albuminocytologic dissociation" (elevated protein without pleocytosis); can be diagnostic by second week
- Electromyogram: segmental demyelination, reduction of velocity (AIDP) or axonal injury (AMSAN and AMAN)
- Spectrum of disease: acute inflammatory demyelinating polyradiculopathy (AIDP), acute motor-sensory axonal neuropathy (AMSAN), acute motor-axonal neuropathy (AMAN), Miller-Fisher syndrome
- Etiologies: idiopathic most common; infection with Campylobacter jejuni, Mycoplasma pneumonia, CMV, EBV, VZV, Hepatitis B
- Risks for persistent disability: progression to quadriparesis in <7 days, need for ventilatory support, mean distal motor amplitude <20% lower limits of normal, age >60
- Recovery typically begins 2-4 wk after progression stops

■ Differential Diagnosis

- Poliomyelitis, myasthenia gravis, botulism, Lambert-Eaton syndrome, diphtheria, transverse myelitis
- Periodic paralysis
- · Heavy metal toxicity
- · Porphyria

■ Treatment

- Monitor vital capacity (VC); intubation may be needed if VC
 <15 mL/kg or to protect against aspiration
- · Monitor for sinus tachycardia; asystole may occur
- Opiates for pain control, adequate nutrition, bowel care, psychological support
- · Plasma exchange or high-dose intravenous immunoglobulin

Pearl

More than one third of patients with Guillain-Barré syndrome will require ICU admission for respiratory failure, dysautonomia, or other complications.

Reference

Hahn AF: Guillain-Barré syndrome. Lancet 1998;352:635. [PMID: 9746040]

Head Injuries

Essentials of Diagnosis

- Manifestations depend on extent and location of injury: asymptomatic; headache, nausea, vomiting, or amnesia; lethargy, increased somnolence, transient loss of consciousness, confusion, or unresponsiveness; papilledema, pupillary changes, Battle sign, "raccoon eyes," or focal neurologic signs
- Primary injuries include skull fracture, concussion, cerebral contusion, intracranial hemorrhage, diffuse axonal injury
- Secondary injuries include intracranial insults (intracranial hypertension, herniation, cerebral ischemia or infarction); systemic insults (hypoxia, hypotension, electrolyte imbalances)
- Complete neurological examination including Glasgow Coma Scale and brain stem function
- CT scan diagnostic; cerebral angiography identifies dissection, traumatic pseudoaneurysm, vasospasm
- Assess for concomitant spinal injury; occurs in 6–8%

Differential Diagnosis

- Seizure, stroke, brain tumor
- Hypoglycemia, neurosyphilis
 Vasculitis

■ Treatment

- Stabilize spine
- Monitor and protect airway; intubation indicated if GCS < 8; fiberoptic guidance for intubation in cervical spine injuries
- Monitor cardiac rhythm; fluid resuscitation for SBP < 110 mm Hg; avoid hypotonic solutions
- Serial neurologic examination to monitor for decompensation
- Stabilize with target Paco₂ 35–40 mm Hg, mean arterial blood pressure ≥ 90 mm Hg, normal intravascular volume and electrolytes
- Manage elevated intracranial pressure: monitor with ventriculostomy; removal of CSF, short-term hyperventilation, head elevation, sedation, correction of hyperthermia; barbiturate coma if maximal medical therapy failed
- Surgical indications: failing medical management; prevent irreversible damage if neurologically deteriorating; certain contusions, hematomas, foreign bodies

Pearl

Improved outcomes associated with head trauma are due in part to early recognition and prevention of disorders that cause secondary brain injury.

Reference

Guidelines for the management of severe head injury, 2nd ed. Brain Trauma Foundation, 2000.

Increased Intracranial Pressure

Essentials of Diagnosis

- Headache; nausea or vomiting; depressed level of consciousness
- Abnormal pupillary response; cranial nerve deficits (particularly CN VI); papilledema; abnormal posturing; hypo- or hyperventilation; focal neurologic deficits or abnormal reflexes
- Cushing triad: hypertension, bradycardia, abnormal respirations (late finding)
- CT scan or MRI: intracranial bleed, mass, midline shift, edema, decreased size of ventricles or basilar cistern, effacement of sulci
- · Direct measurement of ICP diagnostic
- Etiologies: head trauma, intracranial hemorrhage, meningitis/meningoencephalitis, malignancy (primary or metastatic), osmotic changes, hydrocephalus

■ Differential Diagnosis

- · Meningitis/meningoencephalitis, stroke, encephalopathy
- · Intoxication, nutritional deficiency

■ Treatment

- · Intubate for altered mental status and to control Paco₂
- Monitor cardiac rhythm; adequate intravenous access; correct hypovolemia; avoid hypotonic solutions
- Elevate head of bed 15-30°
- Mannitol for acute management; monitor serum osmolarity
- Hyperventilation for acute management; once stabilized, taper over 6–12 hours; avoid profound hyperventilation (keep PacO₂ 30–35 mm Hg)
- Sedate with opioids, benzodiazepines, propofol to lower chance of increasing ICP during suctioning, coughing, repositioning; paralytic agents mask changes in neurologic exam
- Remove cerebrospinal fluid or intracranial mass lesion
- Corticosteroids only useful in malignancy, abscess, postneurosurgical procedure
- · Correct hyperthermia; induced hypothermia controversial
- Pentobarbital used if other maneuvers fail; monitor for hypotension

Pearl

Small changes in intracranial volume may cause intracranial pressure to increase because of the inelastic properties of the skull.

Reference

Allen CH et al: An evidence-based approach to management of increased intracranial pressure. Crit Care Clin 1998;14:485. [PMID: 9700443]

Muscular Dystrophy

Essentials of Diagnosis

- · Progressive muscle wasting and weakness
- Typically proximal muscle involvement; pseudohypertrophy of gastrocnemius muscle
- Mental impairment common in Duchenne muscular dystrophy
- · Elevated creatine kinase
- Characteristic electromyogram and electrocardiogram: tall right precordial R wave and precordial O waves
- Muscle biopsy: fiber necrosis, size variation, infiltration by macrophages; replacement by connective tissue and fat
- Pulmonary complications include respiratory insufficiency and infection; cardiac complications include cardiomyopathy and conduction system abnormalities
- Inherited myogenic disorders: congenital, Duchenne and Becker, Emery-Dreifuss, distal, facioscapulohumeral, oculopharyngeal
- Increase rate of adverse events to anesthetics

■ Differential Diagnosis

- Dermatopolymyositis
- · Myasthenia gravis
- Amyotrophic lateral sclerosis
- · Botulism
- · Guillain-Barré syndrome
- · Lambert-Eaton syndrome

■ Treatment

- · No proven treatment currently available
- Monitor and manage complications
- Consider noninvasive ventilatory support for respiratory insufficiency; elective intubation if vital capacity <15–20 mL/kg; tracheostomy for prolonged support
- Cardiomyopathy treated with standard medications; pacemaker or defibrillator for conduction system defects and arrhythmias

Pearl

Because of the risk of rhabdomyolysis, myoglobinuria, acceleration of muscle weakness, and hyperkalemic cardiac arrest, avoid succinylcholine in patients with Duchenne or Becker muscular dystrophy.

Reference

Emery AE: The muscular dystrophies. Lancet 2002;359:687. [PMID: 11879882]

Myasthenia Gravis

Essentials of Diagnosis

- Painless, fluctuating weakness; pronounced in proximal muscles
- Ptosis and diplopia; reduced facial expression; weakness in speaking and chewing muscles; dysphagia
- · Reflexes and sensory examination normal
- Weakness evident with tests of fatigue: repetitive shoulder abduction or upward gaze
- Acetylcholine receptor antibodies found in 85–90%
- Edrophonium (Tensilon) test yields improved motor function
- · Nerve conduction studies demonstrate decremental response
- · CT or MRI to evaluate for thymoma
- Associated conditions: thymoma, thyroid disease, polymyositis, rheumatoid arthritis, systemic lupus erythematosus
- Myasthenic crisis precipitated by infections; trauma or surgery; medications including antiarrhythmics, antibiotics, antihypertensives, sedatives, paralytics

■ Differential Diagnosis

- Botulism
- Lambert-Eaton syndrome
- Toxins

- · Guillain-Barré syndrome
- · Myopathies
- Cholinergic crisis

Treatment

- Monitor pulmonary function with vital capacity; ventilatory support when vital capacity <15-20 mL/kg
- Anticholinesterase inhibitor: pyridostigmine
- Corticosteroids and other immunosuppressive therapy
- Plasma exchange or intravenous immune globulin if no response
- Thymectomy for young aged onset, AChR antibody–positive, generalized symptoms
- Monitor cardiac status as risk for atrial fibrillation, ventricular fibrillation, asystole
- Discontinue any medications and treat any infection that could worsen crisis
- Ensure adequate nutrition, bowel care, psychological support

Pearl

During an exacerbation, management is dependent on differentiating myasthenic crisis from cholinergic crisis (hypersalivation, lacrimation, miosis, vomiting, and sweating).

Reference

Vincent A et al: Myasthenia gravis. Lancet 2001;357:2122. [PMID: 11445126]

Neuroleptic Malignant Syndrome

Essentials of Diagnosis

- Hyperthermia and muscle rigidity related to use of phenothiazines, butyrophenones, thioxanthenes, benzamides and other postsynaptic dopamine blockers; atypical neuroleptics implicated in case reports
- Mental status varies from agitation or confusion to coma; encephalopathy
- Autonomic dysfunction including diaphoresis, tachycardia, hypertension, tachypnea, urinary incontinence
- Extrapyramidal signs such as tremor, cog-wheel rigidity, dystonia, dyskinesis, chorea, opisthotonos, opsoclonus, posturing
- Granulocytosis, hyperglycemia, elevated creatine kinase, elevated serum catecholamines
- Complications: pulmonary edema, ischemic bowel, paralytic ileus; rhabdomyolysis due to "lead pipe rigidity" of muscles
- Increased risk: organic brain disease, affective illnesses, dehydration, alcoholism, sympathoadrenal hyperactivity

Differential Diagnosis

- Malignant hyperthermia
- Central anticholinergic syndrome
- · Thyrotoxicosis
- · Lethal catatonia

- Encephalitis/meningitis
- · Heat stroke
- Pheochromocytoma
- Toxins: cocaine, methamphetamines, tricyclic antidepressants with lithium or monoamine oxidase inhibitors, metoclopramide, or reserpine

■ Treatment

- Discontinue and avoid dopamine-blocking agents
- · Cooling measures
- Aggressive intravenous crystalloid infusion to stabilize hemodynamics and prevent or treat rhabdomyolysis
- Bromocriptine and dantrolene to control rigidity and high temperature; amantadine and levodopa-carbidopa can reduce hyperthermia
- Continue treatment 2–3 wk until symptoms resolve
- Recurrence common; rechallenge with lower potency medications at lower doses if necessary

Pearl

Differentiate malignant hyperthermia from neuroleptic malignant syndrome by lack of encephalopathy or autonomic dysfunction.

Reference

Adnet P et al: Neuroleptic malignant syndrome. Br J Anaesth 2000;85:129. [PMID: 10928001]

Seizures

Essentials of Diagnosis

- Abrupt onset tonic-clonic activity, focal twitching, eye movements, blinking, confusion, or unresponsiveness
- Simple partial seizures arise from focal area without alteration of consciousness
- Complex partial seizures arise from temporal lobe; autonomic or emotional symptoms, déjà vu or hallucinations; altered consciousness with motionless stare or lip smacking
- Generalized tonic-clonic seizures may start with outburst followed by tonic then rhythmic clonic phase involving all extremities; associated with loss of consciousness
- Absence seizures begin abruptly with loss of contact; occasional eye fluttering, maintenance of body tone followed by abrupt recovery; no postictal state
- Status epilepticus: persistence of seizure > 10 min or incomplete recovery between seizures
- · EEG diagnostic if obtained during or soon after seizure
- · CT scan to assess for structural disease
- · Lumbar puncture if infection suspected

Differential Diagnosis

- · Hypoxic-ischemic event
- · Encephalitis
- Drug withdrawal
- Metabolic encephalopathies
- · Structural brain injury
- · Psychiatric disease
- Medication toxicity

Treatment

- Identify and treat precipitating cause
- Acutely control with benzodiazepines or other anticonvulsants
- Stabilize hemodynamics; ensure adequate intravenous access
- · Infuse thiamine and glucose empirically
- Laboratory evaluation: arterial blood gas, metabolic panel, glucose, toxicologic screen, drug levels, complete blood count
- Status epilepticus: administer intravenous phenytoin; if uncontrolled after 20–30 min intubate and add intravenous phenobarbital; if persistent after 40–60 min add continuous infusion of pentobarbital, midazolam, or propofol with continuous EEG monitoring

Pearl

Although CSF pleocytosis occurs, exclude other causes such as meningitis before attributing this finding to status epilepticus.

Reference

Sirven JI et al: Management of status epilepticus. Am Fam Physician 2003;68:469. [PMID: 12924830]

Spinal Cord Compression

Essentials of Diagnosis

- Axial pain early symptom with localized tenderness over involved spinal segment; thoracic (70%), lumbar (20%), cervical (10%) involvement
- Presentation depends on location of lesion: weakness; tingling or numbness; urinary retention; bowel or bladder incontinence
- Motor impairment can begin distally; tendon reflexes may be increased and Babinski sign may be present
- · Sensory impairment may manifest as sensory level
- · CSF examination typically not helpful
- Radiographs may demonstrate vertebral body collapse or destruction, loss of pedicles
- Obtain emergent MRI; CT myelography if MRI not available
- Biopsy for suspected infections or if primary tumor unknown
- Etiologies: abscesses, hematoma, disk fragments in spinal canal, tumors including lung, breast, prostate, lymphoma, multiple myeloma
- Infectious agents include: cysticercosis, Staphylococcus aureus, Mycobacterium tuberculosis, anaerobes, varicella-zoster virus, polio virus

■ Differential Diagnosis

- · Disk herniation
- Benign neoplasms
- · Transverse myelitis
- · Vascular disease
- Neurologic disorders
- Leptomeningeal carcinomatosis
- Paraneoplastic syndromes

■ Treatment

- Appropriate antibiotics for infectious etiologies
- Neurosurgical consultation indicated for all other etiologies
- Initiate corticosteroids prior to obtaining formal studies in cases of suspected malignancy; localized radiation therapy and tumorspecific chemotherapy if malignancy is confirmed
- In metastatic disease, laminectomy or surgical decompression for spinal instability, no response to radiation therapy, previous XRT up to cord tolerance, high cervical or atlantoaxial disease, radioresistant tumor, solitary metastasis

■ Pearl

Vertebral metastases rarely cross the disk space, unlike infectious causes.

Reference

Daw HA et al: Epidural spinal cord compression in cancer patients: diagnosis and management. Cleve Clin J Med 2000;67:497. [PMID: 10902239]

Spinal Cord Injury

Essentials of Diagnosis

- Incomplete injuries: anterior cord syndrome with loss of motor function, pain and temperature, normal proprioception and vibration; central cord syndrome with motor and sensory findings in distal upper extremities >lower; posterior column syndrome with loss of vibration, proprioception, discrimination; Brown-Séquard syndrome with loss of ipsilateral motor and dorsal column function, contralateral loss of pain and temperature sensation one or two levels below injury
- Damage to upper and lower motor neurons accompanies almost all cases
- · Assess for brain and multilevel injury
- Radiographs to assess prevertebral soft tissue swelling, alignment, angulation of spinal canal, fractures; dynamic views contraindicated with acute neurological dysfunction
- MRI for neurological symptoms with negative plain radiographs
- CT scan for evaluation of fracture or subluxation, poorly visualized areas, or if MRI contraindicated

■ Differential Diagnosis

- Amyotrophic lateral sclerosis, multiple sclerosis, transverse myelitis
- · Aortic dissection, primary or metastatic cancer

■ Treatment

- Stabilize spine; monitor and protect airway; oxygen and aggressive pulmonary toilet; fiberoptic guided intubation if cervical spine injuries
- Intravenous fluids typically improve hypotension from spinal shock; monitor and treat cardiac arrhythmias; atropine or pacemaker for bradycardia
- Assess neurologic examination serially for decompensation
- High dose methylprednisolone within 3–8 hours of injury
- Surgery indicated for: decompression of incompletely injured neural tissue, reduction and stabilization of malaligned or unstable cervical segments
- Nasogastric tube, Foley catheter for atonic GI tract, bladder

Pearl

Depolarizing neuromuscular blocking agents may lead to hyperkalemia and ventricular fibrillation in patients with spinal cord injuries.

Reference

McDonald JW et al: Spinal cord injury. Lancet 2002;359:417. [PMID: 11844532]

Stroke

Essentials of Diagnosis

- Signs depend on location and include hemiplegia, hemiparesis, hemisensory loss, aphasia, cranial nerve abnormalities, hemianopia, impaired cerebellar function, impaired cortical function, dysarthria
- Sudden neurologic symptoms reaching maximal deficit at onset seen with acute embolic strokes
- Acute hemorrhagic stroke with sudden onset; likelihood of hemorrhage increases with coma, vomiting, severe headache, systolic blood pressure >220 mm Hg, warfarin use
- Sudden onset followed by stepwise or progressive involvement seen with occlusive vascular disease
- Head CT scan insensitive in first 24 hours if bland infarct; very sensitive for hemorrhagic stroke
- MRI may have higher sensitivity in early ischemic stroke; MR angiography useful for evaluating occlusive disease
- Risk factors: hypertension, diabetes, smoking, cardiovascular disease, atrial fibrillation, valvular heart disease, family history of premature cardiovascular disease

Differential Diagnosis

- Seizure
- Neurosyphilis
- · Subdural or epidural hematoma
- Hypoglycemia
- · Brain tumor
- Vasculitis

Treatment

- Stabilize and protect airway; ensure adequate intravenous access; monitor and treat cardiac arrhythmias
- Optimal blood pressure control not clear; cautious use of parenteral medication for SBP > 220 mm Hg or DBP > 120 mm Hg
- Assess neurologic examination serially for decompensation
- Aspirin given within 24-48 hours
- Tissue plasminogen activator (r-tPA) for carefully selected patients with ischemic stroke treated within 3 h of onset; intraarterial thrombolysis may be helpful
 - · Correct abnormalities such as hypoglycemia or hyponatremia

Pearl

Hypotension or rapid decreases in blood pressure should be avoided because autoregulation of cerebral blood flow is impaired and regional brain perfusion is dependent upon systemic blood pressure.

Reference

Adams HP et al: Guidelines for the early management of patients with ischemic stroke. Stroke 2003;34:1056. [PMID: 12677087]

Stupor & Coma

Essentials of Diagnosis

- · Patient unresponsive to any stimuli
- Develops as result of diffuse dysfunction of cerebral cortices or injury to reticular activating system
- Diencephalon lesions: 1- to 2-mm pupils, normal eye movements, flexion abnormalities, Cheyne-Stokes respirations
- Midbrain lesions: fixed and midline pupils, disconjugate eye movements, extension abnormalities, hyperventilation
- Pontine lesions: coma, pinpoint pupils, paralysis of extraocular muscles, extension abnormalities, hyperventilation
- Medullary lesions: variable mental status, pupil size, and eye movements; flaccid muscles, apnea, circulatory collapse
- Assess level of consciousness with Glasgow Coma Score; check for nuchal rigidity; asymmetry in neurologic examination; funduscopic examination
- Laboratory studies helpful for etiology or monitoring: metabolic panel, arterial blood gas, toxicologic screen, serum osmolality, serum medication levels
- CT or MRI of brain; LP if possible infection; EEG if seizure suspected
- · Etiologies: metabolic, toxic, structural brain injury

Differential Diagnosis

- Seizure/postictal state, brainstem herniation
- · Hypertensive encephalopathy, catatonia
- Hypercapnia/hypoventilation syndrome
- · Increased intracranial pressure

Treatment

- Protect airway; indications for intubation: absent gag reflex, respiratory compromise, control of Paco₂ to aid in management of intracranial hypertension
- Avoid sudden drops in blood pressure as this may result in herniation or irreversible brain injury
- Intravenous thiamine followed by dextrose and naloxone; consider empiric antibiotics if diagnosis of meningitis or encephalitis entertained

■ Pearl

Under no circumstances should the pupils in a comatose patient be dilated to aid with retinal examination since changes in the pupil size are often the most reliable clinical indication of deterioration following acute brain injury.

Reference

Liao YJ et al: An approach to critically ill patients in coma. West J Med 2002;176:184. [PMID: 12016243]

Subarachnoid Hemorrhage (SAH)

Essentials of Diagnosis

- Symptoms preceded days or weeks by headache from sentinel leak followed by "thunderclap" headache: sudden onset, reaching maximal intensity in minutes, "worst headache of their life"
- · Nausea, vomiting, photophobia, neck stiffness or pain
- Nuchal rigidity, papilledema, retinal hemorrhages, nystagmus
- Neurologic deficits depend on location and severity of bleed: cranial nerve palsies, aphasia, hemiparesis, neglect
- · Subarachnoid blood on CT scan in first 48 hours
- Perform lumbar puncture when CT scan negative but history suggestive; bloody or xanthochromic fluid sensitive finding
- Obtain four-vessel cerebral angiogram once SAH diagnosed: localizes aneurysm, defines anatomy, identifies vasospasm
- Associated diseases: hypertension, polycystic kidney disease, Ehlers-Danlos syndrome, arteriovenous malformations, pseudoxanthoma elasticum, coarctation of aorta
- · Complications: rebleeding, vasospasm, hydrocephalus

Differential Diagnosis

- Meningitis/encephalitis
- Increased intracranial pressure
- · Tension headache

- Stroke
- Temporal arteritis
- Migraine headache

■ Treatment


- Monitor and protect airway; intubate comatose individuals and patients with respiratory compromise
- Stabilize hemodynamics: adequate intravenous access; tight blood pressure control avoiding hypotension or hypertension; transfuse to correct coagulopathy or thrombocytopenia
- Supportive therapy: avoid stress or straining, maintain at bed rest in quiet setting, analgesics for pain control
- · Early intervention with surgical clips or embolization
- Vasospasm prophylaxis with calcium channel blocker nimodipine
- Seizure prophylaxis with phenytoin
- · Correct electrolyte abnormalities, especially hyponatremia

■ Pearl

Vasospasm, a potentially devastating complication of SAH, can be managed with "Triple H" therapy (induced hypervolemia, hemodilution, and hypertension), which augments cerebral blood flow and prevents ischemic cellular damage.

Reference


Edlow JA et al: Avoiding pitfalls in the diagnosis of subarachnoid hemorrhage. N Engl J Med 2000;342:29. [PMID: 10620647]



14 —

Renal Disorders

Acute Tubular Necrosis (ATN)	.207
Glomerulonephritis, Acute	208
Hepatorenal Syndrome	209
Interstitial Nephritis, Acute	210
Pigment Nephropathy: Rhabdomyolysis & Hemolysis	211
Pulmonary-Renal Syndromes	212
Renal Failure, Acute	213
Renal Failure, Drug Clearance in	214
Renal Failure, Prevention	215
Renal Replacement Therapy (Hemodialysis)	216



Acute Tubular Necrosis (ATN)

■ Essentials of Diagnosis

- Acute renal failure without prerenal, postrenal, glomerular, or interstitial features
- History of hypotension, exposure to nephrotoxic antibiotics or radiocontrast agents
- · Reduced urine output, malaise, nausea, altered sensorium
- Acute onset oliguria with ischemic ATN; $Fe_{Na} > 1\%$ but may be nonoliguric
- Urinalysis: muddy brown granular casts, epithelial cells, red cells, white cells; unremarkable sediment in toxin-induced ATN
- · Inability of kidney to regulate sodium, electrolytes, water
- Usually in conjunction with multiorgan failure, ARDS, medications
- Leading cause of acute renal failure in ICU; mortality rate 50–80% among those requiring dialysis

Differential Diagnosis

- · Sepsis
- · Hypoperfusion or ischemia
- · Radiocontrast media administration
- · Medications: aminoglycosides, amphotericin B, cisplatin
- · Myoglobinuria and hemoglobinuria

■ Treatment

- Prevention: N-acetylcysteine and saline prior to radiocontrast; no benefit of mannitol and diuretics over saline alone
- Avoid potential nephrotoxic insults such as hypotension, hypovolemia, nephrotoxic agents
- Maintain adequate renal perfusion
- Nutritional support recommended but benefit not proven
- Hemodialysis with intensive protocols including earlier initiation, increased frequency appears to result in improved outcome
- During recovery phase, monitor electrolytes and volume status closely with post–ATN diuresis

Pearl

Recovery of renal function occurs more often with nonoliguric acute tubular necrosis than when oliguric. The use of diuretics to convert oliguric ATN into the nonoliguric variety, however, does not improve overall prognosis.

Reference

Esson ML et al: Diagnosis and treatment of acute tubular necrosis. Ann Intern Med 2002;137:744. [PMID: 12416948]

Glomerulonephritis, Acute

Essentials of Diagnosis

- Oliguria, hypertension, edema (especially periorbital distribution), pulmonary congestion, fatigue
- Nausea, dyspnea, lethargy, pericarditis, encephalopathy if severe renal failure present
- "Nephritic" urinary sediment with red cell casts, red cells (may be dysmorphic [acanthocytes]), low urinary MCV ([urine/blood MCV < 1]), white cells; variable proteinuria
- History and physical may identify temporally associated infections or systemic vasculitis
- Obtain immunological markers: antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies (ANCA), anti-GBM antibodies, antistreptolysin O (ASO) titer, HIV, hepatitis B/C antibodies, complement, cryoglobulins

Differential Diagnosis

- · IgA nephropathy/Berger disease
- · Henoch-Schönlein purpura
- · Lupus nephritis
- · Goodpasture syndrome and anti-GBM disease
- · Wegener granulomatosis
- Microscopic polyangiitis and other vasculitides
- Poststreptococcal GN
- Hepatitis B and C associated GN
- · Infective endocarditis

Treatment

- Renal biopsy for pathological confirmation
- · Supportive management with sodium and fluid restriction
- · Blood pressure control
- Most etiologies require aggressive immunosuppressive regimens such as high-dose steroids and cyclophosphamide
- Plasmapheresis may be effective in anti-GBM or cryoglobulinassociated diseases
- · Dialysis in renal failure

Pearl

Rapidly progressive glomerulonephritis (RPGN) is associated with a rapid decline in renal function leading to end-stage renal failure within days to weeks. Crescent formation within glomeruli on renal biopsy is the pathological hallmark of this syndrome.

Reference

Vinen CS et al: Acute glomerulonephritis. Postgrad Med J 2003;79:206. [PMID: 12743337]

Hepatorenal Syndrome

Essentials of Diagnosis

- Acute renal failure in conjunction with preexisting liver dysfunction: advanced cirrhosis, severe alcoholic hepatitis, fulminant liver failure
- · Hyperbilirubinemia, coagulopathy, encephalopathy
- Often with stigmata of portal hypertension: varices, ascites
- · Absence of shock, bacterial infection, nephrotoxic agents
- · Reduced urine output but rarely anuric
- Reduced urinary sodium excretion with FE_{Na} < 1%
- · Unresponsive to fluid challenge or withdrawal of diuretics
- Due to severe vasoconstriction of renal arteries accompanied by extrarenal arterial vasodilation, hypotension
- Precipitated by gastrointestinal bleed, spontaneous bacterial peritonitis (SBP), excessive diuresis

■ Differential Diagnosis

- · Volume depletion: diuretics, bleeding
- · Cardiac pump failure
- · Obstructive uropathy
- Acute tubular necrosis: sepsis, prolonged hypoperfusion
- · Drug toxicity: NSAIDs, aminoglycosides, contrast
- Autoimmune glomerulonephritis: vasculitis, cryoglobulinemia

Treatment

- · Restore volume with albumin or blood to euvolemic state
- · Treat infection including SBP
- Splanchnic vasoconstrictors have some reported success: vasopressin, norepinephrine, midodrine combined with octreotide
- Peritoneal jugular shunt (LeVeen) benefits not well established; transjugular intrahepatic portosystemic shunt (TIPS) with some anecdotal benefit
- · Hemodialysis and ultrafiltration
- Prevention: avoid nephrotoxins, excess diuresis, large-volume paracentesis
- Administration of albumin and antibiotics reduces likelihood renal impairment in setting of SBP

Pearl

Renal failure in HRS is "functional"; kidneys transplanted from patients with HRS may resume normal function in the recipient, and renal function returns to normal when patients with HRS undergo liver transplantation.

Reference

Kramer L et al: Hepatorenal syndrome. Semin Nephrol 2002;22:290. [PMID: 12118394]

Interstitial Nephritis, Acute

Essentials of Diagnosis

- Acute decline in renal function with active urinary sediment (not indicative of acute glomerular process)
- May have history of drug hypersensitivity and associated fever, rash, flank pain
- · Hypertension and edema uncommon
- · Hematuria, sterile pyuria, proteinuria, white cell casts
- Eosinophiluria often described; but also seen in atheroembolic renal disease, transplant rejection, urinary tract infections
- FE_{Na} usually >1%
- · May have renal tubular acidosis: proximal or distal
- Positive gallium scan with prolonged renal uptake (>72 hours) supports diagnosis of allergic interstitial nephritis
- · Pathologically marked interstitial inflammation and edema
- · Overall favorable prognosis; generally reversible

Differential Diagnosis

- · Antibiotics: penicillins, cephalosporins, sulfonamides, rifampin
- · Nonsteroidal anti-inflammatory drugs
- · Diuretics: thiazides, furosemide
- · Infections: streptococcal infections, diphtheria, leptospirosis
- · Acute urate nephropathy, tumor lysis syndrome
- · Ethylene glycol ingestion with calcium oxalate deposition
- Immunologic disorders: systemic lupus erythematosis (SLE), Sjögren syndrome, mixed essential cryoglobulinemia
- · Acute allograft rejection

Treatment

- · Identify and eliminate possible inciting factors: drugs, infection
- Steroid use controversial; most often used in drug-induced interstitial nephritis or if renal failure severe, prolonged
- Pretreatment with allopurinol and forced alkaline diuresis in anticipation of aggressive chemotherapy to decrease risk of urate nephropathy
- Dialysis may be indicated on temporary or permanent basis

Pearl

The classic triad of fever, rash, and eosinophilia in the setting of acute renal failure is present only in one third of patients with drug-induced allergic interstitial nephritis.

Reference

Kodner CM et al: Diagnosis and management of acute interstitial nephritis. Am Fam Physician 2003;67:2527. [PMID: 12825841]

Pigment Nephropathy: Rhabdomyolysis & Hemolysis

Essentials of Diagnosis

- Acute renal failure in setting of severe muscle breakdown or hemolysis
- · Dark-colored brown or red urine
- · Muscle pain, weakness may be present in rhabdomyolysis
- · Symptoms of anemia observed in severe hemolysis
- In rhabdomyolysis: elevated creatinine kinase and aldolase, reduced BUN:creatinine ratio; urine dipstick positive for heme in absence of red cells
- In hemolysis: elevated serum free hemoglobin, reduced haptoglobin
- · AST and LDH often elevated in both
- Massive cellular release of myoglobin or hemoglobin toxic to renal tubules
- Risk factors for pigment nephropathy: reduced renal perfusion states, hypovolemia

Differential Diagnosis

- Rhabdomyolysis
- · Trauma: crush injury, electric burn, heat stress
- Excessive contraction: seizure, tetanus, malignant hyperthermia, neuroleptic malignant syndrome
- Electrolytes: hypokalemia, hypophosphatemia
- Infection: clostridial toxin (gas gangrene), pyomyositis
- · Polymyositis, dermatomyositis
- Drugs: combined HMG-CoA reductase inhibitors and fibric acid derivatives, amphetamine
- Hemolysis: transfusion reactions; drugs and toxins (quinine, fava beans, snake venom); mechanical lysis (prosthetic heart valves, extracorporeal circulation)

Treatment

- · Fluid resuscitation to restore adequate renal perfusion
- · Initiate diuresis with mannitol or furosemide once euvolemic
- · Alkalinization of urine confers theoretical benefits
- Monitor electrolyte imbalance: hyperkalemia, hypocalcemia, hyperphosphatemia
- · Manage as acute renal failure/acute tubular necrosis

Pearl

In crush injury, especially involving the thighs, patient must be monitored for not only the development of renal failure from rhabdomy-olysis but also for compartment syndrome.

Reference

Holt SG: Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med 2001;27:803. [PMID: 11430535]

Pulmonary-Renal Syndromes

Essentials of Diagnosis

- · Vasculitic syndromes that involve both lungs and kidneys
- Cough, dyspnea, hemoptysis, alveolar hemorrhage; may have rash, upper respiratory tract involvement depending on disorder
- · Microscopic hematuria often precedes fulminant renal failure
- Radiographically diffuse alveolar infiltrates; occasionally cavitary lesions
- Bronchoalveolar lavage with >20% hemosiderin-laden macrophages indicates alveolar hemorrhage; nonspecific
- Need to exclude correlated pulmonary and renal disorders: CHF with excessive diuresis, renal failure complicated by pulmonary edema, disseminated infection
- Drug/toxin exposure history helpful: penicillamine in Goodpasture syndrome, SLE; leukotriene inhibitors in Churg-Strauss syndrome; hydrocarbon in Goodpasture disease; hydralazine, procainamide, quinidine in SLE
- · Serological markers: ANCA, anti-GBM, ANA, anti-dsDNA
- Definitive diagnosis often with renal biopsy with immunofluorescent staining

Differential Diagnosis

- Wegener granulomatosis
- Goodpasture syndrome
- · Microscopic polyangiitis
- · Churg-Strauss syndrome
- Systemic lupus erythematosus (SLE)

Treatment

- Maintain adequate airway in massive hemoptysis
- Hemodialysis may be indicated in acute renal failure
- · Immunosuppressive agents: corticosteroids, cyclophosphamide
- Plasmapheresis in Goodpasture syndrome
- Adjunctive trimethoprim-sulfamethoxazole may be considered in Wegener granulomatosis
- Renal histopathology in SLE often determines treatment

Pearl

Though first believed that leukotriene inhibitors can trigger development of Churg-Strauss syndrome, it is more likely that the use of these medications in steroid-dependent asthmatics unmasks clinical manifestations of a previously suppressed eosinophilic syndrome.

Reference

Rodriguez W et al: Pulmonary-renal syndromes in the intensive care unit. Crit Care Clin 2002;18:881. [PMID: 12418445]

Renal Failure, Acute

Essentials of Diagnosis

- · Abrupt reduction in renal function resulting in azotemia
- Reduced urine output but may be non-oliguric, anorexia, nausea, vomiting, hiccupping
- Irritability, asterixis, headache, lethargy, confusion, uremic encephalopathy, coma
- If pre-renal, orthostatic blood pressure and heart rate; if volume overloaded, jugular venous distension, gallops, rales
- · Pericardial rub, Kussmaul respirations may be seen
- · Hyperkalemia and acidosis can induce cardiac arrhythmias
- Elevated blood urea nitrogen (BUN) and creatinine (Cr);
 BUN/Cr > 20 in prerenal azotemia, some obstructive uropathy
- Fe_{Na} = [(urine Na × serum Cr)/(urine Cr × serum Na)] × 100;
 1% in prerenal azotemia; >1% in ATN
- Urinalysis: pyuria, crystals, stones, hemoglobin, protein, casts, bacteria

Differential Diagnosis

- Prerenal azotemia: volume depletion, reduced cardiac output, hypotension, renovascular obstruction, NSAIDs, ACE inhibitors
- Intrinsic renal failure: acute tubular necrosis (ATN), acute glomerulonephritis, acute interstitial nephritis
- Postrenal azotemia: prostate enlargement, tumor, blood clots, stones, crystals, retroperitoneal fibrosis
- · Hepatorenal syndrome

Treatment

- · Fluid challenge should be considered
- · Avoid nephrotoxic agents: aminoglycosides, NSAIDs, contrast
- · Dietary restriction of sodium, potassium, phosphate, protein
- · Adjust dose of medications that are renally cleared
- Renal ultrasound useful in evaluating for obstructive process; relieving obstruction essential once identified
- Renal biopsy indicated if diagnosis elusive or when histological diagnosis important for therapy
- Dialysis for hyperkalemia, acidosis, fluid overload, uremic symptoms, very catabolic patients (rapid sustained rise in BUN)

■ Pearl

In complete renal shutdown, the serum creatinine typically increases by 1–2 mg/dL per day. When a more rapid rise is observed, rhabdomyolysis should be considered.

Reference

Abernethy VE et al: Acute renal failure in the critically ill patient. Crit Care Clin 2002;18:203. [PMID: 12053831]

Renal Failure, Drug Clearance in

Essential Concepts

- Clearance is rate of drug elimination from body; reduced clearance rates lead to increased drug half-life and potential toxicity
- Renal failure leads to decreased clearance of drugs eliminated by the kidneys
- Dose adjustment important when drugs predominantly renally eliminated; common medications include most antimicrobials, H-2 blocker, low molecular weight heparin, nitroprusside; doses can be adjusted by reducing dose, frequency, or both
- Metabolites of drugs may remain pharmacologically active and accumulate in setting of renal failure: meperidine, procainamide
- · Most polypeptides metabolized by kidneys: insulin
- Renal failure may affect liver metabolism: increased liver clearance of nafcillin in end-stage renal disease
- Drug levels can be monitored but interpretation should consider clinical context: aminoglycosides, vancomycin, digoxin, anticonvulsants, theophylline
- Degree of drug removal by dialysis determines need for supplemental dosing

Essentials of Management

- Estimate renal function and glomerular filtration rate (GFR) with creatinine clearance (Cl_{cr}) = [(140-age) × (IBW in kg)]/(72 × Cr), where IBW is ideal body weight
- · Monitor rapidity of change in renal function
- Reassess appropriateness of all medication doses and adjust accordingly when renal function changes
- Avoid exclusively relying on nomograms due to complexity and variability of various interactions
- Assess whether drug metabolites pharmacologically active and whether they accumulate in renal failure
- Further modification of drug dosing required when dialysis initiated and depends on mode, frequency and efficiency

Pearl

In addition to impaired drug elimination, several other factors pertaining to drug therapy in patients with renal insufficiency are also affected, including drug absorption and volume of distribution.

Reference

Pichette V et al: Drug metabolism in chronic renal failure. Curr Drug Metab 2003;4:91. [PMID: 12678690]

Renal Failure, Prevention

Essential Concepts

- Acute renal insufficiency associated with increased ICU mortality, but limited studies on renal failure prevention
- Limited data available in certain settings: cardiovascular surgery, sepsis, contrast-induced nephropathy, cirrhosis associated renal dysfunction
- Acute tubular necrosis (ATN) and prerenal azotemia most common causes of renal impairment
- Use of nephrotoxic agents sometimes unavoidable: amphotericin, aminoglycosides, radiographic contrast
- Clinical use of renal dose dopamine and diuretics of unproven benefit
- · Albumin infusion costly and has limited role
- · Atrial natriuretic peptide restricted to clinical trials

Essentials of Management

- · Avoid use of nephrotoxic agents, if possible
- Minimize toxicity exposure: once-daily aminoglycoside dosing, liposomal amphotericin B infusions, nonionic contrast agents
- Maintain adequate renal perfusion with volume expansion; colloid versus crystalloid replacement remains controversial
- Avoid diuretics unless volume overloaded; exception may be mannitol use in myoglobinuria after volume resuscitation
- Premedication with N-acetylcysteine protects from contrast nephropathy; fenoldopam also appears to reduce this nephropathy
- Albumin in conjunction with antibiotics reduced renal impairment and mortality in cirrhosis associated spontaneous bacterial peritonitis
- Splanchnic vasoconstrictors and TIPS have led to some reversal of hepatorenal syndrome although mortality remains high
- Selenium replacement promising in sepsis

Pearl

In the face of life-threatening hypoxemia secondary to pulmonary edema, aggressive diuresis takes precedence even in the setting of worsening renal function, as the availability of renal replacement therapies makes "sacrificing" the kidneys an acceptable therapeutic option.

Reference

Block CA et al: Prevention of acute renal failure in the critically ill. Am J Respir Crit Care Med 2002;165:320. [PMID: 11818313]

Renal Replacement Therapy (Hemodialysis)

Essential Concepts

- Indicated for chronic renal failure with acute illness; acute renal failure unresponsive to other therapy; specific indications with no alternative treatment
- May be needed emergently for volume overload, uremic complications, hyperkalemia, hypercalcemia, metabolic acidosis; overdose of dialyzable drug
- Hemodialysis uses semipermeable membrane to separate blood from dialysate fluid; unwanted solutes move into dialysate by diffusion
- Hemofiltration uses same membrane, solute and water move by convection (high to low pressure); low efficiency of removal of uremic toxins; provide replacement for lost solute and water for desired fluid balance or correction of metabolic acidosis
- Intermittent hemodialysis (±hemofiltration) 3–7 times/wk, 1–4 hours per session; rapid fluid removal; high blood flow (300 ml/min) may cause hypotension; requires anticoagulation
- Continuous venovenous hemofiltration and dialysis (CVVHD); blood flow 100 mL/min; usually less hypotension, low constant fluid removal, better tolerated by critically ill patients
- · Acute peritoneal dialysis rarely used in ICU

Essentials of Management

- · Insert venous double-lumen hemodialysis catheter
- Specify net fluid balance, electrolytes in dialysate, systemic heparin or regional citrate anticoagulation, blood flow, volume of replacement fluids
- Observe heart rate, blood pressure; monitor for bleeding; record fluid balance; adjust drug dosages to meet increased clearance
- Complications: infection, bleeding, deep venous thrombosis, hypotension, thrombocytopenia, acid-base and electrolyte disturbances, hypoxemia, arrhythmias, dialysis disequilibrium syndrome

Pearl

When adjusting medications, keep in mind that hemodialysis and CVVHD may have different rates of elimination for different drugs.


Reference

Abdeen O et al: Dialysis modalities in the intensive care unit. Crit Care Clin 2002;18:223. [PMID: 12053832]

— 15 ——

Rheumatology

Catastrophic Antiphospholipid Syndrome	219
Scleroderma/Progressive Systemic Sclerosis	220
Systemic Lupus Erythematosus (SLE)	221
Vasculitis	222



Catastrophic Antiphospholipid Syndrome

Essentials of Diagnosis

- Multiorgan failure due to systemic small vessel vasoocclusion associated with circulating anticardiolipin antibodies or positive lupus anticoagulant
- Manifestations include: pulmonary insufficiency (ARDS, alveolar hemorrhage, pulmonary infarct); cardiac complications (cardiovascular collapse, valvular lesions, myocardial infarction); CNS abnormalities (altered mental status, seizure); abdominal pain; renal dysfunction; hypertension; livedo reticularis
- Thrombocytopenia and microangiopathic hemolytic anemia
- Risk groups: primary antiphospholipid syndrome (APS) with episodic deep vein thrombosis, thrombocytopenia, or recurrent fetal loss with antiphospholipid antibodies; secondary APS with concomitant SLE.
- Precipitating factors: infection, trauma, surgical procedures, withdrawal of anticoagulation therapy

■ Differential Diagnosis

- Disseminated intravascular coagulation (DIC)
- Heparin-induced thrombocytopenia syndrome (HITS)
- · Hereditary thrombophilia
- Thrombotic thrombocytopenia purpura (TTP)
- · Sepsis syndrome
- · Multiple cholesterol emboli

Treatment

- Support failing organ systems with mechanical ventilation, vasopressor or inotropic drugs, hemodialysis
- Consider pulmonary artery catheter monitoring to guide fluid resuscitation and pressor support
- Anticoagulation to suppress further thrombosis; higher than usual doses of heparin may be needed
- Corticosteroids to treat possible vasculitis, adrenal insufficiency, reduce cytokine effects
- Other modalities with possible value include fibrinolytic agents, plasmapheresis, cyclophosphamide, intravenous gamma globulin, prostacyclin, danazol, cyclosporine, azathioprine

Pearl

Abdominal pain and hypotension in a patient with CAPS may be a sign of adrenal insufficiency in the face of a significant systemic stress.

Reference

Westney GE et al: Catastrophic antiphospholipid syndrome in the intensive care unit. Crit Care Clin 2002;18:805. [PMID: 12418442]

Scleroderma/Progressive Systemic Sclerosis

Essentials of Diagnosis

- Signs and symptoms depend on organ involvement and include dyspnea, fatigue, right-heart failure, cough, hemoptysis, headache, blurred vision
- Autoimmune disease characterized by exuberant fibrosis and small-vessel vasculopathy involving skin, lungs, heart, gastrointestinal tract, musculoskeletal system
- Two major subsets: limited cutaneous sclerosis (CREST syndrome with calcinosis cutis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias) with indolent course; diffuse systemic sclerosis with aggressive course
- Complications requiring ICU care: pulmonary hypertension, aspiration pneumonia, alveolar hemorrhage, renal crisis with malignant hypertension
- · Skin involvement may make intravenous access difficult

Differential Diagnosis

- Pulmonary hypertension: primary or drug-induced, valvular heart disease
- Aspiration pneumonia: community-acquired pneumonia, acute interstitial pneumonitis
- · Alveolar hemorrhage: bleeding telangiectasias, ARDS

Treatment

- Treatment targets systemic inflammation with immunosuppressive agents such as prednisone, cyclophosphamide
- Hyperalimentation may be required if GI involvement causes malabsorption, malnutrition, pseudoobstruction
- Elevate head of bed, prokinetic agents, acid-suppressing drugs to reduce aspiration pneumonia risk
- Pulmonary hypertension may benefit from oxygen, pulmonary vasodilators, cardiac inotropic agents, diuretics
- Renal crisis: avoid corticosteroids; aggressive blood pressure control; ACE inhibitors for treatment and prophylaxis; hemodialysis for hyperkalemia or uremia

Pearl

Scleroderma renal crisis, typically characterized by hypertension and a rapidly rising creatinine, has been associated with the antecedent use of high-dose corticosteroids.

Reference

Cossio M et al: Life-threatening complications of systemic sclerosis. Crit Care Clin 2002;18:819. [PMID: 12418443]

Systemic Lupus Erythematosus (SLE)

Essentials of Diagnosis

- Symptoms depend on organ system involved and include dyspnea, hemoptysis, altered mental status, cerebral dysfunction, chest pain, fever
- Systemic autoimmune disorder that can affect multiple organ systems
- Complications requiring ICU care: acute lupus pneumonitis, alveolar hemorrhage, lupus cerebritis, seizures, premature atherosclerotic coronary artery disease, pericarditis, myocarditis, bowel perforation, pancreatitis
- Infection important cause of ICU admission: bacteria account for >90% including Streptococcus pneumoniae, Staphylococcus aureus, Enterobacteriaceae, nonfermentative gram-negative rods, Salmonella
- Chronic steroid use increases risk of lung and brain infection with Nocardia

Differential Diagnosis

- Lung: pleuritis, alveolar hemorrhage, community-acquired pneumonia, ARDS
- CNS: seizure, stroke, meningitis
- Cardiovascular: pericarditis, pericardial effusion, myocarditis, myocardial infarction, vasculitis
- Gastrointestinal: mesenteric thrombosis, ischemic bowel, ruptured hepatic aneurysm, cholecystitis, pancreatitis

■ Treatment

- Empiric broad-spectrum antibiotics until infection excluded; if routine cultures nonrevealing, bronchoscopy or open-lung biopsy may be necessary if lungs involved
- Severe noninfectious complications typically treated with corticosteroids
- Adjunctive immunosuppressive therapy with cyclophosphamide, azathioprine can be considered in conjunction with plasmapheresis in certain patients

Pearl

Infections are the leading cause of morbidity and mortality in patients with SLE and can be difficult to discern from an exacerbation of this autoimmune disease.

Reference

Raj R et al: Systemic lupus erythematosus in the intensive care unit. Crit Care Clin 2002;18:781. [PMID: 12418441]

Vasculitis

Essentials of Diagnosis

- Signs and symptoms overlap with infection, connective tissues diseases, and malignancy; include fever, rash, neuropathy, visual disturbances, upper-airway symptoms, weight loss, malaise, myalgias, arthralgias
- Vasculitides that may require ICU care: Wegener granulomatosis, microscopic polyangiitis, small-vessel vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA)
- Causes of deterioration: active vasculitis, complication of medical therapy, overwhelming infection
- May have anemia, thrombocytopenia, leukocytosis or leukopenia, elevated BUN and creatinine, active urinary sediment, reduced complement levels, elevated ESR or CRP
- · Leukopenia concerning for drug toxicity or infection
- Specific serologies to evaluate known or suspected vasculitis include ANA, ANCA, anti-GBM
- Diagnosis made by combination of characteristic clinical, laboratory, radiologic, pathologic features; biopsy of involved organ frequently diagnostic
- Underlying vasculitis should be suspected in alveolar hemorrhage syndromes, rapidly progressive glomerulonephritis, pulmonary-renal syndromes

■ Differential Diagnosis

- Collagen vascular disease
 Endocarditis
- · Malignancy with paraneoplastic syndrome

■ Treatment

- Regardless of type and severity of vasculitis, general approach involves immunosuppression with corticosteroids often in conjunction with cyclophosphamide
- Close attention to medication dosing based on renal function and degree of bone marrow suppression
- Plasma exchange for severe renal impairment and some forms of diffuse alveolar hemorrhage

■ Pearl


Distinguishing between a flare-up of the underlying vasculitis from infection or toxicity from medical therapy is extremely important because the therapy for one is contraindicated in the management of the other.

Reference

Frankel SK et al: Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa, and Takayasu arteritis. Crit Care Clin 2002;18:855. [PMID: 12418444]

Toxicology

Acetaminophen Overdose	225
Alcohol Withdrawal	226
Benzodiazepine Withdrawal	227
Beta-Adrenergic Blocker Overdose	228
Calcium Channel Blocker Overdose	229
Cocaine	230
Digitalis Toxicity	231
Iron Overdose	232
Ketamine & Phencyclidine (PCP)	233
Lithium	234
Methanol, Ethylene Glycol, & Isopropanol	235
Opioid Overdose	236
Opioid Withdrawal	237
Organophosphate Poisoning	238
Salicylate Poisoning	239
Sedative-Hypnotic Overdose	240
Sympathomimetic Overdose	241
Theophylline Overdose	242
Tricyclic Antidepressant (TCA) Overdose	243
Warfarin Poisoning	244



Acetaminophen Overdose

Essentials of Diagnosis

- Minimal symptoms in first 24 hours; possible nausea, vomiting, diaphoresis, and lethargy
- 24–48 hours postingestion, onset of hepatic AST, ALT elevation
- 3–4 days postingestion: progressive hepatic damage, nausea, vomiting, jaundice, right upper-quadrant pain, asterixis, bleeding, lethargy, coma
- In adults, <125 mg/kg rarely produce toxicity; 125–250 mg/kg variably cause toxicity; doses >250 mg/kg high risk for liver failure; patients with liver disease more susceptible to toxicity
- Acetaminophen-containing combination medications should be considered in all overdose patients

Differential Diagnosis

- · Severe viral or alcoholic hepatitis
- · Cyclopeptide toxicity from mushroom ingestion

Treatment

- Acetaminophen level >4 hours postingestion >150 μg/mL toxic; use nomogram to ascertain risk for other time points
- · Gastric lavage if within 2-4 hours of ingestion
- Give N-acetylcysteine to patients with suspected or known ingestion of toxic dose or who have toxic levels by nomogram; most effective if given within 8 hours of ingestion
- N-acetylcysteine dose 140 mg/kg orally followed by 70 mg/kg orally every 4 hours for 17 doses
- Intravenous N-acetylcysteine can be given (not approved in US) if cannot tolerate oral
- Supportive care for consequences of hepatic failure: vitamin K for coagulopathy, lactulose for encephalopathy
- Liver transplantation should be considered in appropriate patients who are refractory to treatment

Pearl

Laboratories may use different units for acetaminophen level, as it can be reported in $\mu g/mL$ (toxic >150 $\mu g/mL$ at 4 h), $\mu mol/L$ (toxic >1000 $\mu mol/L$ at 4 h), or mg% (15 mg% = 150 $\mu g/mL$).

Reference

Mokhlesi B et al: Adult toxicology in critical care: Part II: specific poisonings. Chest 2003;123:897. [PMID: 12628894]

Alcohol Withdrawal

Essentials of Diagnosis

- Generalized coarse tremors starting 6–8 hours after last drink, intensifying up to 24–36 hours
- Anxiety, insomnia, anorexia, sweating, facial flushing, mydriasis, tachycardia, and hypertension seen in first days; altered mental status, nightmares, auditory hallucinations in 25% of patients, peaking 24–36 hours
- Generalized tonic-clonic seizures in one third of patients, usually within 12–24 hours; status epilepticus in 3%; patients with previous alcohol withdrawal seizures more likely to have recurrent seizures
- Delirium tremens in 5%, 2–4 days after last drink; confusion, insomnia, vivid hallucinations, delusions, tremor, mydriasis, tachycardia, fever, diaphoresis; may last 1–3 days and relapse over weeks

Differential Diagnosis

- · Hypoglycemia
- · Anticholinergic or stimulant overdose
- · Sedative withdrawal
- · CNS infection, sepsis, thyrotoxicosis

Treatment

- · Supportive care, including IV fluids as needed
- Thiamine 100 mg intravenously, folate, multivitamins
- Benzodiazepines for withdrawal symptoms on an as-needed basis, rather than scheduled dosing
- · Benzodiazepines for seizures
- For delirium tremens, aggressive intravenous hydration, may require high-dose benzodiazepines, such as diazepam 5–10 mg intravenously every 1–4 hours

Pearl

Watch for the presence of other behavioral health problems such as depression in alcoholic patients.

Reference

Korsten TR, O'Connor PG: Management of drug and alcohol withdrawal. N Engl J Med 2003;348:1786. [PMID: 12724485]

Benzodiazepine Withdrawal

Essentials of Diagnosis

- Anxiety, irritability, dysphoria, insomnia, confusion, disorientation; may have hypertension, tachycardia, diaphoresis, tremors, hyperthermia, seizures
- May be due to complete benzodiazepine abstinence, reduced intake, or administration of GABA receptor antagonist such as flumazenil
- Timing of symptom onset depends on half-life of medication being chronically taken by the patient; <24 hours after withdrawal from alprazolam, >1 week after withdrawal from diazepam
- · Symptoms of withdrawal similar to ethanol withdrawal

Differential Diagnosis

- · Ethanol withdrawal
- · Hypoglycemia
- · Anticholinergic or stimulant overdose
- · CNS infection, sepsis, thyrotoxicosis

■ Treatment

- · Supportive care, including IV fluids as needed
- Stabilize withdrawal symptoms by administration of long-acting benzodiazepine such as diazepam; once stabilized, withdraw long-acting benzodiazepine dose by about 10% per day
- IV diazepam for seizures
- If withdrawal precipitated by flumazenil, supportive care will usually suffice, as half-life of flumazenil is very short

■ Pearl

More than 10% of adults in the United States use benzodiazepines on a regular basis.

Reference

Jenkins DH: Substance abuse and withdrawal in the intensive care unit. Contemporary issues. Surg Clin North Am 2000;80:1033. [PMID: 10897277]

Beta-Adrenergic Blocker Overdose

Essentials of Diagnosis

- · Hypotension, bradycardia, heart block
- Can also cause altered mental status, hallucinations, seizures, hypoglycemia
- · In severe overdose, may have cardiogenic shock

Differential Diagnosis

- · Calcium channel blocker overdose
- · Barbiturate overdose
- · Antiarrhythmic toxicity
- · Tricyclic antidepressant toxicity

Treatment

- Supportive care
- Gastric lavage for patients within 2–4 hours of ingestion; activated charcoal and cathartic agents
- Glucagon is most effective agent for reversing bradycardia and hypotension; typical dose 0.05 mg/kg intravenously followed by infusion of 0.07 mg/kg/h as needed
- Atropine for symptomatic bradycardia; consider dopamine or norepinephrine
- If refractory to therapy, consider cardiac pacemaker, isoproterenol, intra-aortic balloon pump
- Charcoal hemoperfusion may be useful for atenolol or nadolol, which have small volume of distribution with limited protein binding

Pearl

Side effects of glucagon include nausea, vomiting, hyperglycemia, hypokalemia, and allergic reactions.

Reference

Kerns W II et al: Beta-blocker and calcium channel blocker toxicity. Emerg Med Clin North Am 1994;12:365. [PMID: 7910555]

Calcium Channel Blocker Overdose

Essentials of Diagnosis

- · Bradycardia, hypotension, heart block, and asystole
- Drowsiness, metabolic acidosis, hyperglycemia, seizure, and coma may also be seen

Differential Diagnosis

- · Beta-blocker toxicity
- · Barbiturate overdose
- · Antiarrhythmic toxicity
- · Tricyclic antidepressant toxicity

■ Treatment

- · Supportive care
- Gastric lavage for patients within 2–4 hours of ingestion; activated charcoal and cathartic agents if acute ingestion
- For cardiotoxicity: calcium chloride, 10% 10 mL intravenously, or calcium gluconate, 30 mL intravenously initially, followed by repeated doses if needed
- Glucagon, 0.1 mg/kg intravenous bolus followed by 0.1 mg/kg/h drip, if intravenous calcium ineffective
- Atropine and vasopressor agents such as dopamine or dobutamine in patients refractory to treatment

■ Pearl

Large ingestions of sustained-release preparations may result in formation of stomach concretions. Whole-bowel irrigation has been suggested for use in such ingestions.

Reference

Proano L et al: Calcium channel blocker overdose. Am J Emerg Med 1995;13:444. [PMID: 7605536]

Cocaine

Essentials of Diagnosis

- · Tachycardia, hypertension, hyperthermia, agitation, and seizures
- Cardiac dysrhythmias, including atrial fibrillation or tachycardia, ventricular tachycardia, or asystole
- End-organ ischemia can cause stroke, myocardial infarction, bowel ischemia, renal infarction, limb ischemia; severe hypertension can lead to intracranial hemorrhage (subarachnoid or intraparenchymal) or aortic dissection
- Pneumothorax or pneumomediastinum can be seen when cocaine smoked or snorted
- Excess muscle activity can lead to rhabdomyolysis or hyperthermia
- · Can be used by snorting, smoking, or intravenous injection

Differential Diagnosis

- Sympathomimetic, theophylline, phencyclidine intoxication
- · Ethanol or benzodiazepine withdrawal
- Thyrotoxicosis
- · CNS infection

Treatment

- Supportive care
- · Active cooling measures for hyperthermia
- · Benzodiazepines for agitation and seizures
- Phenobarbital or phenytoin for seizures refractory to benzodiazepines
- Intravenous nitroprusside for severe hypertension
- If myocardial ischemia or infarction, usual therapy except avoid beta blockers because of potential for severe hypertension from unopposed alpha-adrenergic stimulation; phentolamine may be used for coronary vasospasm
- Intravenous fluids and alkalinization of urine for rhabdomyolysis

■ Pearl

Lidocaine is often ineffective for cocaine-induced ventricular dysrhythmias; consider cocaine toxicity in a young otherwise healthy patient in an agitated state with ventricular dysrhythmia unresponsive to lidocaine.

Reference

Shanti CM, Lucas CE: Cocaine and the critical care challenge. Crit Care Med 2003;31:1851. [PMID: 12794430]

Digitalis Toxicity

Essentials of Diagnosis

- Most asymptomatic but may have anorexia, nausea, vomiting, visual changes (amblyopia, photophobia, scotomata, yellow halos), abdominal pain, headache, hallucinations, drowsiness
- Cardiac dysrhythmias of virtually any type can occur, including bradycardia, AV dissociation, supraventricular tachycardia, ventricular tachyarrhythmias
- Toxicity can occur from acute, chronic, or acute plus chronic use; potential for toxicity increased by age, coexisting conditions, hypokalemia, hypomagnesemia, hypercalcemia, hypoxia, other cardiac medications
- High potassium and digoxin levels seen in acute, but not necessarily with chronic toxicity

Differential Diagnosis

- Ingestion of cardiac glycoside-containing plants, including foxglove, oleander, lily of the valley, dogbane, red squill
- · Calcium channel blocker, beta-adrenergic blockers
- · Tricyclic antidepressant overdose

Treatment

- Discontinue digitalis
- Emesis or gastric lavage if recent ingestion; multidose activated charcoal may be beneficial even if substantial time elapsed from ingestion due to enterohepatic recirculation
- · Monitor cardiac rhythm
- Check electrolytes, digitalis level; replace potassium and magnesium if low
- Purified digoxin-specific antibodies (Fab) indicated for ventricular arrhythmias, bradyarrhythmias, severe hyperkalemia with potassium level >5.0 mEq/L, or digoxin level exceeding 10–15 ng/mL
- If digoxin-specific Fab not available in face of ventricular arrhythmia, phenytoin and lidocaine are drugs of choice

Pearl

Hyperkalemia from digitalis toxicity should not be treated with intravenous calcium chloride, as this may exacerbate intracellular hypercalcemia and cause intractable ventricular tachyarrhythmias.

Reference

Eichhorn EJ, Gheorghiade M: Digoxin. Prog Cardiovasc Dis 2002;44:251. [PMID: 12007081]

Iron Overdose

Essentials of Diagnosis

- GI symptoms <2 hours; abdominal pain, vomiting, diarrhea, hematemesis, hematochezia; few symptoms seen 6–24 hours postingestion
- Shock, coma, coagulopathy, acidosis, multisystem organ failure may occur after 6–72 hours; most deaths occur during this phase
- Hepatic necrosis occurs within 48 hours of ingestion with or without shock; second most common cause of death
- Late complications: bowel obstruction at 2-4 weeks
- Iron overdose during pregnancy associated with spontaneous abortion, preterm delivery, maternal death
- Serum iron level drawn 4–6 hours postingestion >500 μg/dL significant; prognosis worsens with level >1000 μg/dL; levels drawn >6 hours postingestion not useful
- · Iron tablets seen on abdominal radiographs verify ingestion

Differential Diagnosis

· Other causes of acute abdominal pain or GI bleeding

Treatment

- Gastric lavage with large-bore tube followed by whole-bowel irrigation, particularly if tablets seen on abdominal radiograph
- Chelation therapy for severe abdominal symptoms, altered mental status, evidence of systemic hypoperfusion, or serum iron level >500 μg/dL
- Chelation with intravenous deferoxamine, usually 15 mg/kg/h; stop when symptoms resolved, serum iron level <150 μg/dL, metabolic acidosis gone, urine color returns to normal
- Deferoxamine should only be given after intravascular volume deficits corrected to avoid acute renal failure; IV deferoxamine administration >24-48 hours may precipitate acute respiratory distress syndrome
- Evaluation for liver transplantation if acute hepatic necrosis

■ Pearl

If GI symptoms do not occur within 6 hours of ingestion, iron ingestion was likely nontoxic unless the patient ingested enteric-coated iron.

Reference

Tran T et al: Intentional iron overdose in pregnancy—management and outcome. J Emerg Med 2000;18:225. [PMID: 10699527]

Ketamine & Phencyclidine (PCP)

Essentials of Diagnosis

- Ketamine: short-acting anesthetic; no respiratory or cardiovascular depression, but hallucinations; analog of phencyclidine (PCP); both abused as hallucinogens
- · PCP usage declining, recently increasing ketamine abuse
- Variable symptoms and signs; euphoria, agitation, psychosis, violent behavior, seizures; fully alert to comatose
- Nystagmus (horizontal, vertical, rotatory) >50% of PCP (rare with ketamine); hypertension, tachycardia
- Ketamine inhaled or injected; effects rare >1 hour; PCP smoked, intranasal, or ingested; rapidly absorbed; half-life 7–72 hours
- Complicated by rhabdomyolysis, renal failure, concealed injuries due to violent behavior
- Urine PCP level confirms diagnosis; serum creatine kinase levels, urine myoglobin

■ Differential Diagnosis

- Sympathomimetics
- Long-acting hallucinogens (3,4-methylenedioxymethamphetamine ("ecstasy"), LSD
- · Sedative-hypnotics, alcohol; withdrawal from these
- · Head trauma, meningitis, encephalitis
- · Psychiatric disorders
- · Metabolic derangements

Treatment

- · Ketamine generally none; rapid elimination
- PCP: gastric lavage if suspected large ingestion within 1 hour or co-ingestion suspected; follow with multidose activated charcoal
- Supportive care for hypertension, tachycardia; treat hyperthermia
- · Treat seizures with benzodiazepines, phenytoin
- IV fluids, mannitol, bicarbonate for rhabdomyolysis to reduce risk of renal failure
- Avoid excessive stimulation; use benzodiazepines or haloperidol for sedation

Pearl

Some patients suspected of head trauma instead have PCP intoxica-

Reference

Weiner AL et al: Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 2000;18:447. [PMID: 10802423]

Lithium

Essentials of Diagnosis

- · May be acute, chronic, or acute plus chronic lithium toxicity
- CNS symptoms include tremor, weakness, hyperreflexia, muscle rigidity, slurred speech, tinnitus, seizures, confusion, coma;
 GI symptoms more common with acute toxicity, including nausea and vomiting
- May have prolonged QT interval, ST and T wave abnormalities, myocarditis, cardiovascular collapse (rare)
- Nephrogenic diabetes insipidus in 20–70%
- Thyrotoxicosis, hyperthermia, hyperparathyroidism, hypercalcemia
- Risk factors for toxicity in patients previously stable on lithium therapy include ACE inhibitors, NSAIDs, loop diuretics, thiazides, volume depletion, decreased sodium intake, renal insufficiency
- Serum lithium level >1.5 mEq/L is toxic

■ Differential Diagnosis

- Stroke, meningitis, tardive dyskinesia, other CNS disorders
- · Neuroleptic malignant syndrome
- · Sedative-hypnotic or ethanol withdrawal
- Psychotropic or stimulant overdose

Treatment

- Gastric lavage, with whole bowel irrigation for significant ingestions
- Maintenance of fluid and electrolyte balance
- Hemodialysis effective; should be considered early in ingestion of sustained-release preparations, chronic ingestions with toxicity, with impaired renal function, if neurologic findings, or if serum lithium >4.0 mEq/L

Pearl

As lithium is not metabolized and is eliminated entirely via the kidney, any patient with abnormal renal function should be considered a hemodialysis candidate if there are signs of toxicity.

Reference

Timmer RT, Sands JM: Lithium intoxication. J Am Soc Nephrol 1999;10:666. [PMID: 10073618]

Methanol, Ethylene Glycol, & Isopropanol

Essentials of Diagnosis

- Methanol: 12–24 hours after ingestion, visual disturbances, headache, nausea, vomiting, abdominal pain, lethargy, confusion, seizures, coma; retinal and optic disc abnormalities; methanol found in solvents, paint thinners
- Ethylene glycol: First 12 hours, CNS abnormalities; 12–24 hours after ingestion, cardiopulmonary abnormalities including hypertension, high-output cardiac failure, tachycardia; 24–72 hours after ingestion see renal failure, flank pain; may have oxalate crystalluria; ethylene glycol found in antifreeze
- Isopropanol: headache, dizziness, confusion, abdominal pain, nausea, vomiting; isopropanol found in rubbing alcohol, skin and hair products
- Prior to metabolism, all produce increased osmolal gap; all metabolized by alcohol dehydrogenase to toxic metabolites: methanol to formic acid, ethylene glycol to oxalic acid, and isopropanol to acetone; therefore, methanol and ethylene glycol, but not isopropanol, have increased anion gap

Differential Diagnosis

- Ethanol intoxication
- Hyperglycemia
- Sepsis, meningitis
- · Other causes of anion gap acidosis

■ Treatment

- Supportive care, including IV fluids, oxygen, monitoring
- · Gastric decontamination if within 2 hours
- Bicarbonate for severe acidosis with methanol and ethylene glycol
- Folic acid 50 mg intravenously every 4 hours for methanol; thiamine, pyridoxine for ethylene glycol ingestion
- Ethanol infusion to achieve blood ethanol level of 100–150 mg/dL for methanol and ethylene glycol toxicity; saturates alcohol dehydrogenase, preventing formation of toxic metabolites
- Fomepizole (4-methylpyrazole), an alcohol dehydrogenase inhibitor, may be used as an alternative to ethanol
- · Hemodialysis for severe toxicity

Pearl

A large ingestion of any toxic alcohol, including benzyl alcohol, propylene glycol, isopropanol, methanol, or ethylene glycol will cause elevation of serum osmolality.

Reference

Brent J, et al: Fomepizole for the treatment of methanol poisoning. N Engl J Med 2001;344:424. [PMID: 11172179]

Opioid Overdose

Essentials of Diagnosis

- Depressed level of consciousness, decreased respirations, which can be pronounced, miotic pupils
- Less commonly pulmonary edema, hypo- or hyperthermia, emesis, hypoxia, hypotension, depressed deep tendon reflexes

Differential Diagnosis

- · Alcohol intoxication
- · Sedative-hypnotic overdose
- · Cardiogenic pulmonary edema
- Altered mental status due to CNS infection, encephalopathy, hypoglycemia, seizure, hypothyroidism, stroke

Treatment

- Send blood for electrolytes, toxicology screen, blood gases, liver function tests; ethanol and acetaminophen levels to evaluate for co-ingestion
- CXR to evaluate for pulmonary edema or aspiration pneumonia
- Establish airway and ventilation in the comatose patient
- Patients with respiratory depression should receive naloxone, 2 mg IV initially; may be repeated up to a total of 10–20 mg if no reversal of symptoms follows initial dose
- Patients with central nervous system depression without respiratory depression should receive naloxone 0.1–0.4 mg IV initially; partial or absent responses should be followed by naloxone 2 mg IV as described for patients with respiratory depression
- Continuous naloxone infusion or repeated naloxone doses every 20–60 minutes may be required following initial response, especially when long-acting narcotics have been ingested
- Gastrointestinal decontamination with nasogastric lavage followed by activated charcoal and a cathartic can be helpful

Pearl

Acute complications of narcotic use due to sharing of needles include pulmonary hypertension, endocarditis, necrotizing fasciitis, and tetanus.

Reference

Watson WA et al: Opioid toxicity recurrence after an initial response to naloxone. J Toxicol Clin Toxicol 1998;36:11. [PMID: 9541035]

Opioid Withdrawal

Essentials of Diagnosis

- Early symptoms include lacrimation, rhinorrhea, perspiration, yawning; later see restlessness, piloerection, mydriasis, insomnia, nausea, vomiting, abdominal cramps, diarrhea
- · Can see hyperthermia and hypertension in severe cases
- · Frequently see intense drug craving
- Symptoms develop when opioid stopped or opiate antagonist administered; timing of symptom onset depends on half-life of opioid
- For heroin, onset of withdrawal symptoms 6 hours after last dose, peak withdrawal symptoms 36–48 hours after last dose, resolution of withdrawal by 4–5 days
- For methadone, onset of withdrawal symptoms 2–3 days after last dose, with withdrawal resolution after 2 weeks
- Sudden onset of withdrawal can be precipitated by administration of naloxone to opiate-dependent patients

■ Differential Diagnosis

- · Ethanol withdrawal
- · Benzodiazepine withdrawal

Treatment

- · IV fluids, particularly if there is vomiting and diarrhea
- Control withdrawal symptoms with long-acting opioid such as methadone, 10 mg intramuscularly initially, which is often adequate to control withdrawal symptoms; additional doses administered hourly until symptoms subside, usually 20–40 mg
- Clonidine, 0.1–0.2 mg every 6 hours can be used to treat mild opioid withdrawal

Pearl

Patients with pure opioid withdrawal maintain normal mental status. Therefore, altered mental status should prompt a search for other factors contributing to the patient's condition.

Reference

Jenkins DH: Substance abuse and withdrawal in the intensive care unit. Contemporary issues. Surg Clin North Am 2000;80:1033. [PMID: 10897277]

Organophosphate Poisoning

Essentials of Diagnosis

- Peripheral muscarinic effects: salivation, lacrimation, urinary incontinence, diarrhea, (SLUD syndrome); bronchospasm, bronchorrhea, nausea, vomiting, miosis, blurred vision, diaphoresis
- Peripheral nicotinic effects: muscle fasciculations, weakness, ataxia, paralysis.
- CNS effects: headache, slurred speech, confusion, seizures, coma, depressed ventilatory drive
- Death from respiratory center depression, respiratory muscle weakness, bronchospasm, and bronchial secretions
- Found in insecticides and herbicides; exposure due to dermal exposure or ingestion; inactivation of acetylcholinesterases with excessive stimulation of cholinergic receptors
- No definitive laboratory test available; diagnosis based on clinical syndrome and response to therapy; cholinesterase activity level can be obtained, but may take days for results

Differential Diagnosis

· Myasthenia gravis with cholinergic crisis

Treatment

- · Irrigate areas of dermal exposure copiously
- Gastric lavage if ingestion within one hour, followed by activated charcoal
- Intubation and ventilatory support should be considered early
- Atropine to reverse peripheral muscarinic effects; does not reverse skeletal nicotinic effects
- Atropine for diagnostic testing: 1 mg IV; watch for papillary dilatation and increase in heart rate; if no response, cholinergic toxicity suggested
- Atropine for treatment: 2–4 mg intravenously every 10–15 minutes until drying of secretions
- Pralidoxime reverses nicotinic muscle effects; give with atropine in dose of 25–50 mg/kg over 5–15 minutes; observe for increased muscle strength; can repeat every 4–12 hours as needed

Pearl

Chemical weapons known as nerve agents are a very toxic group of organophosphates; these should be considered in a chemical attack.

Reference

Leikin JB et al: A review of nerve agent exposure for the critical care physician. Crit Care Med 2002;30:2346. [PMID: 12394966]

Salicylate Poisoning

■ Essentials of Diagnosis

- Nausea, vomiting, abdominal pain, hematemesis, tinnitus; lethargy, confusion, coma, seizures
- · Noncardiogenic pulmonary edema
- · Hypoglycemia, hyperthermia
- Cardiovascular collapse
- Positive urine ferric chloride or Phenistix test confirms salicylate use
- Arterial blood gases may show respiratory alkalosis with metabolic acidosis
- Salicylate levels peak 4–6 hours after ingestion, or later with enteric-coated preparations
- Dose nomogram estimates severity of acute, but not chronic, toxicity

Differential Diagnosis

- Stimulant toxicity
 Meningitis, encephalitis
- Pneumonia
 Renal Failure
- Diabetic or alcoholic ketoacidosis

Treatment

- Maintenance of airway with continuation of respiratory alkalosis
- Gastric lavage for ingestion of greater than 100 mg/kg within 2 hours of ingestion, or later if enteric-coated preparation
- · Activated charcoal and cathartics
- Fluid and electrolyte replacement
- Urinary alkalinization for patients with salicylate levels greater than 35 mg/dL, or levels less than 35 mg/dL with significant symptoms
- Hemodialysis for salicylate level greater than 100 mg/dL, severe fluid and electrolyte abnormalities, persistent CNS disturbances, or hepatic, pulmonary or renal failure

Pearl

Maintenance of high pH via respiratory alkalosis and urinary alkalinization prevents salicylates from leaving the blood and entering the CNS

Reference

Dargan PI et al: An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose. Emerg Med J 2002;19:206. [PMID: 11971828]

Sedative-Hypnotic Overdose

Essentials of Diagnosis

- Altered sensorium, confusion, dysarthria, ataxia, lethargy, stupor; initial symptoms similar to alcohol intoxication
- With severe overdose, coma, respiratory and cardiovascular collapse
- Horizontal and vertical nystagmus, depressed deep tendon reflexes, slow shallow respiratory efforts, pulmonary edema
- All sedative-hypnotics similar except for duration of action, potential for prolonged effects, especially non-barbiturate/ non-benzodiazepines, such as chloral hydrate, ethchlorvynol, glutethimide, meprobamate, methaqualone, methyprylon

Differential Diagnosis

- Uremia
- · Hepatic encephalopathy
- · Hypoglycemia, hypothyroidism
- · Stroke, seizure, CNS infection

Treatment

- · Always have concern about co-ingestions
- Intubation for airway protection if cough and gag reflexes are depressed; fluid volume resuscitation for hypotension; vasopressors occasionally required for refractory hypotension
- Gastric lavage if ingestion within previous 45 minutes; multidose activated charcoal decreases absorption and enhances elimination in life-threatening phenobarbital overdose
- Mannitol-induced diuresis and alkalinization aid in excretion of long-acting barbiturates, but not other agents

■ Pearl

Bromide intoxication can cause abnormalities in anion gap determination because the autoanalyzer cannot distinguish between bromide and chloride. Therefore, patients with altered mental status, high serum chloride, and narrow anion gap should have a bromide level measured.

Reference

Mokhlesi B et al: Adult toxicology in critical care: Part II: specific poisonings. Chest 2003:123:897. [PMID: 12628894]

Sympathomimetic Overdose

Essentials of Diagnosis

- · Confusion, tremor, paranoia, anxiety, agitation and irritability
- Mydriasis, tachyarrhythmias, hypertension, hyperreflexia, seizures, hyperthermia, rhabdomyolysis, and renal failure
- Overdose of prescribed drugs (methylphenidate, dextroamphetamine, ephedrine, pseudoephedrine, diethylpropion, phentermine) or use of recreational agents such as methamphetamine ("crank") or 3,4-methylenedioxymethamphetamine ("ecstasy")
- In severe cases, life-threatening hyperthermia, arrhythmias, status epilepticus, intracranial hemorrhage, aspiration pneumonia, acute hepatic failure

■ Differential Diagnosis

- · Thyrotoxicosis
- · CNS infection
- Ethanol or benzodiazepine withdrawal
- Toxicity from theophylline, tricyclic antidepressants, anticholinergics, isoniazid, phencyclidine, salicylates

■ Treatment

- Supportive care, maintenance of airway and mechanical ventilation if needed
- Gastric lavage within 2 hours of ingestion; activated charcoal and cathartic
- Active cooling for rectal temperatures >40°C
- · Evaluation of electrolytes and CK
- Phentolamine or nitroprusside can be used for severe hypertension
- Beta-adrenergic blockers (esmolol or propranolol) for tachyarrhythmias
- For severe agitation, benzodiazepines, phenothiazines, or haloperidol
- · Phenobarbital or phenytoin for seizures

Pearl

While duration of toxicity is usually limited for most sympathomimetics, duration may be prolonged if patients have ingested bags containing the drug for illicit transport ("body-packing") or have used "ice," a long-acting smokable form of methamphetamine.

Reference

Mokhlesi B et al:Adult toxicology in critical care: Part II: specific poisonings. Chest 2003;123:897. [PMID: 12628894]

Theophylline Overdose

Essentials of Diagnosis

- · Nausea and vomiting
- Cardiac: atrial fibrillation, multifocal atrial tachycardia, ventricular tachyarrhythmias; central nervous system: agitation, hyperreflexia, tremors, seizures; hypotension due to peripheral beta-adrenergic stimulation with vasodilation; hypokalemia in acute ingestion may be refractory to replacement
- Acute intoxications at serum levels 80–100 µg/mL; with chronic toxicity, serious effects as low as 40 µg/mL

Differential Diagnosis

- Tricyclic antidepressant, anticholinergic, phenothiazine, caffeine overdose
- Meningitis, sepsis
 Alcohol withdrawal

Treatment

- Gastric lavage within 1 hour of ingestion, or within 3–4 hours if sustained-release form ingested
- Activated charcoal essential; administer 1–2 g/kg regardless of time since ingestion, then 0.5–1 g/kg every 2 hours; do not give cathartics after first dose
- IV fluids for hypotension; follow with alpha-adrenergic agonists such as phenylephrine, if necessary; beta-adrenergic blockers may be helpful to reverse peripheral beta-adrenergic mediated vasodilatation
- Verapamil or beta blockers for supraventricular arrhythmias; correct hypokalemia and lidocaine for ventricular dysrhythmias
- · Benzodiazepines, dilantin, or phenobarbital for seizures
- Hemodialysis or hemoperfusion for refractory dysrhythmias, hypotension, seizures, or acute very high theophylline levels (>100 μg/mL in acute intoxication, >60 μg/mL in chronic intoxication)

Pearl

Seizures due to theophylline toxicity may be refractory to drug therapy and are associated with worse prognosis; neuromuscular blockade may be necessary in addition to general anesthesia, ventilatory support, and EEG monitoring to control seizures.

Reference

Shannon M: Life-threatening events after theophylline overdose: a 10-year prospective analysis. Arch Intern Med 1999;159:989. [PMID: 10326941]

Tricyclic Antidepressant (TCA) Overdose

Essentials of Diagnosis

- Constellation of findings reflecting direct CNS, anticholinergic, alpha-adrenergic blockade, direct cardiac effects
- · Mental status varies widely from alert to comatose
- Anticholinergic: tachycardia, mydriasis, dry skin, urinary retention, ileus, fever, altered mental status, seizures
- Cardiovascular: tachycardia, dysrhythmias, atrioventricular block
- Hypotension due to decreased cardiac contractility and alphaadrenergic blockade
- ECG valuable for evaluating suspected TCA overdose; common findings include tachycardia, PR and QT prolongation, nonspecific ST changes
- QRS duration >100 ms suggests serious overdose with potential for significant arrhythmias or seizures; abnormal superior, rightward axis of terminal 40 ms of QRS (wide S in I, aVF and V₆, with prominent R in aVR) strongly suggests TCA overdose and can help discriminate TCA overdose from other drug overdoses

Differential Diagnosis

- Phenothiazines, anticholinergic, theophylline, beta-blocker, calcium blocker, lidocaine overdose
- CNS infection
- Sepsis
- Hypoglycemia
- Head trauma

■ Treatment

- · Cardiac monitor, urinary catheter, IV access
- Gastric lavage if ingestion within 2 hours, followed by activated charcoal
- Alkalinization of blood reverses most adverse effects, including hypotension, cardiac arrhythmias, conduction abnormalities
- Benzodiazepine for agitation or seizures; lidocaine for cardiac arrhythmias unresponsive to bicarbonate

Pearl

Because hypotension is facilitated by alpha-adrenergic blockade, phenylephrine (a pure alpha-adrenergic agonist) is more effective than dopamine for refractory hypotension.

Reference

Kerr GW et al: Tricyclic antidepressant overdose: a review. Emerg Med J 2001;18:236. [PMID: 11435353]

Warfarin Poisoning

Essentials of Diagnosis

- Bleeding from single or multiple sites, with bruising, epistaxis, gingival bleeding, hematuria, hematochezia, hematemesis, menorrhagia
- Prolonged PT, normal or prolonged PTT, normal thrombin time, normal fibrinogen level
- Can occur either by ingestion of warfarin (drug) or ingestion of rodenticides containing similar agents (most rodenticides contain small amounts of anticoagulant and rarely associated with significant toxicity)
- Allopurinol, cephalosporin, cimetidine, tricyclic antidepressant, erythromycin, NSAIDs, ethanol increase anticoagulant actions of warfarin and contribute to toxicity

■ Differential Diagnosis

 Other causes of coagulopathy, including liver disease, vitamin K deficiency, disseminated intravascular coagulation, sepsis-related coagulopathy

Treatment

- · Gastric decontamination within 1 hour of ingestion
- For life-threatening bleeding, immediate reversal with fresh frozen plasma, IV vitamin K
- For non-life-threatening bleeding, oral or IV vitamin K in patients not requiring long-term anticoagulation
- For non-life threatening bleeding in patients requiring subsequent long-term anticoagulation, partial correction with fresh frozen plasma
- For prolonged PT without bleeding, observation alone usually sufficient

Pearl


Warfarin can be associated with several skin abnormalities including urticaria, purple toe syndrome, and skin necrosis.

Reference

Ansell J, et al: Managing oral anticoagulant therapy. Chest 2001;119(1 Suppl):22S. [PMID: 11157641]

Environmental Injuries

Carbon Monoxide (CO) Poisoning	247
Electrical Shock & Lightning Injury	248
Frostbite	249
Heat Stroke	250
Hypothermia	251
Mushroom Poisoning	252
Near Drowning	253
Radiation Injury	254
Snakebite	255
Spider & Scorpion Bites	256



Carbon Monoxide (CO) Poisoning

Essentials of Diagnosis

- Headache, confusion, neuropsychological impairment, generalized malaise, fatigue, nausea, vomiting, chest pain
- Tachycardia, hypotension, focal and non-focal neurological findings; patients do not have cyanosis; if severe, shock, stupor, coma
- Electrocardiogram (ECG) changes of ischemia in susceptible patients
- May be accidental (operation of motor vehicles in enclosed space, malfunctioning furnaces), concomitant with smoke inhalation, deliberate suicide attempt
- Alcohol, drugs associated with poisoning and death; most common poison-related death in United States
- CO binds to tightly to hemoglobin, also increases O₂ affinity to hemoglobin, resulting in impaired O₂ delivery; also may be intracellular toxin

■ Differential Diagnosis

- · Drug overdose
- · Hypoxemia
- · Cyanide toxicity
- · Effects of smoke inhalation

■ Treatment

- Supportive care, especially if cardiovascular compromise, smoke inhalation, burns
- High concentration of inhaled oxygen speeds elimination of carbon monoxide (use non-rebreather O₂ mask or endotracheal intubation with 100% O₂)
- Hyperbaric 100% O₂ increases rate of CO elimination; clinical value unclear
- Transfusion of packed red blood cells may be helpful; consider exchange transfusions in severe toxicity

Pearl

The pulse oximeter is unable to distinguish carboxyhemoglobin from oxyhemoglobin; blood must be sent for carboxyhemoglobin concentration.

Reference

Gorman D et al: The clinical toxicology of carbon monoxide. Toxicology 2003;187:25. [PMID: 12679050]

Electrical Shock & Lightning Injury

■ Essentials of Diagnosis

- · Burns: partial or full thickness skin damage
- Household current shock: transiently unconscious, headache, cramps, fatigue, paralysis, rhabdomyolysis, atrial or ventricular fibrillation, nonspecific ST-T ECG changes
- Lightning strike: para- or quadriplegia, autonomic instability, hypertension, nonspecific ST-T ECG changes; blunt trauma due to falls; burns typically superficial
- · Degree of injury depends on conducted current of electricity
- Alternating current (household) more dangerous than direct current (lightning); high voltage injury defined as >1000 volts

Differential Diagnosis

- · Cardiac arrhythmia
- · Thermal or chemical burns
- Blunt traumatic injury
- · Toxin or smoke inhalation

Treatment

- Intubation and mechanical ventilation for respiratory compromise
- · Fluid resuscitation
- Most immediate risk from cardiac arrhythmia, particularly if electric shock passed through the thorax; most arrhythmias self limited, but may require antiarrhythmic drugs
- Local care for skin wounds; transfer to burn unit if extensive burns
- Monitor creatine kinase levels for rhabdomyolysis; if present, consider alkalinization of urine

■ Pearl

Lightning generates massive peak direct current of 20,000–40,000 amperes for 1–3 microseconds. Despite this, patients surviving the immediate event typically have few complications and often only require observation.

Reference

Koumbourlis AC: Electrical injuries. Crit Care Med 2002;30(11 Suppl):S424. [PMID: 12528784]

Frostbite

Essentials of Diagnosis

- Superficial frostbitten skin and subcutaneous area typically painless, numb, blanched; deep frostbite area may have woody appearance
- Occurs when tissues become frozen; may see line of demarcation between frozen and unfrozen areas
- Severity of frostbite best determined after rewarming; first degree with hyperemia, edema, no blisters; second degree adds blisters, pain during rewarming; third degree with skin necrosis, eschars, hemorrhagic blisters; fourth degree with complete soft tissue, muscle, bone necrosis

Differential Diagnosis

- · Peripheral arterial disease
- · Raynaud disease
- · Necrotizing fasciitis, cellulitis
- Immersion foot (prolonged exposure to cold water, non-freezing injury)

■ Treatment

- Limit cold exposure as soon as possible; avoid rewarming if refreezing likely
- Rewarm extremities in warm water bath between 40–42°C; continue rewarming until all blanched tissues perfused with blood
- Opioid analgesics for pain during rewarming; epidural block during lower extremity rewarming can be used
- Débride white-blistered tissue after rewarming
- Aloe vera, applied topically every 6 hours to affected areas, and ibuprofen both inhibit thromboxane; may reduce tissue injury
- Antibiotic prophylaxis, usually with penicillin, for 48–72 hours
- Avoid amputation until amount of tissue loss clearly defined; may be weeks or months after injury
- · Treat likely concomitant hypothermia

Pearl

Frostbite rarely occurs unless environmental temperature is less than $-6.7^{\circ}C$ (20°F).

Reference

Murphy JV et al: Frostbite: pathogenesis and treatment. J Trauma 2000;48:171. [PMID: 10647591]

Heat Stroke

Essentials of Diagnosis

- · Confusion, stupor, seizures, coma
- Hot dry skin, hypovolemia, hypotension, tachycardia, body temperature approaching 40°C or more
- Rhabdomyolysis, myocardial depression, disseminated intravascular coagulation, platelet dysfunction with bleeding, renal failure; intracerebral hemorrhages and cerebral edema may occur
- Elevated hematocrit, potassium, creatine kinase, prolonged coagulation times
- · Failure of thermoregulatory mechanism.
- · Hyperthermia and CNS dysfunction must be present

Differential Diagnosis

- Sepsis
- Neuroleptic malignant syndrome
- · Malignant hyperthermia

Treatment

- · Intubation, mechanical ventilation if patient unconscious.
- IV fluids
- Rapid reduction of body temperature to 39°C, using surface cooling with ice, ice water, cooling blankets, water plus fans
- May also use cold IV fluids, cold water gastric or rectal lavage, peritoneal dialysis with cold fluid
- Once temperature down to 38°C, cease active cooling measures to avoid hypothermia
- Multiple organ dysfunction may occur after normalization of temperature and should be managed using standard therapies

Pearl

Acetaminophen and other antipyretics are ineffective in heat stroke, as the hyperthermia in heat stroke is not due to an increase in temperature regulatory set point, as it is in other causes of fever.

Reference

Bouchama A et al: Heat stroke. N Engl J Med 2002;346:1978. [PMID: 12075060]

Hypothermia

Essentials of Diagnosis

- Mild (32.2–35°C): shivering, confusion, slurred speech, amnesia, tachycardia, tachypnea
- Moderate (28–32.2°C): decreased shivering, muscle rigidity, lethargy, hallucinations, dilated pupils, bradycardia, hypotension, ventricular arrhythmias, J wave on ECG, hypoventilation
- Severe (<28°C): coma, hypotension, apnea, ventricular fibrillation, asystole, pulmonary edema, pseudo-rigor mortis (appearance of death)
- Measure core temperature with rectal thermometer capable of recording as low as 25°C
- · Usually from exposure; with advanced age, alcoholism

Differential Diagnosis

- · Drug and alcohol intoxication
- · Hypothyroidism, adrenal insufficiency
- · Sepsis, trauma, burns

Treatment

- · Remove wet clothing, protect against further heat loss
- Continuous cardiac monitoring; avoid excessive movement of patient, which can trigger arrhythmias
- Intubation and mechanical ventilation
- IV fluids, as most volume depleted; in moderate to severe hypothermia, warm intravenous fluids to 40–42°C
- Defibrillate for pulseless ventricular rhythm; if unsuccessful, rewarm, defibrillate after every 1–2°C increase
- · Bradycardia, atrial fibrillation often respond to rewarming
- Antiarrhythmics, vasopressors usually ineffective below 30°C
- Mild hypothermia: passive external rewarming with blankets
- Moderate to severe hypothermia: passive external plus active external rewarming (immersion in 40°C bath, radiant heat, heating pads, warmed forced air)
- Severe hypothermia: active core rewarming with heated humidified oxygen, peritoneal irrigation or pleural or gastric lavage; consider extracorporeal blood rewarming

■ Pearl

The hypothermic patient has potential for full recovery once rewarmed despite severely depressed cardiac function.

Reference

Hanania NA et al: Accidental hypothermia. Crit Care Clin 1999;15:235. [PMID: 10331126]

Mushroom Poisoning

Essentials of Diagnosis

- Cyclopeptides (including Amanita phalloides, Galerina marginata): 6–12 hours after ingestion, colicky abdominal pain, profuse diarrhea, nausea, vomiting; latent phase for 3–5 days, then hepatic toxicity phase with liver failure
- Gyromitrins: 6–12 hours post ingestion, gastritis, dizziness, bloating, nausea, vomiting, headache; if severe, hepatic failure 3–4 days after ingestion; seizure, coma
- Other mushrooms cause symptoms early, usually 1–2 hours; several cause hallucinations, altered perceptions, drowsiness
- 50% of ingestions and 95% of deaths from cyclopeptide group; gyromitrin responsible for remainder of fatal ingestions

Differential Diagnosis

- Gastroenteritis
- · Infectious diarrhea
- Hepatic failure (acetaminophen toxicity, viral hepatitis, alcohol)

Treatment

- Gastric emptying if <4 hours after ingestion; repeated-dose activated charcoal if after 4 hours.
- Supportive care for hepatic failure; if severe, liver transplantation
- Thioctic acid, silybin, penicillin G, N-acetylcysteine used in cyclopeptide group toxicity; benefit not validated
- Methylene blue for methemoglobinemia associated with gyromitrin group; pyridoxine for refractory seizures

Pearl

Of the 500 species of mushrooms in the United States, 100 are toxic and 10 are potentially fatal.

Reference

Enjalbert F et al: Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002;40:715. [PMID: 12475187]

Near Drowning

Essentials of Diagnosis

- Fresh water near-drowning associated with hypervolemia, hypotonicity, dilution of serum electrolytes, intravascular hemolysis
- Saltwater near-drowning may have hypovolemia, hypertonicity, hemoconcentration
- Both with hypoxemia, metabolic acidosis, hypothermia; acute respiratory distress syndrome in 50%; cardiac arrhythmias due to hypoxia, acidosis, electrolyte abnormalities
- Renal failure, disseminated intravascular coagulation, rhabdomyolysis may occur

Differential Diagnosis

In SCUBA divers, consider arterial air embolism syndrome, pulmonary barotrauma (pneumothorax)

Treatment

- · Early intubation and mechanical ventilation
- Aggressive volume resuscitation for hypotension
- · Correct electrolyte abnormalities
- Supportive care for complications such as renal failure, rhabdomyolysis, disseminated intravascular coagulation, hypothermia, aspiration pneumonia

Pearl

Intoxication with alcohol or drugs is a factor in more than half of near drowning cases.

Reference

Bierens JJ et al: Drowning. Curr Opin Crit Care 2002;8:578. [PMID: 12454545]

Radiation Injury

Essentials of Diagnosis

- Exposure to accidental or deliberately released material producing ionizing radiation
- Severity related to dose and duration of exposure; more severe if same dose received over shorter period
- Acute radiation syndrome (ARS) responsible for most deaths in first 60 days after exposure; damage to gastrointestinal, hematologic, cardiovascular, central nervous systems
- ARS severity dose-dependent: <2 grays (Gy)—minimal symptoms, mild reduction in platelets and granulocytes after 30 day latent period; 2–4 Gy—transient nausea, vomiting 1–4 hours after exposure; after 1–3 weeks, nausea, vomiting, bloody diarrhea, bone marrow depression; 6–10 Gy—severe GI symptoms, severe hematologic complications; >10 Gy, fulminating course with vomiting, diarrhea, dehydration, circulatory collapse, ataxia, confusion, seizures, coma, death

■ Differential Diagnosis

- Sepsis
- · Gastroenteritis
- · Hematologic malignancy, aplastic anemia

Treatment

- Decontamination at or near the site of exposure; removing clothing, washing with soap and water achieves 95% decontamination; decontaminate wounds; remove inhaled or ingested radiation sources
- · Patient should be isolated
- Prodromal symptoms usually require no treatment; latent period of 1–3 weeks
- Transfuse blood products as needed
- If immunosuppression develops, prophylactic antibiotics directed against gastrointestinal organisms may be useful
- For ARS with exposure >2 Gy, consider possible use of stem cell transfusion, colony stimulating factors

Pearl

Lymphocytes are the most sensitive cells to radiation injury. The pattern of lymphocyte decline over the first 24 hours after exposure can provide an estimate of radiation dose received by referring to standard lymphocyte depletion curves.

Reference

Mettler FA Jr, Voelz GL: Major radiation exposure—what to expect and how to respond. N Engl J Med 2002;346:1554. [PMID: 12015396]

Snakebite

Essentials of Diagnosis

- 95% of poisonous bites from Crotalidae or pit vipers, including rattlesnakes, cottonmouths, copperheads; 5% from Elapidae (coral snakes)
- Crotalid envenomations: swelling, erythema, ecchymosis, perioral paresthesias, coagulopathy, hypotension, tachypnea, and respiratory compromise; bites characterized by two fang marks
- Elapidae envenomations: delayed 1–12 hours, include paralysis, respiratory compromise
- Severity of envenomation estimated by rate of progression of signs, symptoms, coagulopathy; mild with only local effects; moderate with non-severe systemic effects, minimal coagulopathy; severe with life-threatening hypotension, altered sensorium, severe coagulopathy and thrombocytopenia

Differential Diagnosis

- Sepsis
 Insect or spider bites
- · Toxin or chemical ingestion or inhalation

■ Treatment

- Maintain airway in bites of head and neck, or when respiratory compromise present
- · Fluid resuscitation for hypotension
- Two crotalid antivenoms available: Antivenom (Crotalidae)
 Polyvalent (ACP) and newer Crotalidae Polyvalent Immune Fab
 Ovine (FabAV); antivenom recommended for crotalid envenomations with severe signs and symptoms or with progression,
 particularly coagulopathy or hemolysis
- Give ACP slowly: 2–4 vials for minimal envenomation, 5–9 vials for moderate, 10–15 for severe; perform skin test with ACP before administration to predict allergic reaction; 15–20% with moderate to severe antivenom reactions (treat with diphenhydramine and antihistamines)
- Reactions infrequent with FabAV; administer 3–12 vials initially, followed by 2 vials at 6, 12, and 18 hours
- · Watch extremities for evidence of compartment syndrome

Pearl

To distinguish between bites of the poisonous coral snake and nonpoisonous king snake, use this mnemonic: "red on yellow (coral), kills a fellow; red on black (king), venom lack."

Reference

Gold BS et al: Bites of venomous snakes. N Engl J Med 2002;347:347. [PMID: 12151473]

Spider & Scorpion Bites

Essentials of Diagnosis

- Black widow spider bite initially painless, after 10–60 minutes, pain, muscle spasms, headache, nausea, vomiting, rigidity of abdominal wall; symptoms peak 2–3 hours after bite, may persist 24 hours
- Brown recluse spider bites have pain 1–4 hours after bite, erythema with pustule or bull's-eye pattern; ulcer may form after several days; rarely systemic reactions 1–2 days later, including hemolysis, hemoglobinuria, jaundice, renal failure, pulmonary edema, disseminated intravascular coagulation
- Scorpion bites cause severe pain without erythema, swelling; rare systemic reactions include restlessness, jerking, nystagmus, hypertension, diplopia, confusion, seizures

Differential Diagnosis

- · Acute abdomen (black widow spider)
- · Insect bites, including ticks
- · Staphylococcal, streptococcal skin infections
- · Chronic herpes simplex, varicella-zoster
- · Vasculitis, other skin disorders

Treatment

- Black widow spider bites: pain relief with intravenous opioids, antivenom in severe cases, supportive care if organ failure
- Brown recluse spider bites: ice to local area, supportive care, debridement if severe ulceration forms at bite area
- Scorpion bites: ice to local area; antivenom in severe cases; do not use opioids, as they might potentiate venom toxicity

Pearl


When trying to determine if bite is from a spider or other type of insect, spiders usually only bite once, whereas other insects bite multiple times.

Reference

Anderson PC: Spider bites in the United States. Dermatol Clin 1997;15:307. [PMID: 9098639]

Dermatology

Candidiasis (Moniliasis)	259
Contact Dermatitis	260
Disseminated Intravascular Coagulation (DIC) & Purpura	
Fulminans	261
Erythema Multiforme & Stevens-Johnson Syndrome	262
Exfoliative Erythroderma	263
Generalized Pustular Psoriasis	264
Graft-Versus-Host Disease (GVHD)	265
Meningococcemia	266
Miliaria (Heat Rash)	267
Morbilliform, Urticarial, & Bullous Drug Reactions	268
Pemphigus Vulgaris	269
Phenytoin Hypersensitivity Syndrome	270
Rocky Mountain Spotted Fever	271
Rubeola (Measles)	272
Toxic Epidermal Necrolysis (TEN)	273
Toxic Shock Syndrome	274
Varicella-Zoster Virus (VZV)	275



Candidiasis (Moniliasis)

Essentials of Diagnosis

- Mucosal candidiasis: white, curd-like plaques on oral or vaginal mucosa, uncircumcised penis (balanitis); red, macerated base, with painful erosions; oral infection may spread to angles of mouth (angular cheilitis), with fissuring of oral commissures
- Cutaneous candidiasis: easily ruptured pustules in intertriginous areas (groin, under breasts, abdominal folds); with rupture of pustules, bright red base seen, with moist scale at borders; intense pruritus, irritation and burning
- Diagnosis established with potassium hydroxide preparation demonstrating budding yeast or spores and pseudohyphae

■ Differential Diagnosis

- Oral candidiasis: leukoplakia, coated tongue
- Cutaneous candidiasis: eczematous eruptions, dermatophytosis, bacterial skin infections (pyodermas)

■ Treatment

- Keep moist areas clean and dry
- Apply topical anticandidal creams (e.g., clotrimazole) twice a day
- Low-potency topical steroid may reduce inflammatory component

■ Pearl

Patients with mucosal candidiasis should be evaluated for predisposing condition such as diabetes, malignancy, HIV.

Reference

Vazquez JA, Sobel JD: Mucosal candidiasis. Infect Dis Clin North Am 2002;16:793. [PMID: 12512182]

Contact Dermatitis

■ Essentials of Diagnosis

- Circumscribed vesiculobullous eruptions on erythematous base, confined to area of contact
- · History of exposure or contact to allergen or irritant
- Linear pattern or characteristic configuration suggesting external contact
- · Pruritus may be prominent symptom

■ Differential Diagnosis

- · Other eczematous eruptions
- Impetigo
- · Cutaneous candidiasis

Treatment

- · Remove suspected irritant or allergen
- Apply high-potency topical steroid cream twice daily to affected area
- Use low- or medium-potency topical steroid for face or intertriginous areas
- · Antihistamines to control itching

Pearl

Any substance in contact with skin (tape, soap, body fluid, topical medication, even steroid cream) may be offending agent.

Reference

Rietchel RL, Fowler JF Jr: Fisher's Contact Dermatitis, 5th ed. Lippincott Williams & Wilkins, 2001.

Disseminated Intravascular Coagulation (DIC) & Purpura Fulminans

Essentials of Diagnosis

- Ranges from mild bruising and oozing at venipuncture sites to massive hemorrhage and necrosis accompanying abnormal bleeding or clotting as result of uncontrolled activation of coagulation and fibrinolysis
- Purpura fulminans characterized by acute, rapidly enlarging, tender, irregular areas of purpura, especially over extremities; may evolve into hemorrhagic bullae with necrosis and eschar formation
- Excessive generation of thrombin, formation of intravascular fibrin clots, consumption of platelets and coagulation factors
- Laboratory findings: thrombocytopenia, anemia, prolonged prothrombin and partial thromboplastin times, low fibrinogen, increased fibrin degradation products
- May be accompanied by pulmonary, hepatic, or renal failure, gastrointestinal bleeding, and hemorrhagic adrenal infarction

Differential Diagnosis

- · Severe liver disease
- Thrombotic thrombocytopenic purpura
- · Vitamin K deficiency
- · Heparin-induced thrombocytopenia
- Congenital or acquired protein S or C deficiency
- · Microangiopathic hemolytic anemias
- Acute promyelocytic leukemia (M3 variant)

■ Treatment

- · Hemodynamic stabilization
- · Treatment of underlying infection/disorder
- Transfusion of fresh frozen plasma, cryoprecipitate
- · Heparin rarely indicated

Pearl

Clinically overt disseminated intravascular coagulopathy (DIC) is as common in patients with gram-positive sepsis as in those with gram-negative sepsis.

Reference

Levi M et al: Disseminated intravascular coagulation. N Engl J Med 1999;341:586. [PMID: 1045465]

Erythema Multiforme & Stevens-Johnson Syndrome

Essentials of Diagnosis

- Erythema multiforme: hypersensitivity reaction to medications and infectious agents
- Low-grade fever, malaise, upper respiratory symptoms, followed by nonspecific symmetric eruption of erythematous macules, papules, urticarial plaques
- Evolves into concentric rings of erythema with papular, dusky, necrotic or bullous centers ("target lesions") over 1–2 days
- May also appear as annular, polycyclic, or purpuric lesions (multiforme)
- Stevens-Johnson syndrome: high fever, headache, myalgias, sore throat (>1 mucosal surface affected), with conspicuous stomatitis, beginning with vesicles on lips, tongue, buccal mucosa, rapidly evolving into erosions and ulcers covered by hemorrhagic crusts

Differential Diagnosis

- Erythema multiforme without classic target lesions: urticarial eruptions, viral exanthems, vasculitis
- Mucocutaneous ulcerations: Reiter syndrome, Behçet syndrome, herpes gingivostomatitis
- Bullous impetigo, bullous pemphigoid, pemphigus vulgaris, toxic epidermal necrolysis

Treatment

- Supportive care, symptomatic therapy, optimize nutrition
- Discontinue potential offending agents
- Monitor closely for progression to secondary bacterial infection or toxic epidermal necrolysis

Pearl

Erythema multiforme occurs in all age groups, while Stevens-Johnson syndrome most often affects children and young men.

Reference

Prendiville J: Stevens-Johnson syndrome and toxic epidermal necrolysis. Adv Dermatol 2002;18:151. [PMID: 12528405]

Exfoliative Erythroderma

Essentials of Diagnosis

- Generalized diffuse erythema with scaling, induration, variable desquamation; mucous membranes usually spared
- Pruritus, malaise, fever, chills and weight loss may be present; thermoregulatory dysfunction may lead to relative hypothermia and chills; excoriations, peripheral edema, lymphadenopathy common
- Leukocytosis and anemia; eosinophilia suggestive of underlying drug reaction
- Caused by multiple underlying conditions including eczematous conditions, psoriasis, scabies, medications, lymphoma
- Skin biopsy results often nonspecific; may reveal cutaneous T cell lymphoma, leukemia, Norwegian crusted scabies

Differential Diagnosis

- · Morbilliform drug eruptions
- · Viral exanthems
- · Early phase of toxic epidermal necrolysis
- · Toxic shock syndrome
- · Graft-versus-host disease

Treatment

- · Symptomatic relief; specific therapy once etiology known
- Optimize nutrition
- · Discontinue possible offending agents
- Avoid systemic steroids unless indicated as specific therapy for underlying disease
- Daily whirlpool treatments to remove scale; apply medium potency topical steroid cream

Pearl

Serologic testing for HIV is recommended in all patients with erythrodermic psoriasis.

Reference

Rothe MJ et al: Erythroderma. Dermatol Clin 2000;18:405. [PMID: 10943536]

Generalized Pustular Psoriasis

Essentials of Diagnosis

- Serious, potentially fatal form of psoriasis occurring in patients over age 40
- Acute onset of widespread erythematous areas studded with pustules, with accompanying fever, chills, leukocytosis
- · Recurrent waves of pustulation and remission occur
- · Mouth and tongue commonly involved
- Precipitating events: topical and systemic corticosteroid therapy or withdrawal, medications (sulfonamides, penicillin, lithium, pyrazolones), infections, pregnancy, hypocalcemia
- Complications: bacterial superinfection, arthritis, pericholangitis, circulatory shunting with accompanying hypotension, highoutput heart failure, and renal failure

Differential Diagnosis

- Miliaria rubra
- · Secondary syphilis
- · Pustular drug eruption
- · Folliculitis

Treatment

- Retinoids, acitretin, and isotretinoin drugs of choice, but should be avoided in persons with hepatitis, lipid abnormalities; most show improvement in 5–7 days
- Methotrexate, cyclosporine alternatives in select cases
- · Avoid systemic steroids

Pearl

HIV testing should be carried out in all patients with psoriasis, as severe psoriatic exacerbations occur in HIV-infected individuals.

Reference

Mengesha YM, Bennett ML: Pustular skin disorders: diagnosis and treatment. Am J Clin Dermatol 2002;3:389. [PMID: 12113648]

Graft-Versus-Host Disease (GVHD)

Essentials of Diagnosis

- Prior allogeneic transplant of immunologically competent cells, particularly bone marrow, reacts against host tissue
- Acute GVHD (days to weeks following transplant): Pruritic macular and papular erythema, beginning on palms, soles, ears, upper trunk, frequently progressing to generalized erythroderma with bullae in severe cases; incidence 10–80%; extracutaneous manifestations of GVHD (diarrhea, hepatitis, delayed immunologic recovery) follow skin eruption
- Total bilirubin, stool output, and severity of rash are prognostic factors
- Chronic GVHD (50–100 days following transplant): Widespread scaly plaques and desquamation; cicatricial alopecia, dystrophic nails, and sometimes sclerodermatous changes supervene; incidence 30–60%

Differential Diagnosis

- Acute GVHD: toxic epidermal necrolysis, drug-induced eruptions, infectious exanthems
- Chronic GVHD: scleroderma, lupus erythematosus, dermatomyositis

Treatment

- · Prevention of GVHD with immunomodulating agents
- · Irradiate blood products prior to transfusion
- Acute and chronic GVH may respond to increased immunosuppression
- Photochemotherapy with oral psoralen (PUVA) or UVA sometimes used

Pearl

The skin is the most commonly affected organ in acute graft-versushost disease.

Reference

Vargas-Diez E et al: Analysis of risk factors for acute cutaneous graft-versushost disease after allogeneic stem cell transplantation. Br J Dermatol 2003;148:1129. [PMID: 12828739]

Meningococcemia

Essentials of Diagnosis

- Neisseria meningitidis: gram-negative diplococcus causing spectrum of diseases, most commonly in children under age 15
- Incubation period 2-10 days; insidious or abrupt onset
- Petechial rash on trunk, lower extremities, palms, soles and mucous membranes; rash may be urticarial or morbilliform
- May be complicated by purpura fulminans, with extensive hemorrhagic bullae and areas of necrosis
- Other complications include meningitis, arthritis, myocarditis, pericarditis, acute adrenal infarction, hypotension, shock
- Diagnosis confirmed by demonstrating organism by Gram stain or culture (blood, cerebrospinal fluid (CSF), skin lesion) or by serologic testing

Differential Diagnosis

- · Sepsis or meningitis caused by other bacteria
- · Rocky Mountain spotted fever
- Viral infections (echovirus, coxsackievirus, atypical measles)
- · Vasculitis

Treatment

- Supportive care with attention to maintaining blood pressure and organ perfusion
- Intravenous penicillin or ceftriaxone

Pearl

Respiratory isolation is mandatory for suspected meningococcal disease; consider ciprofloxacin or rifampin for close contacts of patients with intimate exposure.

Reference

Stephens DS, Zimmer SM: Pathogenesis, therapy, and prevention of meningo-coccal sepsis. Curr Infect Dis Rep 2002;4:377. [PMID: 12228024]

Miliaria (Heat Rash)

■ Essentials of Diagnosis

- Common disorder characterized by retention of sweat in bedridden patients with fever and increased sweating
- Miliaria crystallina: small, superficial sweat-filled vesicles that rupture easily, without surrounding inflammation ("dew-drops" on skin)
- Miliaria rubra (prickly heat): discrete, pruritic, erythematous papules and vesiculopustules on back, chest, antecubital and popliteal fossae
- Burning, itching, superficial small vesicles, papules or pustules on covered areas of the skin

Differential Diagnosis

• Folliculitis (miliaria rubra)

■ Treatment

- Keep patient cool and dry
- · Symptomatic treatment for pruritus

Pearl

Obstruction of eccrine sweat glands leads to formation of miliaria.

Reference

Feng E et al: Miliaria. Cutis 1995;55:213. [PMID: 7796612]

Morbilliform, Urticarial, & Bullous Drug Reactions

Essentials of Diagnosis

- Onset of rash 5–10 days after exposure to new drug, or 1–2 days following re-exposure to drug to which a patient has been sensitized; occurs in 25–30% of hospitalized patients
- Usually symmetric, widespread, with pruritus and low grade fever; resolution of rash when drug discontinued supports diagnosis
- Morbilliform eruptions most common form of drug-induced rash; usually begins on trunk or dependent areas
- Urticaria characterized by pink, edematous, pruritic wheals of varying size and shape, usually lasting less than 24 hours
- Angioedema represents urticarial involvement of deep dermal and subcutaneous tissues, sometimes involving mucous membranes
- Bullous drug eruptions include fixed-drug eruptions, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, vasculitis, and anticoagulant necrosis

■ Differential Diagnosis

- Morbilliform eruption: bacterial or rickettsial infection, or collagen-vascular disease
- Non-drug-associated urticarial eruptions: food allergies, insect bites or stings, parasitic infections, and vasculitis or serum-sickness
- Bullous drug eruptions: primary bullous dermatoses (bullous pemphigoid, porphyria cutanea tarda)

Treatment

- Identify and discontinue likely causative agents; substitute chemically unrelated alternatives
- Morbilliform eruptions: supportive measures, symptomatic treatment (oral antihistamine, topical anti-pruritic agent)
- Urticarial eruptions: if severe, aggressive supportive measures to support blood pressure; epinephrine, fluids, antihistamines, sometimes corticosteroids
- Blistering eruptions: decompress large bullae; topical compresses to remove exudates or crusts

Pearl

Drug eruptions are most commonly associated with antibiotics, anticonvulsants, and blood products.

Reference

Nigen S et al: Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003;2:278. [PMID: 12848112]

Pemphigus Vulgaris

Essentials of Diagnosis

- Flaccid, easily ruptured blisters on noninflamed skin; after rupture, nonhealing crusted erosions remain; > 50% begin with painful oral erosions
- Superficial detachment of skin after pressure or trauma (Nikolsky sign)
- Skin biopsy: characteristic intraepidermal cleft just above basal cell layer with separation of keratinocytes from one another (acantholysis)
- Direct immunofluorescence of normal-appearing skin shows intercellular IgG and complement throughout epithelium
- Rare, life-threatening disease (mortality rate 60—90% before; 10% after advent of corticosteroids) caused by circulating IgG autoantibodies directed against intercellular substance of epidermis

■ Differential Diagnosis

- Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis
- · Bullous drug eruptions
- · Bullous impetigo
- Other primary blistering diseases (bullous pemphigoid, dermatitis herpetiformis)

■ Treatment

- Discontinue drugs known to be associated with pemphigus (penicillamine, captopril)
- Prednisone, 60–120 mg/d, in combination with azathioprine, 100–150 mg/d, usually effective
- Prior to therapy, patient should be evaluated for contraindications to systemic steroids
- When control of the blistering is achieved, prednisone is gradually reduced as tolerated
- Methotrexate, cyclophosphamide, mycophenolate mofetil, cyclosporine, gold, plasmapheresis alternative modalities
- · Whirlpool treatments helpful in removing crusts from lesions
- Oral mucosal erosions may benefit from topical steroids, antiseptics, viscous lidocaine, attention to oral hygiene

Pearl

Paraneoplastic pemphigus is a very rare complication of cancer, most often non-Hodgkin's lymphoma, with overlapping clinical and histological features to pemphigus vulgaris.

Reference

Fellner MJ, Sapadin AN: Current therapy of pemphigus vulgaris. Mt Sinai J Med 2001;68(4-5):268. [PMID: 11514914]

Phenytoin Hypersensitivity Syndrome

Essentials of Diagnosis

- High spiking fever, malaise, rash 2–3 weeks after starting phenytoin therapy; sooner if prior exposure to drug
- Patchy erythematous rash evolving into extensive pruritic maculopapular rash, occasionally with follicular papules and pustules; may evolve to exfoliative erythroderma, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis
- · Edema of palms, soles, and face
- · Tender localized or generalized lymphadenopathy
- Mild to severe hepatic injury; mortality up to 20% with severe liver damage
- Sometimes conjunctivitis, pharyngitis, diarrhea, myositis, and reversible acute renal failure
- Leukocytosis with eosinophilia (5–50%); normal erythrocyte sedimentation rate, serum complement
- Adverse skin reactions in 3–15% of patients receiving phenytoin; smaller percentage develop syndrome of rash, fever, eosinophilia, hepatic injury
- All age groups affected; incidence highest in blacks; likely immune-mediated

■ Differential Diagnosis

- · Infectious mononucleosis
- Other anticonvulsant medication reactions with rash and multisystemic involvement (phenobarbital)
- · Other drug reactions
- · Vasculitis

Treatment

- · Medication must be discontinued
- Cross-reactivity among anticonvulsants possible; valproic acid or carbamazepine may be safer alternatives
- General supportive care, especially with multisystem involvement
- No demonstrated benefit of systemic corticosteroids

Pearl

In patients with anticonvulsant hypersensitivity syndrome to either phenytoin, phenobarbital or carbamazepine, up to 75% have demonstrated in vitro cross sensitivity to the other two drugs.

Reference

Schlienger RG, Shear NH: Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998;39 (7 Suppl:)S3-7. [PMID: 9798755]

Rocky Mountain Spotted Fever

Essentials of Diagnosis

- · Acute systemic illness with fever and purpuric eruption
- Caused by Rickettsia rickettsii, transmitted by ticks in mid-Atlantic and Rocky Mountain states
- Highest incidence in spring and summer; 1–14 day incubation period, followed by sudden onset of fever, headache, myalgia, nausea and vomiting
- May be complicated by central nervous system, cardiac, pulmonary and renal involvement
- Disseminated intravascular coagulation may lead to shock and death
- Diagnosis established by serologic tests, often retrospectively; tests are not reliable before second week of illness

Differential Diagnosis

- · Viral or bacterial meningitis
- · Meningococcemia
- Measles
- Vasculitis
- · Thrombotic thrombocytopenic purpura

Treatment

 Initiate treatment as soon as diagnosis is suspected with doxycycline or chloramphenicol

Pearl

Rapidly progressive rash with bilateral symmetric petechiae of the palms and soles are the hallmarks of Rocky Mountain spotted fever.

Reference

Masters EJ et al: Rocky Mountain spotted fever: a clinician's dilemma. Arch Intern Med 2003;163:769. [PMID: 12695267]

Rubeola (Measles)

Essentials of Diagnosis

- Acute epidemic disease with marked upper respiratory symptoms and widespread erythematous maculopapular rash
- Incubation period 7–14 days, followed by high fever, cough, coryza, conjunctivitis with photophobia
- Discrete erythematous macules and thin papules appear on day 3-5, first on forehead and behind ears, coalescing and spreading to trunk and extremities
- Koplik spots usually appear on buccal mucosa 1–2 days before exanthema
- Complications: secondary bacterial infection, otitis media, pneumonia, viral myocarditis, liver function abnormalities, and thrombocytopenia

Differential Diagnosis

- · Cutaneous drug reactions
- · Other viral exanthems

Treatment

- · Supportive care
- · No proven antiviral therapy exists for rubeola
- Aerosolized ribavirin, intravenous immunoglobulin (IGIV), and interferon may be useful for treatment of measles pneumonitis or encephalitis
- · Respiratory isolation precautions

Pearl

The clinical presentation of rubeola in the immunocompromised patients is atypical, with 30–40% having no rash.

Reference

Duke T, Mgone CS Measles: not just another viral exanthem. Lancet 2003;361:763. [PMID: 12620751]

Toxic Epidermal Necrolysis (TEN)

Essentials of Diagnosis

- Rare, life-threatening syndrome characterized by skin tenderness, discrete erythematous macules, and exfoliation of epidermis and mucous membranes
- Red, scalded appearance of skin; bullae and epidermal sloughing
- Majority are drug-induced (anticonvulsants, sulfa-containing antibiotics, NSAIDs, allopurinol)
- · Subepidermal separation of skin (Nikolsky sign); not specific
- Features of Stevens-Johnson syndrome (stomatitis, blotchy eruption with target lesions)
- Complications: fluid loss, thermoregulatory impairment; sepsis most common cause of death

■ Differential Diagnosis

- · Staphylococcal scalded skin syndrome
- Pemphigus vulgaris, other blistering diseases
- · Toxic shock syndrome
- · Chemical or thermal burns
- · Kawasaki disease
- · Stevens-Johnson syndrome

Treatment

- Manage as extensive second degree burns, ideally in burn unit
- · Discontinue most likely offending medication
- · Pain control
- Aggressive repletion of fluids, electrolytes, nutritional support (enteral feeding preferred over parenteral nutrition)
- Avoid prophylactic antibiotics to prevent emergence of resistant bacteria
- Ophthalmologic consultation critical to avoid ocular sequelae

Pearl

Avoid silver sulfadiazine in patients with toxic epidermal necrolysis and suspected sulfonamide sensitivity.

Reference

Nigen S et al: Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003;2:278. [PMID: 12848112]

Toxic Shock Syndrome

Essentials of Diagnosis

- Multisystem illness characterized by rapid onset of fever, vomiting, watery diarrhea, pharyngitis, profound myalgias with accompanying hypotension
- Diffuse blanching truncal erythema early, accentuated in axillary and inguinal folds, spreading to extremities; desquamation of skin, palms and soles occurs in second or third week
- Multi-organ system involvement, with acute renal failure, acute respiratory distress syndrome (ARDS), refractory shock, ventricular arrhythmias, and DIC may occur
- Highest incidence in menstruating women, persons with localized or post-surgical staphylococcal infection, and women using diaphragm or contraceptive sponge

■ Differential Diagnosis

- · Scarlet fever/Streptococcal toxic shock-like disease
- · Kawasaki disease
- · Rocky Mountain spotted fever
- · Drug eruptions/Stevens-Johnson syndrome
- Measles
- · Leptospirosis
- · Sepsis syndrome with multi-organ system failure

■ Treatment

- Immediate removal of tampon, contraceptive device, or surgical packing
- · Surgical drainage, irrigation of focal abscess
- Supportive care, with fluid resuscitation and management of organ system failure
- Anti-staphylococcal antibiotic, though effect on outcome unclear

Pearl

Intense hyperemia of conjunctival, oropharyngeal, and vaginal surfaces are frequent findings in toxic shock syndrome.

Reference

Provost TT, Flynn JA (editors): Cutaneous medicine: Cutaneous manifestations of systemic disease. BC Decker, 2001.

Varicella-Zoster Virus (VZV)

Essentials of Diagnosis

- Varicella-zoster virus: herpes virus causing two syndromes, primary varicella and herpes zoster infection (shingles)
- Primary varicella: 11–21 day incubation period with ensuing 1–3 day mild prodrome of fever, malaise; small, erythematous macules appear on trunk, face, with centripetal spread to extremities; formation of clear vesicles which rupture and crust over; oropharyngeal vesicles rupture quickly to form superficial mucosal ulcers
- Complications of primary varicella: hepatitis, pneumonitis, myocarditis, encephalitis, and DIC
- Diagnosis by demonstration of multinucleated giant cells on Tzanck smear; confirmed by immunofluorescent antibody stain or culture
- Reactivation infection: acute, often painful unilateral eruption in dermatomal distribution, with clusters of vesicles on erythematous base

■ Differential Diagnosis

- Extensive impetigo
- · Disseminated herpes simplex infection
- Eczema herpeticum

■ Treatment


- Treat all VZV infections in immunocompromised host with IV acyclovir (10 mg/kg q 8h, 7–10 days)
- Primary varicella in teenagers and adults: oral acyclovir (800 mg PO five times daily for 5–7 days)
- Varicella zoster in elderly: if lesions present < 72 hours, give
 7 days course of oral acyclovir, famciclovir or valacyclovir
- Treat secondary bacterial infection when present
- Symptomatic treatment with cool compresses, antihistamines

Pearl

In immunocompromised persons, herpes zoster lesions may disseminate widely, or become necrotic, hemorrhagic, or both.

Reference


Chen TM et al: Clinical manifestations of varicella-zoster virus infection. Dermatol Clin 2002;20(2):267. [PMID: 12120440]



19 —

Oncology/Oncologic Emergencies

Leukemia, Acute	279
Spinal Cord Compression	280
Superior Vena Cava (SVC) Syndrome	281
Tumor Lysis Syndrome	282



Leukemia, Acute

Essentials of Diagnosis

- Pancytopenia: weakness, fatigue from anemia; bleeding (gingival, epistaxis) from thrombocytopenia; infection from ineffective leukocytes
- No characteristic examination findings; fever; pallor, petechiae, retinal hemorrhages, gingival hypertrophy (monocytic subtypes), lymphadenopathy and splenomegaly (acute lymphoblastic leukemia, evolution from chronic myelogenous leukemia); rarely extramedullary leukemic involvement (chloroma)
- Peripheral blood smear may have no, little, or marked increase in white blood cells; thrombocytopenia; >30% blasts in bone marrow
- Distinguish acute myelogenous leukemia (AML) from acute lymphoblastic leukemia (ALL) by Auer rods (AML), histochemical markers; cytogenetics may have prognostic importance
- AML has 7 subtypes; acute promyelocytic leukemia (APL, AML-M3) associated with disseminated intravascular coagulopathy (DIC), spontaneous hemorrhage

■ Differential Diagnosis

- Aplastic anemia
 Leukemoid reaction
- · Bone marrow infiltration with tumor, microorganisms

■ Treatment

- High-dose chemotherapy based on cell type followed by prolonged pancytopenia requiring aggressive transfusions of red cells, platelets
- Careful hand washing, avoid intramuscular injections; long-term "tunnel" catheter may be helpful
- Evaluate neutropenic fever; treat with empiric antibiotics
- Anticipate tumor lysis syndrome; treat with IV fluids, allopurinol
- APL may respond to all-trans retinoic acid (ATRA) and chemotherapy
- Selected patients may benefit from bone marrow transplantation

Pearl

ATRA treatment of APL may be complicated by retinoic acid syndrome in 6–27%, with fever, weight gain, hypotension, renal failure, pulmonary edema, and pleural and pericardial effusions.

Reference

Massion PB et al: Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med 2002;30:2260. [PMID: 12394954]

Spinal Cord Compression

Essentials of Diagnosis

- Dull aching axial back pain that may radiate to arms or legs; band-like discomfort around chest; worse at night; aggravated by movement
- Neurologic deficits depend on level of involvement: 70% thoracic, 20% lumbar, 10% cervical; typically begins with motor impairment; high cervical cord lesions may be life-threatening; thoracic cord lesions have truncal sensory level, lower extremity weakness, autonomic dysfunction; lumbosacral cord lesions may have radiculopathy and loss of reflexes or conus syndrome
- Acquire imaging studies as soon as possible; MRI, or CT myelogram
- May be first manifestation of malignancy; most common are cancers of lung, breast, prostate, lymphoma, multiple myeloma
- Epidural spinal cord compression develops from direct metastatic spread of cancer to vertebral body or from paravertebral location with extension into epidural space

■ Differential Diagnosis

- Intervertebral disk herniation
- · Benign neoplasms
- · Transverse myelitis
- Paraneoplastic syndrome
- · Spinal cord infarction
- · Multiple sclerosis
- Epidural abscess
- · Carcinomatous meningitis

■ Treatment

- Corticosteroids should be started as soon as diagnosis suspected; delay may lead to progression of neurologic deficit
- · External beam radiation to involved area
- · Chemotherapy based on underlying malignancy
- Surgery indicated for spinal instability or bone deformity, failure to respond to radiation therapy, radioresistant tumor, atlantoaxial compression, solitary spinal cord metastasis
- · Monitor changes in neurologic exam closely

Pearl

Epidural spinal cord compression should be considered in any patient with cancer and axial skeletal pain as pain is the most common early symptom.

Reference

Daw HA et al: Epidural spinal cord compression in cancer patients: diagnosis and management. Cleve Clin J Med 2000;67:497. [PMID: 10902239]

Superior Vena Cava (SVC) Syndrome

Essentials of Diagnosis

- Compression, invasion, or thrombosis of SVC; most commonly caused by malignancy
- · Headache, dizziness, sensation of fullness in head
- · Distention of neck and anterior chest wall veins
- · Facial plethora and edema
- · Cyanosis and edema of upper extremities
- Dyspnea may occur from airway compression
- · Diagnosis made on clinical grounds in majority of cases
- Chest radiographs, tomography, CT scans define extent of mediastinal involvement
- Tissue diagnosis needed to establish etiology and guide therapeutic options
- Etiologies: malignancy with lung cancer and lymphoma most common; benign causes include aortic aneurysm, fibrosing mediastinitis, tuberculosis, pyogenic infection, radiation changes; thrombotic complications from intravascular catheters

■ Differential Diagnosis

- Angioedema
- · Thyroid goiter
- Histoplasmosis
- · Syphilitic aneurysm of aorta
- Upper extremity deep vein thrombosis

■ Treatment

- Chemotherapy treatment of choice for small cell lung cancer, lymphoma, germ cell tumors
- · Radiation therapy only option for all other tumors
- · Symptom relief measures: elevating head of bed, oxygen
- Secure patency of airway with stents if needed to prevent tracheal compression
- Corticosteroids may help decrease edema and secondary inflammatory reaction
- · Saphenous vein bypass grafting useful in selected patients
- Diuretics, anticoagulants, thrombolytic agents are of little help and may actually be dangerous

Pearl

Mortality is related to the underlying malignancy rather than the presence of superior vena caval obstruction.

Reference

Markman M: Diagnosis and management of superior vena cava syndrome. Cleve Clin J Med 1999;66:59. [PMID: 9926632]

Tumor Lysis Syndrome

Essentials of Diagnosis

- Recent administration of chemotherapy for treatment of a rapidly proliferating malignancy with massive destruction of neoplastic cells; described in Burkitt lymphoma and some leukemias without precipitating chemotherapy
- Lysis of cells leads to hyperkalemia, hyperphosphatemia, hyperuricemia
- · Hyperphosphatemia associated with hypocalcemia
- · Hyperuricemia can cause uric acid nephropathy, renal failure
- · Symptoms related to metabolic and electrolyte changes
- Complications: electrocardiographic changes, cardiac arrhythmias, tetany, convulsions, oliguria, muscle cramps, lethargy

Differential Diagnosis

- · Burkitt lymphoma
- · Acute lymphocytic leukemia
- · Chronic lymphocytic leukemia
- · Solid tumors
- · Spontaneous necrosis of malignancies

Treatment

- Aggressive volume resuscitation
- Prevention of hyperuricemia with allopurinol before administration of chemotherapy
- · Appropriate treatment for hyperkalemia and hyperphosphatemia
- Alkalinization of urine (pH 7.0–7.5) while serum uric acid levels are elevated
- Hemodialysis for life-threatening electrolyte abnormalities and renal failure

Pearl

High leukocyte and platelet counts may cause pseudohyperkalemia due to lysis of these cells after blood collection. No electrocardiographic abnormalities will be seen, and plasma instead of serum potassium should be followed.


Reference

Gobel BH: Management of tumor lysis syndrome: prevention and treatment. Semin Oncol Nurs 2002;18:12. [PMID: 12184047]

—

Pregnancy

Acute Fatty Liver of Pregnancy	285
Amniotic Fluid Embolism	286
Asthma in Pregnancy	287
Preeclampsia and Eclampsia	288
Pulmonary Edema in Pregnancy	289
Pyelonephritis in Pregnancy	290
Septic Abortion	291



Acute Fatty Liver of Pregnancy

Essentials of Diagnosis

- Hepatic dysfunction associated with liver biopsy demonstrating microvesicular fatty infiltration of hepatocytes
- Nausea, vomiting, varying degrees of epigastric and right upper quadrant pain, anorexia, malaise
- Most commonly occurs in third trimester and immediate postpartum period
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) usually <1000 IU/L; alkaline phosphatase and bilirubin increase, albumin decreases, WBC elevated, coagulopathy consistent with disseminated intravascular coagulopathy (DIC), hypoglycemia
- Increased incidence in first pregnancies, twin gestations
- Complications: fulminant hepatic failure, hypoglycemia, consumptive coagulopathy, renal failure, cerebral edema, pancreatitis, spontaneous labor, fetal demise

Differential Diagnosis

- Preeclampsia/eclampsia
- Acute hepatic rupture
- Budd-Chiari syndrome
- Viral hepatitis
- · Cholestasis of pregnancy
- HELLP syndrome (hemolysis, elevated liver enzymes, low platelets)
- Fulminant hepatic failure secondary to medications

Treatment

- · Continuous fetal monitoring until delivery
- Maintain patent airway if mental obtundation present; normalize intravascular volume status; correct electrolyte disturbances; dextrose infusions to support hypoglycemia; correct hematologic and coagulation abnormalities
- Delivery should be performed as soon as patient stabilized; delays can result in fetal demise from uteroplacental insufficiency or hypoglycemia; clinical improvement typically follows
- Supportive measures: nutritional support to prevent hypoglycemia; consider lactulose or other ammonia reducing agents if encephalopathic; administer vitamin K if coagulopathic

■ Pearl

AFLP can present with such nonspecific findings as nausea, vomiting, and right upper quadrant pain that the diagnosis can be overlooked with drastic consequences including fulminant hepatic failure if treatment is delayed.

Reference

Sandhu BS et al: Pregnancy and liver disease. Gastroenterol Clin North Am 2003;32:407. [PMID: 12635424]

Amniotic Fluid Embolism

Essentials of Diagnosis

- Dyspnea and hypotension followed by sudden cardiovascular collapse
- Greatest risk during active labor; also reported after vaginal or Cesarean delivery, following termination of first or second trimester pregnancy
- Coagulopathy, seizures, pulmonary edema, ARDS, fetal distress
- Echocardiography reveals left ventricular dysfunction in addition to only mild to moderate pulmonary hypertension
- Appears triggered by release of amniotic fluid and debris into maternal pulmonary circulation
- Classic finding of fetal squamous cells in maternal pulmonary circulation at autopsy; difficult to distinguish maternal from fetal origin of cells if drawn from central catheter premortem
- High maternal mortality rate with all deaths occurring within 5 hours of presentation; only 15% of survivors neurologically intact

Differential Diagnosis

- Pulmonary embolism
- · Acute myocardial infarction
- Placental rupture
- Septic shock
- Peripartum cardiomyopathy
- Anaphylaxis
- Adverse reaction to anesthetic agents

Treatment

- Maintain oxygenation with mechanical ventilation and application of positive end-expiratory pressure (PEEP); circulatory support with volume and vasopressors; consider inotropic agents to improve myocardial function; pulmonary artery catheter may be helpful in directing therapy; correction of coagulopathy
- Consider prompt delivery of fetus if maternal cardiopulmonary arrest as this may improve likelihood of success of resuscitation

Pearl

Amniotic fluid embolism should be suspected in the pregnant or postpartum woman who develops sudden unexpected cardiovascular collapse.

Reference

Davies S: Amniotic fluid embolus: a review of the literature. Can J Anaesth 2001;48:88. [PMID: 11212056]

Asthma in Pregnancy

Essentials of Diagnosis

- · Dyspnea, chest tightness, wheezing, cough
- Accessory muscle use, wheezing, prolonged expiratory phase, tachypnea, tachycardia
- Interpret arterial blood gases in light of physiologic changes associated with pregnancy in which Paco₂ is reduced; development of "hypercapnia" may be subtle sign of impending respiratory failure
- Increased risk of complications if asthma history reveals hospitalizations, intubations, prolonged steroid use, pneumothorax
- Adverse effects on pregnancy when maternal hypoxemia affects oxygenation of fetus: premature labor, low birth weights, increased risk of fetal death

■ Differential Diagnosis

- Congestive heart failure
 Pulmonary embolism
- Pneumothorax
- Dyspnea due to physiologic and mechanical changes of pregnancy

Treatment

- Spirometry useful for assessing severity and following response to therapy
- · Beta-agonists should be titrated to clinical response
- Oral corticosteroids well tolerated and should be considered for use in exacerbations; inhaled corticosteroids may be helpful in maintaining asthma control
- Supplemental oxygen to maintain Pao₂ > 85 mm Hg to ensure adequate fetal oxygenation
- If infectious contribution suspected, avoid certain antibiotics in pregnancy: sulfonamides, erythromycin estolate, tetracycline, chloramphenicol, quinolones
- Consider mechanical ventilation if severe hypoxemia, mental status changes, respiratory acidosis, cardiac arrhythmias, myocardial ischemia

Pearl

A Paco₂ greater than 35 mm Hg in a pregnant woman may be a sign of impending respiratory failure during a severe asthma exacerbation as the normal range of Paco₂ in pregnancy is 28 to 32 mm Hg.

Reference

Graves CR: Acute pulmonary complications during pregnancy. Clin Obstet Gynecol 2002;45:369. [PMID: 12048396]

Preeclampsia and Eclampsia

Essentials of Diagnosis

- Preeclampsia classically defined as clinical triad of hypertension, proteinuria, edema; because of frequency of edema in pregnancy, edema has been omitted from diagnostic criterion
- Severe preeclampsia characterized by additional features: blood pressure >160/110, more proteinuria, elevated creatinine, pulmonary edema, oliguria, hemolytic anemia, liver dysfunction, fetal growth restriction
- · Eclampsia defined by addition of seizures without known cause
- · May be complicated by HELLP syndrome
- Occurs in previously normotensive patients or with preexisting chronic hypertension after 20 weeks gestation; develops earlier with multiple fetuses, hydatiform mole

■ Differential Diagnosis

- · Chronic essential hypertension
- · Gestational hypertension
- · Acute fatty liver of pregnancy
- · Chronic renal disease

Treatment

- Delivery of fetus definitive treatment; delays while administering antihypertensive therapy remains controversial
- Seizure prophylaxis and control with magnesium sulfate from day of diagnosis until delivery; therapeutic goal range 4.8–8.4 mg/dL
- Hypertension control if blood pressure >180/110 with agents including hydralazine and labetalol; in severe cases nitroprusside may be used for limited time due to potential fetal cyanide poisoning
- Pulmonary artery catheter monitoring if oliguria unresponsive to fluids, pulmonary edema unresponsive to diuretics and positional changes, or severe hypertension unresponsive to conventional therapy

■ Pearl

The only known definitive treatment for preeclampsia-eclampsia syndrome is delivery of the fetus.

Reference

Roberts JM et al: Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension 2003;41;437. [PMID: 12623940]

Pulmonary Edema in Pregnancy

Essentials of Diagnosis

- · Dyspnea, cough, chest discomfort, frothy sputum, hypoxemia
- · Bilateral rales; other signs of overt heart failure may be absent
- Chest radiograph with interstitial or alveolar infiltrates and perihilar congestion; unilateral edema possible
- Can occur without known predisposing conditions and typically presents at time of delivery
- Associated conditions: hypertension; undiagnosed heart conditions, especially mitral stenosis; tocolytic agents; fluid overload; peripartum cardiomyopathy
- Proposed mechanisms: fluid overload due to increased extracellular volume during pregnancy; fluid administration during labor; increased capillary permeability; decreased plasma oncotic pressure
- Echocardiography helpful in evaluating valvular heart disease or cardiomyopathy

Differential Diagnosis

- Pulmonary embolism
- Amniotic fluid embolism

Asthma

- Myocardial ischemia
- · Peripartum cardiomyopathy

Treatment

- · Majority improve dramatically within 24 hours of treatment
- · Discontinue tocolytic agents
- Intravenous loop diuretics
- Supplemental oxygen to maintain adequate saturations
- · Antibiotics should be administered if infection suspected
- Continuous fetal heart monitoring until normal maternal pulmonary function restored and hypoxemia has resolved; if fetus affected, late decelerations and loss of heart rate variability may be noted
- If slow in resolving, suspect structural cardiac abnormalities; echocardiography and pulmonary artery catheter may be helpful in guiding therapy in these settings

Pearl

The physiologic adaptations to pregnancy, including increased cardiac output, decreased systemic vascular resistance, and decreased colloid oncotic pressure, predispose to the development of pulmonary edema.

Reference

Siscione AC et al: Acute pulmonary edema in pregnancy. Obstet Gynecol 2003;101:511. [PMID: 12636955]

Pyelonephritis in Pregnancy

Essentials of Diagnosis

- Flank pain (right side > left), fever, rigors, chills
- May complain of lower urinary tract symptoms including dysuria, frequency
- Ominous signs: hypotension, tachypnea, marked tachycardia, high fever
- Pyuria nearly always present; red blood cells and casts frequently found; urine cultures should be obtained to confirm diagnosis and evaluate for antibiotic resistance
- E coli most frequent organism identified
- · Risk of recurrence increases after first episode
- Adverse effects: uterine contractions and premature birth
- Pathogenesis related to ureteral relaxation from increased progesterone levels leading to urinary stasis; bacteria from lower genitourinary tract ascend to kidneys

■ Differential Diagnosis

- · Intra-amniotic infection
- · Renal stones

Appendicitis

· Cholecystitis

Treatment

- Initially treat as inpatient because of greater incidence of severe complications including septic shock and ARDS
- Antibiotics mainstay of treatment with agents chosen empirically to cover major community acquired urinary pathogens
- Supportive care: volume resuscitation; aggressive antipyretics and cooling blankets to prevent premature uterine contractures and fetal neurologic harm from prolonged exposure to febrile state
- Continuous fetal heart monitoring for all pregnancies beyond 22 weeks gestation
- Some advocate prophylactic antibiotics throughout pregnancy after first episode; others suggest monitoring with serial urine cultures

Pearl

Bacteriuria in pregnancy predisposes women to the development of acute pyelonephritis which can be complicated by preterm labor.

Reference

Gilstrap LC III et al: Urinary tract infections during pregnancy. Obstet Gynecol Clin North Am 2001;28:581. [PMID: 11512502]

Septic Abortion

Essentials of Diagnosis

- Sepsis syndrome following recent spontaneous or induced pregnancy termination
- Crampy pelvic pain with serosanguineous or purulent vaginal discharge occurring within 7 days of recent pregnancy termination or other intrauterine instrumentation
- · Hematuria and shock can develop rapidly
- Abdominal and pelvic exam with tenderness and possible peritoneal signs; dilated cervix, lacerations, products of conception, bleeding, discharge
- Blood, urine, and cervical specimens should be obtained for culture
- Polymicrobial infection with aerobic and anaerobic organisms;
 Clostridium species important pathogens and suggested by large gram-positive rods on Gram stain
- Abdominal radiographs helpful in diagnosis of uterine or bowel perforation; gas in myometrium noted on radiographs consistent with clostridial infection and carries grave prognosis; ultrasound to assess for presence of retained products of conception or detecting possible pelvic abscesses
- Likelihood of complications increases with later abortions or with dilation and evacuation procedures

■ Differential Diagnosis

- Perforated viscus
 Puerperal sepsis
- · Septic shock from prolonged rupture of membranes

Treatment


- Prompt broad-spectrum antibiotics followed by planned uterine evacuation procedure
- Hysterectomy may be life saving if clostridial infection suspected by discolored dusky uterus with myonecrosis or crepitation.
- Supportive management of accompanying complications including ARDS, hypotension, anemia, shock

Pearl

Septic abortion is usually a polymicrobial infection with aerobic and anaerobic bacteria including sexually transmitted pathogens and Clostridial species.

Reference

Tamussino K: Postoperative infection. Clin Obstet Gynecol 2002;45:562. (PMID: 12048413)



Index

A	Aminoglycosides, 144, 147, 158, 214, 215
Abdomen, infection in, 143	Amiodarone, 130
Abdominal distension, 102, 124, 162, 170, 173,	Amnesia, 193, 251. See also Mental status,
175	altered
Abdominal girth, in ascites, 163	Amniotic fluid embolism
Abdominal pain, 124, 162, 179, 181, 219, 231,	Amphotericin B, 135, 140, 148, 215
232, 235, 239	Ampicillin, 133, 136
in cholangitis, 165	Amylase, in pancreatitis, 173
in GI bleeding, 171	Amyloidosis, functional asplenic state in, 141
in pancreatic insufficiency, 172	Analgesia, 18
in peritonitis, 150	Anaphylactic shock, 73
in small-bowel obstruction, 175 Abortion, septic, 291	Anaphylaxis, 83 Anemia, 8, 81, 129, 184, 211, 219, 222, 279
Abscess	dermatology disorders associated with, 261,
brain, 138	263
epdural, 138	red blood cell transfusion for, 46
hematologically seeded, 138	sickle cell, 81
in intra-abdominal infection	treatment for, 46
Acetaminophen overdose, 225	Angina, 117, 171, 176
Acetazolamide, 66	pectoris, 115
Acid-base disorders, mixed, 67. See also specific	unstable, 129
disorders	Angiodysplasia, 171
Acidosis, 55, 100, 210, 213, 232	Angioedema, 73, 84, 268
anion gap, 65, 67	Angiography, 124, 174, 201
metabolic, 26, 62, 65, 69, 124	in angina pectoris, 115
respiratory, 68, 100, 105, 109	cerebral, 203
Activated partial thromboplastin time (aPTT), 39, 40, 41	pulmonary, 90 Angioplasty, 115, 126
Acute chest syndrome, in sickle cell anemia, 81	Angiophasty, 113, 120 Angiotensin converting enzyme (ACE)
Acute respiratory distress syndrome (ARDS),	inhibitors, 94, 117, 121, 123, 126, 129
10, 78, 93, 253, 274, 286	Anion gap (AG), in acid-base disorders, 65, 67
management of, 68	Ankle-brachial index (ABI), in arterial
mechanical ventilation in, 97, 98	insufficiency, 118
PEEP for, 104	Ankylosing spondylitis, 107
Acute tubular necrosis (ATN), 207, 215	Anorexia, 124, 163, 169, 173, 182, 213, 226,
Acyclovir, 138, 275	231
Adenosine, 127, 130	in acute fatty liver of pregnancy, 285
Adrenal insufficiency, 179, 219	in diabetic ketoacidosis, 181
Adrenal tumor, 180	in hypercalcemia, 53
Adrenocorticotropic hormone (ACTH), 180	Antacid therapies, 21
Agitation, 3, 186, 189, 230, 233, 241, 242. See also Mental status, altered	Antiarrhythmics, 127, 130, 251. See also
Air embolism, prevention of, 94. See also	specific antiarrhythmics Antibiotics, prophylactic, 249, 254, 274. See
Pulmonary embolism	also specific antibiotics
Airway, in respiratory failure, 108. See also	Anticoagulation, 118, 121, 124, 219
Respiratory failure	for atrial fibrillation, 119
Albumin, 16, 54, 173, 209, 215	for pulmonary thromboembolism, 90
Albuterol, 55, 105, 110	Anticonvulsant hypersensitivity syndrome, 270
Alcoholism, 8, 93, 95, 141	Anticonvulsants, 54, 198, 214, 268. See also
Alcohol withdrawal, 8, 226	specific anticonvulsants
Alkalinization of blood, for TCA overdose, 243	Antiemetics, for pancreatitis, 173
Alkalinization of urine, in tumor lysis syndrome,	Antifungal therapy, 140, 143, 147
282	Antihistamines, 8, 84, 260, 275
Alkalosis, 58	Antimicrobial therapy
metabolic, 66	in HIV-infected patients, 153
respiratory, 69, 239 Allopurinol, 210, 244, 279, 282	for immunocompromised patients, 141 for intra-abdominal infection, 143
All-trans retinoic acid (ATRA), for leukemia,	in neutropenic fever, 147
279	to prevent nosocomial infection, 152
Alopecia, in GVHD, 265	topical, 25
· · · · · · · · · · · · · · · · · · ·	··· r

Antineutrophil cytoplasmic antibodies (ANCA),	Battle sign, 193
Antinovahotica 180	Beck triad, 120 Rehavioral modification, for engine posterio
Antipsychotics, 189 Antipyretics, 139, 250, 290	Behavioral modification, for angina pectoris, 115
Antiretroviral therapy, for HIV-infected patients,	Beneficence, in medical ethics, 33
135	Benzodiazepines, 18, 156, 194, 226, 227, 233,
Antitoxin, in tetanus, 156	242, 243
Antituberculous drugs, 148 Antivenom, for snakebite, 255	in altered mental status, 189 delirium associated with, 8
Anxiety, 3, 109, 183, 226, 227, 241. See also	for seizure activity, 198
Mental status, altered	Benzodiazepine withdrawal, 8, 227
Anxiolytic agents, 9, 18. See also specific	Bernard-Soulier syndrome, 44
anxiolytic agents	"Best interests" decision, 34
Aortic dissection, acute, 116	Beta-blocker overdose, 228
Aortic regurgitation (AR), 117	Beta-blockers, 73, 86, 129, 241, 242
Aortic stenosis (AS), 117, 171 Aortic valvular heart disease, 117	for AMI, 126 for angina pectoris, 115
Aortography, 116	for atrial fibrillation, 119
Aphasia, 201	for ventricular tachyarrhythmias, 130
Apnea, testing for, 31	Bicarbonate (HCO ₃), 55, 233, 235
Areflexia, in Guillain-Barré syndrome, 192	in metabolic acidosis, 65
Argatroban, for HIT, 42	in mixed acid-base disorders, 67
Arrhythmias, 201, 248, 251, 253. See also Dysrhythmias	in respiratory acidosis, 68 in respiratory alkalosis, 69
in acid-base disorders, 66, 69	Biliary sludge, prevention of, 15
in electrolyte imbalances, 56, 58	Biopsy, 199, 221, 263
respiratory failure associated with, 109	in muscular dystrophy, 195
Arterial blood O ₂ saturation, 20. See also	renal, 208, 213
Oxygen	in transplant recipients, 28
Arterial insufficiency, acute, 118, 1118 Arterial pressure, monitoring of, 4	Bites insect, 256
Arteriography, in arterial insufficiency, 118	snakebite, 255
Arthralgias, 222	Bleeding, 30, 39, 174, 225, 244, 250, 279
Ascites, 163	gastrointestinal, 21, 171, 176
in hypervolemia, 63	in hemodialysis, 216
on mechanical ventilation, 102	in septic abortion, 291
in renal failure, 209 respiratory failure associated with, 107	thrombocytopenia associated with, 45 variceal, 167
Aspergillosis, nosocomial pulmonary, 149	in warfarin overdose, 48
Asphyxiation, 96	Bleeding time, in platelet dysfunction, 44
Aspiration	Blistering, 146, 249, 269
ARDS associated with, 93	Bloating, 175, 252
in hepatic failure, 169	Blood pressure, 4, 116, 201, 202, 203. See also
Aspirin, 39, 44, 84, 115, 126, 201 Asterixis, 68, 169, 213, 225	Hypertension in eclampsia, 288
Asthma. See also Status asthmaticus	in hemodialysis, 216
end-tidal PCO _{2 in} , 10	in preeclampsia, 288
mechanical ventilation in, 97	Blood products, 76, 168, 174, 254, 265. See also
in pregnancy, 287	Transfusions
Asystole, in toxicology disorders, 229, 230	drug eruptions associated with, 268
Ataxia, 238, 240, 254 Atelectasis, 107	for GI bleeding, 171, 176 in renal failure, 209
Atherosclerosis, in Cushing syndrome, 180	for variceal bleeding, 167
Atlantoaxial disease, 199	
Atovaquone, for PCP, 151	Bloodstream, infection of, 152
Atrial fibrillation, 119, 186, 242	Bloodstream, infection of, 152 "Body-packing," 241
	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164
Atrial flutter, 127	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279
Atrial flutter, 127 "Atrial kick," 119	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134
Atrial flutter, 127 "Atrial kick," 119	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191 Azathioprine, 221, 269	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232 Bowel sounds, 143, 162, 170 Bowel syndrome, parenteral nutrition in, 15 Bradycardia, 77, 87, 184, 228, 229, 251
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191 Azathioprine, 221, 269 Azotemia, 123, 179, 215	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232 Bowel sounds, 143, 162, 170 Bowel syndrome, parenteral nutrition in, 15 Bradycardia, 77, 87, 184, 228, 229, 251 in respiratory failure, 108
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191 Azathioprine, 221, 269 Azotemia, 123, 179, 215 B	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232 Bowel sounds, 143, 162, 170 Bowel syndrome, parenteral nutrition in, 15 Bradycardia, 77, 87, 184, 228, 229, 251 in respiratory failure, 108 in syncopal event, 128
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191 Azathioprine, 221, 269 Azotemia, 123, 179, 215 B Babinski sign, 58, 199	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232 Bowel sounds, 143, 162, 170 Bowel syndrome, parenteral nutrition in, 15 Bradycardia, 77, 87, 184, 228, 229, 251 in respiratory failure, 108 in syncopal event, 128 Brain death, 31
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191 Azathioprine, 221, 269 Azotemia, 123, 179, 215 B	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232 Bowel sounds, 143, 162, 170 Bowel syndrome, parenteral nutrition in, 15 Bradycardia, 77, 87, 184, 228, 229, 251 in respiratory failure, 108 in syncopal event, 128
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191 Azathioprine, 221, 269 Azotemia, 123, 179, 215 B Babinski sign, 58, 199 Back pain, 138, 174, 280. See also Pain Bacteriuria, in pregnancy, 290 Balanitis, 259	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232 Bowel sounds, 143, 162, 170 Bowel syndrome, parenteral nutrition in, 15 Bradycardia, 77, 87, 184, 228, 229, 251 in respiratory failure, 108 in syncopal event, 128 Brain death, 31 Brain injury, secondary, 193 Breathing trial, for mechanical ventilation, 102 Bromide intoxication, 240
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191 Azathioprine, 221, 269 Azotemia, 123, 179, 215 B Babinski sign, 58, 199 Back pain, 138, 174, 280. See also Pain Bacteriuria, in pregnancy, 290 Balanitis, 259 Balloon pericardial window, for cardiac	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232 Bowel sounds, 143, 162, 170 Bowel syndrome, parenteral nutrition in, 15 Bradycardia, 77, 87, 184, 228, 229, 251 in respiratory failure, 108 in syncopal event, 128 Brain death, 31 Brain injury, secondary, 193 Breathing trial, for mechanical ventilation, 102 Bromide intoxication, 240 Bromocriptine, in neuroleptic malignant
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191 Azathioprine, 221, 269 Azotemia, 123, 179, 215 B Babinski sign, 58, 199 Back pain, 138, 174, 280. See also Pain Bacteriuria, in pregnancy, 290 Balanitis, 259 Balloon pericardial window, for cardiac compressive shock, 74	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232 Bowel sounds, 143, 162, 170 Bowel syndrome, parenteral nutrition in, 15 Bradycardia, 77, 87, 184, 228, 229, 251 in respiratory failure, 108 in syncopal event, 128 Brain death, 31 Brain injury, secondary, 193 Breathing trial, for mechanical ventilation, 102 Bromocriptine, in neuroleptic malignant syndrome, 197
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191 Azathioprine, 221, 269 Azotemia, 123, 179, 215 B Babinski sign, 58, 199 Back pain, 138, 174, 280. See also Pain Bacteriuria, in pregnancy, 290 Balanitis, 259 Balloon pericardial window, for cardiac compressive shock, 74 Balloon pump, intra-aortic, 75, 228	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232 Bowel sounds, 143, 162, 170 Bowel syndrome, parenteral nutrition in, 15 Bradycardia, 77, 87, 184, 228, 229, 251 in respiratory failure, 108 in syncopal event, 128 Brain death, 31 Brain injury, secondary, 193 Breathing trial, for mechanical ventilation, 102 Bromide intoxication, 240 Bromocriptine, in neuroleptic malignant syndrome, 197 Bronchoalveolar lavage, 212
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191 Azathioprine, 221, 269 Azotemia, 123, 179, 215 B Babinski sign, 58, 199 Back pain, 138, 174, 280. See also Pain Bacteriuria, in pregnancy, 290 Balanitis, 259 Balloon pericardial window, for cardiac compressive shock, 74	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232 Bowel sounds, 143, 162, 170 Bowel syndrome, parenteral nutrition in, 15 Bradycardia, 77, 87, 184, 228, 229, 251 in respiratory failure, 108 in syncopal event, 128 Brain death, 31 Brain injury, secondary, 193 Breathing trial, for mechanical ventilation, 102 Bromocriptine, in neuroleptic malignant syndrome, 197
Atrial flutter, 127 "Atrial kick," 119 Atropine, 73, 122, 228, 229, 238 Autonomy, in medical ethics, 33 Axonapathy, distal, 191 Azathioprine, 221, 269 Azottemia, 123, 179, 215 B Babinski sign, 58, 199 Back pain, 138, 174, 280. See also Pain Bacteriuria, in pregnancy, 290 Balanitis, 259 Balloon pericardial window, for cardiac compressive shock, 74 Balloon pump, intra-aortic, 75, 228 Balloon tamponade device, for variceal bleeding,	Bloodstream, infection of, 152 "Body-packing," 241 Boerhaave syndrome, 164 Bone marrow transplantation, 279 Bone necrosis, in frostbite, 249 Botulism, 134 Bowel obstruction, 232 Bowel sounds, 143, 162, 170 Bowel syndrome, parenteral nutrition in, 15 Bradycardia, 77, 87, 184, 228, 229, 251 in respiratory failure, 108 in syncopal event, 128 Brain death, 31 Brain injury, secondary, 193 Breathing trial, for mechanical ventilation, 102 Bromide intoxication, 240 Bromocriptine, in neuroleptic malignant syndrome, 197 Bronchoalveolar lavage, 212 Bronchodilators, 20, 81, 82, 100, 110

"Buffalo hump," in Cushing syndrome, 180 Bullous drug reactions, 268 Burkitt lymphoma, 282	C1 esterase inhibitor deficiency, 94 Charcoal, activated, 231, 236, 239, 240, 242, 252
Burn patients, 25	Charcoal hemoperfusion, in beta-blocker
Burns, in electrical shock, 248	overdose, 228 Chelation therapy, for iron overdose, 232
C	Chemotherapy, 279, 280, 281
Calcific aortic stenosis, 171	Chest pain, 81, 115, 122, 127, 130, 221, 247.
Calcification, metastatic, 61	See also Pleuritic chest pain
Calcitonin, for hypercalcemia, 53	in AMI, 126
Calcium, 54, 57, 229	in aortic dissection, 116
Calcium channel blocker overdose, 229	in aortic valvular disease, 117
Calcium channel blockers, 57, 115, 116, 119,	in atrial fibrillation, 119
203	in pneumothorax, 89
Calcium level, correction of, 53	Chest radiographs, 121, 153, 236, 281, 289
Calorie needs, increased, 16, 172. See also	Chest tube drainage, for pleural effusions, 88
Nutrition	Chest tube thoracostomy, 85
Calorimetry, indirect, 16	Chills, 136, 263, 264, 290
Candidiasis, 140, 259	Chlorida 55 57 66
Capnography, 10	Chloride, 55, 57, 66
Carbamazepine, 270 Carbicarb, in metabolic acidosis, 65	Cholangitis, acute, 165 Cholecystectomy, 161
Carbon dioxide, partial pressure of (PaCO ₂),	Cholecystetiony, 101 Cholecystitis, acalculous, 161
109, 202, 287	Cholecystokinin test, 172
in mixed acid-base disorders, 67	Cholestasis, prevention of intrahepatic, 15
monitoring of end-tidal, 10	Cholestatic syndromes, diarrhea caused by,
in respiratory acidosis, 68	166
in respiratory alkalosis, 69	Cholinergic crisis, 196
Carbon monoxide (CO) poisoning, 247	Chronic obstructive pulmonary disease (COPD)
Carboxyhemoglobin, 247	end-tidal PCO _{2 in} , 10
Carboxyhemoglobinemia, 20	mechanical ventilation in, 97
Carboxyhemoglobin level, in smoke inhalation,	NIPPV in, 103
82	respiratory acidosis associated with, 68
Carcinoma, and large-bowel obstruction, 170	respiratory failure from, 105
Cardiac compressive shock, 74	Chronic renal failure, 26. See also Renal failure
Cardiac index (CI), 19	Churg-Strauss syndrome, 212
Cardiac output, 77, 78	Chvostek sign, in hypocalcemia, 54
on mechanical ventilation, 97, 101	Cimetidine, 8, 244
with PEEP, 104	Ciprofloxacin, for meningococcemia, 266 Cirrhosis, with ascites, 163
Cardiac tamponade, 19, 74, 120 Cardiogenic shock, 19, 75, 228	Clindamycin, 95, 136, 151
Cardiomyopathy, in pregnancy, 289	Clonidine, in opioid withdrawal, 237
Cardiopulmonary resuscitation (CPR), 32, 94	Clopidogrel, 44, 126, 129
Cardiovascular collapse, 239, 240	Clostridial infection, 146
Cardiovascular system, during pregnancy, 27	Clostridium difficile, 136, 166
Cardioversion, 119, 127, 130	Clostridium tetani, 156
Catastrophic antiphospholipid syndrome, 219	Clotrimazole, 259
Cathartics, in salicylate poisoning, 239	Coagulation factor deficiency, 46
Catheterization, cardiac, 75, 117, 121, 125,	Coagulation time, 40
126	Coagulopathies, 39, 40, 41, 232, 255
Catheters	in amniotic fluid embolism, 286
central venous, 94	FFP requirement for, 43
double-lumen hemodialysis, 216	hemoptysis in, 96
Foley, 200	in hepatic failure, 169
intravenous, 144 intraventricular, 13	in renal failure, 209 Cocaine toxicity, 230
pericardial, 74	Cocaine use, AMI associated with, 126
Catheters, pulmonary artery, 19, 74, 75, 120,	Cognitive Test for Delirium (CTD), 189
219, 288	Cold intolerance, in myxedema coma, 184
in cardiogenic shock, 75	Colloid, 64, 76
in preeclampsia and eclampsia, 288	Colonoscopy, 170, 171
Cefotaxime, 133	Colony stimulating factors, 254
Ceftriaxone, 95, 133, 266	Coma, 202, 225, 229, 232, 234, 235, 239, 240,
Celiac disease, 141	243, 250, 254
Centrally suppressing agents, contraindications	in electrolyte imbalances, 57, 62
for, 87	in hepatic failure, 169
Central nervous system infections, in HIV-	in metabolic acidosis, 65
infected patients, 135	myxedema, 184
Central venous catheters, 94	in obesity-hypoventilation syndrome, 86
Central venous pressure (CVP)	in renal failure, 213
in hypovolemia, 64	in respiratory failure, 108
measurement of, 19 monitoring of, 5	in thyroid storm, 186
monitoring or, 5 Cephalosporins, 133, 136, 137, 144, 150, 158,	Community-acquired pneumonia, 136 Compartment syndrome, 211, 255
244	Complement components, in anaphylaxis, 83
Cerebrospinal fluid (CSF), in meningitis, 133	C1 inhibitor concentrate, for angioedema, 84

Confusion, 227, 234, 235, 239, 240, 241, 247, 250, 251, 254, 256. <i>See also</i> Mental status, altered	Cushing syndrome, 180 Cushing triad, in increased ICP, 194 Cyanide toxicity, in inhalation injury, 82
in endocrine problems, 179	Cyanosis, 90, 109, 121, 281
in head injury, 193 in hepatic failure, 169	Cyclopeptides, 252 Cyclophosphamide, 212, 219, 220, 221, 222, 269
in hypoglycemia, 183	Cyclosporine, 264, 269
in myxedema coma, 184	Cystitis, 158
in renal failure, 213 in respiratory alkalosis, 69	D
in respiratory failure, 108	Danazol, 84
in thyroid storm, 186	Dantrolene, 197
Confusion Assessment Method for Intensive Care Unit (CAM-ICU), 189	Dapsone, 151 Death. See also Mortality
Congestive heart failure (CHF), 119, 121	brain, 31
Conjunctivitis, 270, 272 Constipation, 170, 175, 184	from organo-phosphate poisoning, 238
Continuous positive airway pressure (CPAP),	from radiation injury, 254 Debilitated patients, sepsis in, 78
87, 103, 104	Debridement, 134, 143, 155, 156
Continuous venovenous hemofiltration and dialysis (CVVHD), 216	for frostbite, 249 for immunocompromised patients, 141
Cooling measures, 197, 230, 241	for necrotizing infection, 146
for fever, 139	Decision makers, 33, 34, 35
in heat stroke, 250 for pyelonephritis in pregnancy, 290	Decision making "best interest," 34
Coronary artery bypass graft surgery (CABG),	for withdrawing care, 35
115	Decontamination, for radiation injury, 254
Cor pulmonale, 5 Corticosteroids, 73, 151, 185, 219, 220, 281,	Decubitus ulcers, in elderly patients, 11 Deep tendon reflexes (DTRs), 57, 58, 236
287	Deep venous thrombosis (DVT), 6, 7, 11
in adrenal insufficiency, 179 for angioedema, 84	Deferoxamine, 232 Defibrillation, 195, 251
delirium associated with, 8	Defibrillator, implantable, 128
in increased ICP, 194	Dehydration, 254. See also Fluid management
for myasthenia gravis, 196 in renal disorders, 212	Delirium, 8, 11, 189 Delirium tremens, 226
for respiratory failure due to COPD, 105	Demeclocycline, 60
in SLE, 221	Dementia, altered mental status in, 189
for spinal cord compression, 199, 280 for status asthmaticus, 100, 110	Depression, 9, 184, 226 Dermatitis, contact, 260
for thrombocytopenia, 45	Desmopressin, 41, 44, 45
for vasculitis, 222	Desquamation, 263, 274
weakness caused by, 190 Coryza, in measles, 272	Dexamethasone, 179 Dexamethasone-CRH test, 180
Cough, 81, 125, 151, 220, 272	Dexamethasone suppression tes, 180
in aortic valvular disease, 117	Dextran, platelet dysfunction associated with, 44
in asthma, 287 in COPD, 105	Dextrose, 169, 202 Diabetes
in pregnancy, 289	and SSI, 155
in renal disorders, 212 Cough, productive	in transplant recipients, 28
in HIV-infected patients, 153	Diabetes insipidus, 59, 234 Diabetic coma, hyperosmolar non-ketotic, 182
in pneumonia, 136	Diabetic ketoacidosis, 181
in tuberculosis, 145 Cranial nerves, 134	Diabetic patients, infections in, 141 Dialysis. See also Hemodialysis
Crescent formation, within glomeruli, 208	in heat stroke, 250
CREST syndrome, 220	modification of drug dosing in, 214
Crush injury, and renal disorders, 211 Crusted lesions, 269, 275	in renal disorders, 208, 210 Diaphoresis, 3, 109, 129, 197, 225, 227, 238
Cryoprecipitate, 43, 261	Diarrhea, 124, 166, 232, 237, 254, 270
Crystalloid, 83, 169, 173, 174, 197	Clostridium difficile-associated, 136
for gastritis, 168 for GI bleeding, 171, 176	in enteral nutrition, 14, 166 in toxic shock syndrome, 157, 274
in hypovolemia, 64, 76	Diazepam, 226, 227
for variceal bleeding, 167	Dichloroacetate, 65 Diencephalon lesions, 202
CT scans, 89, 193, 199, 200 air embolism on, 94	Diet, in pancreatic insufficiency, 172. See also
in encephalitis, 138	Nutrition
in increased ICP, 194 in intra-abdominal infection	Dietary restriction, in renal failure, 213. See also Fluid restriction; Sodium restriction
for seizure activity, 198	Digitalis toxicity, 231
in stroke, 201	Digoxin, 119, 121, 124, 214
in SVC, 281 Cullen sign, in pancreatitis, 173	Digoxin-specific antibodies (Fab), 231 Dilantin, 242
Cushing disease, 180	Diphenhydramine, 73, 83
Cushing reflex, 77	Diplopia, 134, 196, 256

Directly observed treatment (DOT), 145	pleural effusions associated with, 88
Disorientation, 189, 227. See also Mental status,	in pregnancy, 286, 289
altered	in pulmonary thromboembolism, 90
Disseminated intravascular coagulation (DIC),	in renal disorders, 208, 212
39, 123, 250, 256, 271	in upper GI bleeding, 176
coagulopathies associated with, 40	Dyspnea on exertion (DOE), in CHF, 121
in septic shock, 78	Dysrhythmias, in toxicology disorders, 230, 231
skin disorders associated with, 261	243. See also Arrhythmias
Diuresis, 86, 210, 211, 215, 240	Dysuria, 290
Diuretics, 75, 93, 117, 121, 220	
in ascites, 163	E
in electrolyte imbalances, 53, 54, 55	Ecchymoses, 39, 45, 173, 255
for hypervolemia, 63	Echocardiography, 117, 120, 126, 286, 289
for pulmonary edema in pregnancy, 289	air embolism on, 94
Diverticular disease, 170	for atrial fibrillation, 119
Dizziness, 116, 122, 235, 252, 281. See also	in CHF, 121
Mental status, altered	in mitral valvular disease, 125
in atrial fibrillation, 119	transesophageal, 116
in hypoglycemia, 183	Eclampsia, 288
in ventricular tachyarrhythmias, 130	Edema, 63, 184, 249, 281. See also Laryngeal
Dobutamine, 75, 121, 229	edema; Pulmonary edema
Do-Not-Resuscitate orders (DNR), 32	in dermatology disorders, 263
Dopamine, 63, 75, 83, 122, 185, 228, 229, 243	in necrotizing infection, 146
Dopamine blockers, 197	in pulmonary disease, 82
Doppler exam, in arterial insufficiency, 118	in renal disorders, 208
Doppler ultrasound, for pulmonary	Edrophonium (Tensilon) testacetylcholine
thromboembolism, 90	receptor antibodies, 196
Dorsalis pedis artery, 4	Elderly patients
Dosage, medication	ARDS in, 93
and hemodialysis, 216	and arterial pressure monitoring, 4
in obesity, 17	delirium in, 8
and renal clearance, 214	intra-abdominal infection in, 143
Doxycycline, 137, 271	meningitis in, 133
Drainage	with renal insufficiency, 62
biliary, 165	sepsis in, 78
percutaneous, 161	severe illness in, 11
postural, 99, 149	and SSI, 155
surgical, 143, 154, 157, 274	Electrical countershock, 119. See also
Drowning, near, 253	Cardioversion
Drowsiness, in toxicology disorders, 229, 231	Electrical shock injury, 248
Drug clearance, 214	Electrocardiogram (ECG), 120, 127, 129, 130,
Drug-drug interactions, in transplant recipients,	234, 243, 247, 248
28	in AMI, 126
Drug overdose	in angina pectoris, 115
acetaminophen, 225	in atrial fibrillation, 119
beta-blocker, 228	in cardiac compressive shock, 74
calcium channel blocker, 229 and delirium, 8	in electrolyte imbalances, 53, 54, 55, 56, 57
	in hypertensive crisis, 123
iron, 232	in muscular dystrophy, 195
opioid, 236	in myxedema coma, 184
sedative-hypnotic, 240	in pulmonary thromboembolism, 90
sympathomimetic, 241	in respiratory alkalosis, 69
TCA, 243	in syncopal event, 128
theophylline, 241	Electroencephalogram (EEG), 31, 198
Drug reactions	Electrolyte imbalances, 211, 234. See also
dermatology disorders associated with, 268	specific imbalances
in elderly patients, 11	Electrolyte replacement, 166, 170, 175, 239
fever associated with, 139	Electrolytes
Duchenne muscular dystrophy, 195	in ATN, 207
Duke criteria, for infective endocarditis, 142	in enteral feeding, 16
Duroziez sign, 117	in environmental injury, 253
Dysarthria, 201, 240	Electromyogram, 192, 195
Dysautonomia, in Guillain-Barrén syndrome,	Electrophysiology studies, 127, 128
192	Embolism. See also Pulmonary embolism
Dyslipidemia, 180	amniotic fluid, 286
Dysphagia, 134, 196	in atrial fibrillation, 119
Dysphoria, in toxicology disorders, 227	Embolization, for PUD, 174
Dyspnea, 68, 81, 105, 151, 164, 220, 221, 281,	Emergy-Dreifuss disorders, 195
287	Emesis, 176, 236
in ascites, 163	Emphysema, 105, 164
in cardiac disorders, 116, 117, 119, 120, 122,	Encephalitis, 138
125, 127, 129, 130	Encephalopathy, 208, 209, 213
in GI bleeding, 171	Endocarditis, infective, 142, 158
in hypervolemia, 63	Endophthalmitis, 140
on mechanical respiration, 102	Endoscopic retrograde cholangiopncreatography
in obesity-hypoventilation syndrome, 86	(ERCP), 165
	**

Endoscopy, 170, 174	Fibrinolytic agents, for catastrophic
gastric varices on, 167	antiphospholipid syndrome, 219
pulse oximetry during, 20	Fibrosis, in scleroderma, 220
in upper GI bleeding, 176	5-flucytosine, 135, 148
Enteral feeding, 15, 166	Flank pain, 210, 235, 290
Eosinophilia, 179, 263	Fluconazole, 135, 140, 148
Eosinophilic syndrome, 212	Fludrocortisone, 128, 179
Eosinophiluria, in renal disorders, 210	Fluid challenge
Epilepsy, treatment of, 198	in hypovolemia, 64
Epinephrine, 73, 83, 84, 122	in renal failure, 213
Epistaxis, in toxicology disorders, 244	Fluid management
Equine botulinum antitoxin, 134	in acute cholangitis, 165
Eruptions, 268	in hemodialysis, 216
in Rocky Mountain spotted fever, 271	in SCD, 81
vesiculobullous, 260	Fluid overload
Erythema, 157, 265, 274	dialysis for, 213
in environmental injury, 255	in pregnancy, 289
in pulmonary disease, 82	Fluid replacement, 182, 239
Erythema multiforme, 262	for bowel obstruction, 170, 175
Erythroderma	for diarrhea, 166
exfoliative, 286	in TEN, 273
in GVHD, 265	Fluid restriction
Erythromycin, 162, 244	in ARDS, 93
Erythropoietin, in chronic renal failure, 26	in ascites, 163
Escharotomy, 25	for CHF, 121
Eschars, 249	for hypervolemia, 63
Esmolol, 123, 241	in hyponatremia, 60
Esophageal varices, 167	for renal disorders, 208
Esophagogastroduodenoscopy (EGD), 167, 168,	Fluid resuscitation, 78, 124, 157, 248, 255, 274
174, 176	for burn patients, 25
Esophagram, 164	in electrical shock, 248
Ethambutol, 145	for head injury, 193
Ethanol, in warfarin poisoning, 244	in hypervolemia, 63
Ethanol infusion, in toxicology disorders, 235	in hypovolemia, 64
Ethanol withdrawal, 227	for hypovolemic shock, 76
Ethics, medical, 33	in neurogenic shock, 77
Ethylene glycol toxicity, 235	in renal disorders, 211
Exfoliation, in TEN, 273	Flumazenil, 227
Expectoration, in hemoptysis, 96	Fluoroquinolone, 137, 158
Expiratory pressure airway pressure (EPAP),	Folic acid, 226, 235
103 Extransposidal signs in payrolantic melignant	Formulas
Extrapyramidal signs, in neuroleptic malignant syndrome, 197	enteral, 14
Extremities	for parenteral nutrition, 15
in cardiogenic shock, 75	Fournier disease, 146
in hypovolemic shock, 76	Fractional concentration of inspired oxygen
in neurogenic shock, 77	(FIO ₂), 98, 104, 109
, · ·	Free water deficit, in hypernatremia, 59
F	Frequency, in pyelonephritis, 290
Factor deficiencies, 39, 41	Fresh frozen plasma (FFP), 40, 43, 49, 244
Factor IX, for coagulopathy, 41	for angioedema, 84
Famciclovir, 275	for coagulopathy, 41
Famotidine, 21	for DIC, 261
Fasciotomy, in arterial insufficiency, 118	Frostbite, 249
Fat embolism, ARDS associated with, 93	Furosemide, 60, 211. See also Diuretics
Fatigue, 122, 145, 181, 182, 220, 247, 248, 279.	
See also Weakness	G
in hepatic failure, 169	Gag reflex, 95, 202
in metabolic acidosis, 65	Gallops
in mitral regurgitation, 125	in CHF, 121
in renal disorders, 208	in renal failure, 213
Fatty liver of pregnancy, acute, 285	Gas, inhaled, 82
Fear, anxiety associated with, 3. See also	Gas gangrene, 146
Anxiety	Gastric decontamination, 235, 244
Fecal fat, in pancreatic insufficiency, 172	Gastric emptying, in mushroom poisoning, 252
Fecal occult blood, 168, 174	Gastric lavage, 231, 234
Feeding pump, 14	in heat stroke, 250
Fenoldopam, 215	in overdosing, 225, 228, 229, 232, 240, 241,
Fentanyl, 18	242, 243 in PCP abuse 233
Fetal heart, 27 Fever, 136, 147	in PCP abuse, 233 in poisoning, 238, 239
in ICU, 139 noninfectious causes of, 139	Gastric varices, 167 Gastritis, 168, 252
with rash, 222	Gastrius, 108, 232 Gastrointestinal bleeding, 21, 171, 176
Rocky Mountain spotted, 271	Gastronnestmar breeding, 21, 171, 170 Gastrostomy tube, 14
Fiberoptic intubation, in neurogenic shock, 77	Gene coding abnormal coagulation factor, 41
i iii iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii	congulation factor, 41

Geriatric patients. See Elderly patients	for chronic renal failure, 26
Glanzmann disease, 44	in electrolyte imbalances, 53, 55, 57, 61
Glasgow Coma Scale, 193, 202	in hypertensive crisis, 123
Glomerular filtration rate (GFR), 214	for hypervolemia, 63
Glomerulonephritis, 142, 208	intermittent, 216
Glucagon, 73, 183, 228, 229	in lithium toxicity, 234
Glucocorticoids, 53, 184, 186	management of, 216
Glucose	in metabolic acidosis, 65 in renal failure, 209
for hyperosmolar non-ketotic diabetic coma, 182	Hemofiltration, 216
for hypoglycemia, 183	Hemoglobin, in gastritis, 168
Glycoprotein IIB/IIIa deficiency, 44	Hemoglobinuria, 256
Glycoprotein IIb/IIIa inhibitors, platelet	Hemolysis, 47, 211, 256
dysfunction associated with, 44	Hemoperfusion, in theophylline overdose, 242
Glycosuria, 180, 181, 182	Hemophilia, coagulopathy due to, 41
Goiter, 186	Hemoptysis, 145, 220, 221
Goodpasture syndrome, 212	life-threatening, 96
Graft failure, in transplant recipients, 28	in renal disorders, 212
Graft-versus-host disease (GVHD), 28, 141, 265	Hemorrhage. See also Bleeding alveolar, 212
Gram-positive organisms, in intravenous catheter infection, 144	subarachnoid, 203
Granulocytosis, in neuroleptic malignant	Henderson-Hasselbalch equation, 67
syndrome, 197	Heparin, 49, 90, 124, 129
Grey Turner sign, in pancreatitis, 173	in arterial insufficiency, 118
Group A streptococcal infection, 146	coagulopathies associated with, 40
Guillain-Barré syndrome, 192	flushes, 42
Gynecologic surgery, DVT prophylaxis for, 7	subcutaneous low-dose, 6, 7
п	Heparin-induced thrombocytopenia (HIT), 42
H HACEV group 142	Hepatic encephalopathy, 13, 56, 169
HACEK group, 142 Haemophilus influenzae, 135	Hepatic failure, 169, 183, 225, 252 Hepatic necrosis, in iron overdose, 232
Hallucinations, 189, 226, 228, 231, 251, 252	Hepatic steatosis, prevention of, 15
Haloperidol, 189, 233, 241	Hepatic toxicity, in mushroom poisoning, 252
Hamman crunch, in Boerhaave syndrome, 164	Hepatorenal syndrome, 209
Hand washing, 152	Herbicides, poisoning from, 238
Headache, 138, 231, 235, 247, 248, 252, 256,	Heroin, 134, 237
271	Herpes encephalitis, 138
in head injury, 193	Herpes simplex, 148
in HIV-infected patients, 135	Herpes zoster infection, 275
in increased ICP, 194 in meningitis, 133, 148	Heyde syndrome, 171 Hip replacement, DVT prophylaxis for, 7
in renal failure, 213	Hirsuitism, in Cushing syndrome, 180
in respiratory disorders, 68, 108	Histamine, in anaphylaxis, 83
in SAH, 203	Histamine antagonists, 73, 168
in scleroderma, 220	HIV-infected patients
in SVC, 281	CNS infections in, 135
Head injuries, 13, 193	pulmonary infections in, 151, 153
Head trauma, 77	tuberculosis in, 145
DVT prophylaxis for, 7	HIV testing, in patients with psoriasis, 263, 26
in respiratory failure from neuromuscular disorders, 106	HMG-CoA reductase inhibitors, 115, 129 Hungry-bone syndrome, 54
vs. PCP intoxication, 233	Hydralazine, 117, 121, 123, 288
Heart block, 122, 228, 229	Hydration, for toxicology disorders, 226. See
Heart rate	also Fluid management
in hemodialysis, 216	Hydrocortisone, 73, 78, 83, 179, 183
in hypovolemia, 64	Hyperalimentation, in scleroderma, 220
Heat intolerance, in thyroid storm, 186	Hyperbilirubinemia, in renal failure, 209
Heat rash, 267	Hypercalcemia, 53
Heat stroke, 250 Helical (spiral) CT scan, 90	in endocrine problems, 179 hemodialysis for, 216
HELLP syndrome, 288	in toxicology disorders, 234
Helobacter pylori, 168	Hypercapnia, 87, 89, 93, 287
Hemarthroses, bleeding associated with, 39	arterial, 108
Hematemesis, 174, 175, 232, 239, 244	on mechanical ventilation, 99, 102
in upper GI bleeding, 176	"permissive," 68
and variceal bleeding, 167	and respiratory failure due to COPD, 105
Hematochezia, 167, 171, 174, 176, 232, 244	Hypercortisolism, 180
Hematologic system, during pregnancy, 27	Hyperemesis gravidarum, 15
Hematomas, 7, 39 Hematuria, 123, 210, 212, 244, 291	Hyperemia, 157, 249, 274 Hyperglycemia, 180, 181
Hemianopia, 201	ICU management of, 12
Hemiparesis, 201	in toxicology disorders, 229
Hemiplegia, in stroke, 201	Hyperinflation, in status asthmaticus, 110
Hemodialysis, 207, 216, 219, 235, 239, 242,	Hyperkalemia, 55, 65, 200, 282
282. See also Dialysis	dialysis for, 213
in acute renal failure, 212	from digitalis toxicity, 231

Hyperkalemia (continued)	in neurogenic shock, 77
in endocrine problems, 179	with PEEP, 104
hemodialysis for, 216	in peritonitis, 150
in renal disorders, 211	in pulmonary thromboembolism, 90
in renal failure, 213	in syncopal event, 128
Hyperlipidemia, in transplant recipients, 28	Hypothermia, 31, 181, 184, 251
Hypermagnesemia, 57	in environmental injury, 253
Hypernatremia, 59	in hyperosmolar non-ketotic diabetic coma, 182
Hyperparathyroidism, in lithium toxicity, 234	
Hyperphosphatemia, 61, 62, 211, 282 Hyperpigmentation, with endocrine problems,	in toxicology disorders, 236 Hypotonicity, in near drowning, 253
179	Hypoventilation, 87
Hyperreflexia, 54, 234, 241, 242	in increased ICP, 194
Hypertension, 87, 180, 186, 189, 197, 220. See	on mechanical ventilation, 101
also Portal hypertension; Pulmonary	in metabolic alkalosis, 66
hypertension	Hypovolemia, 64
anxiety associated with, 3	in endocrine problems, 179
in insect bites, 256	in environmental injury, 250
malignant, 123	in hyponatremia, 60
in pregnancy, 289	Hypovolemic shock, 76
in renal disorders, 208	Hypoxemia, 68, 87, 89, 105, 110, 121, 129, 151,
in toxicology disorders, 226, 227, 230, 235,	184
237, 241	in air embolism syndrome, 94
Hypertensive crisis, 123	ARDS associated with, 93
Hyperthermia, 227, 230, 234, 236, 237, 239, 241	in asthma, 287
in environmental injury, 250	life-threatening, 215
malignant, 197	on mechanical ventilation, 99, 102
in neuroleptic malignant syndrome, 197	and PaO ₂ , 109
Hyperthyroidism, 185	PEEP for, 104
Hyperuricemia, in tumor lysis syndrome, 282	in pneumonia, 137
Hyperventilation for head injury, 193	in pregnancy, 289
in increased ICP, 194	in pulmonary thromboembolism, 90 and respiratory failure due to COPD, 105
on mechanical ventilation, 101	respiratory failure from, 109
Hypervolemia, 63, 253	in respiratory failure from neuromuscular
Hypoalbuminemia, 14, 65, 169	disorders, 106
Hypocalcemia, 26, 54, 282	Hypoxia, in opioid overdose, 236
in hyperphosphatemia, 61	Hysterectomy, for septic abortion, 291
hypomagnesemia associated with, 58	3, , .
and phosphate salts, 62	I
in renal disorders, 211	Ibuprofen, 249
Hypogastrium, in large-bowel obstruction, 170	ICU stay
Hypoglycemia, 179, 183, 228, 239	altered mental status during, 189
in hepatic failure, 169	and sedation, 3
in myxedema coma, 184	Idiopathic thrombocytopenic purpura (ITP), 45
Hypokalemia, 56	Ileus
hypomagnesemia associated with, 58	
	adynamic (paralytic), 162
in hypophosphatemia, 62	adynamic (paralytic), 162 in TCA overdose, 243
in hypophosphatemia, 62 in toxicology disorders, 242	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. <i>See also</i> CT scans; Magnetic
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. <i>See also</i> CT scans; Magnetic resonance imaging; Radiographic studies
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients,
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157,	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunocompromised patients
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243,	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunocompromised patients
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243,	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141 intra-abdominal infection in, 143
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290 in air embolism syndrome, 94 in amniotic fluid embolism, 286	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune-suppression, in HIV-infected patients, 153 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141 intra-abdominal infection in, 143 rubeola in, 272 VZV infections in, 275
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 58 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparhyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposphenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290 in air embolism syndrome, 94	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune reconstitution syndrome, 135 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141 intra-abdominal infection in, 143 rubeola in, 272
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290 in air embolism syndrome, 94 in amniotic fluid embolism, 286 in atrial fibrillation, 119	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141 intra-abdominal infection in, 143 rubeola in, 272 VZV infections in, 275 Immunoglobulin, 73, 192, 196
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoperfusion, in hypovolemia, 64 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290 in air embolism syndrome, 94 in amniotic fluid embolism, 286 in atrial fibrillation, 119 and cerebral blood flow, 201 in cholangitis, 165 in endocrine problems, 179	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141 intra-abdominal infection in, 143 rubeola in, 272 VZV infections in, 275 Immunoglobulin, 73, 192, 196 intravenous (IGIV), 272 for thrombocytopenia, 45 Immunological markers, in glomerulonephritis,
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparthyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290 in air embolism syndrome, 94 in amniotic fluid embolism, 286 in atrial fibrillation, 119 and cerebral blood flow, 201 in cholangitis, 165 in endocrine problems, 179 in environmental injury, 247, 250, 251, 255	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141 intra-abdominal infection in, 143 rubeola in, 272 VZV infections in, 275 Immunoglobulin, 73, 192, 196 intravenous (IGIV), 272 for thrombocytopenia, 45 Immunological markers, in glomerulonephritis, 208
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290 in air embolism syndrome, 94 in amniotic fluid embolism, 286 in atrial fibrillation, 119 and cerebral blood flow, 201 in cholangitis, 165 in endocrine problems, 179 in environmental injury, 247, 250, 251, 255 in hepatic failure, 169	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141 intra-abdominal infection in, 143 rubeola in, 272 VZV infections in, 275 Immunoglobulin, 73, 192, 196 intravenous (IGIV), 272 for thrombocytopenia, 45 Immunological markers, in glomerulonephritis, 208 Immunologic reaction, life-threatening, 73
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290 in air embolism syndrome, 94 in amniotic fluid embolism, 286 in atrial fibrillation, 119 and cerebral blood flow, 201 in cholangitis, 165 in endocrine problems, 179 in environmental injury, 247, 250, 251, 255 in hepatic failure, 169 in hypermagnesemia, 57	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141 intra-abdominal infection in, 143 rubeola in, 272 VZV infections in, 275 Immunoglobulin, 73, 192, 196 intravenous (IGIV), 272 for thrombocytopenia, 45 Immunological markers, in glomerulonephritis, 208 Immunologic reaction, life-threatening, 73 Immunologic reaction, life-threatening, 73
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparthyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290 in air embolism syndrome, 94 in amniotic fluid embolism, 286 in atrial fibrillation, 119 and cerebral blood flow, 201 in cholangitis, 165 in endocrine problems, 179 in environmental injury, 247, 250, 251, 255 in hepatic failure, 169 in hypermagnesemia, 57 in hypovolemia, 64	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141 intra-abdominal infection in, 143 rubeola in, 272 VZV infections in, 275 Immunoglobulin, 73, 192, 196 intravenous (IGIV), 272 for thrombocytopenia, 45 Immunological markers, in glomerulonephritis, 208 Immunologic reaction, life-threatening, 73 Immunologic reaction, life-threatening, 73 Immunosuppression in GVHD, 265
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290 in air embolism syndrome, 94 in amniotic fluid embolism, 286 in atrial fibrillation, 119 and cerebral blood flow, 201 in cholangitis, 165 in endocrine problems, 179 in environmental injury, 247, 250, 251, 255 in hepatic failure, 169 in hypermagnesemia, 57 in hypovolemia, 64 in hypovolemia, 64 in hypovolemic shock, 76	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune reconstitution syndrome, 135 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141 intra-abdominal infection in, 143 rubeola in, 272 VZV infections in, 275 Immunoglobulin, 73, 192, 196 intravenous (IGIV), 272 for thrombocytopenia, 45 Immunological markers, in glomerulonephritis, 208 Immunologic reaction, life-threatening, 73 Immunologic reaction, life-threatening, 73 Immunosuppression in GVHD, 265 for vasculitis, 222
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 58 in hypopcalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoperfusion, in hypovolemia, 64 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290 in air embolism syndrome, 94 in amniotic fluid embolism, 286 in atrial fibrillation, 119 and cerebral blood flow, 201 in cholangitis, 165 in endocrine problems, 179 in environmental injury, 247, 250, 251, 255 in hepatic failure, 169 in hypovolemia, 64 in hypovolemia, 64 in hypovolemic, 676 on mechanical ventilation, 97, 100, 101	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunocompromised patients infections in, 141 intra-abdominal infection in, 143 rubeola in, 272 VZV infections in, 275 Immunoglobulin, 73, 192, 196 intravenous (IGIV), 272 for thrombocytopenia, 45 Immunological markers, in glomerulonephritis, 208 Immunologic reaction, life-threatening, 73 Immunosuppression in GVHD, 265 for vasculitis, 222 Immunosuppressive therapy, 196, 221
in hypophosphatemia, 62 in toxicology disorders, 242 Hypomagnesemia, 58 in hypocalcemia, 54 in hypophosphatemia, 62 Hyponatremia, 60 in endocrine problems, 179 in myxedema coma, 184 Hypoparathyroidism, 54 Hypoperfusion, in hypovolemia, 64 Hypophosphatemia, 62 Hyposplenism, 141 Hypotension, 65, 66, 74, 75, 78, 83, 129, 157, 164, 207, 219, 228, 229, 236, 242, 243, 290 in air embolism syndrome, 94 in amniotic fluid embolism, 286 in atrial fibrillation, 119 and cerebral blood flow, 201 in cholangitis, 165 in endocrine problems, 179 in environmental injury, 247, 250, 251, 255 in hepatic failure, 169 in hypermagnesemia, 57 in hypovolemia, 64 in hypovolemia, 64 in hypovolemic shock, 76	adynamic (paralytic), 162 in TCA overdose, 243 Imaging studies. See also CT scans; Magnetic resonance imaging; Radiographic studies for pregnant patients, 27 for pulmonary thromboembolism, 90 in spinal cord compression, 280 in urosepsis, 158 Immune reconstitution syndrome, 135 Immune-suppression, in HIV-infected patients, 153 Immunization, in tetanus, 156 Immunecompromised patients infections in, 141 intra-abdominal infection in, 143 rubeola in, 272 VZV infections in, 275 Immunoglobulin, 73, 192, 196 intravenous (IGIV), 272 for thrombocytopenia, 45 Immunological markers, in glomerulonephritis, 208 Immunologic reaction, life-threatening, 73 Immunosuppression in GVHD, 265 for vasculitis, 222

Incontinence, in spinal cord compression, 199	
meditinence, in spinar cord compression, 199	Irritation, in aspiration pneumonitis, 95
Incoordination, in respiratory acidosis, 68	Ischemia
Infection, 155, 221, 291	in arterial insufficiency, 118
diarrhea caused by, 166	in toxicology disorders, 230
hemoptysis in, 96	Isolation, 145, 272
in immunocompromised hosts, 141	of HIV-infected patients, 153
intra-abdominal, 143	for meningococcemia, 266
intravenous catheter-associated, 144	for radiation injury, 254
necrotizing soft tissue, 146	Isoniazid (INH), 145
polymicrobial, 146, 291	Isopropanol toxicity, 235
prevention of nosocomial, 152	Isoproterenol, 228
in transplant recipients, 28	Isotonic fluids, in adynamic ileus, 162. See also
Infiltrates, in PCP, 151	Fluid management
Inflammation, 161	Isotretinoin drugs, for psoriasis, 264
airway, 100	Itching, in miliaria, 267
in aspiration pneumonitis, 95	
Informed choice, 32, 33	J
Informed consent, 34	Janeway lesions, 142
Informed denial, 34	Jaundice, 161, 165, 169, 225, 256
Inhalation injury, acute, 82	Jejunostomy tubes, 14
Inhalation therapy, delayed effects of, 82	Jugular shunt, in renal failure, 209
Injury, spinal cord, 200. See also Brain injury;	Jugular venous distension, in renal failure, 213
Head injury	Jugular venous pressure (JVP), in cardiac
Inotropic agents, 63, 219, 220	tamponade, 120
Insecticides, poisoning from, 238	Justice, in medical ethics, 33
Insomnia, 226, 227, 237	**
Inspiratory plateau pressure, 100	K
Inspiratory pressure airway pressure (IPAP), 103	Kayexalate, 55
Insulin, 55, 181	Ketamine, 233
intravenous infusion of, 12	Ketoacidosis, diabetic, 181
metabolism of, 183	Ketoconazole, for Cushing syndrome, 180
in parenteral nutrition, 15	Kidneys
in renal failure, 214	sacrificing, 215
in sepsis, 154	transplants, 26, 209
Insulinoma, 183	Knee replacement, DVT prophylaxis for, 7
Insulin resistance, 12, 180	Koplik spots, 272
Intakes and outputs, 64	Kussmaul respirations, 65, 181, 213
Interferon, for rubeola, 272	Kussmaul sign, in cardiac tamponade, 120
Intermittent mandatory ventilation (IMV), 97.	Kyphoscoliosis, respiratory failure associated
See also Ventilation, mechanical	with, 107
	with, 107
International normalized ratio (INR), 48, 49	T
Intracranial pressure	L
in head injury, 193	Labetalol, 116, 123, 288
in hepatic failure, 169	Lacrimation, in opiod withdrawal, 237
increased, 194	Lactic acidosis, in septic shock, 78
on mechanical ventilation, 101	Lactulose, 285
monitoring of, 13	
Intravenous (IV) fluids, 226, 237, 242, 250. See	Laminectomy, 199
	Large-bowel obstruction, 170
also Fluid management	
also Fluid management in benzodiazepine withdrawal, 227	Large-bowel obstruction, 170
in benzodiazepine withdrawal, 227	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137
in benzodiazepine withdrawal, 227 in hypothermia, 251	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic alkalosis, 66
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic alkalosis, 66 in renal disorders, 208, 213
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic aklalosis, 66 in renal disorders, 208, 213 in respiratory failure, 108
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic alkalosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic alkalosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic acidosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic acidosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic alkalosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic acidosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic aikalosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic acidosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109 for respiratory failure from neuromuscular	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic aikalosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemotysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109 for respiratory failure, 107, 108, 109 for respiratory failure from neuromuscular disorders, 106	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic alkalosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173 and strangulated obstruction, 175
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109 for respiratory failure from neuromuscular disorders, 106 Intubation, nasal, 77, 164	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic acidosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173 and strangulated obstruction, 175 in vasculitis, 222
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109 for respiratory failure from neuromuscular disorders, 106 Intubation, nasal, 77, 164 Ipodate sodium, 186	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic aidsosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173 and strangulated obstruction, 175 in vascullitis, 222 Leukopenia, 222 Leukopenia, 222 Leukopenia, 222 Leukopenia, 222
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109 for respiratory failure from neuromuscular disorders, 106 Intubation, nasal, 77, 164 Ipodate sodium, 186 Ipratropium bromide, 105, 110 Iron deficiency anemia, in gastritis, 168	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic acidosis, 65 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173 and strangulated obstruction, 175 in vasculitis, 222 Leukotriene inhibitors, 212 Leukotrienes, in anaphylaxis, 83
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109 for respiratory failure from neuromuscular disorders, 106 Intubation, nasal, 77, 164 Ipodate sodium, 186 Ipratropium bromide, 105, 110 Iron deficiency anemia, in gastritis, 168 Iron overdose, 232	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic acidosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173 and strangulated obstruction, 175 in vasculitis, 222 Leukopenia, 222 Leukotriene inhibitors, 212 Leukotriene inhibitors, 212 Leukotrienes, in anaphylaxis, 83 LeVeen shunt, 209
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109 for respiratory failure from neuromuscular disorders, 106 Intubation, nasal, 77, 164 Ipodate sodium, 186 Ipratropium bromide, 105, 110 Iron deficiency anemia, in gastritis, 168 Iron overdose, 232 Irrigation	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic aikalosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173 and strangulated obstruction, 175 in vasculitis, 222 Leukotriene, 222 Leukotriene, in anaphylaxis, 83 LeVeen shunt, 209 Level of consciousness (LOC). See also Coma
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109 for respiratory failure from neuromuscular disorders, 106 Intubation, nasal, 77, 164 Ipodate sodium, 186 Ipratropium bromide, 105, 110 Iron deficiency anemia, in gastritis, 168 Iron overdose, 232 Irrigation in calcium channel blocker overdose, 229	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic acidosis, 65 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173 and strangulated obstruction, 175 in vasculitis, 222 Leukotriene inhibitors, 212 Leukotrienes, in anaphylaxis, 83 LeVeen shunt, 209 Level of consciousness (LOC). See also Coma in increased ICP, 194
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109 for respiratory failure from neuromuscular disorders, 106 Intubation, nasal, 77, 164 Ipodate sodium, 186 Ipratropium bromide, 105, 110 Iron deficiency anemia, in gastritis, 168 Iron overdose, 232 Irrigation in calcium channel blocker overdose, 229 in toxic shock syndrome, 274	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic acidosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173 and strangulated obstruction, 175 in vascultis, 222 Leukotriene inhibitors, 212 Leukotrienes, in anaphylaxis, 83 LeVeen shunt, 209 Level of consciousness (LOC). See also Coma in increased ICP, 194 in toxicology disorders, 236
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109 for respiratory failure from neuromuscular disorders, 106 Intubation, nasal, 77, 164 Ipodate sodium, 186 Ipratropium bromide, 105, 110 Iron deficiency anemia, in gastritis, 168 Iron overdose, 232 Irrigation in calcium channel blocker overdose, 229 in toxic shock syndrome, 274 Irritability, 69, 227, 241. See also Agitation	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic acidosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173 and strangulated obstruction, 175 in vasculitis, 222 Leukotrienes, in anaphylaxis, 83 LeVeen shunt, 209 Level of consciousness (LOC). See also Coma in increased ICP, 194 in toxicology disorders, 236 Levofloxacin, 95, 137
in benzodiazepine withdrawal, 227 in hypothermia, 251 in spinal cord injury, 200 Intubation, 169, 238, 240, 248, 250, 251, 253 in coma, 202 in electrical shock, 248 for head injury, 193 in increased ICP, 194 in inhalation injury, 82 for pancreatitis, 173 Intubation, endotracheal, 83, 87, 93, 110 in hemoptysis, 96 in neurogenic shock, 77 in respiratory failure, 107, 108, 109 for respiratory failure from neuromuscular disorders, 106 Intubation, nasal, 77, 164 Ipodate sodium, 186 Ipratropium bromide, 105, 110 Iron deficiency anemia, in gastritis, 168 Iron overdose, 232 Irrigation in calcium channel blocker overdose, 229 in toxic shock syndrome, 274	Large-bowel obstruction, 170 Laryngeal edema, 73, 83 Legionella, 137 Lepirudin, for HIT, 42 Lethargy, 86, 193, 225, 235, 239, 240, 251 in diabetic ketoacidosis, 181 in metabolic acidosis, 65 in metabolic acidosis, 66 in renal disorders, 208, 213 in respiratory failure, 108 Leucovorin, for HIV-infected patients, 135 Leukemia, acute, 279 Leukocytosis, 81, 124, 161, 162, 164, 169, 180 in C. difficile-associated diarrhea, 136 in cholangitis, 165 in dermatology disorders, 263, 264 in pancreatitis, 173 and strangulated obstruction, 175 in vascultis, 222 Leukotriene inhibitors, 212 Leukotrienes, in anaphylaxis, 83 LeVeen shunt, 209 Level of consciousness (LOC). See also Coma in increased ICP, 194 in toxicology disorders, 236

Lidocaine, 8, 130, 230, 231, 243	Mental status, altered, 169, 182, 184, 189, 197,
Lightheadedness, 69. See also Dizziness	221
in GI bleeding, 171, 176	in electrolyte imbalances, 53, 54, 59, 62
in hypovolemia, 64	in endocrine problems, 179
Lightning injury, 248	in hypovolemia, 64
Lipase, in pancreatitis, 173	and sedation, 3
Lithium toxicity, 234	in toxicology disorders, 228
Liver disease	Meperidine, 18, 214
acute fatty liver of pregnancy, 285	Mesenteric ischemia and infarction, acute, 124
chronic, 167	Metabolic acidosis, 65, 69, 229, 253
coagulopathies associated with, 40	in chronic renal failure, 26
FFP in, 43	hemodialysis for, 216
Liver failure, in mushroom poisoning, 252. See	hyperchloremic non-gap, 181
also Hepatic failure	in mesenteric ischemia and infarction, 124
Lockjaw, 156	and phosphate salts, 62
Loss of consciousness (LOC), 128, 193	Metabolic alkalosis, 66
Lumbar puncture, 192, 198, 203	Metastases, vertebral, 199
Lung injury	Methadone, 237
on mechanical ventilation, 101	Methamphetamine toxicity, 241
transfusion-related acute, 47	Methanol toxicity, 235
Lungs. See also Pulmonary edema; Pulmonary	Methemoglobin levels, 20
embolism	Methodorousta 264, 260
chest tube thoracostomy for, 85	Methylana 252
PETCO ₂ and perfusion of, 10 Lymphadenopathy, 263, 270, 279	Methylene, 252 Methylprednisolone, 110, 200
Lymphochoriomeningitis (LCM), 148	Metoclopramide, 162
Lymphocytes, in radiation injury, 254	Metronidazole, 95, 136, 166
Lymphocytopenia, 180	Metyrapone, 180
Lymphocytosis, in endocrine problems, 179	Midbrain lesions, 202
Zymphocytosis, in chaocime problems, 177	Midodrine, 209
	Miliaria (heat rash), 267
M	Miller-Fisher syndrome, 192
Macrolides, 137	Milrinone, 121
Magnesium, 56, 66, 110, 130, 181, 182	Mineralocorticoid replacement, for adrenal
in hypermagnesemia, 57	insufficiency, 179
replacement of, 58	Mini Mental Status Examination (MMSE), 189
Magnetic resonance imaging (MRI), 199, 200,	Mitral regurgitation (MR), 125
201	Mitral stenosis (MS), 125, 289
in encephalitis, 138	Mitral valvular heart disease, 125
in increased ICP, 194	Mixed acid-base disorders, 67
Malabsorption, diarrhea caused by, 166	Moniliasis, 259
Malaise, 169, 222, 247, 270, 275, 285	Monitoring, 129, 134
in ATN, 207	for AMI, 126
in dermatology disorders, 262, 263	arterial pressure, 4
Malignancy, 281	central venous pressure, 5
and spinal cord compression, 280 in transplant recipients, 28	of end-tidal PCO ₂ , 10 fetal, 27, 289
Malnutrition, enteral nutrition in, 14	in hypothermia, 251
Mannitol, 118, 194, 211, 215, 233, 240	of ICP, 13
Marfan/Ehlers-Danlos syndromes, 116	Morbilliform drug reactions, 268
Mastoiditis, meningitis associated with, 133	Morphine, 18, 63, 121, 129. See also Opioids
Measles, 272	Mortality, 147, 173, 185, 221, 269
Mediastinitis, suppurative, 164	of aortic valvular disease, 117
Medications	and depression, 9
diarrhea caused by, 166	of pneumonia, 137
and hepatic failure, 169	in septic patients, 154
in renal failure, 213	of upper GI bleeding, 176
in renal insufficiency, 214	Mortality rates
in transplant recipients, 28	from acute aortic dissection, 116
Medicolegal principles, 34	in amniotic fluid embolism, 286
Medroxyprogesterone, 86	for nosocomial infection, 149
Medullary lesions, 202	for symptomatic heart failure, 121
Melena, 168, 174	Multifocal atrial tachycardia (MFAT), 127
in upper GI bleeding, 176	Multivitamins, in alcohol withdrawal, 226
and variceal bleeding, 167	Mumps, meningitis associated with, 148
Meningismus, in cryptococcal meningitis, 135	Murphy sign, in acalculous cholecystitis, 161
Meningitis, 148	Muscle cramps, in hypomagnesemia, 58
bacterial, 133	Muscle fasciculations, in toxicology disorders,
cryptococcal, 135, 148 viral, 148	238 Muscle spasms, 256
Meningococcemia, 266	Muscle spasms, 250 Muscle wasting, 195
Menstrual irregularities, 180, 184, 244	Muscle washing, 175 Muscle weakness. See also Weakness
Mental status	in electrolyte imbalances, 54, 56, 62
in muscular dystrophy, 195	and respiratory failure, 106, 107
in opioid withdrawal, 237	Muscular dystrophy, 195

Myalgias, 157, 222, 271, 274	Noninvasive positive pressure ventilation
Myasthenia gravis, 196	(NIPPV), 99, 103, 105, 110, 111
Mycobacterium tuberculosis, 145	Nonmaleficence, in medical ethics, 33
Mycophenolate mofetil, for pemphigus vulgaris, 269	Nonsteroidal antiinflammatory drugs (NSAIDs), 162, 244
Mycoplasma pneumoniae, 135	angioedema associated with, 84
Mydriasis, in toxicology disorders, 226, 237,	bleeding associated with, 39
241, 243	platelet dysfunction associated with, 44
Myelinolysis, central pontine, 60	Non-ST-segment elevation myocardial infarction
Myelography, in spinal cord compression, 199	(NSTEMI), 129
Myocardial depression, in heat stroke, 250	Norepinephrine, 75, 77, 209, 228
Myocardial infarction (MI), 75, 230	Nosocomial infection, prevention of, 152
acute (AMI), 126	Nuchal rigidity, 203
hyperglycemia following, 12 non-ST-segment, 129	Numbness, 118, 199 Nutrition, 16, 155, 185, 192, 196, 273, 285
pulmonary catheterization in, 19	and dermatology disorders, 262, 263
Myogenic disorders, 195	enteral, 14
Myonecrosis, 146	in pancreatitis, 173
Myopathy, 106, 180, 190	parenteral, 15
Myositis, in phenytoin hypersensitivity	for pregnant patients, 27
syndrome, 270	Nystagmus, 203, 233, 240, 256
Myxedema coma, 184	
N	Ohavity 17 155 190
N-acetylcysteine, 169, 207, 215, 225, 252	Obesity, 17, 155, 180 intra-abdominal infection in, 143
Nafcillin, 214	respiratory failure associated with, 107
Naloxone, 202, 236	Obesity-hypoventilation syndrome (OHS), 17,
Narcotics, and sharing of needles, 236	86, 107
Nasogastric aspiration, 167	Obstipation, 162, 170, 175
Nasogastric lavage, 171, 236	Obstruction
Nasogastric tube, 14, 200	of eccrine sweat glands, 267
Near drowning, 253	large-bowel, 170
Neck stiffness, 133, 148, 203 Neck veins, 74, 75, 76	small-bowel, 175 Obstructive sleep apnea (OSA), 17, 103, 107
Necrolysis, toxic epidermal, 262	Obstructive sleep apnea syndrome, 87, 8787
Needles, sharing of, 236	Obtundation, in infectious disease, 138. See also
Neisseria meningitidis, 266	Coma
Nephritis, interstitial, 210	Octreotide, 167, 176, 185, 209
Nephrolithiasis, 180	Ogilvie syndrome, 162 Oliguria, 64, 76, 116, 120, 207, 208
Nephropathy, pigment, 211 Nerve agents, 238	Omegrazole, 21
Nerve conduction studies, 191	Opioid overdose, 236
Neurogenic shock, 77	Opioids, 106, 192, 194, 249. See also Morphine
Neuroleptic malignant syndrome, 197	Opioid withdrawal, 237
Neuroleptics, delirium associated with, 8	Opisthotonos, in tetanus, 156
Neurologic deficits, 135, 203, 280	Oral phosphate binders, in chronic renal failure,
Neuromuscular blockers, 190 Neuromuscular disorders	26 Organ failure, 232. See also Hepatic failure;
mechanical ventilation in, 99	Renal failure
respiratory failure from, 106	Organomegaly, respiratory failure associated
Neuropathy	with, 107
acute motor-axonal (AMAN), 192	Organophosphate poisoning, 238
acute motor-sensory axonal (AMSAN), 192	Organ transplant recipients, infections in, 141.
in hypophosphatemia, 62 rash, 222	See also Transplant recipients Orthopnea, 117, 120, 121, 125
Neuropsychiatric problems, 8, 180	Orthostatic blood pressure, 64, 213
Neuropsychological impairment, in CO	Orthostatic hypotension, 76, 167, 171, 176
poisoning, 247	Osler nodes, 142
Neurosurgical consultation, for spinal cord	Osmolality, and toxic alcohol, 235
compression, 199	Osteomyelitis, meningitis associated with, 133
Neutropenic fever, 147 Neutropenic patients, 141, 149	Otitis, meningitis associated with, 133 Oximetry, pulse, 20
Night sweats, 145	Oxygen, 81, 86, 151, 154, 200, 247, 287
Nikolsky sign, 273	for air embolism syndrome, 94
Nimodipine, 203	for AMI, 126
Nitrates, 115, 129	in angina, 115, 129
for aortic valvular heart disease, 117	for CHF, 121
for CHF, 121	for pulmonary edema in pregnancy, 289
Nitrogen balance, 16 Nitroglycerin, 75, 123	in respiratory failure, 106, 107, 109 in scleroderma, 220
Nitroprusside, 75, 230, 241, 288	in status asthmaticus, 110
for aortic valvular heart disease, 117	
for CHF, 121	Oxygen, partial pressure of (FaO ₂), in elderly
	Oxygen, partial pressure of (PaO ₂), in elderly patients, 11
in hypertensive crisis, 123	patients, 11 Oxygenation goal, in mechanical ventilation,
	patients, 11

Oxygen therapy, 87, 93	Phenytoin hypersensitivity syndrome, 270
for hypervolemia, 63	Phosphate, 181, 182
in inhalation injury, 82	in electrolyte imbalances, 61, 62
pulse oximetry during, 20 Oxygen toxicity, on mechanical ventilation, 101	in renal insufficiency, 62 Phosphate-binders, 61
Oxyhemoglobin, 247	Phosphorus replacement, 62
onynemograpin, 217	Photochemotherapy, 265
P	Photophobia, 203, 272
Pacemaker, 122, 128, 195, 228	Piloerection, in opioid withdrawal, 237
Pacing, for supraventricular tachycardia, 127	Pituitary adenoma, 180
Pain, 18, 174, 192, 225, 249, 256, 285. See also	Plaques, 262, 265
Abdominal pain; Chest pain	Plasma exchange, 192, 196
anxiety associated with, 3	in gastritis, 168
in arterial insufficiency, 118	for vasculitis, 222
axial skeletal, 280 in pancreatitis, 173	Plasmapheresis, 219, 221 for pemphigus vulgaris, 269
in renal disorders, 211	in renal disorders, 208, 212
in SAH, 203	Plasma transfusions, 43
in sickle cell disease, 81	Platelet dysfunction, 39, 44, 250
Pain control, 32	Platelet glycoprotein IIb/IIIa antagonists, 129
for AMI, 126	Platelet inhibitors, bleeding associated with, 39
in arterial insufficiency, 118	Platelet transfusion, 76
in pancreatic insufficiency, 172	Pleocytosis, CSF, 198
for pancreatitis, 173	Pleural effusions, 88
Pallor, 128, 279	in hypervolemia, 63
Palpitations, 119, 120, 127, 130, 183	respiratory failure associated with, 107
Pancreatic insufficiency, 172	thoracostomy for, 85
Pancreatitis, 173 ARDS associated with, 93	Pleuritic chest pain, 90, 120 in HIV-infected patients, 153
chronic, 172	pleural effusions associated with, 88
in transplant recipients, 28	in pneumonia, 136
Pancytopenia, in leukemia, 279	Pneumocystis jiroveci pneumonia (PCP), 151,
Pantoprazole, 21	153
Papaverine, 124	Pneumomediastinum, 97, 101, 230
Papilledema, 68, 193, 194, 203	Pneumonia, 99, 149, 152, 220
Paracentesis, 63, 163	ARDS associated with, 93
Paralysis, 192, 238, 248, 255	aspiration, 95
in arterial insufficiency, 118	community-acquired, 137
in hypokalemia, 56	end-tidal PCO _{2 in} , 10
Paranoia, 241 Paraproteinemia, pathological, 65	hematogenous, 149 in HIV-infected patients, 153
Parathyroidectomy, hypocalcemia following, 54	nosocomial, 149
Paresthesias, 66, 69, 192	pneumocystis, 151, 153
in electrolyte imbalances, 54, 56	ventilator-associated, 99, 101, 111, 152
perioral, 255	Pneumonitis, aspiration, 95
Paroxysmal nocturnal dyspnea, 125	Pneumothorax, 89
Partial thromboplastin times, dermatology	on mechanical ventilation, 97, 101
disorders associated with, 261	tension, 85
Pelvic pain, in septic abortion, 291	thoracostomy for, 85
Pemphigus vulgaris, 269	in toxicology disorders, 230
Penicillins, 156, 158, 249, 252, 266 Pentamidine, 151	Poisoning carbon monoxide, 247
Peptic ulcer disease (PUD), 174	mushroom, 252
Perceptions, altered, 252. See also Mental status,	organophosphate, 238
altered	salicylate, 239
Percutaneous coronary intervention (PCI), 129	warfarin, 244
Pericardial catheter, 74	Polydipsia, 181, 182
Pericardial effusion, 120	Polyneuropathy, 106, 190, 191
Pericardial rub, 120, 213	Polyphagia, in hyperosmolar non-ketotic diabetic
Pericardial window, 120	coma, 182
Pericardiocentesis, 74, 120	Polypharmacy, 11
Pericarditis, 26, 208	Polyradiculopathy, acute inflammatory
Periodontal infection, 95 Peripheral parenteral nutrition (PPN), 15	demyelinating (AIDP), 192 Polyuria, 53, 59, 181, 182
Peritonitis, 150	Polyvalent, in snakebite, 255
Perspiration, 128, 237. See also diaphoresis	Pontine lesions, 202
Petechiae, 45, 49, 271, 279	Portal hypertension, 209
Peutz-Jeghers syndrome, 176	Positioning, 128, 220
pH, in acid-base disorders, 65, 66, 67, 68, 69	to decrease aspiration risk, 95
Pharyngitis, 157, 270, 274	in increased ICP, 194
Phencyclidine (PCP), 233	Positive end-expiratory pressure (PEEP), 93, 98,
Phenobarbital, 230, 241, 242	99, 104, 109
Phenothiazines, 241	Positive pressure ventilation, 68, 86, 101
Phentolamine, 123, 241 Phenylephrine, 77, 243	Postsplenectomy patients, infections in, 141 Posttransplant lymphoproliferative disorder
Phenytoin, 203, 230, 231, 233, 241	(PTLD), 28
,,, 200, 201, 200, 211	(-122), 20

Potassium, 181, 182	Pulmonary-renal syndromes, 212
in electrolyte imbalances, 55, 56, 62	Pulmonary thromboembolism, 90
in metabolic alkalosis, 66	Pulmonary vascular resistance (PVR), 19
replacement of, 56	Pulse oximetry, 20
Pralidoxime, 238	Pulsus paradoxus, 110
Prealbumin, in enteral feeding, 16	Pulsus parvus et tardus, 117
Prednisone, 220, 269	Pupils, 134, 236, 251
Preeclampsia, 288	in comatose patient, 202
Pregnancy	in head injury, 193 in increased ICP, 194
acute fatty liver of, 285	
amniotic fluid embolism in, 286 asthma in, 287	Purple toe syndrome, 244 Purpura fulminans, 261
eclampsia in, 288	Pustules, 264, 267, 270
iron overdose during, 232	Pyelonephritis, 158, 290
physiologic adaptations to, 289	Pyrazinamide, 145
preeclampsia in, 288	Pyridostigmine, 196
pulmonary edema in, 289	Pyridoxine, 252
pyelonephritis in, 290	Pyrimethamine, 135
respiratory failure associated with, 107	Pyuria, 210, 290
Pregnant patients	- ,,,
management of, 27	_
physiology of, 27	Q
Pressure-controlled ventilation (PCV), 97. See	Quincke pulse, 117
also Ventilation, mechanical	
Pressure-support ventilation (PSV), 97. See also	R
Ventilation, mechanical	Radiation injury, 254
Preventive measures. See also Antibiotics,	Radiation syndrome, acute, 254
prophylactic; Prophylaxis	Radiation therapy, 280, 281
for DVT, 6	Radiculopathy, in infectious disease, 138
in pneumonia, 149	Radiocontrast agents
Prickly heat, 267	anaphylaxis caused by, 83
Primaquine, 151	and renal failure, 215
Procainamide, 127, 130, 214	Radiographs, 89, 90, 100, 164, 184, 199, 200,
Progressive multifocal leukoencephalopathy, 135	291
Progressive systemic sclerosis, 220	in cardiac disorders, 116, 120
Prokinetic agents, 162, 220	in GI disorders, 162, 175
Prophylaxis	in mechanical ventilation, 98, 99
antimicrobial, 155	of pleural effusions, 88
infective endocarditis, 117, 125	in pneumonia, 137
for syncopal event, 128	Radionuclide ventilation-perfusion scan, for
for upper GI bleeding, 21	pulmonary thromboembolism, 90
Propofol, 194	Rales, 63, 81
Propranolol, 186, 241	Ranitidine, 21, 73
Propylthiouracil, in thyroid storm, 186	Ranson criteria, 173
Prostaglandins, in anaphylaxis, 83	Rapidly progressive glomerulonephritis (RPGN)
Protein, in enteral nutrition, 14	208
Protein C, human activated, 78, 154	Rashes, 210, 266, 268, 270, 272
Proteinuria, 123, 210	Raynaud phenomenon, 220
Prothrombin, dermatology disorders associated	Rectal lavage, 250
with, 261	Red blood cell transfusion, 45, 46, 169, 247
Prothrombin time (PT), 39, 40, 41, 48 Proton pump inhibitors, 167, 168, 174, 176	Red cell casts, in hypertensive crisis, 123 Reflexes
Proton pump inhibitors, 167, 168, 174, 176	
Pruritus, 83, 260, 263, 268 Pseudohyperkalemia, 282	deep tendon, 57, 58, 236 in polyneuropathy, 191
Pseudothrombocytopenia, 45	Refusal of care, 34
Psoralen (PUVA), in GVHD, 265	Renal failure, 26, 78, 207, 213, 241, 253, 256,
Psoriasis, 263, 264	270, 282
Psychiatric consultation, in depression, 9	bleeding associated with, 39
Psychosis, 186, 233	drug clearance in, 214
Ptosis, in myasthenia gravis, 196	end-stage, 208
Pulmonary artery wedge pressure (PAWP), 19,	in hepatorenal syndrome, 209
93	hyperphosphatemia associated with, 61
Pulmonary capillary wedge pressure (PCWP), in	hypoglycemia in, 183
hypovolemia, 64	in pigment nephropathy, 211
Pulmonary congestion, in renal disorders, 208	prevention of, 215
Pulmonary edema, 73, 236, 239, 256, 286	Renal function, 64, 214, 234
in hypervolemia, 63	Renal insufficiency, in hypermagnesemia, 57
in mitral regurgitation, 125	Renal replacement therapy, 216
NIPPV in, 103	Respirations, in opioid overdose, 236
in pregnancy, 289	Respiratory acidosis, 68
pulmonary catheterization in, 19	and mechanical ventilation, 100
Pulmonary embolism (PE), 6, 7, 10	respiratory failure associated with, 109
Pulmonary hypertension, 86, 220	and respiratory failure due to COPD, 105
Pulmonary infiltrates, in SCD, 81	Respiratory alkalosis, 69, 239
Pulmonary insufficiency, in catastrophic	Respiratory compromise, in snakebite, 255
antiphospholipid syndrome, 219	Respiratory distress, 81, 94, 136

Respiratory failure, 56, 83, 86, 105, 109, 192	and DIC, 261
in acute lung injury, 95	following pregnancy termination, 291
from arterial hypercapnia, 108	urosepsis, 158
fulminant, 66	Septic shock, 78, 154 Serum-ascites albumin gradient (SAAG), 163
hemoptysis in, 96 in HIV-infected patients, 153	Shingles, 275
from neuromuscular disorders, 106	Shock
nonpulmonary causes of, 108	anaphylactic, 73
pleural effusions associated with, 88	cardiac compressive, 74
from thoracic cage disorders, 107	cardiogenic, 75
Respiratory system, during pregnancy, 27	in hypovolemia, 64, 76
Restlessness, 3, 237, 256. See also Agitation Retching, in Boerhaave syndrome, 164. See also	in mitral regurgitation, 125 neurogenic, 77
Vomiting	septic, 78, 154
Retinal hemorrhages	in septic abortion, 291
in hypertensive crisis, 123	in toxicology disorders, 232
in leukemia, 279	Shortness of breath (SOB), 83, 89, 121, 173
in SAH, 203	Sick euthyroid syndrome, 185
Retinoic acid syndrome, 279	Sickle cell anemia, 81
Retinoids, for psoriasis, 264 Reye syndrome, ICP monitoring in, 13	Sickle cell disease, 141 Sigmoidoscopy, 166, 170, 171
Rhabdomyolysis, 62, 213	Silybin, in mushroom poisoning, 252
diagnosis of, 211	Sinusitis, 133, 152
in environmental injury, 248, 250	Skin, 78, 157, 184, 186
in toxicology disorders, 230, 241	necrosis, 49, 244, 249
Rheumatoid arthritis, 141	in scleroderma, 220
Rhinorrhea, in opioid withdrawal, 237	in toxicology disorders, 243
Ribavirin, for rubeola, 272 Rickettsia rickettsii, 271	Sleep apnea, 20, 86 Sleep apnea syndrome, obstructive, 87
Rifampin, 145, 266	Sloughing, epidermal, 273
Right-heart failure, 220	SLUD syndrome, 238
Rigors, 290. See also Tremor	Slurred speech, 234, 251
"Risus sardonicus," 156	Small-bowel obstruction, 175
Rocky Mountain spotted fever, 271	Smokers, ARDS in, 93
Roth spots, 142	Smoking, and SSI, 155
Rubeola (measles), 272	Snakebite, 255 Snoring, and obstructive sleep apnea syndrome,
G.	
S	87
Salicylate poisoning, 239	87 Sodium
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186	
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. <i>See also</i> Fluid	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in sacites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Sclerosis, progressive systemic, 220 Scerption bites, 256 Secretin test, in pancreatic insufficiency, 172	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spidal cord, in neurogenic shock, 77 Spinal cord, compression, 199, 280
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in sacites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedation, 3	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedation, 3 Sedative-hypnotics, 87, 240	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in sacites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedation, 3	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedative, hypnotics, 87, 240 Sedatives, 106	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedation, 3 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegally, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150,
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in sacites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedative-hypnotics, 87, 240 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedation, 3 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Sclerooterma, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedation, 3 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedation, 3 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcal endocarditis, 142
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in sacites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedative-hypnotics, 87, 240 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in sacites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedative-hypnotics, 87, 240 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62 in infectious disease, 138 in meningitis, 133 in respiratory alkalosis, 69	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcal endocarditis, 142 Staphylococcus aureus, in intravenous catheter infection, 144 Status asthmaticus, 100, 110
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedative-hypnotics, 87, 240 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62 in infectious disease, 138 in meningitis, 133 in respiratory alkalosis, 69 tonic-clonic, 198, 226	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcual endocarditis, 142 Staphylococcus aureus, in intravenous catheter infection, 144 Status asthmaticus, 100, 110 Status epilepticus, 198
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedation, 3 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62 in infectious disease, 138 in meningitis, 133 in respiratory alkalosis, 69 tonic-clonic, 198, 226 Selective serotonin reuptake inhibitors (SSRIs),	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcal endocarditis, 142 Staphylococcal endocarditis, 142 Staphylococcal endocarditis, in intravenous catheter infection, 144 Status asthmaticus, 100, 110 Status epilepticus, 198 Steatorrhea, 172
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in sacites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedative-hypnotics, 87, 240 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62 in infectious disease, 138 in meningitis, 133 in respiratory alkalosis, 69 tonic-clonic, 198, 226 Selective serotonin reuptake inhibitors (SSRIs), in depression, 9	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcal endocarditis, 142 Staphylococcus aureus, in intravenous catheter infection, 144 Status asthmaticus, 100, 110 Status epilepticus, 198 Steatorrhea, 172 Stem cell transfusion, 254
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedation, 3 Sedative-hypnotics, 87, 240 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227-230, 233-235, 239, 241-243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62 in infectious disease, 138 in meningitis, 133 in respiratory alkalosis, 69 tonic-clonic, 198, 226 Selective serotonin reuptake inhibitors (SSRIs), in depression, 9 Selenium, in renal failure, 215	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcal endocarditis, 142 Staphylococcal endocarditis, 142 Staphylococcal endocarditis, in intravenous catheter infection, 144 Status asthmaticus, 100, 110 Status epilepticus, 198 Steatorrhea, 172
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in sacites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedative-hypnotics, 87, 240 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62 in infectious disease, 138 in meningitis, 133 in respiratory alkalosis, 69 tonic-clonic, 198, 226 Selective serotonin reuptake inhibitors (SSRIs), in depression, 9	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcal endocarditis, 142 Staphylococcal endocarditis, 142 Staphylococcus aureus, in intravenous catheter infection, 144 Status asthmaticus, 100, 110 Status epilepticus, 198 Steatorrhea, 172 Stem cell transfusion, 254 Stent placement, for large-bowel obstruction, 170 Steroids for candidiasis, 259
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedative, 30 Sedative-hypnotics, 87, 240 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62 in infectious disease, 138 in meningitis, 133 in respiratory alkalosis, 69 tonic-clonic, 198, 226 Selective serotonin reuptake inhibitors (SSRIs), in depression, 9 Selenium, in renal failure, 215 Sensorium, altered, 133, 207, 240, 255 in acute cholangitis, 165 altered mental status associated with, 189	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcal endocarditis, 142 Staphylococcus aureus, in intravenous catheter infection, 144 Status asthmaticus, 100, 110 Status epilepticus, 198 Steatorrhea, 172 Stem cell transfusion, 254 Stent placement, for large-bowel obstruction, 170 Steroids for candidiasis, 259 topical, 260, 263, 269
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in ascites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedation, 3 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62 in infectious disease, 138 in meningitis, 133 in respiratory alkalosis, 69 tonic-clonic, 198, 226 Selective serotonin reuptake inhibitors (SSRIs), in depression, 9 Selenium, in renal failure, 215 Sensorium, altered, 133, 207, 240, 255 in acute cholangitis, 165 altered mental status associated with, 189 in infectious disease, 138	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcus aureus, in intravenous catheter infection, 144 Status asthmaticus, 100, 110 Status epilepticus, 198 Steatorrhea, 172 Stem cell transfusion, 254 Stent placement, for large-bowel obstruction, 170 Steroids for candidiasis, 259 topical, 260, 263, 269 Steroid therapy. See also Corticosteroids;
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in sacites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedative, 190 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62 in infectious disease, 138 in meningitis, 133 in respiratory alkalosis, 69 tonic-clonic, 198, 226 Selective serotonin reuptake inhibitors (SSRIs), in depression, 9 Selenium, in renal failure, 215 Sensorium, altered, 133, 207, 240, 255 in acute cholangitis, 165 altered mental status associated with, 189 in infectious disease, 138 Sensory deficits, 191, 199	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcus aureus, in intravenous catheter infection, 144 Status asthmaticus, 100, 110 Status epilepticus, 198 Steatorrhea, 172 Stem cell transfusion, 254 Stent placement, for large-bowel obstruction, 170 Steroids for candidiasis, 259 topical, 260, 263, 269 Steroid therapy. See also Corticosteroids; Glucocorticoids
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in sacites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedative-hypnotics, 87, 240 Sedative-hypnotics, 87, 240 Sedative-s, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62 in infectious disease, 138 in meningitis, 133 in respiratory alkalosis, 69 tonic-clonic, 198, 226 Selective serotonin reuptake inhibitors (SSRIs), in depression, 9 Selenium, in renal failure, 215 Sensorium, altered, 133, 207, 240, 255 in acute cholangitis, 165 altered mental status associated with, 189 in infectious disease, 138 Sensory deficits, 191, 199 Sepsis, 154	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal cord injury, 7, 200 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcal endocarditis, 142 Staphylococcus aureus, in intravenous catheter infection, 144 Status asthmaticus, 100, 110 Status epilepticus, 198 Steatorrhea, 172 Stem cell transfusion, 254 Stent placement, for large-bowel obstruction, 170 Steroids for candidiasis, 259 topical, 260, 263, 269 Steroid therapy. See also Corticosteroids; Gluccocrticoids in inhalation injury, 82
Salicylate poisoning, 239 Salicylates, and thyroid storm, 186 Saline infusion, 60, 61, 66, 207. See also Fluid management Saphenous vein bypass grafting, in SVC, 281 Satiety, in sacites, 163 Scalded appearance, in TEN, 273 Scaling, in dermatology disorders, 263 Scleroderma, 220 Sclerosis, progressive systemic, 220 Scorpion bites, 256 Secretin test, in pancreatic insufficiency, 172 Sedative, 190 Sedative-hypnotics, 87, 240 Sedatives, 106 Seizure prophylaxis, 203, 288 Seizures, 198, 242, 250, 254, 256 228, 227–230, 233–235, 239, 241–243 absence, 198 in amniotic fluid embolism, 286 in hypocalcemia, 54 in hypophosphatemia, 62 in infectious disease, 138 in meningitis, 133 in respiratory alkalosis, 69 tonic-clonic, 198, 226 Selective serotonin reuptake inhibitors (SSRIs), in depression, 9 Selenium, in renal failure, 215 Sensorium, altered, 133, 207, 240, 255 in acute cholangitis, 165 altered mental status associated with, 189 in infectious disease, 138 Sensory deficits, 191, 199	Sodium in ATN, 207 in electrolyte imbalances, 59, 60, 62 excessively rapid correction of, 60 for hypervolemia, 63 Sodium restriction, 121, 163, 208 Soft tissue infection, necrotizing, 146 Somnolence, 57, 65, 87, 184, 193 Spasms, in tetanus, 156 Spider bites, 256 Spinal cord, in neurogenic shock, 77 Spinal cord compression, 199, 280 Spinal epidural abscess, 138 Spirometry, for asthma in pregnancy, 287 Spironolactone, 66, 121, 163 Splenomegaly, in leukemia, 279 Spontaneous bacterial peritonitis (SBP), 150, 163, 209 Sputum production, in SCD, 81 Sputum smear, in HIV-infected patients, 153 Staphylococcus aureus, in intravenous catheter infection, 144 Status asthmaticus, 100, 110 Status epilepticus, 198 Steatorrhea, 172 Stem cell transfusion, 254 Stent placement, for large-bowel obstruction, 170 Steroids for candidiasis, 259 topical, 260, 263, 269 Steroid therapy. See also Corticosteroids; Glucocorticoids

Streptococcus pneumoniae, 135	Theophylline overdose, 242
"Stress ulcer," 174	Thermal injury, inhalation, 82
Stroke, 201, 230	Thiamine, 198, 202, 226
and blood pressure reduction, 123	Thinking, disorganized, 189
hemorrhagic, 6, 201	Thioctic acid, in mushroom poisoning, 252
hyperglycemia following, 12	Thirst, in hypovolemia, 64. See also Fluid
and infective endocarditis, 142	management
Stupor, 202, 240, 250	Thoracentesis, 63, 88, 89, 153
Subarachnoid hemorrhage (SAH), 13, 203	Thoracic cage disorders, 107
Succinylcholine, in muscular dystrophy, 195	Thoracostomy, 85
Sucralfate, 21	Thrombin inhibitor, for HIT, 42
Suctioning, 164, 173, 175	Thrombocytopenia, 45, 81, 169, 219, 255, 279
in mechanical ventilation, 99	bleeding associated with, 39
nasogastric, 162	dermatology disorders associated with, 261
in pneumonia, 149	heparin-induced, 42
pulse oximetry during, 20	multiple transfusions associated with, 46
for ventilator-associated pneumonia, 111 Sulfadiazine, 135	in vasculitis, 222
	Thromboembolism, pulmonery, 90
Sulfonamide sensitivity, 273 Sulfonylureas, 183	Thromboembolism, pulmonary, 90 Thromboembolism prophylaxis, 27
Superior vena cava (SVC) syndrome, 281	Thrombolytic reperfusion, for AMI, 126
Supraventricular tachycardia, 127, 231	Thrombolytic therapy, 75, 90
Surgery, 124, 170, 280	in arterial insufficiency, 118
antimicrobial prophylaxis in, 155	for mesenteric ischemia and infarction, 124
DVT prophylaxis for, 7	"Thumbprinting" signs, 124
pulse oximetry during, 20	"Thunderclap" headache, 203
Surgical exploration, for necrotizing infection,	Thymectomy, 196
146	Thyroid conditions, 184, 185
Surgical site infection (SSI), 155	Thyroid storm, 186
Sweating, 183, 186. See also Diaphoresis	Thyrotoxicosis, 129, 234
in AMI, 126	Thyroxine (T ₄), 184, 185, 186
in dermatology disorders, 267	Ticlopidine, 44
in toxicology disorders, 226	Tidal volume, 93, 98, 99, 101, 104
Sympathomimetic overdose, 241	Tilt-table testing, 128
Syncope, 90, 128	Tingling, in spinal cord compression, 199 Tinnitus, in toxicology disorders, 234, 239
in cardiac disorders, 117, 122, 126, 130 in GI bleeding, 171, 176	Tissue plasminogen activator (r-tPA), 201
vasovagal, 128	Tongue, in myxedema coma, 184
Syndrome of inappropriate diuretic hormone	Torsade de pointes, 58, 130
(SIADH), 60	Total body surface area (TBSA), 25
Systemic inflammatory response syndrome	Total body water (TBW), in hypernatremia, 59
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212,	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273
(SIRS), 78, 154	Total parenteral nutrition (TPN), 15, 164
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212,	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226,	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TRN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion-reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion-reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279
(SIRS), 78, 154 Systemic lupus crythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167 Tachypnea, 81, 90, 121, 164, 197, 290	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients infections in, 141
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167 Tachypnea, 81, 90, 121, 164, 197, 290 altered mental status associated with, 189	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusion-selated acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients infections in, 141 management of, 28
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167 Tachypnea, 81, 90, 121, 164, 197, 290 altered mental status associated with, 189 in asthma, 287	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients infections in, 141 management of, 28 posttransplant lymphoproliferative disorder
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167 Tachypnea, 81, 90, 121, 164, 197, 290 altered mental status associated with, 189 in asthma, 287 in environmental injury, 251, 255	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion-related acute lung injury (TRALI), 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients infections in, 141 management of, 28 posttransplant lymphoproliferative disorder (PTLD)in, 28
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167 Tachypnea, 81, 90, 121, 164, 197, 290 altered mental status associated with, 189 in asthma, 287 in environmental injury, 251, 255 in pneumonia, 136	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients infections in, 141 management of, 28 posttransplant lymphoproliferative disorder (PTLD)in, 28 Transtubular potassium gradient (TTKG), 55, 56
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167 Tachypnea, 81, 90, 121, 164, 197, 290 altered mental status associated with, 189 in asthma, 287 in environmental injury, 251, 255	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion-related acute lung injury (TRALI), 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients infections in, 141 management of, 28 posttransplant lymphoproliferative disorder (PTLD)in, 28
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167 Tachypnea, 81, 90, 121, 164, 197, 290 altered mental status associated with, 189 in asthma, 287 in environmental injury, 251, 255 in pneumonia, 136 respiratory failure associated with, 109	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients infections in, 141 management of, 28 posttransplant lymphoproliferative disorder (PTLD)in, 28 Transtubular potassium gradient (TTKG), 55, 56 Trauma, 77, 93. See also Head injuries
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167 Tachypnea, 81, 90, 121, 164, 197, 290 altered mental status associated with, 189 in asthma, 287 in environmental injury, 251, 255 in pneumonia, 136 respiratory failure associated with, 109 TB skin test (PPD), 145 Telangiectasias, 171, 176 Terlipressin, 167, 176	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients infections in, 141 management of, 28 posttransplant lymphoproliferative disorder (PTLD)in, 28 Transtubular potassium gradient (TTKG), 55, 56 Trauma, 77, 93. See also Head injuries Treatment, forgoing of, 34 Trembling, in hypoglycemia, 183 Tremor, 68, 226, 227, 234, 241, 242
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167 Tachypnea, 81, 90, 121, 164, 197, 290 altered mental status associated with, 189 in asthma, 287 in environmental injury, 251, 255 in pneumonia, 136 respiratory failure associated with, 109 TB skin test (PPD), 145 Telangiectasias, 171, 176 Tetanus, 156	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients infections in, 141 management of, 28 posttransplant lymphoproliferative disorder (PTLD)in, 28 Transtubular potassium gradient (TTKG), 55, 56 Trauma, 77, 93. See also Head injuries Treatment, forgoing of, 34 Trembling, in hypoglycemia, 183 Tremor, 68, 226, 227, 234, 241, 242 Tricyclic antidepressants (TCAs), 9, 244
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167 Tachypnea, 81, 90, 121, 164, 197, 290 altered mental status associated with, 189 in asthma, 287 in environmental injury, 251, 255 in pneumonia, 136 respiratory failure associated with, 109 TB skin test (PPD), 145 Telangiectasias, 171, 176 Terlipressin, 167, 176 Tetanus, 156 Tetanus, 156 Tetanus, 156	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients infections in, 141 management of, 28 posttransplant lymphoproliferative disorder (PTLD)in, 28 Transtubular potassium gradient (TTKG), 55, 56 Trauma, 77, 93. See also Head injuries Treatment, forgoing of, 34 Trembling, in hypoglycemia, 183 Tremor, 68, 226, 227, 234, 241, 242 Tricyclic antidepressants (TCAs), 9, 244 Tricyclic antidepressants (TCAs), 9, 244
(SIRS), 78, 154 Systemic lupus erythematosus (SLE), 141, 212, 221 Systemic vascular resistance (SVR), 19 T Tachyarrhythmias, 130, 241 Tachycardia, 74, 78, 81, 120, 164, 186, 226, 227, 230, 235, 242, 243, 247, 250, 251 altered mental status associated with, 189 anxiety associated with, 3 in aortic dissection, 116 in asthma, 287 in hepatic failure, 169 in hypertensive crisis, 123 in metabolic alkalosis, 66 in necrotizing infection, 146 in neuroleptic malignant syndrome, 197 in pulmonary thromboembolism, 90 respiratory failure associated with, 109 supraventricular, 127, 231 and variceal bleeding, 167 Tachypnea, 81, 90, 121, 164, 197, 290 altered mental status associated with, 189 in asthma, 287 in environmental injury, 251, 255 in pneumonia, 136 respiratory failure associated with, 109 TB skin test (PPD), 145 Telangiectasias, 171, 176 Tetanus, 156	Total parenteral nutrition (TPN), 15, 164 Toxic epidermal necrolysis (TEN) 273 Toxic shock syndrome, 157, 274 Toxoplasmosis, in HIV-infected patients, 135 Tracheostomy, 87, 156, 195 Transfusion reactions, 46, 47 Transfusion-related acute lung injury (TRALI), 47 Transfusions. See also Blood products for leukemia, 279 nonspecific complications of, 47 plasma, 43 platelet, 76 red blood cell, 45, 46, 169, 247 in SCD, 81 unnecessary RBC, 46 Transjugular intrahepatic portosystemic shunt (TIPS), 163, 167, 209, 215 Transplantation bone marrow, 279 kidney, 26, 209 liver, 169, 225, 232 Transplant recipients infections in, 141 management of, 28 posttransplant lymphoproliferative disorder (PTLD)in, 28 Transtubular potassium gradient (TTKG), 55, 56 Trauma, 77, 93. See also Head injuries Treatment, forgoing of, 34 Trembling, in hypoglycemia, 183 Tremor, 68, 226, 227, 234, 241, 242 Tricyclic antidepressants (TCAs), 9, 244

Trismus (lockjaw), 156	Ventilation, mechanical, 68, 69, 86, 97, 98, 151,
Trousseau sign, in hypocalcemia, 54	184, 219, 248, 250, 253, 287
TTP/HUS, 43, 45	complications of, 101
Tuberculosis, 96, 145	in metabolic acidosis, 65
Tumor, ectopic ACTH-producing, 180	in neuromuscular disorders, 99
Tumor lysis syndrome, 282	for obese patient, 17
Tunnel infection, 144	in respiratory failure, 105, 106, 107, 109
Tzanck smear, 275	in status asthmaticus, 100, 110
	weaning from, 102, 103, 191
U	Ventilation-perfusion scan, 90
Ulcerations, in pulmonary disease, 82	Ventilatory control disorders, 99
Ulcerative colitis, functional asplenic state in, 141	Ventilatory support, 77, 86, 195, 238. See also
Ulcer disease, peptic, 174	Ventilation, mechanical
Ulcers, in VZV, 275	in anaphylactic shock, 73
Ultrafiltration, 63, 209	for hypervolemia, 63
Ultrasonography, in renal failure, 213	in sepsis, 154
Universal precautions, 152	in septic shock, 78
Uremia, 44	Ventricular tachyarrhythmias, 130, 230, 231,
Urinalysis, 207, 213	242
Urinary alkalinization, 239	Vision
Urinary incontinence, 197	in hypoglycemia, 183
Urinary tract infection (UTI), 139, 152, 158	in toxicology disorders, 231, 235, 238
Urine osmolality, 59, 60, 76	Vital capacity, 106
Urine output, in renal failure, 213	Vitamin deficiency, 191
Urine urea nitrogen, 16	Vitamin K deficiency, 39, 40
Urologic surgery, DVT prophylaxis for, 7	Volume-cycle ventilation (VCV), 97, 100. See
Urosepsis, 158	also Ventilation, mechanical
Urticaria, 73, 83, 244, 268	Volume depletion, 173, 181, 182. See also Fluid
Urticarial drug reactions, 268	management
Urticarial plaques, 262	Von Willebrand disease, 41
•	•••
V	W
Vaccination, 141, 156	Warfarin, 39, 40, 48, 49
Valve repair, 117	poisoning, 244
Valve replacement, 142	skin necrosis, 244
Valvuloplasty, 117	Weakness, 180, 186, 190, 199, 234, 238, 279.
Vancomycin, 133, 136, 137, 144, 147, 166, 214	See also Muscle weakness
Variceal bleeding, 167	in electrolyte imbalances, 55, 58
Varicella,	in endocrine disorders, 179, 181, 182, 183
primary, 275	in metabolic acidosis, 65
zoster, 275	in muscular dystrophy, 195
Vascular resistance, 19, 78	in myasthenia gravis, 196
Vasculitis, 212, 222	in polyneuropathy, 191
Vaso-occlusive crisis, in sickle cell disease	in renal disorders, 211
(SCD), 81 Vasopressors, 77, 78, 124, 165, 179, 219, 229,	Wegener granulomatosis, 212, 222 Weight, ideal, 16, 17
251	Whipple triad, 183
	White cell casts, in renal disorders, 210
Vasospasm, in SAH, 203 Vasospasm prophylaxis, in SAH, 203	Withdrawal
Vegetative state, 31	alcohol, 226
Venodilators, 63	benzodiazepine, 227
minute, 108	opioid, 237
PCO ₂ and, 10	Withholding care, 35
in respiratory failure, 108	Wolff-Parkinson-White syndrome, 127